data_2dj4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dj4 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.6 t . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.826 0.346 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -118.23 94.96 47.82 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.569 0.699 . . . . 0.0 110.883 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -0.11 6.45 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.77 2.313 . . . . 0.0 112.312 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.7 m -99.12 1.87 45.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.852 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -104.65 -6.76 20.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.405 ' CG1' HG21 ' A' ' 92' ' ' ILE . 2.9 p -90.12 129.31 41.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.115 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.416 ' C ' HG22 ' A' ' 16' ' ' ILE . 0.5 OUTLIER -130.27 176.19 8.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.833 179.934 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.557 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 13.2 pt -145.61 134.59 17.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.158 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.98 120.74 13.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.087 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.52 168.76 40.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -26.48 27.54 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.723 2.282 . . . . 0.0 112.292 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.76 -25.58 70.57 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.484 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.8 mt -98.73 -9.98 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.08 -178.48 14.6 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.528 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.8 m -91.58 -6.93 51.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.905 0.383 . . . . 0.0 110.863 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.4 47.24 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.491 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.442 HG12 ' NE2' ' A' ' 31' ' ' GLN . 88.1 t -98.01 139.85 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 111.105 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.434 ' N ' HG12 ' A' ' 25' ' ' VAL . 80.8 mtt-85 -121.97 146.23 47.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.826 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.28 151.82 39.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.085 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.2 mtt180 53.83 37.0 25.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.904 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -127.47 148.82 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.169 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.4 tp -71.56 111.38 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.462 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 36.5 mm-40 -114.92 127.48 55.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.8 t -144.44 155.86 43.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.522 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.2 p90 -148.02 -178.21 6.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.866 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -121.17 129.88 53.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.6 t -108.26 106.37 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -88.98 111.82 22.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.9 p -128.11 24.41 5.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 t -68.36 -34.71 76.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.25 -8.24 57.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.556 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -83.0 -35.33 25.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.12 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.29 -144.07 15.36 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.415 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -110.43 17.71 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.796 0.332 . . . . 0.0 110.917 -179.906 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.515 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.01 148.65 81.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.579 0.704 . . . . 0.0 111.095 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 167.67 23.77 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.68 2.253 . . . . 0.0 112.317 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 tp -125.43 127.32 46.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -110.95 148.42 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.92 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 35.7 t -139.45 153.9 24.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.405 ' NH2' HG23 ' A' ' 56' ' ' VAL . 18.5 mtp85 -157.36 138.04 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.88 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.403 ' C ' HD21 ' A' ' 50' ' ' LEU . 77.2 t -117.98 116.65 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.095 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.456 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.4 mm? -110.98 123.28 49.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.95 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.22 178.56 1.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.499 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.557 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.5 Cg_endo -69.77 -39.2 6.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.628 2.219 . . . . 0.0 112.365 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.21 -28.77 22.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.843 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.9 34.37 0.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.53 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.423 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 18.1 tp -83.16 156.45 23.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.898 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 12.7 p -119.46 111.72 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.15 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -112.8 143.5 29.18 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 110.875 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 169.41 19.04 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.676 2.251 . . . . 0.0 112.336 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.5 m -142.65 157.07 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.6 t30 -109.63 143.51 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.13 120.82 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 97.8 t -136.08 132.12 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.134 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -87.04 128.75 35.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.911 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -71.37 -42.1 68.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.868 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.14 -20.95 25.44 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.83 -42.74 9.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.47 36.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.496 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 64.7 p -153.11 176.38 11.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.14 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -143.92 133.99 24.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.2 m -96.35 132.9 41.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.134 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.522 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.2 t -126.37 108.16 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.135 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 51.8 p -98.28 142.26 30.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.106 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.498 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 7.2 p90 -159.73 169.28 24.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -145.04 113.77 4.91 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.64 0.733 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.498 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.73 97.12 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.374 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 75' ' ' PRO . 57.8 p -35.35 -47.98 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -132.08 -175.54 3.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.442 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.5 pp20? -101.47 170.27 8.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.5 176.81 14.57 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.533 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 88.07 0.55 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.557 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.4 m-85 -85.21 173.67 10.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.942 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 23.6 ttp -146.62 117.49 7.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.919 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 63.0 t -107.56 100.26 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.0 t -84.46 148.48 26.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.8 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.3 t -142.57 138.85 28.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.079 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -126.52 169.27 13.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.556 ' CE2' ' HB1' ' A' ' 40' ' ' ALA . 11.8 t80 -156.45 105.0 2.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 66.81 42.04 2.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.058 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 64.0 32.93 12.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.899 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -143.11 105.01 4.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.953 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -54.54 109.5 0.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.432 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 47.5 pt -47.52 152.95 1.09 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.648 0.737 . . . . 0.0 111.122 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 3.93 2.48 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.629 2.219 . . . . 0.0 112.374 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 39.1 mmt-85 -113.31 -4.15 13.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.533 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -111.84 154.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.685 0.755 . . . . 0.0 110.838 -179.787 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.533 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.7 -179.97 20.55 Favored 'Cis proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 -1.797 . . . . 0.0 112.353 -0.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.557 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 86.5 m-85 -120.62 118.86 31.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -82.06 105.16 12.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.7 t -116.38 105.21 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 43.8 tttm -82.49 102.55 11.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.491 HG23 ' CD1' ' A' ' 81' ' ' TYR . 38.9 t -70.21 150.73 9.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.113 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.53 153.84 52.16 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.598 0.713 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.87 122.65 9.3 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.681 2.254 . . . . 0.0 112.305 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 53.5 m -34.7 -34.51 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.173 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.458 ' N ' ' O ' ' A' ' 103' ' ' PRO . 64.9 m-85 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.887 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.5 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.76 0.314 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -128.89 95.73 31.08 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -2.73 10.65 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.752 2.301 . . . . 0.0 112.316 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.7 p -98.99 9.31 43.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.796 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -113.79 -7.65 13.23 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -83.85 125.1 40.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.109 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -120.9 173.66 7.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.509 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 38.1 pt -147.02 137.6 17.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.72 138.22 32.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.084 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.3 168.84 27.0 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -30.97 21.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.668 2.245 . . . . 0.0 112.354 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.55 -46.65 58.55 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.483 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.0 mt -76.64 -28.63 56.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.875 0.369 . . . . 0.0 110.982 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -47.62 169.83 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.479 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 69.7 m -87.06 -7.92 57.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -93.7 49.21 2.3 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.449 HG12 ' NE2' ' A' ' 31' ' ' GLN . 70.1 t -101.05 142.31 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.772 0.32 . . . . 0.0 111.15 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 57.0 mtt180 -118.33 147.89 43.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -67.71 149.61 49.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 56.18 40.73 30.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.458 ' N ' HG23 ' A' ' 74' ' ' THR . 53.6 t -133.62 148.11 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.099 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 18.6 tp -68.18 114.52 6.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.449 ' NE2' HG12 ' A' ' 25' ' ' VAL . 44.4 mm-40 -120.64 128.36 52.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.927 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.3 t -144.9 150.69 37.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.54 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 1.4 p90 -139.58 -178.29 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -121.0 133.78 55.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.12 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.6 t -115.34 107.57 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -91.33 106.86 18.81 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.451 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.1 p -117.01 20.4 13.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 50.6 p -63.05 -42.52 99.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? -77.03 -15.06 59.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.6 -32.38 47.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.062 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.01 -140.11 11.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.504 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.68 22.69 12.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.858 0.361 . . . . 0.0 110.949 -179.933 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.441 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -79.27 151.64 75.48 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.708 . . . . 0.0 111.074 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 167.05 25.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.659 2.239 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.7 tp -125.78 139.06 53.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.981 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -121.24 145.26 48.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.9 t -134.22 141.18 44.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -146.64 130.99 17.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.417 HG22 ' CG1' ' A' ' 59' ' ' VAL . 82.0 t -116.21 125.15 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -115.07 144.2 44.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.72 169.7 43.1 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.552 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -31.74 19.91 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.624 2.216 . . . . 0.0 112.369 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -95.36 -27.37 15.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.881 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 133.28 27.46 0.56 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.8 tp -86.79 148.66 25.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.895 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.3 t -110.96 121.54 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.123 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -112.62 142.92 27.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.641 0.734 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.18 22.24 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.337 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 49' ' ' VAL . 5.7 m -141.74 157.55 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -115.32 140.92 48.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.861 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 84.5 t -132.22 107.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.12 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -131.64 119.13 41.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.136 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t0 -76.07 133.47 40.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.859 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.477 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 7.1 m-80 -72.37 -43.33 64.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.71 -24.7 10.09 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.437 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -86.99 -39.1 15.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.78 34.21 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.552 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.479 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 72.6 p -150.16 176.74 10.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.837 0.351 . . . . 0.0 111.144 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.479 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.4 m-70 -145.78 131.18 18.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.859 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 21.9 m -91.61 139.58 30.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.54 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 99.3 t -129.59 102.32 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.111 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 46.7 p -92.51 138.81 31.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.173 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -164.01 160.78 22.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.458 HG23 ' N ' ' A' ' 29' ' ' VAL . 84.9 m -137.98 117.27 9.88 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.607 0.718 . . . . 0.0 111.152 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' SER . 53.8 Cg_endo -69.74 90.45 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.689 2.259 . . . . 0.0 112.305 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' PRO . 64.6 p -34.97 -53.6 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.881 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -122.22 158.39 29.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pp20? -79.7 174.95 11.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.948 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.35 177.16 14.89 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.516 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 86.59 0.59 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.623 2.216 . . . . 0.0 112.32 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -79.07 169.75 17.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -145.16 119.08 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.892 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.1 t -110.89 97.12 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.141 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.4 m -81.4 142.56 32.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 87.2 t -135.61 145.14 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.403 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 23.7 tttt -132.35 168.66 17.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.451 ' CZ ' ' HB2' ' A' ' 37' ' ' SER . 7.1 t80 -154.39 105.74 2.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.969 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 63.49 44.39 5.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.186 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.403 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.1 m-20 63.2 33.3 14.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -142.49 105.06 4.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -56.21 111.62 1.01 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.481 HD12 ' CE2' ' A' ' 97' ' ' PHE . 47.7 pt -49.24 153.2 1.78 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.59 0.709 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 4.41 2.16 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.664 2.243 . . . . 0.0 112.377 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.4 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 9.4 mtm-85 -116.18 0.09 12.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -115.21 153.32 47.36 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.644 0.735 . . . . 0.0 110.803 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.5 Cg_endo -69.76 171.26 54.53 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.35 -0.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.509 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 87.1 m-85 -109.78 140.8 43.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.3 ptmm? -100.75 110.32 22.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 98.9 t -119.44 101.95 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.1 tttm -81.0 101.6 9.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.9 t -73.22 147.66 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.128 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.8 mt -114.96 154.79 47.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 0.0 110.86 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.0 Cg_endo -69.74 124.16 10.82 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.671 2.247 . . . . 0.0 112.346 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.407 ' C ' ' O ' ' A' ' 103' ' ' PRO . 51.5 m -36.34 -30.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.185 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.479 ' N ' ' O ' ' A' ' 103' ' ' PRO . 70.1 m-85 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.882 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.117 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -132.7 95.94 19.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.6 0.714 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 -0.81 7.36 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.705 2.27 . . . . 0.0 112.412 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 55.8 p -99.92 7.62 44.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.932 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.3 mmpt? -112.16 -9.62 13.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -84.32 121.77 37.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -118.12 173.68 6.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.526 ' CD1' ' CZ ' ' A' ' 97' ' ' PHE . 23.1 pt -146.86 135.93 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.185 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.59 156.57 45.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.059 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 143.07 177.02 17.67 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.86 -33.76 15.56 Favored 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.662 2.241 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -53.57 -23.5 20.66 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.538 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.423 ' CD1' HG13 ' A' ' 16' ' ' ILE . 7.7 mt -109.67 -19.95 13.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.88 0.372 . . . . 0.0 110.925 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -59.83 166.81 9.48 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.6 m -82.6 11.22 6.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.881 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.83 43.4 1.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.409 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.461 HG11 ' NE2' ' A' ' 31' ' ' GLN . 59.7 t -101.97 143.85 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.908 0.385 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -124.68 155.48 39.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.866 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.7 150.32 43.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.7 mtm-85 57.26 37.78 28.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.12 147.76 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.085 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.9 tp -69.0 113.14 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.498 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 51.0 mm-40 -117.76 130.9 56.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 36.0 t -144.83 150.89 37.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.875 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.546 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 8.7 p90 -141.52 176.88 8.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 60.5 m -119.43 135.88 54.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.175 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.22 105.97 19.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.056 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -84.93 103.32 13.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.86 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 81.2 p -116.88 25.68 10.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 p -73.68 -29.76 62.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.854 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 30.5 mmtm -90.37 -5.47 56.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.919 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.521 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -89.46 -34.68 16.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.65 -140.18 11.6 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.396 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.34 20.98 12.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.798 0.332 . . . . 0.0 110.895 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.52 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -79.34 151.37 75.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.598 0.713 . . . . 0.0 111.049 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.9 20.14 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.745 2.296 . . . . 0.0 112.373 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.437 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.7 tp -132.0 135.4 46.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.918 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -112.19 152.97 27.75 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.72 132.91 41.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 48.8 mtm180 -139.11 132.75 30.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 59' ' ' VAL . 81.6 t -117.18 121.28 67.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 10.8 mt -116.94 129.29 55.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.27 175.03 40.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.534 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.416 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.79 -32.62 18.08 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.712 2.275 . . . . 0.0 112.308 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.29 -25.87 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.887 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 130.84 22.86 1.0 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.499 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 16.7 tp -74.08 149.04 41.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 0.0 110.838 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.3 t -113.7 112.93 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -113.15 141.63 26.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.611 0.719 . . . . 0.0 110.893 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 174.88 8.86 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.623 2.215 . . . . 0.0 112.362 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.445 ' CG1' HG21 ' A' ' 49' ' ' VAL . 8.9 m -144.32 162.83 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 19.0 t30 -119.49 145.02 46.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.896 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.46 120.48 42.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.59 122.58 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -82.17 127.23 32.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.926 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -71.76 -47.71 51.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.52 -16.17 24.25 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -95.14 -38.22 10.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.963 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.69 33.97 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.457 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.6 p -152.76 176.15 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 111.175 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.457 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.2 m-70 -145.85 130.7 18.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.968 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.7 m -92.89 139.78 30.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.157 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.546 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 36.9 t -131.22 108.94 15.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.171 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.3 p -93.34 146.42 23.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.103 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.533 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 9.3 p90 -163.26 166.87 22.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.5 m -144.22 110.64 5.05 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 121.612 0.72 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.533 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.73 91.9 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.724 2.283 . . . . 0.0 112.315 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 22.8 t -34.21 -50.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.801 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -129.62 173.61 10.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.888 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.92 170.21 10.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.861 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.73 172.59 13.18 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.461 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 90.85 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.704 2.27 . . . . 0.0 112.367 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.416 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.0 m-85 -85.07 161.65 19.61 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -131.42 112.8 13.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.842 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.3 t -103.51 95.98 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.8 t -79.34 145.7 33.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.437 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.1 t -143.54 130.13 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.137 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.3 tttt -118.13 169.81 9.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.521 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 6.3 t80 -156.89 106.12 2.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 66.3 40.79 3.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.13 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.99 34.57 11.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.856 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -145.7 105.03 3.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -54.17 114.53 1.65 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.863 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.45 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 48.2 pt -52.12 152.81 5.36 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.574 0.702 . . . . 0.0 111.178 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 4.29 2.27 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.701 2.267 . . . . 0.0 112.296 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -116.13 1.33 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.848 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.53 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -115.23 153.83 47.38 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.683 0.754 . . . . 0.0 110.825 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.69 -179.41 18.97 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.392 -0.132 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.526 ' CZ ' ' CD1' ' A' ' 16' ' ' ILE . 85.2 m-85 -119.45 123.38 43.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.912 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 8.5 pttp -83.89 96.77 8.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 86.9 t -102.28 103.99 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.103 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 23.9 ttpt -85.0 102.53 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.87 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.4 t -75.38 143.43 13.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.134 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 33.8 mt -107.79 154.51 40.92 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.52 0.676 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.7 Cg_endo -69.7 122.51 9.2 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.3 m -33.97 -36.21 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.44 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.8 m-85 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.865 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.838 0.352 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -131.85 96.86 19.6 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.799 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -0.43 6.89 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.676 2.251 . . . . 0.0 112.337 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -99.38 6.95 45.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -112.99 -7.2 13.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.33 126.93 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.413 ' C ' HG23 ' A' ' 16' ' ' ILE . 21.7 mtmm -125.57 170.37 11.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.926 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.572 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 41.1 pt -145.25 137.01 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.173 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.21 143.26 34.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.076 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.0 169.97 24.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.72 -29.71 23.63 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.703 2.268 . . . . 0.0 112.343 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.59 -45.93 94.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.467 HD13 ' CD1' ' A' ' 16' ' ' ILE . 12.5 mt -73.91 -26.9 60.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.876 0.369 . . . . 0.0 110.933 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.16 169.35 0.36 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.501 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.5 p -85.26 -7.78 58.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.914 0.388 . . . . 0.0 110.841 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.67 44.7 2.73 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.508 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.456 HG12 ' NE2' ' A' ' 31' ' ' GLN . 97.7 t -92.15 143.0 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.831 0.348 . . . . 0.0 111.181 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.415 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . 46.5 mtm180 -118.33 156.17 29.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.52 147.08 44.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 82.5 mtm-85 54.94 35.79 25.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.415 ' CG2' ' HB2' ' A' ' 26' ' ' ARG . 23.3 t -121.71 151.84 25.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.126 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.402 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 7.9 tp -75.62 109.33 9.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.456 ' NE2' HG12 ' A' ' 25' ' ' VAL . 40.7 mm-40 -112.72 127.64 56.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 23.1 t -143.85 149.51 37.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.441 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 9.8 p90 -145.85 171.25 15.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -110.68 130.61 55.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.46 ' CG2' HG22 ' A' ' 16' ' ' ILE . 100.0 t -108.55 107.05 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.126 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -90.56 106.73 18.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 86.8 p -121.87 25.95 8.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.915 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 78.1 p -71.25 -35.85 71.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.861 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -80.02 -14.91 58.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.918 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.497 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -78.29 -38.2 43.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.13 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -138.19 9.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.609 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.19 17.73 13.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.885 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -75.92 151.52 84.29 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.525 0.679 . . . . 0.0 111.119 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 166.87 26.0 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.703 2.269 . . . . 0.0 112.362 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.47 HD12 ' CG1' ' A' ' 85' ' ' VAL . 4.7 tp -122.92 136.33 54.82 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -119.21 139.47 51.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.885 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -130.73 144.44 37.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.079 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 20.1 ttm180 -148.11 141.8 25.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -122.78 122.04 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.138 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -108.13 151.34 26.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.44 167.35 32.5 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.471 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -29.84 23.47 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.18 3.62 12.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.55 62.98 0.5 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.542 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.1 tp -120.48 134.75 55.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.872 0.368 . . . . 0.0 110.911 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.1 t -102.78 129.78 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.157 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -134.46 141.43 38.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.655 0.741 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 168.47 21.41 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.689 2.259 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.7 t -142.64 151.61 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -100.82 138.52 37.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.85 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.2 p -133.43 112.47 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.181 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 66.1 t -133.4 127.61 54.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -84.08 130.87 34.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.423 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 8.1 m-80 -72.21 -46.14 57.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.24 -22.21 11.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -88.6 -40.59 13.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.814 0.34 . . . . 0.0 110.852 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.28 33.99 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.509 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.575 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.7 p -150.2 175.39 11.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.876 0.369 . . . . 0.0 111.107 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.575 ' CD2' ' C ' ' A' ' 68' ' ' THR . 6.2 m-70 -147.0 125.21 12.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 38.8 m -85.7 141.28 29.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.441 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.0 t -131.13 104.56 9.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.9 p -96.89 135.13 39.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.132 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.51 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.6 p90 -155.4 175.05 14.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.913 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 89.7 m -151.71 117.18 3.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.526 0.679 . . . . 0.0 111.109 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.51 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.3 Cg_endo -69.77 98.12 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.723 2.282 . . . . 0.0 112.357 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' PRO . 1.5 t -34.32 -60.3 0.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.883 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -127.36 164.19 22.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -72.73 167.36 20.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 132.46 171.08 12.68 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.443 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 92.76 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.678 2.252 . . . . 0.0 112.363 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -87.94 173.99 8.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 18.3 ttp -148.5 117.17 6.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.79 96.64 4.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.101 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -79.0 144.71 34.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.872 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.47 ' CG1' HD12 ' A' ' 45' ' ' LEU . 55.7 t -139.58 135.91 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -126.47 169.62 12.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.497 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 5.9 t80 -155.71 117.9 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 57.04 31.58 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.126 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.0 t70 74.22 31.74 1.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -141.79 106.69 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -53.73 114.89 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.434 HD12 ' CE1' ' A' ' 97' ' ' PHE . 43.4 pt -53.49 152.79 8.37 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.667 0.746 . . . . 0.0 111.136 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 4.47 2.19 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -115.64 0.76 13.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.881 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.518 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -114.72 153.36 46.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.622 0.725 . . . . 0.0 110.855 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.518 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.85 178.63 25.01 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.285 0.077 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.572 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 81.8 m-85 -117.2 117.73 30.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.897 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -78.49 113.33 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.836 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -128.99 101.95 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.119 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.5 tttm -83.95 102.51 12.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.9 t -67.15 145.67 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.177 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.7 mt -114.03 156.17 44.39 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.8 121.28 7.96 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.687 2.258 . . . . 0.0 112.351 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.429 ' C ' ' O ' ' A' ' 103' ' ' PRO . 54.0 m -35.21 -31.75 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.075 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.496 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.941 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.6 t . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.827 0.346 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -134.14 96.21 16.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.635 0.731 . . . . 0.0 110.897 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 1.49 4.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.747 2.298 . . . . 0.0 112.305 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 63.7 m -99.2 -5.23 30.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.5 mmpt? -97.9 -7.66 29.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.43 ' CG1' HG22 ' A' ' 92' ' ' ILE . 4.9 p -86.43 131.17 35.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.193 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mppt? -128.44 172.61 10.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.864 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.564 HD11 ' CE2' ' A' ' 97' ' ' PHE . 24.2 pt -143.3 134.96 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.122 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.93 128.17 20.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.79 163.59 28.21 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -24.88 29.44 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.664 2.243 . . . . 0.0 112.365 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.77 95.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.536 HD12 ' CD2' ' A' ' 33' ' ' PHE . 7.1 mt -84.13 -17.19 40.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.973 0.416 . . . . 0.0 110.968 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.31 176.71 1.31 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.509 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -91.26 -13.29 33.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.986 0.422 . . . . 0.0 110.87 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.47 49.86 3.49 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.459 HG12 ' NE2' ' A' ' 31' ' ' GLN . 74.6 t -99.34 147.15 7.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.798 0.332 . . . . 0.0 111.103 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.404 ' N ' HG11 ' A' ' 25' ' ' VAL . 89.2 mtt180 -121.26 144.84 48.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.76 150.45 44.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 45.7 mtm180 54.65 43.05 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.8 t -135.06 147.65 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -69.96 113.93 7.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.945 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.459 ' NE2' HG12 ' A' ' 25' ' ' VAL . 42.4 mm-40 -120.51 129.02 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.8 t -144.75 157.72 44.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.536 ' CD2' HD12 ' A' ' 21' ' ' LEU . 1.3 p90 -147.21 179.95 7.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.931 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 58.2 m -120.08 130.82 54.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.142 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.72 109.07 27.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -89.83 110.39 21.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 25.6 p -125.75 24.73 7.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.757 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 89.0 p -69.64 -33.76 73.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.7 mmmt -86.31 -12.66 48.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.562 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -78.58 -35.3 46.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.133 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.82 -138.86 10.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.566 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.583 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -121.14 19.37 11.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.745 0.307 . . . . 0.0 110.852 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.446 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -77.86 151.78 79.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.604 0.716 . . . . 0.0 111.103 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 167.16 25.27 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.435 HD13 ' CG1' ' A' ' 85' ' ' VAL . 6.4 tp -125.32 136.0 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.911 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -120.94 149.38 42.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.91 150.15 20.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.196 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -148.58 136.16 20.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 93.5 t -116.4 124.8 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -123.89 133.73 53.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.53 -179.86 49.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.491 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -45.17 1.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.674 2.25 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.439 ' NE ' HE22 ' A' ' 77' ' ' GLN . 0.1 OUTLIER -76.2 -35.24 59.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.889 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.9 31.59 0.26 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.2 tp -85.31 152.04 23.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.917 0.389 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.4 t -119.25 122.59 69.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -120.25 142.64 34.08 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.56 0.695 . . . . 0.0 110.97 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 169.01 19.94 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.632 2.221 . . . . 0.0 112.33 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.7 m -138.29 167.7 21.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -114.34 140.67 48.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 93.1 t -133.32 114.9 21.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.166 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.0 t -140.47 117.55 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -73.63 139.45 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.933 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -78.42 -45.56 21.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.61 -20.7 11.95 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.447 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.95 -39.03 13.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.807 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.59 34.96 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.487 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.8 p -153.27 177.39 10.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 111.072 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.1 m-70 -144.8 130.59 19.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.87 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 81.8 m -88.54 140.98 28.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.462 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.0 t -133.04 102.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.146 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 45.2 p -95.09 143.84 26.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.501 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 5.2 p90 -163.35 175.46 10.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.971 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -151.91 116.95 3.07 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.651 0.738 . . . . 0.0 111.121 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.501 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.76 92.92 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.664 2.243 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 75' ' ' PRO . 40.2 t -34.44 -54.7 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.854 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . 0.439 HE22 ' NE ' ' A' ' 53' ' ' ARG . 7.3 pt20 -125.83 171.71 10.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.969 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -84.82 172.81 11.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.52 170.04 12.99 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.5 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.13 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.726 2.284 . . . . 0.0 112.319 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -83.11 168.59 16.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.978 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.5 ttp -139.54 117.95 12.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.9 t -107.21 97.59 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 m -81.53 147.44 29.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.832 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.442 HG13 ' N ' ' A' ' 86' ' ' LYS . 64.5 t -140.94 138.11 34.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.442 ' N ' HG13 ' A' ' 85' ' ' VAL . 34.6 tttt -125.27 173.91 8.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.926 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.562 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 8.7 t80 -160.44 110.54 1.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.974 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.446 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 60.68 38.31 18.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.154 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 68.02 34.02 4.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -144.23 105.02 4.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.875 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -54.39 108.38 0.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.438 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 45.8 pt -46.9 153.02 0.87 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.583 0.706 . . . . 0.0 111.144 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.68 2.04 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.668 2.245 . . . . 0.0 112.347 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.457 ' O ' ' CE1' ' A' ' 97' ' ' PHE . 84.2 mmt-85 -114.48 -3.73 12.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.529 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 0.9 OUTLIER -112.28 154.45 44.43 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.631 0.729 . . . . 0.0 110.848 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.529 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.0 Cg_endo -69.72 -178.53 16.86 Favored 'Cis proline' 0 C--N 1.342 0.206 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.38 -0.084 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.564 ' CE2' HD11 ' A' ' 16' ' ' ILE . 81.2 m-85 -121.25 132.78 55.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 ptmt -93.16 108.31 19.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.7 t -118.59 103.68 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.104 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 106.85 13.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.908 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 41.5 t -76.81 138.08 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.155 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.6 mt -108.64 155.24 40.91 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 121.675 0.75 . . . . 0.0 110.941 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.6 Cg_endo -69.73 122.46 9.14 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.782 2.321 . . . . 0.0 112.296 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 103' ' ' PRO . 91.9 m -34.83 -35.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.084 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.442 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.4 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.0 t . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.853 0.359 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -133.23 96.18 17.66 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.598 0.713 . . . . 0.0 110.927 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.72 -1.63 8.78 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.682 2.255 . . . . 0.0 112.359 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.5 p -98.11 5.93 48.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.808 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -110.53 -7.74 14.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.408 ' CG1' HG21 ' A' ' 92' ' ' ILE . 1.6 p -86.29 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.106 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.408 ' C ' HG23 ' A' ' 16' ' ' ILE . 30.9 mttt -127.21 173.72 9.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.931 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.566 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 31.4 pt -147.35 135.79 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.4 153.19 46.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.142 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.52 174.6 20.35 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -36.04 11.46 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.671 2.247 . . . . 0.0 112.315 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.28 -32.68 29.87 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.561 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.443 HD11 ' CD1' ' A' ' 16' ' ' ILE . 13.0 mt -94.4 -21.38 18.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.912 0.387 . . . . 0.0 110.95 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.43 167.96 2.67 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -87.49 13.75 9.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.893 0.378 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.02 44.9 1.37 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.518 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.456 HG13 ' NE2' ' A' ' 31' ' ' GLN . 60.0 t -97.14 145.96 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 111.095 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -120.89 151.65 39.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.887 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -69.56 150.73 46.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.068 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.9 mtp180 55.09 41.55 31.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.3 t -133.88 144.33 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.2 tp -68.43 112.99 5.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.456 ' NE2' HG13 ' A' ' 25' ' ' VAL . 54.5 mm-40 -117.47 130.66 56.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.2 t -144.89 149.1 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.532 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.4 p90 -140.08 179.77 6.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.946 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 89.3 m -117.8 131.55 56.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' CG2' HG22 ' A' ' 16' ' ' ILE . 92.8 t -110.38 105.47 18.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.096 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -89.67 101.76 14.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.858 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.475 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 82.6 p -117.33 27.94 8.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.1 t -70.04 -38.13 75.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 37.7 mttp -76.06 -14.88 60.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.506 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -81.2 -38.59 26.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.09 -137.44 9.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.532 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.597 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.86 19.91 12.32 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.793 0.33 . . . . 0.0 110.912 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.437 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -77.18 151.62 81.47 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.585 0.707 . . . . 0.0 111.084 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 166.86 26.18 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.685 2.256 . . . . 0.0 112.322 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -129.61 129.37 44.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -108.73 151.71 25.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.9 t -139.53 144.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.084 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -149.64 135.06 18.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.832 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 61.5 t -116.73 128.36 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.1 mt -125.12 121.15 33.41 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.949 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.29 174.44 7.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.534 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -43.62 2.52 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.625 2.216 . . . . 0.0 112.381 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.6 -32.2 47.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.1 32.64 0.3 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.46 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 9.4 tp -85.85 149.69 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 0.0 110.874 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -114.38 115.23 48.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -113.79 142.84 28.42 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 169.58 18.59 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.237 . . . . 0.0 112.299 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.23 167.94 19.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.139 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 t30 -123.21 140.6 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 85.5 t -133.21 113.84 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 85.5 t -138.32 119.85 17.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.093 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -75.12 136.58 41.1 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.765 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.431 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 5.7 m-80 -75.69 -43.44 47.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.903 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.88 -24.9 9.84 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.506 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -86.05 -44.21 12.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.837 0.351 . . . . 0.0 110.898 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.34 33.57 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.493 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.433 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 64.0 p -149.92 177.78 9.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.86 0.362 . . . . 0.0 111.078 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.433 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.3 m-70 -144.99 133.56 22.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 52.4 m -93.02 141.49 28.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.148 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.532 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 66.4 t -131.36 103.28 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.172 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.6 p -95.19 136.86 35.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.131 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.475 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 8.0 p90 -157.41 176.12 13.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.7 m -150.78 115.35 3.24 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.586 0.708 . . . . 0.0 111.122 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.8 95.04 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.345 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 13.4 t -38.91 -54.79 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.772 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -121.98 169.94 10.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.497 ' C ' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -86.97 173.75 9.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.86 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.11 176.23 15.05 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.488 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 89.15 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.699 2.266 . . . . 0.0 112.279 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.62 163.54 25.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.938 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 16.3 ttp -135.17 113.09 11.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.856 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 69.3 t -105.48 97.78 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.5 t -82.98 144.29 30.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.899 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 55.7 t -139.83 142.37 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.079 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.421 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 39.9 tttt -128.29 170.56 12.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.506 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 4.5 t80 -156.42 109.42 2.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 62.27 40.82 11.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.421 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 4.9 m-20 64.31 35.99 9.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.887 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -147.05 105.04 3.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -52.48 117.01 2.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.425 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 46.5 pt -55.61 153.16 16.06 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.58 0.705 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 4.74 2.01 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 2.251 . . . . 0.0 112.412 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 29.7 mmt85 -117.04 2.96 12.74 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.53 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.64 153.98 49.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.637 0.732 . . . . 0.0 110.861 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.69 -179.92 20.38 Favored 'Cis proline' 0 C--O 1.231 0.135 0 C-N-CA 122.663 -1.807 . . . . 0.0 112.37 -0.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.566 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 80.1 m-85 -117.45 128.98 55.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.878 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -93.64 107.34 19.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.9 t -119.43 107.04 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 19.8 ttpt -81.96 105.5 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.885 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.8 152.49 6.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.18 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 68.4 mt -117.55 154.83 50.79 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.575 0.702 . . . . 0.0 110.93 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.7 122.21 8.91 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.692 2.261 . . . . 0.0 112.377 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m -34.83 -32.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.152 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.6 m-85 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.1 t . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.424 ' CG ' ' HG2' ' A' ' 13' ' ' LYS . 8.8 t0 -123.95 95.1 44.71 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.614 0.721 . . . . 0.0 110.897 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 0.78 5.12 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.71 2.273 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 m -100.7 3.67 42.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.424 ' HG2' ' CG ' ' A' ' 10' ' ' ASP . 14.4 mmmt -104.74 -12.12 16.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.444 ' CG1' HG21 ' A' ' 92' ' ' ILE . 6.4 p -84.37 133.67 28.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.413 ' C ' HG21 ' A' ' 16' ' ' ILE . 29.0 mtmt -135.69 169.94 16.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.471 HD12 ' CE2' ' A' ' 97' ' ' PHE . 26.3 pt -142.67 137.25 27.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 143.79 33.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.077 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 155.83 178.57 30.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.87 -38.81 7.06 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.656 2.237 . . . . 0.0 112.315 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.27 -24.99 11.0 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.498 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.41 HD11 ' CD1' ' A' ' 16' ' ' ILE . 3.3 mt -104.41 -22.16 13.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.864 0.364 . . . . 0.0 110.896 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -58.19 176.82 1.84 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.469 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -91.17 11.78 22.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.884 0.374 . . . . 0.0 110.853 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.84 47.03 1.09 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.505 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.433 HG12 ' N ' ' A' ' 26' ' ' ARG . 72.4 t -98.54 138.29 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.805 0.336 . . . . 0.0 111.11 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.433 ' N ' HG12 ' A' ' 25' ' ' VAL . 57.4 mtt85 -118.76 146.33 44.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -66.69 151.51 47.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.034 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 56.18 35.6 25.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 76.2 t -128.91 154.4 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.125 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.1 tp -76.19 112.24 12.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.451 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 61.8 mm-40 -113.83 127.54 56.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 13.6 t -142.19 154.1 44.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.872 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.56 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.0 p90 -149.54 176.2 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.948 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.455 HG22 ' N ' ' A' ' 35' ' ' VAL . 96.1 m -114.64 138.01 51.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.456 ' CG1' HD22 ' A' ' 45' ' ' LEU . 52.3 t -117.48 106.97 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -85.78 110.65 19.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.6 p -125.34 25.77 7.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.8 t -75.67 -35.82 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.876 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? -81.6 -18.52 44.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.518 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -75.29 -39.98 59.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.139 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.8 -140.66 11.42 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -116.35 16.97 15.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.785 0.326 . . . . 0.0 110.907 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.452 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -75.63 151.3 84.85 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.61 0.719 . . . . 0.0 111.063 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.436 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.7 Cg_endo -69.77 167.37 24.65 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.652 2.234 . . . . 0.0 112.297 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.456 HD22 ' CG1' ' A' ' 35' ' ' VAL . 10.8 tp -128.19 131.11 48.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.897 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -111.86 151.53 29.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.82 149.81 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.412 ' HG2' ' CD2' ' A' ' 50' ' ' LEU . 2.5 ttp-105 -152.61 143.12 22.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 58.3 t -118.69 122.06 68.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.464 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.0 mm? -110.48 128.92 55.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.59 165.03 52.6 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.502 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.51 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.75 -26.29 27.76 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.743 2.295 . . . . 0.0 112.365 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.09 3.35 9.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.08 65.16 0.52 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.48 148.0 44.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.59 118.64 57.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -120.65 141.69 32.78 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.639 0.733 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 169.21 19.39 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.663 2.242 . . . . 0.0 112.378 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.8 m -144.31 162.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 29.9 t30 -125.2 141.15 52.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 3.6 p -133.52 110.94 15.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.144 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 74.7 t -139.79 116.04 9.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -67.45 138.8 56.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.551 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 6.3 m-80 -73.18 -41.98 63.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.89 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.21 -22.05 12.59 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.485 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -91.58 -43.05 9.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.357 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.77 34.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.551 ' HG1' ' ND2' ' A' ' 64' ' ' ASN . 57.3 p -152.23 177.87 10.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.413 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.1 m-70 -143.76 125.12 14.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.864 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 31.3 m -84.03 139.02 32.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.56 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 73.3 t -131.3 106.71 12.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.5 p -97.07 147.4 24.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.453 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.1 p90 -166.02 164.37 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 92.0 m -140.85 112.38 6.88 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.623 0.725 . . . . 0.0 111.129 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.453 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 54.1 Cg_endo -69.69 100.59 0.82 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.367 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 75' ' ' PRO . 33.3 t -34.86 -57.85 0.53 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -129.86 166.5 19.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.41 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 5.7 pm0 -76.25 172.11 13.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.887 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.92 173.83 13.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.457 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 93.93 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.513 ' CD1' HG22 ' A' ' 101' ' ' VAL . 6.3 m-85 -90.11 173.91 7.92 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 27.7 ttp -147.61 117.74 7.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.841 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 93.2 t -106.29 100.22 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 12.4 t -84.37 143.49 29.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.81 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 84.4 t -141.21 135.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -122.28 171.69 8.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.518 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 12.9 t80 -157.56 112.81 2.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.929 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 60.45 32.51 20.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.083 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 73.47 31.4 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.808 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -141.99 105.05 4.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -53.36 107.9 0.28 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.444 HG21 ' CG1' ' A' ' 14' ' ' VAL . 44.9 pt -45.93 153.0 0.69 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.609 0.719 . . . . 0.0 111.104 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 4.31 2.26 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.361 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 14.2 mmm180 -113.46 -4.65 13.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.836 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -112.21 153.98 44.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.659 0.742 . . . . 0.0 110.845 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.4 Cg_endo -69.65 179.15 22.84 Favored 'Cis proline' 0 C--N 1.341 0.168 0 C-N-CA 122.8 -1.75 . . . . 0.0 112.347 -0.116 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.471 ' CE2' HD12 ' A' ' 16' ' ' ILE . 89.5 m-85 -120.21 114.8 22.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 106.08 9.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.901 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 79.7 t -117.51 106.71 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.078 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -85.91 96.88 9.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.889 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.513 HG22 ' CD1' ' A' ' 81' ' ' TYR . 47.7 t -63.61 147.28 12.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.065 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.5 mt -113.02 154.05 45.12 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.59 0.709 . . . . 0.0 110.958 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.5 Cg_endo -69.71 124.06 10.73 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.741 2.294 . . . . 0.0 112.345 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.415 ' C ' ' O ' ' A' ' 103' ' ' PRO . 88.6 m -35.58 -32.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.473 ' N ' ' O ' ' A' ' 103' ' ' PRO . 23.0 m-85 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.9 t . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.875 0.369 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -128.08 96.92 30.39 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.58 0.705 . . . . 0.0 110.832 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 -0.43 6.86 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.687 2.258 . . . . 0.0 112.369 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.2 p -99.67 10.39 41.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.863 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 mmpt? -114.82 -8.78 12.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.898 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.427 ' CG1' HG22 ' A' ' 92' ' ' ILE . 1.1 p -83.87 123.11 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.166 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -116.69 173.33 6.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.544 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 33.0 pt -147.13 138.82 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.89 138.1 31.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.95 167.59 22.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.541 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.75 -24.93 29.17 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.85 -28.09 65.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.472 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.7 mt -98.13 -19.78 17.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.41 166.37 5.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.7 t -83.29 8.59 13.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.972 0.415 . . . . 0.0 110.922 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.14 51.0 0.73 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.7 t -102.08 141.78 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.845 0.355 . . . . 0.0 111.102 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 75.3 mtt85 -118.97 150.75 39.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.888 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.74 150.16 48.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.432 ' HB3' ' NH1' ' A' ' 28' ' ' ARG . 12.2 mtp-105 54.91 40.32 31.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 66.4 t -129.9 150.74 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.149 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.7 tp -73.94 110.36 8.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.951 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.3 mm-40 -115.3 127.68 55.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.975 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.3 t -143.44 149.48 37.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 1.0 OUTLIER -141.33 -178.38 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 88.4 m -123.21 137.67 54.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t -117.65 107.18 21.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.106 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.48 94.74 9.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.875 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.479 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 59.9 p -103.64 20.02 18.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.9 t -68.41 -34.94 76.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.814 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -82.75 -12.24 57.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.478 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -83.35 -39.66 20.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.047 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.415 ' C ' HD11 ' A' ' 42' ' ' LEU . . . 135.66 -146.97 18.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.5 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.452 HD11 ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.07 14.99 24.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.928 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -75.58 151.32 84.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.619 0.723 . . . . 0.0 111.046 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 169.36 19.1 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.64 2.227 . . . . 0.0 112.377 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.433 HD12 ' CG1' ' A' ' 85' ' ' VAL . 7.8 tp -124.82 139.47 53.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -112.96 143.4 44.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 88.9 t -135.72 131.1 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -141.12 143.0 34.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.441 HG22 ' CG1' ' A' ' 59' ' ' VAL . 60.9 t -125.23 132.38 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.5 mp -120.57 148.46 43.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.09 172.69 36.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.405 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.4 Cg_endo -69.82 -30.75 21.49 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.657 2.238 . . . . 0.0 112.325 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.86 4.78 17.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 105.45 66.5 0.67 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.54 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 26.9 tp -118.36 138.59 52.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.911 0.386 . . . . 0.0 110.91 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.1 t -109.02 108.98 26.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -110.93 143.13 27.66 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.618 0.723 . . . . 0.0 110.875 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 168.02 22.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.655 2.237 . . . . 0.0 112.363 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.441 ' CG1' HG22 ' A' ' 49' ' ' VAL . 30.0 m -141.83 163.15 19.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.063 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -115.47 141.31 48.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.866 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 86.9 t -132.86 116.31 26.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 76.6 t -138.25 124.74 26.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -80.45 132.75 35.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.58 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 9.2 m-80 -72.84 -40.74 65.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 114.42 -27.37 8.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -83.27 -47.27 11.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.846 0.355 . . . . 0.0 110.931 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.28 30.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.529 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.58 ' HG1' ' ND2' ' A' ' 64' ' ' ASN . 60.4 p -144.76 177.78 8.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.498 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.5 m-70 -146.66 132.16 18.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 23.2 m -93.16 141.86 27.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.144 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.475 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 57.8 t -132.85 104.78 7.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.17 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -94.74 139.97 30.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.5 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -159.36 171.54 19.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.863 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.2 m -147.07 114.97 4.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.567 0.699 . . . . 0.0 111.149 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.5 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.6 Cg_endo -69.73 91.39 0.51 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.346 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.5 t -34.08 -59.64 0.42 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -121.56 158.34 28.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.886 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -77.19 173.67 11.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.07 176.9 14.64 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 86.19 0.58 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.678 2.252 . . . . 0.0 112.387 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.405 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.1 m-85 -83.0 173.59 11.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.5 ttp -149.16 120.83 8.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.0 t -109.43 100.17 10.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.9 t -82.99 145.4 29.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.848 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.433 ' CG1' HD12 ' A' ' 45' ' ' LEU . 54.3 t -140.52 138.42 36.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.103 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -126.79 172.99 9.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.507 ' CZ ' ' O ' ' A' ' 43' ' ' ALA . 5.5 t80 -160.18 109.47 1.76 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 63.0 37.84 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.047 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 67.94 34.18 4.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -144.35 105.07 4.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.59 111.68 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.429 HD11 ' CE2' ' A' ' 97' ' ' PHE . 47.0 pt -49.41 153.03 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.683 0.754 . . . . 0.0 111.1 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 3.85 2.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.71 2.273 . . . . 0.0 112.327 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.418 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 19.6 mmm180 -114.08 -2.03 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.862 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.536 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -113.61 153.27 45.86 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.681 0.753 . . . . 0.0 110.849 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.536 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.78 175.83 35.07 Favored 'Cis proline' 0 C--N 1.341 0.151 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.318 0.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.544 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 87.8 m-85 -116.15 118.07 31.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -78.7 107.24 11.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.903 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 96.1 t -119.26 102.92 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.101 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -83.58 100.42 10.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.8 145.09 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.173 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.6 mt -111.69 154.67 43.88 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.589 0.709 . . . . 0.0 110.958 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.9 Cg_endo -69.66 123.33 10.03 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.67 2.246 . . . . 0.0 112.334 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 103' ' ' PRO . 49.7 m -36.11 -30.82 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.171 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.485 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.8 m-85 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.2 t . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.822 0.344 . . . . 0.0 111.124 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.2 t0 -125.88 99.45 32.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.564 0.697 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.6 Cg_endo -69.81 0.37 5.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.66 2.24 . . . . 0.0 112.386 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.7 p -98.7 9.09 44.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.999 0.428 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -114.18 -8.02 12.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.417 ' CG1' HG23 ' A' ' 92' ' ' ILE . 1.8 p -84.54 123.5 39.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.215 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.4 mtpp -119.66 167.74 11.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.558 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 37.6 pt -144.09 140.06 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.8 165.92 26.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 133.82 176.11 14.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.41 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.65 -41.44 4.42 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.715 2.277 . . . . 0.0 112.321 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -44.77 -35.44 4.32 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.494 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 8.2 mt -94.43 -26.6 16.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.897 0.379 . . . . 0.0 110.896 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -50.86 163.81 0.92 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.479 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.4 m -86.24 22.91 1.67 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.959 0.409 . . . . 0.0 110.904 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.69 38.05 2.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.461 HG12 ' NE2' ' A' ' 31' ' ' GLN . 78.9 t -89.41 144.3 9.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 65.6 mtt180 -121.63 149.8 42.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.04 150.16 48.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.6 mtt85 55.35 34.83 23.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.876 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 73.2 t -127.46 146.98 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.7 tp -68.25 111.6 4.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.461 ' NE2' HG12 ' A' ' 25' ' ' VAL . 58.0 mm-40 -116.66 126.62 53.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.3 t -144.45 148.43 34.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.471 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -140.86 177.61 7.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.791 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 82.6 m -118.36 141.17 48.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.215 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.2 t -118.09 109.47 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -92.32 98.23 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.1 p -111.71 21.38 16.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.5 p -67.01 -35.4 79.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.839 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -79.16 -15.89 57.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.61 -38.68 47.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.092 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.49 -138.45 9.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.444 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.47 HD11 ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.8 16.35 16.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.88 0.371 . . . . 0.0 110.956 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.454 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -75.78 151.64 84.64 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.581 0.705 . . . . 0.0 111.105 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.487 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.1 Cg_endo -69.77 169.27 19.31 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.622 2.215 . . . . 0.0 112.327 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.454 HD11 ' CG1' ' A' ' 85' ' ' VAL . 4.7 tp -127.32 135.4 50.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.961 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -120.42 145.42 47.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.437 HG13 ' N ' ' A' ' 48' ' ' ARG . 49.7 t -137.49 145.93 28.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.108 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.437 ' N ' HG13 ' A' ' 47' ' ' VAL . 24.8 mmt180 -146.38 138.16 24.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.8 t -115.41 129.15 72.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.035 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -126.2 119.52 27.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.85 177.77 3.76 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.531 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.422 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 53.7 Cg_endo -69.7 -41.39 4.39 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.649 2.232 . . . . 0.0 112.4 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.422 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -84.05 -33.66 24.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.976 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.31 33.21 0.15 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.458 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 11.1 tp -85.52 155.67 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.887 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.458 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 94.3 t -119.33 111.1 31.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -106.13 143.15 26.35 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.651 0.738 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.691 2.261 . . . . 0.0 112.34 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 m -139.98 162.83 24.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -118.88 143.6 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.936 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 74.0 t -129.51 116.31 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.98 110.77 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.203 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -72.15 129.05 37.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -72.73 -44.74 61.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.856 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.11 -24.31 10.09 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -85.87 -46.49 10.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.841 0.353 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.7 30.54 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.537 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.527 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.3 p -145.89 177.63 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 111.098 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.527 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.5 m-70 -147.82 131.41 16.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 3.4 m -94.78 137.51 33.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.471 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 35.6 t -127.04 107.35 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 35.1 p -92.68 141.06 28.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.193 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -163.94 161.59 22.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.973 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -137.38 117.19 10.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.603 0.716 . . . . 0.0 111.117 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.75 94.59 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.349 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 75' ' ' PRO . 43.0 t -35.88 -54.88 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -125.12 168.94 12.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -85.35 173.68 10.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.33 175.42 14.22 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.465 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 90.13 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.702 2.268 . . . . 0.0 112.364 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.531 ' CD1' HG22 ' A' ' 101' ' ' VAL . 4.0 m-85 -81.06 169.75 17.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.947 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 11.2 ttp -145.31 115.73 7.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.5 t -107.58 97.14 5.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -79.83 142.88 34.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.454 ' CG1' HD11 ' A' ' 45' ' ' LEU . 89.5 t -138.05 142.0 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.084 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.417 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 15.5 tttp -130.49 168.05 17.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.941 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' A' ' 44' ' ' PRO . 6.7 t80 -154.61 115.99 4.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.944 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 59.41 33.27 22.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.115 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.417 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 11.6 m-20 71.04 33.5 2.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -144.4 105.34 4.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.891 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -49.99 114.14 1.02 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.84 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.417 HG23 ' CG1' ' A' ' 14' ' ' VAL . 42.1 pt -54.56 153.52 10.35 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.661 0.743 . . . . 0.0 111.113 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.68 4.33 2.22 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 53.1 mtp85 -114.5 0.29 13.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.908 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.512 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -115.71 153.37 47.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.684 0.754 . . . . 0.0 110.866 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.512 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.73 178.01 26.82 Favored 'Cis proline' 0 C--O 1.232 0.18 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.396 -0.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.558 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 86.3 m-85 -117.84 116.47 27.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.0 pttm -81.65 108.8 15.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.02 104.14 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -81.35 103.01 10.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.531 HG22 ' CD1' ' A' ' 81' ' ' TYR . 44.2 t -71.25 144.61 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 77.2 mt -111.88 154.5 44.09 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.583 0.706 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.495 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.4 Cg_endo -69.69 123.84 10.52 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.724 2.283 . . . . 0.0 112.324 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.9 m -34.12 -33.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.193 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.495 ' N ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m-85 . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.775 0.321 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -130.53 96.64 23.44 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 0.3 5.85 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.663 2.242 . . . . 0.0 112.347 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 30.8 m -98.46 -7.12 29.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -94.23 -5.15 47.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -90.42 135.73 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.152 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 22.8 mtmt -133.42 168.9 17.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.568 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 42.2 pt -142.9 139.42 27.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.066 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.72 153.67 43.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.32 171.68 17.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -29.14 24.27 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 0.0 112.372 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.79 -29.43 67.37 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.2 mt -97.04 -26.43 15.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.894 0.378 . . . . 0.0 110.965 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.92 168.33 2.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.564 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.8 p -83.86 18.49 1.99 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.21 40.83 2.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.462 HG13 ' NE2' ' A' ' 31' ' ' GLN . 58.3 t -92.96 147.46 5.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -123.03 157.26 33.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.835 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -75.35 149.48 38.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 42.5 mtt180 54.09 30.27 11.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 t -119.99 144.48 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.178 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.5 tp -67.81 110.12 3.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.562 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 59.6 mm-40 -113.29 126.95 55.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.923 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -143.2 152.53 41.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.502 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.5 p90 -146.39 -176.48 5.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 48.0 m -122.23 135.5 54.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.09 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.1 t -113.15 108.75 26.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.157 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -91.47 104.04 16.59 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.913 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.0 p -121.4 30.19 6.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.9 t -73.04 -36.61 66.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.853 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 6.4 mmpt? -79.95 -16.95 54.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.859 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.539 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -74.05 -38.64 63.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.042 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.7 -137.25 9.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.577 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.31 18.91 12.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.868 0.366 . . . . 0.0 110.973 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.472 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.35 151.89 83.5 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.71 . . . . 0.0 111.076 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 166.64 26.92 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.673 2.249 . . . . 0.0 112.338 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.471 HD11 ' CG1' ' A' ' 85' ' ' VAL . 15.4 tp -126.08 134.49 51.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -119.4 147.52 44.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.468 ' CG1' HG13 ' A' ' 59' ' ' VAL . 65.6 t -137.3 149.77 25.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -152.26 136.85 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.837 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 71.9 t -119.43 126.18 75.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.169 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -123.58 122.9 39.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.6 -179.36 1.66 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.472 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.465 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.74 -47.93 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.14 -37.25 61.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.919 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.24 33.38 0.13 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.464 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.3 tp -85.37 147.96 26.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.915 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.4 t -107.87 126.0 64.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.106 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -127.92 140.35 37.93 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.603 0.716 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 168.65 20.95 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.702 2.268 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.468 HG13 ' CG1' ' A' ' 47' ' ' VAL . 44.5 t -139.91 149.33 22.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.191 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -98.67 139.18 34.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.82 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 p -131.94 123.48 51.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.196 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.5 t -141.28 129.43 22.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.174 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.22 132.06 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.84 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -73.23 -48.04 38.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.83 -21.04 10.59 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -90.43 -43.97 9.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.8 32.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.572 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 63.2 p -151.02 177.73 9.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 111.152 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.572 ' CD2' ' C ' ' A' ' 68' ' ' THR . 5.3 m-70 -146.61 131.07 17.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.846 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 26.2 m -90.21 138.41 31.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.196 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.502 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 47.4 t -130.37 110.37 18.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.171 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 55.7 p -101.04 145.33 28.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.188 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.562 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.0 p90 -164.91 169.06 16.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -146.29 112.6 4.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.586 0.708 . . . . 0.0 111.089 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.81 94.39 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.665 2.243 . . . . 0.0 112.383 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.7 t -34.23 -59.43 0.44 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -116.3 168.75 9.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 pm0 -89.21 169.37 11.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.86 177.71 15.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 93.9 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.661 2.241 . . . . 0.0 112.393 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.465 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 3.3 m-85 -88.28 172.98 9.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 7.5 ttp -144.43 117.13 8.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 81.2 t -108.57 95.69 4.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.134 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.7 t -79.72 147.2 32.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.8 t -142.54 134.27 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.149 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -121.44 168.64 11.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.989 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.539 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 7.0 t80 -154.9 106.86 2.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 65.4 42.22 3.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 62.96 34.83 13.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -146.32 105.05 3.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -51.2 114.93 1.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.822 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.412 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 38.1 pt -53.79 153.26 8.58 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.542 0.687 . . . . 0.0 111.198 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.66 5.83 1.51 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.267 . . . . 0.0 112.361 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.1 mmm180 -118.49 3.61 11.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.804 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.512 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -118.48 153.26 51.88 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.724 0.773 . . . . 0.0 110.838 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.512 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.81 176.68 31.76 Favored 'Cis proline' 0 C--N 1.343 0.243 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.41 -0.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.568 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 72.8 m-85 -114.86 121.68 43.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.882 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 pttp -80.94 107.71 13.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 57.8 t -119.2 106.43 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.164 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -89.12 99.1 12.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.9 t -65.75 150.69 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 78.1 mt -118.94 154.69 53.19 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.618 0.723 . . . . 0.0 110.932 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.447 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.76 119.08 6.08 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.718 2.279 . . . . 0.0 112.299 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.6 m -39.38 -27.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.447 ' N ' ' O ' ' A' ' 103' ' ' PRO . 4.7 m-85 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.949 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 72.9 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.947 0.403 . . . . 0.0 111.087 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -133.21 98.18 15.76 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.549 0.69 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -2.02 9.44 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.751 2.301 . . . . 0.0 112.344 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.2 m -100.07 13.87 32.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.827 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -9.03 10.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.79 134.34 27.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.187 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.417 ' C ' HG23 ' A' ' 16' ' ' ILE . 5.2 mtpm? -129.44 174.29 9.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.969 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.572 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 27.4 pt -150.01 135.97 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.127 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.3 154.74 44.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.129 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 146.15 178.54 21.67 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.48 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -39.55 6.5 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.711 2.274 . . . . 0.0 112.407 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -47.8 -35.61 12.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.549 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.416 ' CD1' HG13 ' A' ' 16' ' ' ILE . 9.4 mt -93.48 -27.49 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.88 167.95 1.0 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.1 m -85.57 16.86 3.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.961 0.41 . . . . 0.0 110.91 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.35 40.17 2.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 26' ' ' ARG . 64.9 t -93.02 139.6 17.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 111.153 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.475 ' N ' HG13 ' A' ' 25' ' ' VAL . 89.2 mtt180 -121.74 148.15 45.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.869 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.36 154.86 37.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 23.1 mtm180 50.65 41.72 26.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.894 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.414 HG11 ' N ' ' A' ' 30' ' ' LEU . 70.0 t -134.23 151.32 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' HG11 ' A' ' 29' ' ' VAL . 21.2 tp -73.97 111.21 8.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.987 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.542 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 65.2 mm-40 -112.01 127.33 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.0 t -141.03 149.98 42.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.55 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.4 p90 -144.62 168.77 19.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.825 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 92.7 m -110.18 130.09 55.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.177 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.434 ' CG2' HG22 ' A' ' 16' ' ' ILE . 65.2 t -111.41 105.61 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.117 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -87.01 104.72 16.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.775 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 75.7 p -118.72 27.2 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.909 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.9 p -74.22 -37.41 63.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.821 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -73.93 -23.32 59.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.49 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -70.62 -41.28 72.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.092 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.48 -135.19 7.44 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.45 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.548 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.98 19.55 13.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.764 0.316 . . . . 0.0 110.901 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.564 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.65 152.01 80.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.671 0.748 . . . . 0.0 111.047 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 165.94 29.33 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.691 2.26 . . . . 0.0 112.328 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.458 HD11 ' CG1' ' A' ' 85' ' ' VAL . 4.5 tp -125.36 136.68 53.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.937 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -121.13 143.4 49.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.33 144.98 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.432 ' HG2' ' CD1' ' A' ' 50' ' ' LEU . 12.7 ttm180 -148.24 144.6 27.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.414 HG23 ' CG1' ' A' ' 59' ' ' VAL . 67.3 t -120.89 130.37 74.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.432 ' CD1' ' HG2' ' A' ' 48' ' ' ARG . 3.8 mp -125.11 134.78 52.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.46 173.88 54.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.444 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -44.36 2.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.21 -35.52 41.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 138.77 31.32 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.436 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.7 tp -91.63 150.11 21.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.1 t -110.62 132.12 59.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.098 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 48.0 mp0 -120.02 142.74 33.95 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.631 0.729 . . . . 0.0 110.841 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 167.93 23.1 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.346 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.414 ' CG1' HG23 ' A' ' 49' ' ' VAL . 20.8 m -144.31 164.79 13.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.155 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -122.85 142.69 50.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 89.8 t -133.5 103.06 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.2 t -127.96 115.25 38.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.159 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -71.12 135.0 47.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.532 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 7.0 m-80 -75.64 -43.09 49.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.22 -26.0 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.487 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -85.66 -40.09 16.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.863 0.363 . . . . 0.0 110.872 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.82 34.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.478 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.532 ' HG1' ' ND2' ' A' ' 64' ' ' ASN . 61.2 p -151.47 177.65 10.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.168 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -145.77 131.38 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.842 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 51.9 m -90.84 137.74 32.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.132 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.55 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 40.3 t -133.19 105.72 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.061 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 71.1 p -98.32 142.15 30.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.223 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.553 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 10.0 p90 -156.53 169.89 23.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.964 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.3 m -145.74 110.67 4.48 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.552 0.691 . . . . 0.0 111.233 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.553 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.75 94.52 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.661 2.241 . . . . 0.0 112.372 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 60.6 p -39.38 -27.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . 0.462 ' N ' ' O ' ' A' ' 75' ' ' PRO . 10.4 pt20 -147.74 175.49 10.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.98 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.93 173.28 7.67 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.72 174.76 13.86 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.547 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.71 81.66 0.79 Allowed 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.697 2.265 . . . . 0.0 112.382 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -80.52 147.33 30.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.908 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' MET . . . . . 0.449 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.1 tmm? -117.61 127.09 53.62 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.03 95.3 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 t -76.1 139.92 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.825 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.458 ' CG1' HD11 ' A' ' 45' ' ' LEU . 64.9 t -138.86 129.8 34.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.158 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.417 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 40.4 tttt -121.6 170.52 9.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.564 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.0 t80 -157.09 107.82 2.31 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 64.16 41.82 5.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.417 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 44.0 m-20 63.22 36.07 12.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -146.15 104.97 3.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -53.75 117.34 3.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.87 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.464 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 40.3 pt -55.75 153.57 15.8 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.657 0.741 . . . . 0.0 111.113 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.401 ' HD2' ' HB ' ' A' ' 92' ' ' ILE . 53.8 Cg_endo -69.74 6.2 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.727 2.285 . . . . 0.0 112.377 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -120.59 5.55 10.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.973 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -119.93 153.37 54.96 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.688 0.756 . . . . 0.0 110.781 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.71 172.95 46.4 Favored 'Cis proline' 0 C--N 1.342 0.21 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.3 -0.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.572 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 68.1 m-85 -110.43 139.82 45.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.824 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 34.0 mttm -100.29 107.3 19.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.1 t -117.06 101.54 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.087 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 39.9 tttp -81.0 97.78 7.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 49.4 t -69.61 144.14 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 42.1 mt -109.56 155.17 41.78 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.573 0.701 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.3 Cg_endo -69.82 123.22 9.86 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.737 2.291 . . . . 0.0 112.368 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.434 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -33.87 -35.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.182 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 103' ' ' PRO . 20.0 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 76.8 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.827 0.346 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -129.43 96.72 26.88 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.648 0.737 . . . . 0.0 110.803 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -1.5 8.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.8 m -100.39 12.29 37.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.5 mmpt? -116.54 -7.41 11.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -85.85 127.07 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.214 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.403 ' C ' HG21 ' A' ' 16' ' ' ILE . 34.7 mttt -121.68 173.28 7.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.913 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.572 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 31.8 pt -148.47 134.38 11.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.07 152.17 45.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.124 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 149.08 176.58 22.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.495 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -38.65 7.55 Favored 'Trans proline' 0 N--CA 1.466 -0.118 0 C-N-CA 122.709 2.273 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.92 -24.39 13.8 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.554 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.47 HD12 ' CD1' ' A' ' 16' ' ' ILE . 6.5 mt -105.77 -18.23 14.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.949 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.62 177.85 3.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 97.9 p -92.31 15.0 14.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.36 . . . . 0.0 110.854 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.03 42.88 1.78 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.481 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.44 HG13 ' NE2' ' A' ' 31' ' ' GLN . 75.9 t -96.46 141.13 15.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.884 0.373 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -121.11 148.84 43.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.854 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.45 150.18 48.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 58.7 mtt-85 53.98 41.09 32.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.878 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.6 t -132.85 143.59 39.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.078 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.1 tp -66.82 114.03 5.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.44 ' NE2' HG13 ' A' ' 25' ' ' VAL . 53.7 mm-40 -116.49 134.7 54.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.858 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 28.9 t -146.94 148.98 32.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.487 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 2.5 p90 -142.73 173.14 11.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 73.8 m -112.79 133.32 54.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.192 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.95 106.75 21.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.141 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -88.5 99.41 12.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.5 p -112.99 26.08 10.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.848 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.4 p -72.62 -38.14 67.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.834 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -76.43 -17.11 59.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.952 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.489 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -78.39 -38.36 41.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.42 -138.79 9.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.574 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.4 20.68 12.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.798 0.332 . . . . 0.0 110.913 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.469 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . . . -79.05 151.54 76.02 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.567 0.698 . . . . 0.0 111.085 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 166.56 27.19 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.292 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.471 HD13 ' CG1' ' A' ' 85' ' ' VAL . 5.4 tp -125.72 135.86 52.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.892 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -116.05 142.33 46.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.844 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.423 HG13 ' N ' ' A' ' 48' ' ' ARG . 60.9 t -130.0 142.3 44.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.423 ' N ' HG13 ' A' ' 47' ' ' VAL . 20.2 ttm180 -148.16 142.46 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 49.0 t -121.2 133.51 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.162 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.415 ' CD2' ' HG2' ' A' ' 48' ' ' ARG . 4.5 mm? -124.78 133.19 53.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.928 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.13 170.26 53.56 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.504 179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -42.26 3.54 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -82.51 -34.85 27.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.13 31.65 0.19 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.428 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.9 tp -91.7 146.01 24.12 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.97 125.88 67.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.154 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -118.86 141.81 30.76 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.621 0.724 . . . . 0.0 110.932 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 171.5 14.44 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.662 2.241 . . . . 0.0 112.336 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.0 m -142.29 165.77 16.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -124.24 143.3 50.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.872 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -133.47 118.52 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.116 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 60.1 t -134.91 121.62 34.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.203 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -75.04 137.2 41.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.794 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -80.64 -40.97 24.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.1 -29.73 7.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -82.79 -47.12 12.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.786 0.327 . . . . 0.0 110.87 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.38 30.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.513 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.4 p -144.14 177.34 8.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.826 0.346 . . . . 0.0 111.044 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.513 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.0 m-70 -146.07 127.63 15.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 97.2 m -88.38 138.94 30.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.179 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.487 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 64.4 t -129.75 109.81 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.146 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -97.68 140.2 32.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.136 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.44 ' CE2' ' HB2' ' A' ' 31' ' ' GLN . 5.9 p90 -159.72 170.69 20.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.93 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 m -146.02 116.15 4.79 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 111.147 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.425 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.74 92.97 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.683 2.256 . . . . 0.0 112.36 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 m -35.92 -51.59 0.71 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.848 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -131.78 163.17 28.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.6 170.35 16.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.81 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.77 172.66 13.28 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 84.2 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.37 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -76.54 173.57 11.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.1 ttp -144.95 114.37 7.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.803 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -103.51 96.91 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.125 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.1 t -80.3 139.91 36.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.934 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.471 ' CG1' HD13 ' A' ' 45' ' ' LEU . 51.5 t -136.11 140.59 43.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.467 ' N ' HG11 ' A' ' 85' ' ' VAL . 18.2 tttp -128.61 169.22 14.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.919 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 37' ' ' SER . 6.0 t80 -153.86 107.7 3.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.959 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.469 ' HB2' ' CB ' ' A' ' 43' ' ' ALA . . . 63.65 43.02 5.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.092 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.424 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 32.8 m-20 62.65 36.95 13.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.446 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 14.9 mt-10 -147.58 105.05 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -52.58 118.32 3.53 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.427 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 45.2 pt -57.75 153.07 33.29 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.646 0.736 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 4.34 2.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.711 2.274 . . . . 0.0 112.362 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -116.94 4.93 12.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.524 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -117.8 153.72 50.91 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.722 0.772 . . . . 0.0 110.827 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.524 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.71 178.36 25.6 Favored 'Cis proline' 0 C--N 1.342 0.211 0 C-N-CA 122.743 -1.774 . . . . 0.0 112.383 -0.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.572 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 77.0 m-85 -115.56 119.92 37.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 ptpt -79.7 100.0 7.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 90.9 t -108.35 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.0 ttpm? -83.2 98.61 9.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.934 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.35 145.34 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.121 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 82.0 mt -110.35 154.3 43.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.614 0.721 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.71 124.22 10.89 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.707 2.271 . . . . 0.0 112.289 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.423 ' C ' ' O ' ' A' ' 103' ' ' PRO . 77.9 m -34.73 -32.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 67.1 m-85 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.9 t . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.883 0.373 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -125.76 98.11 34.68 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.546 0.689 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -1.87 9.22 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.689 2.26 . . . . 0.0 112.321 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.3 p -101.66 14.48 31.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.893 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.426 ' NZ ' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -117.59 -9.62 10.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.883 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.79 134.66 27.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.461 ' HD3' ' CZ ' ' A' ' 94' ' ' ARG . 14.0 mmmt -127.67 173.27 10.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.541 HD13 ' CZ ' ' A' ' 97' ' ' PHE . 26.5 pt -148.55 134.82 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.166 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.63 130.13 22.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.181 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.84 170.04 34.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -35.9 11.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.66 2.24 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.35 -42.77 50.72 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.446 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.1 mt -80.78 -20.03 43.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.906 0.384 . . . . 0.0 110.929 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.81 174.21 0.48 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 91.2 p -89.47 -13.89 36.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.932 0.396 . . . . 0.0 110.833 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -90.43 52.14 3.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.469 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.424 HG13 ' NE2' ' A' ' 31' ' ' GLN . 79.4 t -99.94 143.61 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.852 0.358 . . . . 0.0 111.09 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 48.6 mtt85 -118.43 148.59 42.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.928 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.22 152.56 45.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.159 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 54.45 35.15 22.54 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.5 t -127.1 149.47 32.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.068 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -71.87 112.01 7.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.942 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.515 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 40.5 mm-40 -116.28 126.79 54.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.8 t -143.46 163.0 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.544 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 2.0 p90 -155.07 -176.96 6.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.1 m -120.87 129.79 53.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.106 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.5 t -108.68 105.74 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.069 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -86.54 98.91 11.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.842 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 97.5 p -113.18 31.19 6.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.1 t -73.48 -40.99 63.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -73.87 -24.79 59.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.933 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.548 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -69.1 -32.86 72.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.103 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.426 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 126.26 -147.47 16.75 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.475 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.487 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -106.64 18.41 21.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.803 0.335 . . . . 0.0 110.92 -179.914 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.567 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -75.21 151.61 85.86 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.583 0.706 . . . . 0.0 111.078 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 167.49 24.28 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.681 2.254 . . . . 0.0 112.297 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 tp -122.96 144.49 49.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.412 ' C ' HG23 ' A' ' 47' ' ' VAL . 5.1 tp10 -130.25 143.79 50.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.901 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.459 ' CG1' HG12 ' A' ' 59' ' ' VAL . 46.1 t -136.71 153.74 30.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 39.2 mtt180 -155.71 145.19 21.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.4 t -125.72 125.96 69.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.156 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.39 126.54 49.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.65 176.98 23.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.471 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -49.24 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.641 2.227 . . . . 0.0 112.372 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -72.56 -37.24 68.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.98 37.37 0.11 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.444 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.7 tp -91.32 150.65 21.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.877 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.95 126.72 72.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.133 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -127.16 141.63 41.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.653 0.74 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.402 ' C ' HG23 ' A' ' 59' ' ' VAL . 53.7 Cg_endo -69.84 168.03 22.84 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.704 2.27 . . . . 0.0 112.327 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.459 HG12 ' CG1' ' A' ' 47' ' ' VAL . 44.0 t -138.41 149.8 24.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.427 ' N ' HG13 ' A' ' 59' ' ' VAL . 13.5 t30 -96.37 137.87 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.3 p -133.51 114.36 20.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.106 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 84.9 t -135.56 123.56 37.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -77.01 134.63 38.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -76.88 -42.06 41.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.57 9.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.548 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.408 ' CG ' ' N ' ' A' ' 67' ' ' GLY . 0.6 OUTLIER -83.75 -46.96 11.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 0.0 110.891 -179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.408 ' N ' ' CG ' ' A' ' 66' ' ' ASP . . . 164.03 30.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.444 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.5 p -144.54 177.77 8.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.767 0.318 . . . . 0.0 111.155 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.6 m-70 -147.19 124.92 11.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.413 HG23 ' N ' ' A' ' 71' ' ' VAL . 89.1 m -83.24 139.7 32.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.159 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.544 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 60.5 t -131.45 106.27 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.4 p -100.18 145.49 27.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.566 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -165.45 174.32 10.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.2 m -152.05 114.11 2.92 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 121.53 0.681 . . . . 0.0 111.123 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.566 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 94.38 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 0.0 112.357 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.7 m -38.04 -49.64 1.3 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -127.13 158.26 37.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -78.54 170.52 16.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.52 175.09 13.88 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.465 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 83.24 0.7 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.646 2.231 . . . . 0.0 112.315 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -77.99 171.84 14.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 19.2 ttp -143.74 119.03 10.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 91.6 t -104.21 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.0 t -84.22 138.14 33.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 86' ' ' LYS . 91.1 t -133.86 141.42 44.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.417 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 28.3 tttt -130.51 168.42 17.08 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.567 ' CE2' ' HB1' ' A' ' 43' ' ' ALA . 9.6 t80 -153.54 108.7 3.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 62.88 42.58 7.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.417 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.2 m-20 63.18 35.31 12.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -145.63 104.99 3.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -51.75 121.79 7.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.548 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 33.5 pt -59.74 153.25 53.71 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.673 0.749 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 6.02 1.49 Allowed 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.565 2.176 . . . . 0.0 112.419 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.461 ' CZ ' ' HD3' ' A' ' 15' ' ' LYS . 11.9 mtt85 -121.55 9.57 10.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.531 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.41 153.54 58.89 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.747 0.784 . . . . 0.0 110.832 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.8 Cg_endo -69.88 176.78 31.57 Favored 'Cis proline' 0 C--N 1.343 0.253 0 C-N-CA 122.6 -1.834 . . . . 0.0 112.325 0.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.548 ' CZ ' HD11 ' A' ' 92' ' ' ILE . 84.8 m-85 -113.99 132.02 56.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.4 ptmm? -87.28 111.65 21.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.2 t -123.49 101.66 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -84.99 100.05 11.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 81.5 t -71.23 148.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.132 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 60.4 mt -113.86 155.5 45.12 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 0.0 110.908 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.6 Cg_endo -69.71 121.63 8.32 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.69 2.26 . . . . 0.0 112.378 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 103' ' ' PRO . 99.5 m -33.96 -34.94 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.139 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.468 ' N ' ' O ' ' A' ' 103' ' ' PRO . 26.7 m-85 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.5 t . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.828 0.347 . . . . 0.0 111.124 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -129.88 95.42 28.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 0.0 110.878 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 -0.79 7.47 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.668 2.245 . . . . 0.0 112.385 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.8 m -98.7 2.1 46.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.819 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -108.48 -7.16 15.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.447 ' CG1' HG23 ' A' ' 92' ' ' ILE . 1.7 p -88.86 123.93 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.157 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -123.21 174.46 7.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.536 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 20.5 pt -145.59 133.45 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.09 135.69 29.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.99 170.46 35.2 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.444 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -31.64 20.27 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.349 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.89 -42.6 98.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 7.8 mt -77.39 -23.72 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.82 173.85 0.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.445 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.5 m -87.16 -11.84 48.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.96 0.409 . . . . 0.0 110.859 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.28 45.33 3.26 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.432 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.454 HG11 ' NE2' ' A' ' 31' ' ' GLN . 74.8 t -93.19 146.49 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 0.0 111.138 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.466 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . 28.7 mtm-85 -121.27 151.32 40.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.839 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.72 147.07 49.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.063 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.0 mtm-85 56.32 33.68 22.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 26' ' ' ARG . 85.8 t -123.74 143.8 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.2 tp -68.0 111.05 4.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.968 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.454 ' NE2' HG11 ' A' ' 25' ' ' VAL . 52.3 mm-40 -114.13 130.45 56.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 38.6 t -145.48 148.76 33.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.867 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.53 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.9 p90 -140.66 -178.22 5.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 98.8 m -119.92 129.13 54.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.471 ' CG1' HG21 ' A' ' 16' ' ' ILE . 55.4 t -108.94 106.11 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.144 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -87.57 107.19 18.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 84.5 p -123.12 22.09 9.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.877 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.3 t -66.78 -35.96 81.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.886 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.4 mmtm -83.1 -8.64 59.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.478 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -82.91 -34.32 26.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.149 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.15 -135.48 8.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.514 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.477 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -122.77 22.1 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.857 0.361 . . . . 0.0 110.945 -179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.482 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -79.25 151.71 75.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.579 0.704 . . . . 0.0 111.071 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.441 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.3 Cg_endo -69.77 166.52 27.31 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.39 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.469 HD12 ' CG1' ' A' ' 85' ' ' VAL . 11.4 tp -124.26 134.88 53.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.941 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -119.41 147.06 44.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 48' ' ' ARG . 48.3 t -136.97 150.38 26.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.149 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.418 ' N ' HG13 ' A' ' 47' ' ' VAL . 18.6 mtt-85 -154.23 133.37 12.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.424 HG22 ' CG1' ' A' ' 59' ' ' VAL . 62.0 t -112.91 128.61 69.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.141 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -124.44 127.45 47.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.971 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.72 179.71 37.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.479 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.486 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.84 -37.95 8.28 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.669 2.246 . . . . 0.0 112.316 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.62 -31.27 21.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.913 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.06 30.19 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.8 tp -81.75 147.51 29.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.936 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.3 t -110.41 105.63 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.128 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -96.46 144.91 28.66 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.671 0.748 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 168.12 22.52 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.717 2.278 . . . . 0.0 112.317 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.424 ' CG1' HG22 ' A' ' 49' ' ' VAL . 20.5 m -142.75 167.45 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.16 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.426 ' ND2' ' C ' ' A' ' 60' ' ' ASN . 0.4 OUTLIER -125.05 141.74 51.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.5 t -132.84 111.03 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.169 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 90.3 t -138.93 115.42 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.146 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.523 ' OD2' ' CE1' ' A' ' 69' ' ' HIS . 10.2 t70 -72.51 139.9 47.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.884 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -77.68 -43.25 31.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.46 ' N ' ' OD1' ' A' ' 63' ' ' ASP . . . 115.38 -20.07 14.19 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.473 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -91.61 -41.73 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.876 0.37 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.13 33.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.433 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.508 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 71.0 p -149.34 177.33 9.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.796 0.331 . . . . 0.0 111.158 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.523 ' CE1' ' OD2' ' A' ' 63' ' ' ASP . 12.5 m-70 -146.94 125.06 12.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 34.5 m -84.53 140.4 31.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.083 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.53 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 67.3 t -131.03 103.78 8.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.139 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.0 p -93.44 139.29 30.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.2 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.505 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.1 p90 -159.9 169.15 24.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.927 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -147.14 115.66 4.32 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.631 0.729 . . . . 0.0 111.104 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.505 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.74 99.01 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.255 . . . . 0.0 112.331 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 75' ' ' PRO . 32.5 t -35.6 -54.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.859 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -128.77 177.55 6.98 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.18 166.35 14.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.99 173.14 13.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.555 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 92.49 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.366 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.486 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.3 m-85 -92.0 151.97 20.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' MET . . . . . 0.455 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.7 tmm? -119.91 129.19 54.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.873 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.45 95.84 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.159 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -79.24 139.06 38.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.469 ' CG1' HD12 ' A' ' 45' ' ' LEU . 61.5 t -136.92 134.22 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 42.7 tttt -123.25 167.18 14.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.482 ' CE2' ' HB1' ' A' ' 43' ' ' ALA . 10.9 t80 -154.5 105.55 2.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 64.8 42.96 4.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.09 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.418 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 13.2 m-20 63.35 32.94 14.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -142.69 105.11 4.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -56.98 111.79 1.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.454 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 46.3 pt -49.5 152.86 2.12 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 111.097 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 4.11 2.41 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.651 2.234 . . . . 0.0 112.365 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 49.7 mtt85 -115.04 -1.28 13.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.531 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -113.37 153.83 45.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.672 0.748 . . . . 0.0 110.863 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.3 Cg_endo -69.74 177.96 27.02 Favored 'Cis proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.351 -0.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.536 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 79.9 m-85 -116.93 140.83 49.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -100.2 111.46 23.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -121.52 103.45 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.078 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.3 tttp -81.91 103.25 11.44 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.61 143.14 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.07 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 74.7 mt -111.83 155.76 42.69 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.557 0.694 . . . . 0.0 110.964 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.493 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.85 123.54 10.18 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.656 2.237 . . . . 0.0 112.334 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 54.4 m -39.02 -25.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.493 ' N ' ' O ' ' A' ' 103' ' ' PRO . 10.3 m-85 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.5 t . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.843 0.354 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -131.73 97.62 18.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.611 0.72 . . . . 0.0 110.819 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 -1.75 9.0 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.645 2.23 . . . . 0.0 112.365 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -101.12 14.04 33.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.8 mmpt? -117.83 -8.38 10.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -84.31 132.4 31.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.119 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.2 mtmt -126.49 169.48 12.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.552 HD13 ' CZ ' ' A' ' 97' ' ' PHE . 37.3 pt -145.74 133.81 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.144 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.65 146.18 35.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 160.13 172.15 26.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -33.41 16.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.674 2.249 . . . . 0.0 112.366 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.45 -42.05 93.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.469 HD13 ' CD1' ' A' ' 16' ' ' ILE . 8.6 mt -80.43 -25.87 38.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.17 176.63 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.479 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.7 t -89.46 -16.58 30.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.976 0.417 . . . . 0.0 110.917 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.82 47.79 3.86 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.414 HG11 ' CD ' ' A' ' 31' ' ' GLN . 66.1 t -99.81 141.5 16.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.784 0.326 . . . . 0.0 111.156 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -117.64 151.54 37.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.67 152.41 42.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 55.32 40.2 31.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.27 144.37 34.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 14.7 tp -66.4 115.17 6.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.512 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 47.6 mm-40 -120.32 127.06 52.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.867 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -141.45 149.63 41.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.839 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 3.5 p90 -142.18 176.55 8.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 83.9 m -114.21 136.96 52.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.5 t -115.16 105.33 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.158 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -87.74 98.47 11.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.903 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 95.5 p -114.4 30.36 7.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.928 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 87.9 p -76.68 -34.68 58.21 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -76.6 -22.01 54.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.537 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -74.56 -41.34 60.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.075 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.427 ' C ' HD11 ' A' ' 42' ' ' LEU . . . 138.34 -147.04 18.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.482 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.48 HD11 ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -107.18 17.01 23.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.494 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -75.39 151.44 85.42 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.607 0.718 . . . . 0.0 111.112 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 167.56 24.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.26 . . . . 0.0 112.362 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.1 tp -125.88 139.72 53.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.961 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -117.01 146.69 42.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 58.4 t -139.51 134.22 39.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.137 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -140.79 141.12 34.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.859 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 98.9 t -123.32 127.49 74.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.056 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -125.11 124.57 42.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.77 167.87 47.49 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -47.78 0.86 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -71.44 -38.63 71.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.931 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.28 34.93 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.501 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.409 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 8.4 tp -94.44 149.21 21.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.87 0.367 . . . . 0.0 110.903 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.409 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.7 t -115.64 116.25 51.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.146 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -115.63 139.32 24.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.719 0.771 . . . . 0.0 110.851 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 174.74 9.03 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.771 2.314 . . . . 0.0 112.381 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.7 m -140.34 162.13 24.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.9 t30 -117.59 138.54 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.5 p -131.68 119.93 43.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.072 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 92.2 t -138.81 126.32 26.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -79.09 133.29 36.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.813 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -75.29 -46.51 33.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.884 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.15 -23.81 9.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.444 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.4 -44.15 10.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.891 0.376 . . . . 0.0 110.873 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.6 33.94 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.417 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.2 p -150.93 177.59 9.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.329 . . . . 0.0 111.144 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.4 m-70 -145.99 126.62 14.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 35.0 m -86.04 142.49 28.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.111 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.4 t -132.48 108.47 13.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.092 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 27.8 p -97.6 142.31 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.089 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.512 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 8.7 p90 -161.49 175.75 11.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.946 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -150.42 114.27 3.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.639 0.733 . . . . 0.0 111.137 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.483 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 89.09 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.697 2.265 . . . . 0.0 112.329 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 75' ' ' PRO . 44.4 t -35.67 -53.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -122.44 166.64 14.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.953 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -89.69 166.48 13.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.84 179.59 16.12 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.71 86.45 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.691 2.261 . . . . 0.0 112.345 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -76.93 171.66 14.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.1 ttp -143.8 113.25 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.06 96.11 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.084 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 2.0 m -81.46 145.52 30.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 88.7 t -139.29 138.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.094 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -125.92 170.19 11.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.923 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.537 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 8.2 t80 -155.24 110.69 3.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.962 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 61.63 39.77 14.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.115 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 65.52 35.52 7.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.828 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -145.49 105.02 3.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -53.44 118.01 3.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.414 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 47.0 pt -57.18 153.43 25.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.567 0.698 . . . . 0.0 111.163 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 5.15 1.82 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.665 2.244 . . . . 0.0 112.354 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 75.8 mtt85 -118.49 6.32 11.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.528 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -119.8 154.07 54.93 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.612 0.72 . . . . 0.0 110.835 -179.803 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.528 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.76 178.86 24.0 Favored 'Cis proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.717 -1.784 . . . . 0.0 112.318 0.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.552 ' CZ ' HD13 ' A' ' 16' ' ' ILE . 68.7 m-85 -115.5 126.56 54.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.4 ptmt -90.94 107.42 19.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.9 t -117.67 107.82 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.13 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -84.62 97.64 9.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.8 t -69.19 147.39 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.134 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 61.6 mt -112.24 155.51 43.45 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.641 0.734 . . . . 0.0 110.949 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.68 123.93 10.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.723 2.282 . . . . 0.0 112.31 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 103' ' ' PRO . 59.6 m -34.61 -32.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.192 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.488 ' N ' ' O ' ' A' ' 103' ' ' PRO . 15.6 m-85 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.964 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.885 0.374 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.29 96.21 25.4 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.63 0.729 . . . . 0.0 110.84 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.74 3.11 2.95 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 50.3 m -102.77 -0.29 31.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.0 mmpt? -103.94 -8.82 19.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.411 ' CG1' HG23 ' A' ' 92' ' ' ILE . 2.6 p -85.79 128.18 39.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.411 ' N ' ' HD3' ' A' ' 15' ' ' LYS . 1.2 mppt? -126.83 171.15 11.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.873 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.549 HD12 ' CE2' ' A' ' 97' ' ' PHE . 18.2 pt -144.08 135.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.99 126.58 17.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.3 171.38 38.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -32.58 18.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.637 2.225 . . . . 0.0 112.365 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.9 -36.05 65.41 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.403 HD13 ' CD1' ' A' ' 16' ' ' ILE . 4.7 mt -87.04 -15.5 38.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.851 0.358 . . . . 0.0 110.901 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.67 178.65 3.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.513 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 90.0 p -92.48 -11.77 33.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.96 46.03 3.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.455 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.421 HG13 ' N ' ' A' ' 26' ' ' ARG . 97.8 t -95.69 142.21 14.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 111.092 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.421 ' N ' HG13 ' A' ' 25' ' ' VAL . 95.1 mtt180 -118.55 153.65 33.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.845 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.51 145.36 47.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.072 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.6 mtt180 59.59 42.23 17.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.95 148.35 30.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.126 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -70.5 112.31 6.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mm-40 -117.43 128.95 55.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.4 t -148.41 161.16 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.486 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -151.85 -176.08 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.8 m -117.86 128.79 55.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.167 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.2 t -109.34 107.98 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.152 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -88.79 103.93 16.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.943 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.2 p -122.61 27.24 7.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 28.1 t -68.82 -37.32 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.872 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -81.07 -19.87 42.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.543 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -69.71 -37.5 76.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 131.58 -143.12 14.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.449 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.551 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -113.69 19.0 17.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.827 0.346 . . . . 0.0 110.875 -179.906 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.471 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -77.15 151.37 81.42 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.562 0.696 . . . . 0.0 111.153 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.452 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.6 Cg_endo -69.72 167.1 25.37 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 tp -127.29 130.97 50.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -118.57 143.91 46.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.826 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 81.8 t -137.44 124.56 29.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.152 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -115.07 149.04 38.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.462 HG23 ' CG2' ' A' ' 59' ' ' VAL . 48.6 t -123.7 120.59 60.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.211 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -96.68 175.21 6.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.34 159.73 24.17 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.478 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -41.75 4.06 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.689 2.26 . . . . 0.0 112.397 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.22 -14.9 34.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 114.58 36.58 1.28 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.439 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.4 tp -100.27 146.55 26.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 37.8 t -116.21 123.76 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.204 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.474 ' N ' ' OE1' ' A' ' 57' ' ' GLU . 27.1 mp0 -117.07 140.62 27.29 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.637 0.732 . . . . 0.0 110.853 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 176.96 6.11 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.659 2.239 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.462 ' CG2' HG23 ' A' ' 49' ' ' VAL . 61.8 t -144.29 160.16 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.152 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.45 ' N ' HG11 ' A' ' 59' ' ' VAL . 20.5 t30 -106.79 138.3 43.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 95.9 t -132.77 113.31 20.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 67.1 t -141.15 125.37 17.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -75.15 142.83 43.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -80.24 -43.2 21.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.5 -20.91 13.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.454 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -92.99 -39.44 11.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.887 0.375 . . . . 0.0 110.842 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.43 34.48 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.503 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.4 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 67.9 p -151.74 176.82 11.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.819 0.342 . . . . 0.0 111.146 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.4 ' CD2' ' C ' ' A' ' 68' ' ' THR . 18.4 m-70 -142.96 129.7 20.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.3 m -86.76 137.71 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.486 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 33.1 t -130.11 101.51 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 64.3 p -95.31 144.32 25.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.166 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.499 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 3.9 p90 -163.88 168.32 19.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -146.09 115.99 4.74 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.607 0.718 . . . . 0.0 111.161 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.499 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.0 Cg_endo -69.76 93.42 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.658 2.239 . . . . 0.0 112.357 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 t -34.77 -58.85 0.5 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -120.87 168.76 11.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -86.53 170.24 12.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.47 178.16 15.22 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 93.71 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.705 2.27 . . . . 0.0 112.352 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -94.91 171.55 8.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 ttp -147.72 120.26 8.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.21 96.49 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.415 ' C ' HG23 ' A' ' 85' ' ' VAL . 31.8 t -78.58 150.46 32.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.871 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.415 HG23 ' C ' ' A' ' 84' ' ' SER . 86.2 t -140.86 133.77 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.077 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 39.7 tttt -125.02 170.0 11.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.543 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 7.5 t80 -157.41 112.81 2.8 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.469 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 59.49 35.57 22.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.141 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 71.4 30.73 2.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -139.16 105.82 5.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.926 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -56.69 112.24 1.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.438 HD13 ' CZ ' ' A' ' 97' ' ' PHE . 44.5 pt -50.46 152.73 3.04 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.641 0.734 . . . . 0.0 111.141 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 4.27 2.33 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.422 ' O ' ' CE1' ' A' ' 97' ' ' PHE . 22.9 mmm180 -114.85 -1.26 13.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.805 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -113.51 154.27 45.56 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.607 0.717 . . . . 0.0 110.863 -179.745 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.1 Cg_endo -69.84 179.67 21.81 Favored 'Cis proline' 0 C--O 1.232 0.191 0 C-N-CA 122.646 -1.814 . . . . 0.0 112.299 0.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.549 ' CE2' HD12 ' A' ' 16' ' ' ILE . 85.9 m-85 -120.87 119.54 32.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.63 116.23 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.51 102.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -85.18 102.31 13.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.39 147.21 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.174 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.2 mt -117.54 154.81 50.76 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.604 0.716 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 123.81 10.46 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.716 2.277 . . . . 0.0 112.338 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.3 m -39.6 -30.33 0.07 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.139 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 -179.885 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.3 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.843 0.354 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.03 97.08 18.87 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.905 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 -2.05 9.54 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.719 2.279 . . . . 0.0 112.295 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 44.5 p -101.71 17.68 22.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.894 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 mmpt? -121.05 -7.37 9.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.881 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -84.66 128.49 38.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.16 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.6 mtpt -124.28 168.08 13.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.936 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.523 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 13.1 pt -144.83 134.79 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.173 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.07 130.58 22.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.041 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.64 168.82 35.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -32.09 19.18 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.298 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.4 -43.78 84.99 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.4 mt -78.33 -26.23 46.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -49.48 172.68 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.487 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.5 m -86.35 -18.62 31.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.822 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -82.83 45.46 3.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.519 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.471 HG11 ' N ' ' A' ' 26' ' ' ARG . 43.9 t -94.95 142.5 13.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.871 0.367 . . . . 0.0 111.102 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.471 ' N ' HG11 ' A' ' 25' ' ' VAL . 49.7 mtm180 -117.79 160.01 22.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -78.2 149.58 33.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.091 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 51.6 mtm-85 55.63 32.04 18.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.85 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.48 HG13 ' N ' ' A' ' 30' ' ' LEU . 61.4 t -121.48 140.02 46.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.11 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.48 ' N ' HG13 ' A' ' 29' ' ' VAL . 8.7 tp -65.8 110.84 2.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.532 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 54.7 mm-40 -113.12 133.12 55.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 22.1 t -146.37 154.35 41.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.535 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.1 p90 -148.13 -178.49 6.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.878 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.5 m -122.22 132.02 54.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.174 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.3 t -112.07 105.12 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.132 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -86.07 98.22 10.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 95.6 p -113.03 25.33 11.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.8 t -72.57 -37.49 68.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -74.39 -20.78 59.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.511 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -73.99 -38.67 64.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.063 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.58 -136.49 8.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.573 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.53 20.0 13.12 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.759 0.314 . . . . 0.0 110.839 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.47 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -76.99 151.67 82.02 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.556 0.693 . . . . 0.0 111.091 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 166.73 26.6 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.381 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.439 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.3 tp -124.72 135.13 52.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -116.9 145.86 43.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.941 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.466 ' CG1' HG12 ' A' ' 59' ' ' VAL . 60.2 t -134.18 147.68 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.125 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -152.07 133.29 14.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 87.6 t -116.92 124.98 73.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.43 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.2 mm? -123.65 121.67 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.946 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.21 172.83 8.81 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.487 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -48.44 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.707 2.271 . . . . 0.0 112.373 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -71.83 -39.2 69.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.84 32.79 0.12 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.506 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.447 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 9.1 tp -91.3 153.32 20.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.807 0.336 . . . . 0.0 110.92 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.447 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.8 t -115.37 130.08 70.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.068 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -133.12 140.85 38.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.699 0.761 . . . . 0.0 110.869 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 170.68 15.95 Favored 'Trans proline' 0 C--N 1.343 0.247 0 C-N-CA 122.617 2.211 . . . . 0.0 112.419 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 ' CG1' ' A' ' 47' ' ' VAL . 67.2 t -141.52 154.66 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -100.35 137.69 38.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.411 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 10.6 p -133.54 116.55 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 82.3 t -138.31 130.29 38.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.134 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -82.3 140.48 33.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -79.95 -45.33 18.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.09 -25.22 8.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -88.11 -41.63 12.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.877 0.37 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.96 34.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 62.3 p -149.35 177.5 9.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.139 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.6 m-70 -145.92 123.73 11.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 65.7 m -85.23 136.47 33.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.166 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.535 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.6 t -129.09 112.71 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.4 p -103.93 146.72 28.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.566 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.9 p90 -165.79 177.44 7.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.986 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.1 m -154.31 113.74 2.47 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.551 0.691 . . . . 0.0 111.109 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.566 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.2 Cg_endo -69.82 93.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.642 2.228 . . . . 0.0 112.333 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 75' ' ' PRO . 31.2 t -34.14 -59.78 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -116.35 167.81 10.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.937 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -83.76 166.26 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.836 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.78 169.31 12.32 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.98 91.24 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.605 2.203 . . . . 0.0 112.276 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -82.97 172.06 13.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 17.6 ttp -140.74 118.72 11.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.846 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 71.8 t -110.26 96.88 5.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.178 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.3 m -81.6 145.08 30.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.924 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.456 HG13 ' N ' ' A' ' 86' ' ' LYS . 98.0 t -138.75 137.29 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.456 ' N ' HG13 ' A' ' 85' ' ' VAL . 43.1 tttt -123.22 169.1 11.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.899 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.511 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 5.6 t80 -155.59 111.46 3.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.413 ' HB2' ' CB ' ' A' ' 43' ' ' ALA . . . 62.56 37.9 12.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.036 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.419 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 5.6 m-20 66.4 35.34 5.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.817 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -145.78 104.99 3.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -52.26 113.0 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.481 HD12 ' CE2' ' A' ' 97' ' ' PHE . 45.6 pt -51.37 153.14 3.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.604 0.716 . . . . 0.0 111.179 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 4.89 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.696 2.264 . . . . 0.0 112.326 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 20.1 mmt180 -116.98 1.54 12.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.841 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.527 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.09 154.34 48.51 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.661 0.743 . . . . 0.0 110.883 -179.798 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.2 Cg_endo -69.78 177.47 28.8 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.654 -1.811 . . . . 0.0 112.353 -0.022 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.523 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 86.9 m-85 -116.84 146.29 42.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.839 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.03 131.49 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.914 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 69.5 t -134.98 101.62 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.113 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -82.78 94.0 7.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.918 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -71.07 145.22 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.073 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 57.3 mt -118.77 155.82 52.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.634 0.731 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.2 Cg_endo -69.67 116.25 4.46 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.672 2.248 . . . . 0.0 112.408 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 52.1 m -34.01 -33.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.498 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.5 m-85 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.955 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.798 0.332 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -133.79 96.86 16.02 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.652 0.739 . . . . 0.0 110.801 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -1.5 8.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.642 2.228 . . . . 0.0 112.364 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 48.0 m -100.97 12.56 37.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.819 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.1 mmpt? -117.47 -9.16 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.38 135.84 24.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.116 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.405 ' C ' HG23 ' A' ' 16' ' ' ILE . 7.8 mtpm? -132.64 168.0 19.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.561 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 36.8 pt -144.33 135.37 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.98 133.14 26.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.056 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.01 175.36 40.13 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.445 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 -35.35 12.72 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.667 2.245 . . . . 0.0 112.362 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.36 -42.56 83.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.46 HD13 ' CD1' ' A' ' 16' ' ' ILE . 11.8 mt -77.45 -28.33 52.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.943 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.85 176.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 t -92.01 -18.03 24.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.906 0.384 . . . . 0.0 110.839 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.26 48.76 4.09 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.459 HG12 ' N ' ' A' ' 26' ' ' ARG . 59.5 t -94.11 140.56 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.336 . . . . 0.0 111.169 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.459 ' N ' HG12 ' A' ' 25' ' ' VAL . 52.4 mtt180 -118.46 148.63 42.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.51 42.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 44.7 mtp180 54.73 39.19 31.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 30' ' ' LEU . 42.6 t -134.79 143.15 38.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.154 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.456 ' N ' HG12 ' A' ' 29' ' ' VAL . 22.5 tp -66.24 114.43 5.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.973 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.492 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 42.3 mm-40 -117.73 128.3 54.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.2 t -139.86 164.82 28.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.822 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.556 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -157.86 167.89 28.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -107.3 131.19 54.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.468 ' CG2' HG22 ' A' ' 16' ' ' ILE . 58.1 t -111.41 105.27 18.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.083 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -88.5 103.17 15.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.9 p -117.96 26.12 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.817 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.1 t -71.67 -39.05 70.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.861 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -72.99 -22.09 60.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.472 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -72.26 -41.58 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.084 179.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 139.23 -136.67 8.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.596 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.22 18.24 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.839 0.352 . . . . 0.0 110.983 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.37 152.0 83.51 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.568 0.699 . . . . 0.0 111.102 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.81 166.79 26.46 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 0.0 112.272 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.455 HD11 ' CG1' ' A' ' 85' ' ' VAL . 3.5 tp -125.48 139.57 53.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.891 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -125.27 148.03 48.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.423 HG11 ' N ' ' A' ' 48' ' ' ARG . 40.2 t -140.82 152.12 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.111 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.423 ' N ' HG11 ' A' ' 47' ' ' VAL . 49.4 mtm-85 -153.16 138.53 17.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.893 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.446 HG22 ' CG2' ' A' ' 59' ' ' VAL . 93.4 t -118.31 124.09 72.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.1 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.413 ' N ' HD23 ' A' ' 50' ' ' LEU . 3.2 mm? -113.32 152.34 30.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.927 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.67 168.48 22.7 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.472 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.85 -44.74 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.675 2.25 . . . . 0.0 112.299 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -78.14 -29.67 48.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.37 28.38 0.48 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.476 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.4 tp -88.85 144.37 26.26 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -115.93 117.1 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.108 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -112.94 141.98 26.47 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.7 0.762 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 175.85 7.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.46 ' CG1' ' CG1' ' A' ' 71' ' ' VAL . 23.4 t -144.35 153.63 15.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.092 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.453 ' N ' HG11 ' A' ' 59' ' ' VAL . 13.2 t30 -99.63 139.16 35.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.832 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.1 t -133.26 108.38 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 86.4 t -131.51 129.67 62.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.1 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -84.13 133.65 34.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -74.42 -44.24 52.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.49 -25.2 9.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.3 m-20 -88.42 -44.38 10.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.908 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.33 33.49 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.513 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 73.3 p -147.64 177.13 9.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -145.4 131.56 19.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.3 m -92.81 134.94 34.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.556 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 39.3 t -129.7 106.36 13.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.145 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.7 p -103.67 140.82 37.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.195 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.566 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 15.7 p90 -156.78 -176.02 5.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -156.53 112.2 2.03 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 121.569 0.699 . . . . 0.0 111.081 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.566 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.81 90.22 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.695 2.263 . . . . 0.0 112.359 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 75' ' ' PRO . 27.8 m -33.85 -57.61 0.45 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.934 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -118.73 166.36 12.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -85.34 172.28 11.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.908 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.07 174.15 13.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.472 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.73 89.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.628 2.219 . . . . 0.0 112.386 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -86.25 164.35 17.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 39.7 ttp -137.32 119.02 15.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.8 t -105.07 95.91 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 41.3 t -80.51 143.26 33.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.455 ' CG1' HD11 ' A' ' 45' ' ' LEU . 87.0 t -139.25 142.98 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.446 ' N ' HG12 ' A' ' 85' ' ' VAL . 14.5 tttp -129.62 168.37 16.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 37' ' ' SER . 4.9 t80 -154.03 114.68 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 59.7 36.06 22.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.127 179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.429 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 0.8 OUTLIER 68.57 35.3 3.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.861 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -147.59 105.17 3.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -50.39 120.13 4.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.401 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 43.7 pt -58.62 153.93 37.94 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.634 0.73 . . . . 0.0 111.105 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 5.72 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.66 2.24 . . . . 0.0 112.39 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -119.81 8.17 11.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.531 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.84 153.71 60.42 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.5 Cg_endo -69.72 177.93 27.06 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.399 -0.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.561 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 52.2 m-85 -115.2 127.96 55.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.929 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.2 ptpt -87.72 110.07 20.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.99 101.64 9.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -83.11 103.64 12.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.5 t -70.22 143.72 14.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -112.26 155.91 42.86 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.584 0.707 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.494 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.77 121.29 7.98 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.688 2.258 . . . . 0.0 112.307 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 33.3 m -35.24 -31.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.188 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.6 m-85 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -128.46 95.33 33.22 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.627 0.727 . . . . 0.0 110.859 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.87 9.2 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.645 2.23 . . . . 0.0 112.37 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.4 p -99.71 9.06 43.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.811 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.9 mmpt? -113.06 -6.64 13.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.889 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -86.5 127.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.422 ' C ' HG22 ' A' ' 16' ' ' ILE . 26.4 mtmm -124.44 168.16 13.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.877 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.516 HD13 ' CE2' ' A' ' 97' ' ' PHE . 25.9 pt -144.07 136.34 22.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.165 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.54 144.96 33.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.094 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.34 177.06 30.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -39.67 6.21 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.689 2.259 . . . . 0.0 112.34 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.61 -30.26 13.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.454 ' CD1' HG13 ' A' ' 16' ' ' ILE . 15.1 mt -95.6 -22.52 17.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.862 0.363 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.47 164.67 5.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p -83.95 14.56 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.924 0.393 . . . . 0.0 110.898 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.9 44.25 1.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.415 HG13 ' NE2' ' A' ' 31' ' ' GLN . 76.3 t -95.65 149.12 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.849 0.357 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 93.0 mtt-85 -124.31 153.63 41.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.4 151.94 40.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 54.47 39.29 30.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.3 t -134.13 144.62 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.3 tp -66.85 113.9 5.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.918 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 48.2 mm-40 -117.43 130.03 56.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 25.0 t -143.74 163.32 33.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.835 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.513 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -154.88 -177.8 6.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.4 m -119.06 131.03 55.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.7 105.07 18.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.11 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -86.5 102.54 14.19 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.448 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.7 p -119.31 29.01 7.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.3 t -76.29 -34.53 59.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.3 mttp -80.17 -16.09 55.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.544 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -79.05 -38.25 36.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.128 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -141.4 12.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.559 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -114.98 19.02 16.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.763 0.316 . . . . 0.0 110.854 -179.908 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.451 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -76.24 151.47 83.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.606 0.717 . . . . 0.0 111.154 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 166.76 26.42 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.262 . . . . 0.0 112.376 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.432 HD13 ' CG1' ' A' ' 85' ' ' VAL . 5.3 tp -126.18 136.54 52.97 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.941 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -121.9 146.38 47.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 84.9 t -138.77 129.11 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.198 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.3 ttm-85 -125.05 140.26 53.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.438 HG21 ' CG2' ' A' ' 59' ' ' VAL . 92.1 t -119.82 116.97 52.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -115.37 125.69 53.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.28 175.23 15.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.465 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.0 Cg_endo -69.73 -43.27 2.79 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.31 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.422 ' HB2' ' NH1' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -75.3 -38.08 60.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.865 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.67 33.24 0.14 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.481 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.449 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 6.4 tp -90.33 155.84 18.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 110.937 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.449 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 91.9 t -117.94 118.65 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -117.38 143.37 31.91 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.679 0.752 . . . . 0.0 110.886 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 168.18 22.32 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.688 2.259 . . . . 0.0 112.359 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.438 ' CG2' HG21 ' A' ' 49' ' ' VAL . 3.5 t -140.59 144.49 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.125 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -93.12 138.41 31.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -133.23 117.97 30.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 80.4 t -135.55 138.44 48.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -89.63 138.54 31.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.865 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -81.45 -46.38 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.58 -25.08 9.3 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.531 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -87.94 -43.63 11.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.821 0.343 . . . . 0.0 110.785 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.56 33.85 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.431 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.547 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.8 p -150.43 177.66 9.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.822 0.344 . . . . 0.0 111.114 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.547 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.9 m-70 -145.7 127.36 15.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 54.6 m -86.38 132.5 33.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.145 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.513 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.1 t -125.58 111.01 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.081 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 61.9 p -102.38 147.02 27.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.108 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.54 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.6 p90 -165.36 173.47 11.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.6 m -149.49 113.87 3.51 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.577 0.703 . . . . 0.0 111.125 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.54 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.79 93.3 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.702 2.268 . . . . 0.0 112.292 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 3.7 m -34.26 -45.52 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.882 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -135.29 170.76 15.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.404 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.1 pp20? -86.2 177.63 7.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.33 173.98 14.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 83.45 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.684 2.256 . . . . 0.0 112.343 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.465 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.8 m-85 -78.43 172.53 13.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.947 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.6 ttp -143.68 115.61 8.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.827 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.1 t -104.36 95.4 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.129 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 33.8 t -77.32 147.26 36.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.432 ' CG1' HD13 ' A' ' 45' ' ' LEU . 49.4 t -139.93 137.44 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.079 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.417 ' N ' HG12 ' A' ' 85' ' ' VAL . 17.3 tttp -128.65 169.36 14.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.544 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 5.2 t80 -155.0 110.76 3.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.451 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 60.71 39.79 17.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.044 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.408 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 39.3 m-20 67.15 32.66 6.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.968 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -142.55 105.22 4.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -53.79 116.89 2.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.414 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 45.5 pt -56.13 153.12 19.45 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.593 0.711 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 4.69 2.05 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.653 2.235 . . . . 0.0 112.421 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 39.3 mmt180 -117.19 4.53 12.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.909 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.53 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -117.96 153.98 51.24 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.672 0.749 . . . . 0.0 110.873 -179.85 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.8 -178.83 17.64 Favored 'Cis proline' 0 C--N 1.341 0.15 0 C-N-CA 122.756 -1.768 . . . . 0.0 112.303 0.089 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.516 ' CE2' HD13 ' A' ' 16' ' ' ILE . 77.4 m-85 -118.48 125.38 49.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 29.8 pttt -83.52 109.87 17.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 94.7 t -123.36 101.86 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.099 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 12.5 tttp -84.19 94.08 8.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.992 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.404 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 63.4 t -63.39 145.94 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 65.9 mt -111.23 155.95 41.86 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.554 0.692 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.72 122.4 9.09 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.7 2.266 . . . . 0.0 112.33 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -34.12 -35.21 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.461 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.841 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.8 t . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.794 0.33 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 m-20 -121.15 98.22 47.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.623 0.725 . . . . 0.0 110.862 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.74 2.4 3.55 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.684 2.256 . . . . 0.0 112.389 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 51.0 m -97.43 -6.74 33.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.453 ' HB3' ' CB ' ' A' ' 39' ' ' LYS . 8.0 mmmm -96.48 -7.09 35.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.917 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.464 ' CG1' HG22 ' A' ' 92' ' ' ILE . 2.3 p -89.37 124.12 41.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.423 ' C ' HG22 ' A' ' 16' ' ' ILE . 8.1 mtmp? -127.27 169.15 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.562 HD12 ' CE2' ' A' ' 97' ' ' PHE . 29.9 pt -141.66 133.31 27.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.101 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.79 129.09 22.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 175.51 42.08 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.86 -34.33 14.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.704 2.27 . . . . 0.0 112.28 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.19 -32.5 67.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.469 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.8 mt -91.64 -14.54 29.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.65 -175.12 4.31 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.495 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.8 t -95.61 -15.59 22.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.906 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.03 47.15 3.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.472 HG11 ' N ' ' A' ' 26' ' ' ARG . 55.4 t -97.0 142.39 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 111.197 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.472 ' N ' HG11 ' A' ' 25' ' ' VAL . 66.9 mtt180 -119.4 150.8 39.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.42 152.57 42.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.079 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.4 mtp180 52.81 41.66 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.932 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.9 t -135.14 149.23 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.0 tp -69.41 113.11 6.42 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.459 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 28.9 mm-40 -118.9 126.75 52.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.887 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 35.1 t -142.17 161.87 36.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.878 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.539 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.4 p90 -151.65 -176.16 5.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.918 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 90.1 m -118.27 134.73 54.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.443 ' CG1' HD23 ' A' ' 45' ' ' LEU . 40.4 t -113.85 105.91 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.11 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -90.62 109.85 21.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -126.45 27.76 6.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.8 m -70.13 -36.39 74.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.453 ' CB ' ' HB3' ' A' ' 13' ' ' LYS . 39.4 mtmt -84.44 -7.7 59.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.912 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.504 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -81.88 -34.72 29.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.07 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.26 -139.56 11.14 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.478 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.453 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.75 19.83 14.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.813 0.34 . . . . 0.0 110.864 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.551 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -77.74 150.21 78.53 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.625 0.726 . . . . 0.0 111.042 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.461 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 54.4 Cg_endo -69.75 168.55 21.2 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.68 2.254 . . . . 0.0 112.386 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.443 HD23 ' CG1' ' A' ' 35' ' ' VAL . 7.4 tp -127.52 128.73 46.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -108.75 155.06 21.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.953 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 65.5 t -141.58 135.97 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 -142.37 142.06 32.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.966 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.46 HG21 ' CG1' ' A' ' 59' ' ' VAL . 60.9 t -124.37 131.24 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.158 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.444 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.0 mm? -102.5 179.24 4.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -128.05 153.6 19.48 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.49 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -26.02 27.78 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.695 2.263 . . . . 0.0 112.293 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.36 12.58 10.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.95 27.92 8.05 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 15.0 tp -94.35 145.34 24.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.399 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -115.5 140.71 35.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.158 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -131.29 145.63 58.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.597 0.713 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 172.64 12.3 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.294 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.46 ' CG1' HG21 ' A' ' 49' ' ' VAL . 3.7 m -144.21 159.66 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.142 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -123.04 140.97 52.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.8 p -133.39 117.03 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.142 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.7 t -139.47 132.04 36.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.093 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -80.2 136.21 36.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -75.04 -42.32 57.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.95 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.82 -23.04 15.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -90.44 -43.28 10.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 33.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.509 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.9 p -151.71 177.75 10.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.8 m-70 -141.73 127.05 18.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.939 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.0 m -86.79 139.88 30.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.164 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.539 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.7 t -131.45 107.69 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -95.43 141.46 28.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.544 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.9 p90 -159.44 167.46 28.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.6 m -145.28 113.67 4.82 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.58 0.705 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.544 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.9 Cg_endo -69.69 94.62 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.684 2.256 . . . . 0.0 112.392 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' PRO . 5.7 m -34.16 -55.4 0.5 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -130.33 158.96 38.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.911 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -72.37 172.95 9.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.925 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.82 176.2 14.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 84.06 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.723 2.282 . . . . 0.0 112.312 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -82.68 173.85 11.53 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 ttp -150.77 129.81 12.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.911 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -115.88 97.99 6.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -80.72 132.71 35.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.774 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 99.0 t -128.25 134.55 64.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.145 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -124.11 167.25 14.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.551 ' CZ ' ' O ' ' A' ' 43' ' ' ALA . 11.9 t80 -153.96 105.61 2.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 66.49 42.65 2.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.13 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.0 33.52 14.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -143.19 105.72 4.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -55.06 112.59 1.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.511 HD13 ' CE2' ' A' ' 97' ' ' PHE . 44.8 pt -50.42 152.99 2.83 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.6 0.714 . . . . 0.0 111.152 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.437 ' HG2' ' NH1' ' A' ' 94' ' ' ARG . 54.5 Cg_endo -69.73 8.3 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.716 2.277 . . . . 0.0 112.368 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . 0.481 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 0.6 OUTLIER -120.7 -2.47 9.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.516 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.3 t -111.56 152.55 44.09 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.675 0.75 . . . . 0.0 110.844 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.516 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.77 175.17 37.64 Favored 'Cis proline' 0 C--O 1.231 0.153 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.317 0.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . 0.562 ' CE2' HD12 ' A' ' 16' ' ' ILE . 82.4 m-85 -115.45 117.7 31.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -77.97 115.56 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.871 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.5 t -128.01 103.91 11.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 24.3 ttpt -83.32 99.27 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.929 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.3 t -68.51 145.67 13.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.118 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.3 mt -112.08 155.32 43.59 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.631 0.729 . . . . 0.0 110.875 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' TYR . 52.9 Cg_endo -69.83 121.7 8.37 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.246 . . . . 0.0 112.319 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.1 m -33.87 -36.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.173 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.446 ' N ' ' O ' ' A' ' 103' ' ' PRO . 31.3 m-85 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.986 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 112.494 -0.243 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.8 t -90.03 114.92 26.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.959 0.409 . . . . 0.0 110.818 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 84.2 p -145.55 135.8 23.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.874 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 118.62 148.82 8.53 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.495 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 t -125.1 96.89 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.888 0.375 . . . . 0.0 110.891 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.9 t -148.47 145.95 28.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.827 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.33 50.32 0.89 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.423 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.4 p -93.08 155.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.933 0.397 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.6 t -98.25 125.66 51.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.211 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -118.23 94.96 47.82 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.569 0.699 . . . . 0.0 110.883 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -0.11 6.45 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.77 2.313 . . . . 0.0 112.312 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.7 m -99.12 1.87 45.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.852 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -104.65 -6.76 20.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.405 ' CG1' HG21 ' A' ' 92' ' ' ILE . 2.9 p -90.12 129.31 41.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.115 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.416 ' C ' HG22 ' A' ' 16' ' ' ILE . 0.5 OUTLIER -130.27 176.19 8.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.833 179.934 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.557 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 13.2 pt -145.61 134.59 17.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.158 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.98 120.74 13.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.087 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.52 168.76 40.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -26.48 27.54 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.723 2.282 . . . . 0.0 112.292 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.76 -25.58 70.57 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.484 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.8 mt -98.73 -9.98 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.08 -178.48 14.6 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.528 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.8 m -91.58 -6.93 51.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.905 0.383 . . . . 0.0 110.863 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.4 47.24 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.491 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.442 HG12 ' NE2' ' A' ' 31' ' ' GLN . 88.1 t -98.01 139.85 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 111.105 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.434 ' N ' HG12 ' A' ' 25' ' ' VAL . 80.8 mtt-85 -121.97 146.23 47.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.826 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.28 151.82 39.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.085 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.2 mtt180 53.83 37.0 25.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.904 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.2 t -127.47 148.82 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.169 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.4 tp -71.56 111.38 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.462 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 36.5 mm-40 -114.92 127.48 55.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.8 t -144.44 155.86 43.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.522 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.2 p90 -148.02 -178.21 6.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.866 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -121.17 129.88 53.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.6 t -108.26 106.37 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -88.98 111.82 22.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.9 p -128.11 24.41 5.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 t -68.36 -34.71 76.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.25 -8.24 57.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.556 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -83.0 -35.33 25.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.12 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.29 -144.07 15.36 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.415 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -110.43 17.71 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.796 0.332 . . . . 0.0 110.917 -179.906 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.515 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.01 148.65 81.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.579 0.704 . . . . 0.0 111.095 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 167.67 23.77 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.68 2.253 . . . . 0.0 112.317 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.9 tp -125.43 127.32 46.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -110.95 148.42 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.92 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 35.7 t -139.45 153.9 24.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.405 ' NH2' HG23 ' A' ' 56' ' ' VAL . 18.5 mtp85 -157.36 138.04 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.88 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.403 ' C ' HD21 ' A' ' 50' ' ' LEU . 77.2 t -117.98 116.65 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.095 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.456 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.4 mm? -110.98 123.28 49.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.95 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.22 178.56 1.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.499 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.557 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.5 Cg_endo -69.77 -39.2 6.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.628 2.219 . . . . 0.0 112.365 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.21 -28.77 22.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.843 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.9 34.37 0.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.53 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.423 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 18.1 tp -83.16 156.45 23.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.898 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 12.7 p -119.46 111.72 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.15 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -112.8 143.5 29.18 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 110.875 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 169.41 19.04 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.676 2.251 . . . . 0.0 112.336 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.5 m -142.65 157.07 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 36.6 t30 -109.63 143.51 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.13 120.82 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 97.8 t -136.08 132.12 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.134 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -87.04 128.75 35.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.911 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -71.37 -42.1 68.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.868 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.14 -20.95 25.44 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.83 -42.74 9.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.47 36.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.496 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 64.7 p -153.11 176.38 11.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.14 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -143.92 133.99 24.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.2 m -96.35 132.9 41.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.134 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.522 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.2 t -126.37 108.16 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.135 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 51.8 p -98.28 142.26 30.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.106 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.498 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 7.2 p90 -159.73 169.28 24.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -145.04 113.77 4.91 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.64 0.733 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.498 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.73 97.12 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.374 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 75' ' ' PRO . 57.8 p -35.35 -47.98 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -132.08 -175.54 3.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.442 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.5 pp20? -101.47 170.27 8.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.5 176.81 14.57 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.533 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 88.07 0.55 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.557 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.4 m-85 -85.21 173.67 10.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.942 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 23.6 ttp -146.62 117.49 7.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.919 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 63.0 t -107.56 100.26 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.0 t -84.46 148.48 26.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.8 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.3 t -142.57 138.85 28.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.079 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -126.52 169.27 13.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.556 ' CE2' ' HB1' ' A' ' 40' ' ' ALA . 11.8 t80 -156.45 105.0 2.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 66.81 42.04 2.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.058 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 64.0 32.93 12.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.899 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -143.11 105.01 4.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.953 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -54.54 109.5 0.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.432 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 47.5 pt -47.52 152.95 1.09 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.648 0.737 . . . . 0.0 111.122 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 3.93 2.48 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.629 2.219 . . . . 0.0 112.374 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 39.1 mmt-85 -113.31 -4.15 13.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.533 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -111.84 154.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.685 0.755 . . . . 0.0 110.838 -179.787 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.533 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.7 -179.97 20.55 Favored 'Cis proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 -1.797 . . . . 0.0 112.353 -0.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.557 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 86.5 m-85 -120.62 118.86 31.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -82.06 105.16 12.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.7 t -116.38 105.21 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 43.8 tttm -82.49 102.55 11.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.491 HG23 ' CD1' ' A' ' 81' ' ' TYR . 38.9 t -70.21 150.73 9.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.113 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.53 153.84 52.16 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.598 0.713 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.87 122.65 9.3 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.681 2.254 . . . . 0.0 112.305 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 53.5 m -34.7 -34.51 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.173 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.458 ' N ' ' O ' ' A' ' 103' ' ' PRO . 64.9 m-85 -97.86 120.0 37.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -85.96 120.43 27.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.7 78.85 8.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.846 -179.787 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 3' ' ' SER . 82.1 p -130.17 167.05 19.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.855 0.359 . . . . 0.0 110.884 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 2' ' ' SER . 78.7 p 36.77 42.26 0.21 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.871 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -77.74 -98.09 0.2 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.1 t -82.33 109.89 17.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.902 0.382 . . . . 0.0 110.845 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 87.7 p -163.6 155.1 16.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.46 83.41 0.16 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.428 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.464 HG21 ' N ' ' A' ' 9' ' ' VAL . 11.7 p -123.89 148.71 27.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.889 0.376 . . . . 0.0 111.16 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.464 ' N ' HG21 ' A' ' 8' ' ' VAL . 37.5 t -92.61 130.28 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.152 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -128.89 95.73 31.08 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -2.73 10.65 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.752 2.301 . . . . 0.0 112.316 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.7 p -98.99 9.31 43.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.796 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -113.79 -7.65 13.23 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -83.85 125.1 40.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.109 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -120.9 173.66 7.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.509 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 38.1 pt -147.02 137.6 17.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.72 138.22 32.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.084 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.3 168.84 27.0 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -30.97 21.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.668 2.245 . . . . 0.0 112.354 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.55 -46.65 58.55 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.483 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.0 mt -76.64 -28.63 56.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.875 0.369 . . . . 0.0 110.982 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -47.62 169.83 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.479 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 69.7 m -87.06 -7.92 57.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -93.7 49.21 2.3 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.449 HG12 ' NE2' ' A' ' 31' ' ' GLN . 70.1 t -101.05 142.31 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.772 0.32 . . . . 0.0 111.15 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 57.0 mtt180 -118.33 147.89 43.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -67.71 149.61 49.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 56.18 40.73 30.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.458 ' N ' HG23 ' A' ' 74' ' ' THR . 53.6 t -133.62 148.11 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.099 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 18.6 tp -68.18 114.52 6.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.449 ' NE2' HG12 ' A' ' 25' ' ' VAL . 44.4 mm-40 -120.64 128.36 52.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.927 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.3 t -144.9 150.69 37.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.54 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 1.4 p90 -139.58 -178.29 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -121.0 133.78 55.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.12 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.6 t -115.34 107.57 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -91.33 106.86 18.81 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.451 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.1 p -117.01 20.4 13.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 50.6 p -63.05 -42.52 99.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? -77.03 -15.06 59.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.6 -32.38 47.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.062 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.01 -140.11 11.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.504 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.68 22.69 12.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.858 0.361 . . . . 0.0 110.949 -179.933 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.441 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -79.27 151.64 75.48 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.708 . . . . 0.0 111.074 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 167.05 25.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.659 2.239 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.7 tp -125.78 139.06 53.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.981 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -121.24 145.26 48.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.9 t -134.22 141.18 44.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -146.64 130.99 17.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.417 HG22 ' CG1' ' A' ' 59' ' ' VAL . 82.0 t -116.21 125.15 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -115.07 144.2 44.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.72 169.7 43.1 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.552 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -31.74 19.91 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.624 2.216 . . . . 0.0 112.369 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -95.36 -27.37 15.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.881 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 133.28 27.46 0.56 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.8 tp -86.79 148.66 25.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.895 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.3 t -110.96 121.54 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.123 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -112.62 142.92 27.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.641 0.734 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.18 22.24 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.337 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 49' ' ' VAL . 5.7 m -141.74 157.55 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -115.32 140.92 48.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.861 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 84.5 t -132.22 107.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.12 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -131.64 119.13 41.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.136 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t0 -76.07 133.47 40.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.859 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.477 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 7.1 m-80 -72.37 -43.33 64.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.71 -24.7 10.09 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.437 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -86.99 -39.1 15.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.78 34.21 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.552 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.479 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 72.6 p -150.16 176.74 10.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.837 0.351 . . . . 0.0 111.144 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.479 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.4 m-70 -145.78 131.18 18.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.859 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 21.9 m -91.61 139.58 30.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.54 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 99.3 t -129.59 102.32 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.111 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 46.7 p -92.51 138.81 31.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.173 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -164.01 160.78 22.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.458 HG23 ' N ' ' A' ' 29' ' ' VAL . 84.9 m -137.98 117.27 9.88 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.607 0.718 . . . . 0.0 111.152 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' SER . 53.8 Cg_endo -69.74 90.45 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.689 2.259 . . . . 0.0 112.305 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' PRO . 64.6 p -34.97 -53.6 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.881 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -122.22 158.39 29.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pp20? -79.7 174.95 11.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.948 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.35 177.16 14.89 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.516 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 86.59 0.59 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.623 2.216 . . . . 0.0 112.32 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -79.07 169.75 17.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -145.16 119.08 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.892 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.1 t -110.89 97.12 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.141 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.4 m -81.4 142.56 32.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 87.2 t -135.61 145.14 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.403 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 23.7 tttt -132.35 168.66 17.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.451 ' CZ ' ' HB2' ' A' ' 37' ' ' SER . 7.1 t80 -154.39 105.74 2.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.969 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 63.49 44.39 5.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.186 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.403 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.1 m-20 63.2 33.3 14.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -142.49 105.06 4.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -56.21 111.62 1.01 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.481 HD12 ' CE2' ' A' ' 97' ' ' PHE . 47.7 pt -49.24 153.2 1.78 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.59 0.709 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 4.41 2.16 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.664 2.243 . . . . 0.0 112.377 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.4 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 9.4 mtm-85 -116.18 0.09 12.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -115.21 153.32 47.36 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.644 0.735 . . . . 0.0 110.803 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.5 Cg_endo -69.76 171.26 54.53 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.35 -0.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.509 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 87.1 m-85 -109.78 140.8 43.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.3 ptmm? -100.75 110.32 22.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 98.9 t -119.44 101.95 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.1 tttm -81.0 101.6 9.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.9 t -73.22 147.66 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.128 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.8 mt -114.96 154.79 47.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 0.0 110.86 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.0 Cg_endo -69.74 124.16 10.82 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.671 2.247 . . . . 0.0 112.346 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.407 ' C ' ' O ' ' A' ' 103' ' ' PRO . 51.5 m -36.34 -30.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.185 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.479 ' N ' ' O ' ' A' ' 103' ' ' PRO . 70.1 m-85 -102.17 143.56 31.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.882 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.9 p-10 -109.06 121.79 45.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.916 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.419 ' O ' ' C ' ' A' ' 108' ' ' SER . . . -111.66 78.73 1.14 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 107' ' ' ALA . 1.5 t . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.78 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 96.0 p -159.99 125.94 4.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.855 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 m -61.21 148.54 40.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.845 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.4 -129.37 2.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.557 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.6 t -94.64 138.55 32.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.948 0.404 . . . . 0.0 110.781 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -69.48 90.54 0.54 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.08 69.4 0.27 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.486 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.435 HG23 ' N ' ' A' ' 9' ' ' VAL . 9.6 p -132.84 143.63 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.897 0.38 . . . . 0.0 111.1 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.435 ' N ' HG23 ' A' ' 8' ' ' VAL . 59.3 t -108.33 133.88 51.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.117 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -132.7 95.94 19.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.6 0.714 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 -0.81 7.36 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.705 2.27 . . . . 0.0 112.412 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 55.8 p -99.92 7.62 44.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.932 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.3 mmpt? -112.16 -9.62 13.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.2 p -84.32 121.77 37.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -118.12 173.68 6.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.526 ' CD1' ' CZ ' ' A' ' 97' ' ' PHE . 23.1 pt -146.86 135.93 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.185 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.59 156.57 45.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.059 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 143.07 177.02 17.67 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.86 -33.76 15.56 Favored 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.662 2.241 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -53.57 -23.5 20.66 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.538 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.423 ' CD1' HG13 ' A' ' 16' ' ' ILE . 7.7 mt -109.67 -19.95 13.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.88 0.372 . . . . 0.0 110.925 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -59.83 166.81 9.48 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.6 m -82.6 11.22 6.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.881 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.83 43.4 1.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.409 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.461 HG11 ' NE2' ' A' ' 31' ' ' GLN . 59.7 t -101.97 143.85 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.908 0.385 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -124.68 155.48 39.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.866 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.7 150.32 43.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.7 mtm-85 57.26 37.78 28.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.12 147.76 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.085 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.9 tp -69.0 113.14 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.498 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 51.0 mm-40 -117.76 130.9 56.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 36.0 t -144.83 150.89 37.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.875 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.546 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 8.7 p90 -141.52 176.88 8.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 60.5 m -119.43 135.88 54.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.175 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.22 105.97 19.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.056 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -84.93 103.32 13.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.86 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 81.2 p -116.88 25.68 10.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 p -73.68 -29.76 62.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.854 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 30.5 mmtm -90.37 -5.47 56.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.919 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.521 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -89.46 -34.68 16.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.65 -140.18 11.6 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.396 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.34 20.98 12.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.798 0.332 . . . . 0.0 110.895 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.52 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -79.34 151.37 75.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.598 0.713 . . . . 0.0 111.049 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.9 20.14 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.745 2.296 . . . . 0.0 112.373 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.437 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.7 tp -132.0 135.4 46.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.918 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -112.19 152.97 27.75 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.72 132.91 41.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 48.8 mtm180 -139.11 132.75 30.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 59' ' ' VAL . 81.6 t -117.18 121.28 67.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 10.8 mt -116.94 129.29 55.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.27 175.03 40.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.534 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.416 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.79 -32.62 18.08 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.712 2.275 . . . . 0.0 112.308 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.29 -25.87 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.887 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 130.84 22.86 1.0 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.499 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 16.7 tp -74.08 149.04 41.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 0.0 110.838 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.3 t -113.7 112.93 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -113.15 141.63 26.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.611 0.719 . . . . 0.0 110.893 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 174.88 8.86 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.623 2.215 . . . . 0.0 112.362 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.445 ' CG1' HG21 ' A' ' 49' ' ' VAL . 8.9 m -144.32 162.83 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 19.0 t30 -119.49 145.02 46.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.896 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -132.46 120.48 42.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.59 122.58 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -82.17 127.23 32.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.926 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -71.76 -47.71 51.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.52 -16.17 24.25 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -95.14 -38.22 10.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.963 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.69 33.97 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.457 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.6 p -152.76 176.15 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 111.175 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.457 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.2 m-70 -145.85 130.7 18.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.968 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.7 m -92.89 139.78 30.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.157 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.546 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 36.9 t -131.22 108.94 15.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.171 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.3 p -93.34 146.42 23.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.103 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.533 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 9.3 p90 -163.26 166.87 22.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.5 m -144.22 110.64 5.05 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 121.612 0.72 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.533 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.73 91.9 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.724 2.283 . . . . 0.0 112.315 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 22.8 t -34.21 -50.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.801 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -129.62 173.61 10.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.888 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.92 170.21 10.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.861 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.73 172.59 13.18 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.461 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 90.85 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.704 2.27 . . . . 0.0 112.367 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.416 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.0 m-85 -85.07 161.65 19.61 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -131.42 112.8 13.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.842 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.3 t -103.51 95.98 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.8 t -79.34 145.7 33.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.437 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.1 t -143.54 130.13 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.137 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.3 tttt -118.13 169.81 9.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.521 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 6.3 t80 -156.89 106.12 2.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 66.3 40.79 3.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.13 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.99 34.57 11.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.856 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -145.7 105.03 3.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -54.17 114.53 1.65 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.863 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.45 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 48.2 pt -52.12 152.81 5.36 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.574 0.702 . . . . 0.0 111.178 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 4.29 2.27 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.701 2.267 . . . . 0.0 112.296 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -116.13 1.33 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.848 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.53 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -115.23 153.83 47.38 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.683 0.754 . . . . 0.0 110.825 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.69 -179.41 18.97 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.392 -0.132 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.526 ' CZ ' ' CD1' ' A' ' 16' ' ' ILE . 85.2 m-85 -119.45 123.38 43.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.912 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 8.5 pttp -83.89 96.77 8.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 86.9 t -102.28 103.99 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.103 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 23.9 ttpt -85.0 102.53 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.87 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.4 t -75.38 143.43 13.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.134 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 33.8 mt -107.79 154.51 40.92 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.52 0.676 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.7 Cg_endo -69.7 122.51 9.2 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.3 m -33.97 -36.21 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.44 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.8 m-85 -76.21 139.1 41.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.865 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -155.7 116.94 3.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -101.73 80.51 2.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.139 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.802 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 87.8 p 41.72 41.89 1.92 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.874 0.369 . . . . 0.0 110.906 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.6 m -79.2 92.18 5.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.864 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -46.6 139.62 7.21 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.465 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 95.2 p -165.41 135.02 3.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.788 0.328 . . . . 0.0 110.851 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 97.8 p -124.81 148.77 47.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 67.97 90.07 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.497 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 9' ' ' VAL . 7.3 p -137.19 139.62 43.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.368 . . . . 0.0 111.131 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.466 ' N ' HG22 ' A' ' 8' ' ' VAL . 53.3 t -120.9 134.46 64.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.156 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -131.85 96.86 19.6 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.799 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -0.43 6.89 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.676 2.251 . . . . 0.0 112.337 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -99.38 6.95 45.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -112.99 -7.2 13.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.33 126.93 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.413 ' C ' HG23 ' A' ' 16' ' ' ILE . 21.7 mtmm -125.57 170.37 11.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.926 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.572 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 41.1 pt -145.25 137.01 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.173 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.21 143.26 34.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.076 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.0 169.97 24.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.72 -29.71 23.63 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.703 2.268 . . . . 0.0 112.343 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.59 -45.93 94.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.467 HD13 ' CD1' ' A' ' 16' ' ' ILE . 12.5 mt -73.91 -26.9 60.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.876 0.369 . . . . 0.0 110.933 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.16 169.35 0.36 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.501 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.5 p -85.26 -7.78 58.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.914 0.388 . . . . 0.0 110.841 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.67 44.7 2.73 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.508 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.456 HG12 ' NE2' ' A' ' 31' ' ' GLN . 97.7 t -92.15 143.0 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.831 0.348 . . . . 0.0 111.181 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.415 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . 46.5 mtm180 -118.33 156.17 29.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.52 147.08 44.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 82.5 mtm-85 54.94 35.79 25.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.415 ' CG2' ' HB2' ' A' ' 26' ' ' ARG . 23.3 t -121.71 151.84 25.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.126 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.402 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 7.9 tp -75.62 109.33 9.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.456 ' NE2' HG12 ' A' ' 25' ' ' VAL . 40.7 mm-40 -112.72 127.64 56.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 23.1 t -143.85 149.51 37.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.441 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 9.8 p90 -145.85 171.25 15.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -110.68 130.61 55.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.46 ' CG2' HG22 ' A' ' 16' ' ' ILE . 100.0 t -108.55 107.05 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.126 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -90.56 106.73 18.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 86.8 p -121.87 25.95 8.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.915 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 78.1 p -71.25 -35.85 71.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.861 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -80.02 -14.91 58.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.918 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.497 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -78.29 -38.2 43.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.13 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -138.19 9.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.609 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.19 17.73 13.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.885 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -75.92 151.52 84.29 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.525 0.679 . . . . 0.0 111.119 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 166.87 26.0 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.703 2.269 . . . . 0.0 112.362 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.47 HD12 ' CG1' ' A' ' 85' ' ' VAL . 4.7 tp -122.92 136.33 54.82 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -119.21 139.47 51.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.885 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -130.73 144.44 37.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.079 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 20.1 ttm180 -148.11 141.8 25.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -122.78 122.04 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.138 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -108.13 151.34 26.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.44 167.35 32.5 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.471 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -29.84 23.47 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.18 3.62 12.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.55 62.98 0.5 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.542 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.1 tp -120.48 134.75 55.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.872 0.368 . . . . 0.0 110.911 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.1 t -102.78 129.78 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.157 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -134.46 141.43 38.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.655 0.741 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 168.47 21.41 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.689 2.259 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.7 t -142.64 151.61 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -100.82 138.52 37.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.85 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.2 p -133.43 112.47 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.181 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 66.1 t -133.4 127.61 54.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -84.08 130.87 34.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.423 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 8.1 m-80 -72.21 -46.14 57.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.24 -22.21 11.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -88.6 -40.59 13.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.814 0.34 . . . . 0.0 110.852 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.28 33.99 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.509 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.575 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.7 p -150.2 175.39 11.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.876 0.369 . . . . 0.0 111.107 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.575 ' CD2' ' C ' ' A' ' 68' ' ' THR . 6.2 m-70 -147.0 125.21 12.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 38.8 m -85.7 141.28 29.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.441 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.0 t -131.13 104.56 9.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.9 p -96.89 135.13 39.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.132 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.51 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.6 p90 -155.4 175.05 14.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.913 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 89.7 m -151.71 117.18 3.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.526 0.679 . . . . 0.0 111.109 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.51 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.3 Cg_endo -69.77 98.12 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.723 2.282 . . . . 0.0 112.357 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' PRO . 1.5 t -34.32 -60.3 0.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.883 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -127.36 164.19 22.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -72.73 167.36 20.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 132.46 171.08 12.68 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.443 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 92.76 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.678 2.252 . . . . 0.0 112.363 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -87.94 173.99 8.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 18.3 ttp -148.5 117.17 6.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.79 96.64 4.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.101 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -79.0 144.71 34.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.872 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.47 ' CG1' HD12 ' A' ' 45' ' ' LEU . 55.7 t -139.58 135.91 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -126.47 169.62 12.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.497 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 5.9 t80 -155.71 117.9 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 57.04 31.58 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.126 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.0 t70 74.22 31.74 1.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -141.79 106.69 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -53.73 114.89 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.434 HD12 ' CE1' ' A' ' 97' ' ' PHE . 43.4 pt -53.49 152.79 8.37 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.667 0.746 . . . . 0.0 111.136 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 4.47 2.19 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 22.7 mmt180 -115.64 0.76 13.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.881 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.518 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -114.72 153.36 46.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.622 0.725 . . . . 0.0 110.855 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.518 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.85 178.63 25.01 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.285 0.077 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.572 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 81.8 m-85 -117.2 117.73 30.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.897 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -78.49 113.33 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.836 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -128.99 101.95 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.119 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.5 tttm -83.95 102.51 12.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.9 t -67.15 145.67 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.177 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.7 mt -114.03 156.17 44.39 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.8 121.28 7.96 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.687 2.258 . . . . 0.0 112.351 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.429 ' C ' ' O ' ' A' ' 103' ' ' PRO . 54.0 m -35.21 -31.75 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.075 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.496 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 -112.34 167.64 10.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.941 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -124.59 172.72 9.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.903 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -117.33 41.67 2.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.085 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 58.3 m . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.772 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.7 p -117.28 166.59 12.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.844 0.354 . . . . 0.0 110.89 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.4 m -70.11 108.91 4.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.902 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.7 -174.84 4.21 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.7 t 41.49 41.76 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.877 0.37 . . . . 0.0 110.883 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.5 m -104.35 120.05 40.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.846 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.97 95.34 0.69 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.533 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.43 158.41 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.869 0.366 . . . . 0.0 111.077 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.6 t -97.54 132.84 41.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -134.14 96.21 16.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.635 0.731 . . . . 0.0 110.897 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 1.49 4.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.747 2.298 . . . . 0.0 112.305 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 63.7 m -99.2 -5.23 30.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.5 mmpt? -97.9 -7.66 29.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.43 ' CG1' HG22 ' A' ' 92' ' ' ILE . 4.9 p -86.43 131.17 35.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.193 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mppt? -128.44 172.61 10.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.864 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.564 HD11 ' CE2' ' A' ' 97' ' ' PHE . 24.2 pt -143.3 134.96 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.122 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.93 128.17 20.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.79 163.59 28.21 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -24.88 29.44 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.664 2.243 . . . . 0.0 112.365 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.77 95.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.536 HD12 ' CD2' ' A' ' 33' ' ' PHE . 7.1 mt -84.13 -17.19 40.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.973 0.416 . . . . 0.0 110.968 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.31 176.71 1.31 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.509 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -91.26 -13.29 33.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.986 0.422 . . . . 0.0 110.87 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.47 49.86 3.49 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.459 HG12 ' NE2' ' A' ' 31' ' ' GLN . 74.6 t -99.34 147.15 7.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.798 0.332 . . . . 0.0 111.103 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.404 ' N ' HG11 ' A' ' 25' ' ' VAL . 89.2 mtt180 -121.26 144.84 48.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.76 150.45 44.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 45.7 mtm180 54.65 43.05 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.8 t -135.06 147.65 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -69.96 113.93 7.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.945 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.459 ' NE2' HG12 ' A' ' 25' ' ' VAL . 42.4 mm-40 -120.51 129.02 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.8 t -144.75 157.72 44.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.536 ' CD2' HD12 ' A' ' 21' ' ' LEU . 1.3 p90 -147.21 179.95 7.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.931 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 58.2 m -120.08 130.82 54.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.142 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.2 t -110.72 109.07 27.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -89.83 110.39 21.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 25.6 p -125.75 24.73 7.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.757 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 89.0 p -69.64 -33.76 73.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.7 mmmt -86.31 -12.66 48.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.562 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -78.58 -35.3 46.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.133 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.82 -138.86 10.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.566 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.583 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -121.14 19.37 11.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.745 0.307 . . . . 0.0 110.852 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.446 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -77.86 151.78 79.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.604 0.716 . . . . 0.0 111.103 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 167.16 25.27 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.435 HD13 ' CG1' ' A' ' 85' ' ' VAL . 6.4 tp -125.32 136.0 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.911 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -120.94 149.38 42.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.91 150.15 20.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.196 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -148.58 136.16 20.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 93.5 t -116.4 124.8 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -123.89 133.73 53.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.53 -179.86 49.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.491 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -45.17 1.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.674 2.25 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.439 ' NE ' HE22 ' A' ' 77' ' ' GLN . 0.1 OUTLIER -76.2 -35.24 59.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.889 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.9 31.59 0.26 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.2 tp -85.31 152.04 23.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.917 0.389 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.4 t -119.25 122.59 69.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -120.25 142.64 34.08 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.56 0.695 . . . . 0.0 110.97 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 169.01 19.94 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.632 2.221 . . . . 0.0 112.33 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.7 m -138.29 167.7 21.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -114.34 140.67 48.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 93.1 t -133.32 114.9 21.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.166 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.0 t -140.47 117.55 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -73.63 139.45 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.933 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -78.42 -45.56 21.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.61 -20.7 11.95 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.447 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.95 -39.03 13.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.807 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.59 34.96 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.487 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.8 p -153.27 177.39 10.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 111.072 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.1 m-70 -144.8 130.59 19.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.87 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 81.8 m -88.54 140.98 28.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.462 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.0 t -133.04 102.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.146 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 45.2 p -95.09 143.84 26.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.501 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 5.2 p90 -163.35 175.46 10.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.971 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -151.91 116.95 3.07 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.651 0.738 . . . . 0.0 111.121 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.501 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.76 92.92 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.664 2.243 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 75' ' ' PRO . 40.2 t -34.44 -54.7 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.854 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . 0.439 HE22 ' NE ' ' A' ' 53' ' ' ARG . 7.3 pt20 -125.83 171.71 10.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.969 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -84.82 172.81 11.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.52 170.04 12.99 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.5 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.13 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.726 2.284 . . . . 0.0 112.319 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -83.11 168.59 16.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.978 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.5 ttp -139.54 117.95 12.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.9 t -107.21 97.59 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 m -81.53 147.44 29.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.832 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.442 HG13 ' N ' ' A' ' 86' ' ' LYS . 64.5 t -140.94 138.11 34.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.442 ' N ' HG13 ' A' ' 85' ' ' VAL . 34.6 tttt -125.27 173.91 8.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.926 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.562 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 8.7 t80 -160.44 110.54 1.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.974 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.446 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 60.68 38.31 18.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.154 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 68.02 34.02 4.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -144.23 105.02 4.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.875 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -54.39 108.38 0.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.438 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 45.8 pt -46.9 153.02 0.87 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.583 0.706 . . . . 0.0 111.144 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.68 2.04 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.668 2.245 . . . . 0.0 112.347 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.457 ' O ' ' CE1' ' A' ' 97' ' ' PHE . 84.2 mmt-85 -114.48 -3.73 12.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.529 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 0.9 OUTLIER -112.28 154.45 44.43 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.631 0.729 . . . . 0.0 110.848 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.529 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.0 Cg_endo -69.72 -178.53 16.86 Favored 'Cis proline' 0 C--N 1.342 0.206 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.38 -0.084 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.564 ' CE2' HD11 ' A' ' 16' ' ' ILE . 81.2 m-85 -121.25 132.78 55.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 ptmt -93.16 108.31 19.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.7 t -118.59 103.68 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.104 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 106.85 13.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.908 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 41.5 t -76.81 138.08 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.155 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.6 mt -108.64 155.24 40.91 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 121.675 0.75 . . . . 0.0 110.941 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.6 Cg_endo -69.73 122.46 9.14 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.782 2.321 . . . . 0.0 112.296 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 103' ' ' PRO . 91.9 m -34.83 -35.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.084 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.442 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.4 m-85 -93.84 147.34 23.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.53 38.21 2.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.862 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.98 93.26 1.35 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.014 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 23.6 t . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.894 -179.88 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.8 m -81.98 164.43 21.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.835 0.35 . . . . 0.0 110.859 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.9 p -75.22 -52.95 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.852 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 144.67 -137.04 6.98 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.54 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m -118.19 168.89 10.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 110.851 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.7 t -122.93 171.71 9.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.35 -65.93 0.36 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.503 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -62.93 163.07 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.866 0.365 . . . . 0.0 111.106 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.0 t -120.62 135.65 60.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -133.23 96.18 17.66 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.598 0.713 . . . . 0.0 110.927 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.72 -1.63 8.78 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.682 2.255 . . . . 0.0 112.359 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.5 p -98.11 5.93 48.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.808 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -110.53 -7.74 14.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.408 ' CG1' HG21 ' A' ' 92' ' ' ILE . 1.6 p -86.29 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.106 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.408 ' C ' HG23 ' A' ' 16' ' ' ILE . 30.9 mttt -127.21 173.72 9.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.931 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.566 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 31.4 pt -147.35 135.79 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.4 153.19 46.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.142 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.52 174.6 20.35 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -36.04 11.46 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.671 2.247 . . . . 0.0 112.315 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.28 -32.68 29.87 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.561 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.443 HD11 ' CD1' ' A' ' 16' ' ' ILE . 13.0 mt -94.4 -21.38 18.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.912 0.387 . . . . 0.0 110.95 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.43 167.96 2.67 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -87.49 13.75 9.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.893 0.378 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.02 44.9 1.37 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.518 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.456 HG13 ' NE2' ' A' ' 31' ' ' GLN . 60.0 t -97.14 145.96 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 111.095 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 50.1 mtt85 -120.89 151.65 39.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.887 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -69.56 150.73 46.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.068 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.9 mtp180 55.09 41.55 31.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 59.3 t -133.88 144.33 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.2 tp -68.43 112.99 5.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.456 ' NE2' HG13 ' A' ' 25' ' ' VAL . 54.5 mm-40 -117.47 130.66 56.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.2 t -144.89 149.1 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.532 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.4 p90 -140.08 179.77 6.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.946 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 89.3 m -117.8 131.55 56.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' CG2' HG22 ' A' ' 16' ' ' ILE . 92.8 t -110.38 105.47 18.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.096 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -89.67 101.76 14.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.858 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.475 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 82.6 p -117.33 27.94 8.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.1 t -70.04 -38.13 75.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 37.7 mttp -76.06 -14.88 60.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.506 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -81.2 -38.59 26.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.09 -137.44 9.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.532 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.597 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.86 19.91 12.32 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.793 0.33 . . . . 0.0 110.912 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.437 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -77.18 151.62 81.47 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.585 0.707 . . . . 0.0 111.084 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 166.86 26.18 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.685 2.256 . . . . 0.0 112.322 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -129.61 129.37 44.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -108.73 151.71 25.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.9 t -139.53 144.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.084 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -149.64 135.06 18.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.832 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 61.5 t -116.73 128.36 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.1 mt -125.12 121.15 33.41 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.949 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.29 174.44 7.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.534 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -43.62 2.52 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.625 2.216 . . . . 0.0 112.381 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.6 -32.2 47.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.1 32.64 0.3 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.46 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 9.4 tp -85.85 149.69 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 0.0 110.874 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -114.38 115.23 48.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -113.79 142.84 28.42 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 169.58 18.59 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.237 . . . . 0.0 112.299 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.23 167.94 19.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.139 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 t30 -123.21 140.6 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 85.5 t -133.21 113.84 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 85.5 t -138.32 119.85 17.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.093 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -75.12 136.58 41.1 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.765 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.431 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 5.7 m-80 -75.69 -43.44 47.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.903 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.88 -24.9 9.84 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.506 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -86.05 -44.21 12.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.837 0.351 . . . . 0.0 110.898 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.34 33.57 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.493 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.433 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 64.0 p -149.92 177.78 9.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.86 0.362 . . . . 0.0 111.078 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.433 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.3 m-70 -144.99 133.56 22.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 52.4 m -93.02 141.49 28.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.148 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.532 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 66.4 t -131.36 103.28 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.172 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.6 p -95.19 136.86 35.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.131 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.475 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 8.0 p90 -157.41 176.12 13.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.7 m -150.78 115.35 3.24 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.586 0.708 . . . . 0.0 111.122 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.8 95.04 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.345 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 13.4 t -38.91 -54.79 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.772 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -121.98 169.94 10.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.497 ' C ' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -86.97 173.75 9.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.86 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.11 176.23 15.05 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.488 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 89.15 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.699 2.266 . . . . 0.0 112.279 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.62 163.54 25.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.938 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 16.3 ttp -135.17 113.09 11.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.856 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 69.3 t -105.48 97.78 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.5 t -82.98 144.29 30.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.899 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 55.7 t -139.83 142.37 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.079 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.421 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 39.9 tttt -128.29 170.56 12.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.506 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 4.5 t80 -156.42 109.42 2.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 62.27 40.82 11.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.421 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 4.9 m-20 64.31 35.99 9.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.887 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -147.05 105.04 3.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -52.48 117.01 2.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.425 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 46.5 pt -55.61 153.16 16.06 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.58 0.705 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 4.74 2.01 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 2.251 . . . . 0.0 112.412 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 29.7 mmt85 -117.04 2.96 12.74 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.53 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.64 153.98 49.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.637 0.732 . . . . 0.0 110.861 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.69 -179.92 20.38 Favored 'Cis proline' 0 C--O 1.231 0.135 0 C-N-CA 122.663 -1.807 . . . . 0.0 112.37 -0.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.566 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 80.1 m-85 -117.45 128.98 55.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.878 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -93.64 107.34 19.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.9 t -119.43 107.04 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 19.8 ttpt -81.96 105.5 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.885 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.8 152.49 6.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.18 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 68.4 mt -117.55 154.83 50.79 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.575 0.702 . . . . 0.0 110.93 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.7 122.21 8.91 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.692 2.261 . . . . 0.0 112.377 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m -34.83 -32.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.152 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.6 m-85 -90.05 38.71 0.93 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 7.5 t70 -81.82 123.62 28.96 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.894 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -108.41 78.53 1.17 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.84 -179.794 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 m -67.61 -56.87 7.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.818 0.342 . . . . 0.0 110.78 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 44.5 m -74.78 86.36 2.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -128.03 -123.24 2.58 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.527 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -94.96 164.58 12.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 110.888 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.1 t -46.02 -60.54 2.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.65 66.98 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.509 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 30.7 m -69.18 165.35 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 111.024 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.1 t -99.18 134.04 39.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.211 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.424 ' CG ' ' HG2' ' A' ' 13' ' ' LYS . 8.8 t0 -123.95 95.1 44.71 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.614 0.721 . . . . 0.0 110.897 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 0.78 5.12 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.71 2.273 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 m -100.7 3.67 42.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.424 ' HG2' ' CG ' ' A' ' 10' ' ' ASP . 14.4 mmmt -104.74 -12.12 16.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.444 ' CG1' HG21 ' A' ' 92' ' ' ILE . 6.4 p -84.37 133.67 28.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.413 ' C ' HG21 ' A' ' 16' ' ' ILE . 29.0 mtmt -135.69 169.94 16.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.471 HD12 ' CE2' ' A' ' 97' ' ' PHE . 26.3 pt -142.67 137.25 27.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 143.79 33.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.077 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 155.83 178.57 30.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.87 -38.81 7.06 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.656 2.237 . . . . 0.0 112.315 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.27 -24.99 11.0 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.498 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.41 HD11 ' CD1' ' A' ' 16' ' ' ILE . 3.3 mt -104.41 -22.16 13.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.864 0.364 . . . . 0.0 110.896 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -58.19 176.82 1.84 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.469 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -91.17 11.78 22.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.884 0.374 . . . . 0.0 110.853 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.84 47.03 1.09 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.505 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.433 HG12 ' N ' ' A' ' 26' ' ' ARG . 72.4 t -98.54 138.29 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.805 0.336 . . . . 0.0 111.11 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.433 ' N ' HG12 ' A' ' 25' ' ' VAL . 57.4 mtt85 -118.76 146.33 44.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -66.69 151.51 47.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.034 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 56.18 35.6 25.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 76.2 t -128.91 154.4 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.125 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.1 tp -76.19 112.24 12.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.451 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 61.8 mm-40 -113.83 127.54 56.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 13.6 t -142.19 154.1 44.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.872 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.56 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.0 p90 -149.54 176.2 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.948 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.455 HG22 ' N ' ' A' ' 35' ' ' VAL . 96.1 m -114.64 138.01 51.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.456 ' CG1' HD22 ' A' ' 45' ' ' LEU . 52.3 t -117.48 106.97 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -85.78 110.65 19.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.6 p -125.34 25.77 7.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.8 t -75.67 -35.82 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.876 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? -81.6 -18.52 44.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.518 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -75.29 -39.98 59.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.139 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.8 -140.66 11.42 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -116.35 16.97 15.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.785 0.326 . . . . 0.0 110.907 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.452 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -75.63 151.3 84.85 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.61 0.719 . . . . 0.0 111.063 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.436 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.7 Cg_endo -69.77 167.37 24.65 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.652 2.234 . . . . 0.0 112.297 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.456 HD22 ' CG1' ' A' ' 35' ' ' VAL . 10.8 tp -128.19 131.11 48.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.897 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -111.86 151.53 29.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.82 149.81 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.412 ' HG2' ' CD2' ' A' ' 50' ' ' LEU . 2.5 ttp-105 -152.61 143.12 22.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 58.3 t -118.69 122.06 68.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.464 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.0 mm? -110.48 128.92 55.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.59 165.03 52.6 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.502 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.51 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.75 -26.29 27.76 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.743 2.295 . . . . 0.0 112.365 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.09 3.35 9.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.08 65.16 0.52 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.48 148.0 44.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.59 118.64 57.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -120.65 141.69 32.78 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.639 0.733 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 169.21 19.39 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.663 2.242 . . . . 0.0 112.378 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.8 m -144.31 162.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 29.9 t30 -125.2 141.15 52.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 3.6 p -133.52 110.94 15.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.144 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 74.7 t -139.79 116.04 9.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -67.45 138.8 56.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.551 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 6.3 m-80 -73.18 -41.98 63.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.89 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.21 -22.05 12.59 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.485 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -91.58 -43.05 9.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.357 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.77 34.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.551 ' HG1' ' ND2' ' A' ' 64' ' ' ASN . 57.3 p -152.23 177.87 10.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.413 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.1 m-70 -143.76 125.12 14.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.864 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 31.3 m -84.03 139.02 32.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.56 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 73.3 t -131.3 106.71 12.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.5 p -97.07 147.4 24.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.453 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.1 p90 -166.02 164.37 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 92.0 m -140.85 112.38 6.88 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.623 0.725 . . . . 0.0 111.129 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.453 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 54.1 Cg_endo -69.69 100.59 0.82 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.367 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 75' ' ' PRO . 33.3 t -34.86 -57.85 0.53 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -129.86 166.5 19.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.41 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 5.7 pm0 -76.25 172.11 13.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.887 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.92 173.83 13.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.457 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 93.93 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.513 ' CD1' HG22 ' A' ' 101' ' ' VAL . 6.3 m-85 -90.11 173.91 7.92 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 27.7 ttp -147.61 117.74 7.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.841 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 93.2 t -106.29 100.22 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 12.4 t -84.37 143.49 29.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.81 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 84.4 t -141.21 135.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.123 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -122.28 171.69 8.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.518 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 12.9 t80 -157.56 112.81 2.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.929 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 60.45 32.51 20.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.083 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 73.47 31.4 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.808 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -141.99 105.05 4.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -53.36 107.9 0.28 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.444 HG21 ' CG1' ' A' ' 14' ' ' VAL . 44.9 pt -45.93 153.0 0.69 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.609 0.719 . . . . 0.0 111.104 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 4.31 2.26 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.361 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 14.2 mmm180 -113.46 -4.65 13.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.836 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -112.21 153.98 44.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.659 0.742 . . . . 0.0 110.845 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.4 Cg_endo -69.65 179.15 22.84 Favored 'Cis proline' 0 C--N 1.341 0.168 0 C-N-CA 122.8 -1.75 . . . . 0.0 112.347 -0.116 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.471 ' CE2' HD12 ' A' ' 16' ' ' ILE . 89.5 m-85 -120.21 114.8 22.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 106.08 9.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.901 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 79.7 t -117.51 106.71 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.078 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -85.91 96.88 9.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.889 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.513 HG22 ' CD1' ' A' ' 81' ' ' TYR . 47.7 t -63.61 147.28 12.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.065 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.5 mt -113.02 154.05 45.12 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.59 0.709 . . . . 0.0 110.958 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.5 Cg_endo -69.71 124.06 10.73 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.741 2.294 . . . . 0.0 112.345 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.415 ' C ' ' O ' ' A' ' 103' ' ' PRO . 88.6 m -35.58 -32.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.473 ' N ' ' O ' ' A' ' 103' ' ' PRO . 23.0 m-85 -101.28 154.81 18.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -125.05 36.42 4.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.796 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -79.87 43.45 0.59 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.828 -179.725 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.0 p -141.14 170.91 14.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.888 0.375 . . . . 0.0 110.849 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 66.4 m -99.47 145.0 27.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.839 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.47 162.21 47.35 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.6 m -96.49 147.69 23.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -123.9 113.54 18.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.809 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 159.22 -42.06 0.48 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.457 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 9' ' ' VAL . 3.8 p -85.45 138.26 19.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 111.15 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.442 ' N ' HG22 ' A' ' 8' ' ' VAL . 48.9 t -103.77 130.47 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.079 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -128.08 96.92 30.39 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.58 0.705 . . . . 0.0 110.832 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 -0.43 6.86 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.687 2.258 . . . . 0.0 112.369 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.2 p -99.67 10.39 41.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.863 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 mmpt? -114.82 -8.78 12.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.898 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.427 ' CG1' HG22 ' A' ' 92' ' ' ILE . 1.1 p -83.87 123.11 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.166 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -116.69 173.33 6.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.544 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 33.0 pt -147.13 138.82 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.89 138.1 31.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.95 167.59 22.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.541 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.75 -24.93 29.17 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.85 -28.09 65.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.472 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.7 mt -98.13 -19.78 17.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.41 166.37 5.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.7 t -83.29 8.59 13.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.972 0.415 . . . . 0.0 110.922 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.14 51.0 0.73 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.7 t -102.08 141.78 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.845 0.355 . . . . 0.0 111.102 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 75.3 mtt85 -118.97 150.75 39.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.888 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.74 150.16 48.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.432 ' HB3' ' NH1' ' A' ' 28' ' ' ARG . 12.2 mtp-105 54.91 40.32 31.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 66.4 t -129.9 150.74 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.149 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.7 tp -73.94 110.36 8.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.951 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.3 mm-40 -115.3 127.68 55.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.975 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.3 t -143.44 149.48 37.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 1.0 OUTLIER -141.33 -178.38 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 88.4 m -123.21 137.67 54.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t -117.65 107.18 21.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.106 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.48 94.74 9.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.875 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.479 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 59.9 p -103.64 20.02 18.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.9 t -68.41 -34.94 76.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.814 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -82.75 -12.24 57.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.478 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -83.35 -39.66 20.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.047 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.415 ' C ' HD11 ' A' ' 42' ' ' LEU . . . 135.66 -146.97 18.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.5 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.452 HD11 ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.07 14.99 24.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.928 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -75.58 151.32 84.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.619 0.723 . . . . 0.0 111.046 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 169.36 19.1 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.64 2.227 . . . . 0.0 112.377 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.433 HD12 ' CG1' ' A' ' 85' ' ' VAL . 7.8 tp -124.82 139.47 53.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -112.96 143.4 44.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 88.9 t -135.72 131.1 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -141.12 143.0 34.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.441 HG22 ' CG1' ' A' ' 59' ' ' VAL . 60.9 t -125.23 132.38 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.5 mp -120.57 148.46 43.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.09 172.69 36.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.405 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.4 Cg_endo -69.82 -30.75 21.49 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.657 2.238 . . . . 0.0 112.325 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.86 4.78 17.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 105.45 66.5 0.67 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.54 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 26.9 tp -118.36 138.59 52.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.911 0.386 . . . . 0.0 110.91 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.1 t -109.02 108.98 26.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -110.93 143.13 27.66 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.618 0.723 . . . . 0.0 110.875 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 168.02 22.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.655 2.237 . . . . 0.0 112.363 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.441 ' CG1' HG22 ' A' ' 49' ' ' VAL . 30.0 m -141.83 163.15 19.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.063 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -115.47 141.31 48.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.866 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 86.9 t -132.86 116.31 26.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 76.6 t -138.25 124.74 26.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -80.45 132.75 35.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.58 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 9.2 m-80 -72.84 -40.74 65.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 114.42 -27.37 8.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -83.27 -47.27 11.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.846 0.355 . . . . 0.0 110.931 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.28 30.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.529 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.58 ' HG1' ' ND2' ' A' ' 64' ' ' ASN . 60.4 p -144.76 177.78 8.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.498 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.5 m-70 -146.66 132.16 18.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 23.2 m -93.16 141.86 27.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.144 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.475 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 57.8 t -132.85 104.78 7.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.17 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -94.74 139.97 30.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.5 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -159.36 171.54 19.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.863 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.2 m -147.07 114.97 4.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.567 0.699 . . . . 0.0 111.149 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.5 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.6 Cg_endo -69.73 91.39 0.51 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.346 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.5 t -34.08 -59.64 0.42 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -121.56 158.34 28.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.886 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -77.19 173.67 11.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.07 176.9 14.64 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 86.19 0.58 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.678 2.252 . . . . 0.0 112.387 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.405 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.1 m-85 -83.0 173.59 11.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.5 ttp -149.16 120.83 8.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.0 t -109.43 100.17 10.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.9 t -82.99 145.4 29.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.848 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.433 ' CG1' HD12 ' A' ' 45' ' ' LEU . 54.3 t -140.52 138.42 36.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.103 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -126.79 172.99 9.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.507 ' CZ ' ' O ' ' A' ' 43' ' ' ALA . 5.5 t80 -160.18 109.47 1.76 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 63.0 37.84 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.047 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 67.94 34.18 4.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -144.35 105.07 4.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.59 111.68 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.429 HD11 ' CE2' ' A' ' 97' ' ' PHE . 47.0 pt -49.41 153.03 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.683 0.754 . . . . 0.0 111.1 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 3.85 2.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.71 2.273 . . . . 0.0 112.327 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.418 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 19.6 mmm180 -114.08 -2.03 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.862 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.536 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -113.61 153.27 45.86 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.681 0.753 . . . . 0.0 110.849 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.536 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.78 175.83 35.07 Favored 'Cis proline' 0 C--N 1.341 0.151 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.318 0.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.544 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 87.8 m-85 -116.15 118.07 31.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -78.7 107.24 11.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.903 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 96.1 t -119.26 102.92 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.101 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -83.58 100.42 10.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.8 145.09 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.173 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.6 mt -111.69 154.67 43.88 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.589 0.709 . . . . 0.0 110.958 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.9 Cg_endo -69.66 123.33 10.03 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.67 2.246 . . . . 0.0 112.334 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 103' ' ' PRO . 49.7 m -36.11 -30.82 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.171 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.485 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.8 m-85 -83.18 140.07 32.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.68 96.26 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.838 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.91 44.03 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 61.0 p . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.903 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.248 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 t -157.89 161.48 38.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.931 0.396 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -53.58 113.06 1.04 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.876 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -39.2 113.16 0.28 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.471 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 95.7 p -106.06 119.16 38.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 110.807 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.5 t -118.69 107.37 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.898 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.442 ' O ' ' C ' ' A' ' 8' ' ' VAL . . . -150.71 -68.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.503 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' A' ' 7' ' ' GLY . 28.3 t -33.97 135.73 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.855 0.36 . . . . 0.0 111.129 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.2 t -82.15 125.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.2 t0 -125.88 99.45 32.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.564 0.697 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.6 Cg_endo -69.81 0.37 5.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.66 2.24 . . . . 0.0 112.386 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.7 p -98.7 9.09 44.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.999 0.428 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -114.18 -8.02 12.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.417 ' CG1' HG23 ' A' ' 92' ' ' ILE . 1.8 p -84.54 123.5 39.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.215 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.4 mtpp -119.66 167.74 11.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.558 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 37.6 pt -144.09 140.06 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.8 165.92 26.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 133.82 176.11 14.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.41 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.65 -41.44 4.42 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.715 2.277 . . . . 0.0 112.321 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -44.77 -35.44 4.32 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.494 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 8.2 mt -94.43 -26.6 16.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.897 0.379 . . . . 0.0 110.896 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -50.86 163.81 0.92 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.479 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.4 m -86.24 22.91 1.67 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.959 0.409 . . . . 0.0 110.904 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.69 38.05 2.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.461 HG12 ' NE2' ' A' ' 31' ' ' GLN . 78.9 t -89.41 144.3 9.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 65.6 mtt180 -121.63 149.8 42.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.04 150.16 48.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.6 mtt85 55.35 34.83 23.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.876 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 73.2 t -127.46 146.98 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.7 tp -68.25 111.6 4.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.461 ' NE2' HG12 ' A' ' 25' ' ' VAL . 58.0 mm-40 -116.66 126.62 53.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.3 t -144.45 148.43 34.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.471 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -140.86 177.61 7.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.791 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 82.6 m -118.36 141.17 48.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.215 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.2 t -118.09 109.47 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -92.32 98.23 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.1 p -111.71 21.38 16.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.5 p -67.01 -35.4 79.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.839 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -79.16 -15.89 57.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.61 -38.68 47.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.092 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.49 -138.45 9.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.444 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.47 HD11 ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.8 16.35 16.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.88 0.371 . . . . 0.0 110.956 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.454 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -75.78 151.64 84.64 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.581 0.705 . . . . 0.0 111.105 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.487 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.1 Cg_endo -69.77 169.27 19.31 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.622 2.215 . . . . 0.0 112.327 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.454 HD11 ' CG1' ' A' ' 85' ' ' VAL . 4.7 tp -127.32 135.4 50.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.961 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -120.42 145.42 47.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.437 HG13 ' N ' ' A' ' 48' ' ' ARG . 49.7 t -137.49 145.93 28.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.108 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.437 ' N ' HG13 ' A' ' 47' ' ' VAL . 24.8 mmt180 -146.38 138.16 24.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.8 t -115.41 129.15 72.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.035 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -126.2 119.52 27.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.85 177.77 3.76 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.531 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.422 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 53.7 Cg_endo -69.7 -41.39 4.39 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.649 2.232 . . . . 0.0 112.4 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.422 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -84.05 -33.66 24.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.976 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.31 33.21 0.15 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.458 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 11.1 tp -85.52 155.67 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.887 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.458 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 94.3 t -119.33 111.1 31.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -106.13 143.15 26.35 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.651 0.738 . . . . 0.0 110.876 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.691 2.261 . . . . 0.0 112.34 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 m -139.98 162.83 24.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -118.88 143.6 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.936 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 74.0 t -129.51 116.31 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.98 110.77 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.203 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -72.15 129.05 37.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -72.73 -44.74 61.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.856 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.11 -24.31 10.09 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -85.87 -46.49 10.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.841 0.353 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.7 30.54 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.537 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.527 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.3 p -145.89 177.63 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 111.098 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.527 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.5 m-70 -147.82 131.41 16.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 3.4 m -94.78 137.51 33.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.471 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 35.6 t -127.04 107.35 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 35.1 p -92.68 141.06 28.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.193 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -163.94 161.59 22.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.973 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -137.38 117.19 10.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.603 0.716 . . . . 0.0 111.117 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.75 94.59 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.349 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 75' ' ' PRO . 43.0 t -35.88 -54.88 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -125.12 168.94 12.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -85.35 173.68 10.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.33 175.42 14.22 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.465 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 90.13 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.702 2.268 . . . . 0.0 112.364 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.531 ' CD1' HG22 ' A' ' 101' ' ' VAL . 4.0 m-85 -81.06 169.75 17.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.947 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 11.2 ttp -145.31 115.73 7.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.5 t -107.58 97.14 5.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -79.83 142.88 34.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.454 ' CG1' HD11 ' A' ' 45' ' ' LEU . 89.5 t -138.05 142.0 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.084 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.417 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 15.5 tttp -130.49 168.05 17.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.941 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' A' ' 44' ' ' PRO . 6.7 t80 -154.61 115.99 4.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.944 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 59.41 33.27 22.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.115 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.417 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 11.6 m-20 71.04 33.5 2.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -144.4 105.34 4.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.891 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -49.99 114.14 1.02 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.84 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.417 HG23 ' CG1' ' A' ' 14' ' ' VAL . 42.1 pt -54.56 153.52 10.35 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.661 0.743 . . . . 0.0 111.113 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.68 4.33 2.22 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.404 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 53.1 mtp85 -114.5 0.29 13.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.908 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.512 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -115.71 153.37 47.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.684 0.754 . . . . 0.0 110.866 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.512 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.73 178.01 26.82 Favored 'Cis proline' 0 C--O 1.232 0.18 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.396 -0.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.558 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 86.3 m-85 -117.84 116.47 27.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.0 pttm -81.65 108.8 15.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.02 104.14 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -81.35 103.01 10.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.531 HG22 ' CD1' ' A' ' 81' ' ' TYR . 44.2 t -71.25 144.61 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 77.2 mt -111.88 154.5 44.09 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.583 0.706 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.495 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.4 Cg_endo -69.69 123.84 10.52 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.724 2.283 . . . . 0.0 112.324 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.9 m -34.12 -33.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.193 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.495 ' N ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m-85 -95.09 126.65 40.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -92.05 121.5 33.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.934 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -68.02 81.87 0.21 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.5 m . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.459 -0.256 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.6 m -151.87 164.34 37.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.36 . . . . 0.0 110.9 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 t -97.1 123.5 40.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.905 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.45 155.63 7.31 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.2 t -95.43 135.88 36.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.919 0.39 . . . . 0.0 110.873 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.2 p -94.62 162.97 13.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.818 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -150.6 74.0 0.27 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.53 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 9' ' ' VAL . 7.1 p -124.35 141.42 44.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.943 0.401 . . . . 0.0 111.086 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.447 ' N ' HG23 ' A' ' 8' ' ' VAL . 54.2 t -107.52 133.73 51.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -130.53 96.64 23.44 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 0.3 5.85 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.663 2.242 . . . . 0.0 112.347 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 30.8 m -98.46 -7.12 29.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -94.23 -5.15 47.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -90.42 135.73 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.152 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 22.8 mtmt -133.42 168.9 17.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.568 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 42.2 pt -142.9 139.42 27.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.066 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.72 153.67 43.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.32 171.68 17.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -29.14 24.27 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 0.0 112.372 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.79 -29.43 67.37 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.2 mt -97.04 -26.43 15.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.894 0.378 . . . . 0.0 110.965 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.92 168.33 2.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.564 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.8 p -83.86 18.49 1.99 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.21 40.83 2.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.462 HG13 ' NE2' ' A' ' 31' ' ' GLN . 58.3 t -92.96 147.46 5.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -123.03 157.26 33.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.835 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -75.35 149.48 38.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 42.5 mtt180 54.09 30.27 11.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 t -119.99 144.48 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.178 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.5 tp -67.81 110.12 3.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.562 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 59.6 mm-40 -113.29 126.95 55.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.923 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -143.2 152.53 41.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.502 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.5 p90 -146.39 -176.48 5.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 48.0 m -122.23 135.5 54.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.09 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.1 t -113.15 108.75 26.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.157 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -91.47 104.04 16.59 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.913 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.0 p -121.4 30.19 6.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.9 t -73.04 -36.61 66.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.853 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 6.4 mmpt? -79.95 -16.95 54.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.859 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.539 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -74.05 -38.64 63.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.042 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.7 -137.25 9.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.577 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.31 18.91 12.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.868 0.366 . . . . 0.0 110.973 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.472 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.35 151.89 83.5 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.71 . . . . 0.0 111.076 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 166.64 26.92 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.673 2.249 . . . . 0.0 112.338 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.471 HD11 ' CG1' ' A' ' 85' ' ' VAL . 15.4 tp -126.08 134.49 51.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -119.4 147.52 44.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.468 ' CG1' HG13 ' A' ' 59' ' ' VAL . 65.6 t -137.3 149.77 25.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -152.26 136.85 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.837 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 71.9 t -119.43 126.18 75.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.169 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -123.58 122.9 39.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.6 -179.36 1.66 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.472 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.465 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.74 -47.93 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.14 -37.25 61.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.919 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.24 33.38 0.13 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.464 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.3 tp -85.37 147.96 26.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.915 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.4 t -107.87 126.0 64.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.106 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -127.92 140.35 37.93 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.603 0.716 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 168.65 20.95 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.702 2.268 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.468 HG13 ' CG1' ' A' ' 47' ' ' VAL . 44.5 t -139.91 149.33 22.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.191 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -98.67 139.18 34.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.82 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 p -131.94 123.48 51.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.196 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.5 t -141.28 129.43 22.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.174 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.22 132.06 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.84 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -73.23 -48.04 38.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.83 -21.04 10.59 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -90.43 -43.97 9.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.8 32.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.572 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 63.2 p -151.02 177.73 9.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 111.152 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.572 ' CD2' ' C ' ' A' ' 68' ' ' THR . 5.3 m-70 -146.61 131.07 17.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.846 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 26.2 m -90.21 138.41 31.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.196 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.502 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 47.4 t -130.37 110.37 18.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.171 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 55.7 p -101.04 145.33 28.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.188 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.562 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.0 p90 -164.91 169.06 16.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -146.29 112.6 4.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.586 0.708 . . . . 0.0 111.089 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.81 94.39 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.665 2.243 . . . . 0.0 112.383 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.7 t -34.23 -59.43 0.44 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -116.3 168.75 9.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 pm0 -89.21 169.37 11.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.86 177.71 15.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 93.9 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.661 2.241 . . . . 0.0 112.393 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.465 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 3.3 m-85 -88.28 172.98 9.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 7.5 ttp -144.43 117.13 8.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 81.2 t -108.57 95.69 4.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.134 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.7 t -79.72 147.2 32.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.8 t -142.54 134.27 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.149 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -121.44 168.64 11.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.989 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.539 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 7.0 t80 -154.9 106.86 2.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 65.4 42.22 3.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.072 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 62.96 34.83 13.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -146.32 105.05 3.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -51.2 114.93 1.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.822 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.412 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 38.1 pt -53.79 153.26 8.58 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.542 0.687 . . . . 0.0 111.198 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.66 5.83 1.51 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.267 . . . . 0.0 112.361 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.1 mmm180 -118.49 3.61 11.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.804 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.512 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -118.48 153.26 51.88 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.724 0.773 . . . . 0.0 110.838 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.512 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.81 176.68 31.76 Favored 'Cis proline' 0 C--N 1.343 0.243 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.41 -0.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.568 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 72.8 m-85 -114.86 121.68 43.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.882 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 pttp -80.94 107.71 13.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 57.8 t -119.2 106.43 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.164 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -89.12 99.1 12.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.9 t -65.75 150.69 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 78.1 mt -118.94 154.69 53.19 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.618 0.723 . . . . 0.0 110.932 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.447 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.76 119.08 6.08 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.718 2.279 . . . . 0.0 112.299 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.6 m -39.38 -27.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 107' ' ' ALA . 4.7 m-85 -82.25 38.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.949 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 105' ' ' TYR . 0.9 OUTLIER 36.44 29.37 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.813 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.51 ' N ' ' O ' ' A' ' 105' ' ' TYR . . . 44.81 49.33 8.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 37.3 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.77 -179.705 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.5 m 54.65 44.94 27.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.864 0.364 . . . . 0.0 110.886 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.3 p -144.02 140.56 29.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.858 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.49 144.46 7.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.498 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -69.11 169.45 11.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.876 0.37 . . . . 0.0 110.857 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 m -123.39 116.56 23.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.902 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.61 89.56 1.07 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.485 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.54 153.59 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.356 . . . . 0.0 111.128 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 72.9 t -101.22 131.3 49.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -133.21 98.18 15.76 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.549 0.69 . . . . 0.0 110.863 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -2.02 9.44 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.751 2.301 . . . . 0.0 112.344 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.2 m -100.07 13.87 32.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.827 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -9.03 10.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.79 134.34 27.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.187 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.417 ' C ' HG23 ' A' ' 16' ' ' ILE . 5.2 mtpm? -129.44 174.29 9.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.969 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.572 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 27.4 pt -150.01 135.97 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.127 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.3 154.74 44.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.129 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 146.15 178.54 21.67 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.48 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -39.55 6.5 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.711 2.274 . . . . 0.0 112.407 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -47.8 -35.61 12.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.549 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.416 ' CD1' HG13 ' A' ' 16' ' ' ILE . 9.4 mt -93.48 -27.49 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.88 167.95 1.0 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.1 m -85.57 16.86 3.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.961 0.41 . . . . 0.0 110.91 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.35 40.17 2.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 26' ' ' ARG . 64.9 t -93.02 139.6 17.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 111.153 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.475 ' N ' HG13 ' A' ' 25' ' ' VAL . 89.2 mtt180 -121.74 148.15 45.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.869 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.36 154.86 37.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 23.1 mtm180 50.65 41.72 26.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.894 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.414 HG11 ' N ' ' A' ' 30' ' ' LEU . 70.0 t -134.23 151.32 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' HG11 ' A' ' 29' ' ' VAL . 21.2 tp -73.97 111.21 8.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.987 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.542 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 65.2 mm-40 -112.01 127.33 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.0 t -141.03 149.98 42.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.55 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.4 p90 -144.62 168.77 19.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.825 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 92.7 m -110.18 130.09 55.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.177 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.434 ' CG2' HG22 ' A' ' 16' ' ' ILE . 65.2 t -111.41 105.61 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.117 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -87.01 104.72 16.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.775 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 75.7 p -118.72 27.2 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.909 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.9 p -74.22 -37.41 63.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.821 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -73.93 -23.32 59.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.49 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -70.62 -41.28 72.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.092 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.48 -135.19 7.44 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.45 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.548 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.98 19.55 13.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.764 0.316 . . . . 0.0 110.901 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.564 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.65 152.01 80.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.671 0.748 . . . . 0.0 111.047 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 165.94 29.33 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.691 2.26 . . . . 0.0 112.328 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.458 HD11 ' CG1' ' A' ' 85' ' ' VAL . 4.5 tp -125.36 136.68 53.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.937 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -121.13 143.4 49.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.33 144.98 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.432 ' HG2' ' CD1' ' A' ' 50' ' ' LEU . 12.7 ttm180 -148.24 144.6 27.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.414 HG23 ' CG1' ' A' ' 59' ' ' VAL . 67.3 t -120.89 130.37 74.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.432 ' CD1' ' HG2' ' A' ' 48' ' ' ARG . 3.8 mp -125.11 134.78 52.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.46 173.88 54.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.444 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -44.36 2.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.21 -35.52 41.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 138.77 31.32 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.436 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.7 tp -91.63 150.11 21.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.1 t -110.62 132.12 59.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.098 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 48.0 mp0 -120.02 142.74 33.95 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.631 0.729 . . . . 0.0 110.841 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 167.93 23.1 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.346 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.414 ' CG1' HG23 ' A' ' 49' ' ' VAL . 20.8 m -144.31 164.79 13.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.155 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -122.85 142.69 50.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 89.8 t -133.5 103.06 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.2 t -127.96 115.25 38.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.159 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -71.12 135.0 47.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.532 ' ND2' ' HG1' ' A' ' 68' ' ' THR . 7.0 m-80 -75.64 -43.09 49.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.22 -26.0 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.487 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -85.66 -40.09 16.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.863 0.363 . . . . 0.0 110.872 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.82 34.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.478 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.532 ' HG1' ' ND2' ' A' ' 64' ' ' ASN . 61.2 p -151.47 177.65 10.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.168 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -145.77 131.38 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.842 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 51.9 m -90.84 137.74 32.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.132 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.55 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 40.3 t -133.19 105.72 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.061 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 71.1 p -98.32 142.15 30.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.223 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.553 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 10.0 p90 -156.53 169.89 23.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.964 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.3 m -145.74 110.67 4.48 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.552 0.691 . . . . 0.0 111.233 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.553 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.75 94.52 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.661 2.241 . . . . 0.0 112.372 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 60.6 p -39.38 -27.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . 0.462 ' N ' ' O ' ' A' ' 75' ' ' PRO . 10.4 pt20 -147.74 175.49 10.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.98 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.93 173.28 7.67 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.72 174.76 13.86 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.547 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.71 81.66 0.79 Allowed 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.697 2.265 . . . . 0.0 112.382 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -80.52 147.33 30.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.908 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' MET . . . . . 0.449 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.1 tmm? -117.61 127.09 53.62 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.03 95.3 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 t -76.1 139.92 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.825 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.458 ' CG1' HD11 ' A' ' 45' ' ' LEU . 64.9 t -138.86 129.8 34.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.158 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.417 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 40.4 tttt -121.6 170.52 9.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.564 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.0 t80 -157.09 107.82 2.31 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 64.16 41.82 5.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.417 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 44.0 m-20 63.22 36.07 12.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -146.15 104.97 3.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -53.75 117.34 3.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.87 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.464 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 40.3 pt -55.75 153.57 15.8 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.657 0.741 . . . . 0.0 111.113 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.401 ' HD2' ' HB ' ' A' ' 92' ' ' ILE . 53.8 Cg_endo -69.74 6.2 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.727 2.285 . . . . 0.0 112.377 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -120.59 5.55 10.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.973 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -119.93 153.37 54.96 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.688 0.756 . . . . 0.0 110.781 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.71 172.95 46.4 Favored 'Cis proline' 0 C--N 1.342 0.21 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.3 -0.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.572 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 68.1 m-85 -110.43 139.82 45.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.824 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 34.0 mttm -100.29 107.3 19.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.1 t -117.06 101.54 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.087 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 39.9 tttp -81.0 97.78 7.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 49.4 t -69.61 144.14 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 42.1 mt -109.56 155.17 41.78 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.573 0.701 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.3 Cg_endo -69.82 123.22 9.86 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.737 2.291 . . . . 0.0 112.368 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.434 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -33.87 -35.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.182 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 103' ' ' PRO . 20.0 m-85 -105.45 159.45 15.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -118.96 96.38 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.867 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -124.55 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.122 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 12.7 t . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.875 -179.77 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.439 -0.265 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.4 t -161.15 134.54 6.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.967 0.413 . . . . 0.0 110.752 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.7 m -151.24 142.51 23.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.49 -160.64 25.52 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.439 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.9 t -135.2 155.77 50.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.852 0.358 . . . . 0.0 110.849 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 95.1 p -83.0 40.0 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.49 -63.41 2.36 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.434 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -42.99 155.74 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.152 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 76.8 t -95.68 132.16 40.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -129.43 96.72 26.88 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.648 0.737 . . . . 0.0 110.803 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -1.5 8.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.8 m -100.39 12.29 37.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.5 mmpt? -116.54 -7.41 11.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -85.85 127.07 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.214 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.403 ' C ' HG21 ' A' ' 16' ' ' ILE . 34.7 mttt -121.68 173.28 7.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.913 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.572 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 31.8 pt -148.47 134.38 11.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.07 152.17 45.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.124 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 149.08 176.58 22.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.495 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -38.65 7.55 Favored 'Trans proline' 0 N--CA 1.466 -0.118 0 C-N-CA 122.709 2.273 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.92 -24.39 13.8 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.554 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.47 HD12 ' CD1' ' A' ' 16' ' ' ILE . 6.5 mt -105.77 -18.23 14.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.949 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.62 177.85 3.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 97.9 p -92.31 15.0 14.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.36 . . . . 0.0 110.854 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.03 42.88 1.78 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.481 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.44 HG13 ' NE2' ' A' ' 31' ' ' GLN . 75.9 t -96.46 141.13 15.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.884 0.373 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -121.11 148.84 43.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.854 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.45 150.18 48.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 58.7 mtt-85 53.98 41.09 32.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.878 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.6 t -132.85 143.59 39.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.078 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.1 tp -66.82 114.03 5.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.44 ' NE2' HG13 ' A' ' 25' ' ' VAL . 53.7 mm-40 -116.49 134.7 54.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.858 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 28.9 t -146.94 148.98 32.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.487 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 2.5 p90 -142.73 173.14 11.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 73.8 m -112.79 133.32 54.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.192 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.95 106.75 21.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.141 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -88.5 99.41 12.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.5 p -112.99 26.08 10.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.848 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.4 p -72.62 -38.14 67.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.834 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -76.43 -17.11 59.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.952 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.489 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -78.39 -38.36 41.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.42 -138.79 9.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.574 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.4 20.68 12.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.798 0.332 . . . . 0.0 110.913 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.469 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . . . -79.05 151.54 76.02 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.567 0.698 . . . . 0.0 111.085 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 166.56 27.19 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.292 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.471 HD13 ' CG1' ' A' ' 85' ' ' VAL . 5.4 tp -125.72 135.86 52.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.892 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -116.05 142.33 46.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.844 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.423 HG13 ' N ' ' A' ' 48' ' ' ARG . 60.9 t -130.0 142.3 44.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.423 ' N ' HG13 ' A' ' 47' ' ' VAL . 20.2 ttm180 -148.16 142.46 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 49.0 t -121.2 133.51 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.162 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.415 ' CD2' ' HG2' ' A' ' 48' ' ' ARG . 4.5 mm? -124.78 133.19 53.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.928 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.13 170.26 53.56 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.504 179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -42.26 3.54 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -82.51 -34.85 27.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.13 31.65 0.19 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.428 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.9 tp -91.7 146.01 24.12 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.97 125.88 67.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.154 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -118.86 141.81 30.76 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.621 0.724 . . . . 0.0 110.932 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 171.5 14.44 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.662 2.241 . . . . 0.0 112.336 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.0 m -142.29 165.77 16.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -124.24 143.3 50.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.872 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -133.47 118.52 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.116 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 60.1 t -134.91 121.62 34.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.203 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -75.04 137.2 41.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.794 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -80.64 -40.97 24.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.1 -29.73 7.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -82.79 -47.12 12.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.786 0.327 . . . . 0.0 110.87 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.38 30.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.513 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.4 p -144.14 177.34 8.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.826 0.346 . . . . 0.0 111.044 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.513 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.0 m-70 -146.07 127.63 15.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 97.2 m -88.38 138.94 30.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.179 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.487 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 64.4 t -129.75 109.81 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.146 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -97.68 140.2 32.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.136 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.44 ' CE2' ' HB2' ' A' ' 31' ' ' GLN . 5.9 p90 -159.72 170.69 20.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.93 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 m -146.02 116.15 4.79 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 111.147 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.425 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.74 92.97 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.683 2.256 . . . . 0.0 112.36 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 m -35.92 -51.59 0.71 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.848 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -131.78 163.17 28.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.6 170.35 16.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.81 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.77 172.66 13.28 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 84.2 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.37 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -76.54 173.57 11.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.1 ttp -144.95 114.37 7.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.803 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -103.51 96.91 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.125 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.1 t -80.3 139.91 36.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.934 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.471 ' CG1' HD13 ' A' ' 45' ' ' LEU . 51.5 t -136.11 140.59 43.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.467 ' N ' HG11 ' A' ' 85' ' ' VAL . 18.2 tttp -128.61 169.22 14.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.919 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 37' ' ' SER . 6.0 t80 -153.86 107.7 3.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.959 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.469 ' HB2' ' CB ' ' A' ' 43' ' ' ALA . . . 63.65 43.02 5.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.092 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.424 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 32.8 m-20 62.65 36.95 13.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.446 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 14.9 mt-10 -147.58 105.05 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -52.58 118.32 3.53 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.427 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 45.2 pt -57.75 153.07 33.29 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.646 0.736 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 4.34 2.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.711 2.274 . . . . 0.0 112.362 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -116.94 4.93 12.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.524 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -117.8 153.72 50.91 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.722 0.772 . . . . 0.0 110.827 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.524 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.71 178.36 25.6 Favored 'Cis proline' 0 C--N 1.342 0.211 0 C-N-CA 122.743 -1.774 . . . . 0.0 112.383 -0.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.572 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 77.0 m-85 -115.56 119.92 37.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 ptpt -79.7 100.0 7.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 90.9 t -108.35 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.0 ttpm? -83.2 98.61 9.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.934 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.35 145.34 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.121 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 82.0 mt -110.35 154.3 43.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.614 0.721 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.71 124.22 10.89 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.707 2.271 . . . . 0.0 112.289 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.423 ' C ' ' O ' ' A' ' 103' ' ' PRO . 77.9 m -34.73 -32.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 67.1 m-85 -109.09 168.26 9.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -120.47 151.68 39.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.25 79.43 7.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.08 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 32.6 p . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.821 -179.785 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 t -81.15 100.5 9.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.861 0.362 . . . . 0.0 110.891 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.4 m -92.43 92.66 8.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.853 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.2 141.64 6.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 t -64.47 105.95 1.04 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.889 0.376 . . . . 0.0 110.85 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 m -110.09 150.81 28.04 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.903 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.41 52.0 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.455 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.0 p -104.31 145.83 12.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.9 t -106.98 125.31 63.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.181 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -125.76 98.11 34.68 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.546 0.689 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -1.87 9.22 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.689 2.26 . . . . 0.0 112.321 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.3 p -101.66 14.48 31.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.893 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.426 ' NZ ' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -117.59 -9.62 10.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.883 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.79 134.66 27.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.461 ' HD3' ' CZ ' ' A' ' 94' ' ' ARG . 14.0 mmmt -127.67 173.27 10.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.541 HD13 ' CZ ' ' A' ' 97' ' ' PHE . 26.5 pt -148.55 134.82 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.166 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.63 130.13 22.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.181 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.84 170.04 34.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -35.9 11.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.66 2.24 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.35 -42.77 50.72 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.446 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.1 mt -80.78 -20.03 43.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.906 0.384 . . . . 0.0 110.929 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.81 174.21 0.48 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 91.2 p -89.47 -13.89 36.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.932 0.396 . . . . 0.0 110.833 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -90.43 52.14 3.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.469 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.424 HG13 ' NE2' ' A' ' 31' ' ' GLN . 79.4 t -99.94 143.61 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.852 0.358 . . . . 0.0 111.09 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 48.6 mtt85 -118.43 148.59 42.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.928 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.22 152.56 45.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.159 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 54.45 35.15 22.54 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 98.5 t -127.1 149.47 32.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.068 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -71.87 112.01 7.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.942 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.515 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 40.5 mm-40 -116.28 126.79 54.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.8 t -143.46 163.0 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.544 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 2.0 p90 -155.07 -176.96 6.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.1 m -120.87 129.79 53.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.106 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.5 t -108.68 105.74 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.069 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -86.54 98.91 11.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.842 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 97.5 p -113.18 31.19 6.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.1 t -73.48 -40.99 63.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -73.87 -24.79 59.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.933 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.548 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -69.1 -32.86 72.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.103 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.426 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 126.26 -147.47 16.75 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.475 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.487 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -106.64 18.41 21.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.803 0.335 . . . . 0.0 110.92 -179.914 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.567 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -75.21 151.61 85.86 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.583 0.706 . . . . 0.0 111.078 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 167.49 24.28 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.681 2.254 . . . . 0.0 112.297 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 tp -122.96 144.49 49.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.412 ' C ' HG23 ' A' ' 47' ' ' VAL . 5.1 tp10 -130.25 143.79 50.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.901 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.459 ' CG1' HG12 ' A' ' 59' ' ' VAL . 46.1 t -136.71 153.74 30.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 39.2 mtt180 -155.71 145.19 21.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.4 t -125.72 125.96 69.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.156 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.39 126.54 49.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.65 176.98 23.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.471 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -49.24 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.641 2.227 . . . . 0.0 112.372 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -72.56 -37.24 68.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.98 37.37 0.11 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.444 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.7 tp -91.32 150.65 21.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.877 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.5 t -114.95 126.72 72.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.133 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -127.16 141.63 41.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.653 0.74 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.402 ' C ' HG23 ' A' ' 59' ' ' VAL . 53.7 Cg_endo -69.84 168.03 22.84 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.704 2.27 . . . . 0.0 112.327 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.459 HG12 ' CG1' ' A' ' 47' ' ' VAL . 44.0 t -138.41 149.8 24.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.427 ' N ' HG13 ' A' ' 59' ' ' VAL . 13.5 t30 -96.37 137.87 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.3 p -133.51 114.36 20.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.106 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 84.9 t -135.56 123.56 37.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -77.01 134.63 38.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -76.88 -42.06 41.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.57 9.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.548 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.408 ' CG ' ' N ' ' A' ' 67' ' ' GLY . 0.6 OUTLIER -83.75 -46.96 11.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 0.0 110.891 -179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.408 ' N ' ' CG ' ' A' ' 66' ' ' ASP . . . 164.03 30.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.444 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.5 p -144.54 177.77 8.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.767 0.318 . . . . 0.0 111.155 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.6 m-70 -147.19 124.92 11.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.413 HG23 ' N ' ' A' ' 71' ' ' VAL . 89.1 m -83.24 139.7 32.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.159 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.544 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 60.5 t -131.45 106.27 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.4 p -100.18 145.49 27.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.566 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -165.45 174.32 10.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.2 m -152.05 114.11 2.92 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 121.53 0.681 . . . . 0.0 111.123 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.566 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 94.38 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 0.0 112.357 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.7 m -38.04 -49.64 1.3 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -127.13 158.26 37.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -78.54 170.52 16.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.52 175.09 13.88 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.465 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 83.24 0.7 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.646 2.231 . . . . 0.0 112.315 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -77.99 171.84 14.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 19.2 ttp -143.74 119.03 10.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 91.6 t -104.21 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.0 t -84.22 138.14 33.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 86' ' ' LYS . 91.1 t -133.86 141.42 44.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.417 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 28.3 tttt -130.51 168.42 17.08 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.567 ' CE2' ' HB1' ' A' ' 43' ' ' ALA . 9.6 t80 -153.54 108.7 3.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 62.88 42.58 7.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.417 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.2 m-20 63.18 35.31 12.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -145.63 104.99 3.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -51.75 121.79 7.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.548 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 33.5 pt -59.74 153.25 53.71 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.673 0.749 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 6.02 1.49 Allowed 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.565 2.176 . . . . 0.0 112.419 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.461 ' CZ ' ' HD3' ' A' ' 15' ' ' LYS . 11.9 mtt85 -121.55 9.57 10.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.531 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.41 153.54 58.89 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.747 0.784 . . . . 0.0 110.832 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.8 Cg_endo -69.88 176.78 31.57 Favored 'Cis proline' 0 C--N 1.343 0.253 0 C-N-CA 122.6 -1.834 . . . . 0.0 112.325 0.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.548 ' CZ ' HD11 ' A' ' 92' ' ' ILE . 84.8 m-85 -113.99 132.02 56.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.4 ptmm? -87.28 111.65 21.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.2 t -123.49 101.66 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -84.99 100.05 11.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 81.5 t -71.23 148.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.132 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 60.4 mt -113.86 155.5 45.12 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 0.0 110.908 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.6 Cg_endo -69.71 121.63 8.32 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.69 2.26 . . . . 0.0 112.378 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 103' ' ' PRO . 99.5 m -33.96 -34.94 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.139 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.468 ' N ' ' O ' ' A' ' 103' ' ' PRO . 26.7 m-85 -106.61 156.39 18.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.95 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -113.94 96.88 6.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -68.06 82.92 0.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 60.2 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 -179.8 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.431 -0.268 . . . . 0.0 112.431 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 m -68.94 122.98 19.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.871 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 4' ' ' GLY . 15.1 t -109.23 163.29 13.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.838 -179.784 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 3' ' ' SER . . . -35.82 131.83 0.75 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.445 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' SER . 16.5 m -103.65 108.31 19.54 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.91 0.386 . . . . 0.0 110.903 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 5' ' ' SER . 2.7 m 34.65 42.14 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.841 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 83.39 108.38 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.469 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.2 m -74.59 152.42 6.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.145 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.5 t -107.93 136.76 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.124 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -129.88 95.42 28.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 0.0 110.878 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 -0.79 7.47 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.668 2.245 . . . . 0.0 112.385 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.8 m -98.7 2.1 46.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.819 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -108.48 -7.16 15.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.447 ' CG1' HG23 ' A' ' 92' ' ' ILE . 1.7 p -88.86 123.93 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.157 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -123.21 174.46 7.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.536 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 20.5 pt -145.59 133.45 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.09 135.69 29.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.99 170.46 35.2 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.444 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -31.64 20.27 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.349 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.89 -42.6 98.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 7.8 mt -77.39 -23.72 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.82 173.85 0.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.445 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.5 m -87.16 -11.84 48.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.96 0.409 . . . . 0.0 110.859 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.28 45.33 3.26 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.432 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.454 HG11 ' NE2' ' A' ' 31' ' ' GLN . 74.8 t -93.19 146.49 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 0.0 111.138 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.466 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . 28.7 mtm-85 -121.27 151.32 40.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.839 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.72 147.07 49.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.063 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.0 mtm-85 56.32 33.68 22.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 26' ' ' ARG . 85.8 t -123.74 143.8 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.2 tp -68.0 111.05 4.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.968 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.454 ' NE2' HG11 ' A' ' 25' ' ' VAL . 52.3 mm-40 -114.13 130.45 56.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 38.6 t -145.48 148.76 33.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.867 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.53 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.9 p90 -140.66 -178.22 5.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 98.8 m -119.92 129.13 54.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.471 ' CG1' HG21 ' A' ' 16' ' ' ILE . 55.4 t -108.94 106.11 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.144 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -87.57 107.19 18.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 84.5 p -123.12 22.09 9.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.877 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.3 t -66.78 -35.96 81.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.886 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.4 mmtm -83.1 -8.64 59.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.478 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -82.91 -34.32 26.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.149 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.15 -135.48 8.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.514 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.477 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -122.77 22.1 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.857 0.361 . . . . 0.0 110.945 -179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.482 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -79.25 151.71 75.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.579 0.704 . . . . 0.0 111.071 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.441 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.3 Cg_endo -69.77 166.52 27.31 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.39 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.469 HD12 ' CG1' ' A' ' 85' ' ' VAL . 11.4 tp -124.26 134.88 53.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.941 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -119.41 147.06 44.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 48' ' ' ARG . 48.3 t -136.97 150.38 26.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.149 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.418 ' N ' HG13 ' A' ' 47' ' ' VAL . 18.6 mtt-85 -154.23 133.37 12.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.424 HG22 ' CG1' ' A' ' 59' ' ' VAL . 62.0 t -112.91 128.61 69.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.141 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -124.44 127.45 47.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.971 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.72 179.71 37.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.479 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.486 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.84 -37.95 8.28 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.669 2.246 . . . . 0.0 112.316 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.62 -31.27 21.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.913 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.06 30.19 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.8 tp -81.75 147.51 29.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.936 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.3 t -110.41 105.63 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.128 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -96.46 144.91 28.66 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.671 0.748 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 168.12 22.52 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.717 2.278 . . . . 0.0 112.317 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.424 ' CG1' HG22 ' A' ' 49' ' ' VAL . 20.5 m -142.75 167.45 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.16 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.426 ' ND2' ' C ' ' A' ' 60' ' ' ASN . 0.4 OUTLIER -125.05 141.74 51.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.5 t -132.84 111.03 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.169 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 90.3 t -138.93 115.42 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.146 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.523 ' OD2' ' CE1' ' A' ' 69' ' ' HIS . 10.2 t70 -72.51 139.9 47.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.884 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -77.68 -43.25 31.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.46 ' N ' ' OD1' ' A' ' 63' ' ' ASP . . . 115.38 -20.07 14.19 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.473 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -91.61 -41.73 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.876 0.37 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.13 33.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.433 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.508 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 71.0 p -149.34 177.33 9.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.796 0.331 . . . . 0.0 111.158 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.523 ' CE1' ' OD2' ' A' ' 63' ' ' ASP . 12.5 m-70 -146.94 125.06 12.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 34.5 m -84.53 140.4 31.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.083 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.53 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 67.3 t -131.03 103.78 8.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.139 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.0 p -93.44 139.29 30.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.2 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.505 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.1 p90 -159.9 169.15 24.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.927 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -147.14 115.66 4.32 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.631 0.729 . . . . 0.0 111.104 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.505 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.74 99.01 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.255 . . . . 0.0 112.331 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 75' ' ' PRO . 32.5 t -35.6 -54.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.859 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -128.77 177.55 6.98 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.18 166.35 14.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.99 173.14 13.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.555 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 92.49 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.366 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.486 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.3 m-85 -92.0 151.97 20.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' MET . . . . . 0.455 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.7 tmm? -119.91 129.19 54.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.873 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.45 95.84 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.159 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -79.24 139.06 38.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.469 ' CG1' HD12 ' A' ' 45' ' ' LEU . 61.5 t -136.92 134.22 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 42.7 tttt -123.25 167.18 14.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.482 ' CE2' ' HB1' ' A' ' 43' ' ' ALA . 10.9 t80 -154.5 105.55 2.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 64.8 42.96 4.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.09 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.418 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 13.2 m-20 63.35 32.94 14.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -142.69 105.11 4.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -56.98 111.79 1.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.454 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 46.3 pt -49.5 152.86 2.12 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 111.097 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 4.11 2.41 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.651 2.234 . . . . 0.0 112.365 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 49.7 mtt85 -115.04 -1.28 13.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.531 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -113.37 153.83 45.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.672 0.748 . . . . 0.0 110.863 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.3 Cg_endo -69.74 177.96 27.02 Favored 'Cis proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.351 -0.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.536 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 79.9 m-85 -116.93 140.83 49.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -100.2 111.46 23.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -121.52 103.45 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.078 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.3 tttp -81.91 103.25 11.44 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.61 143.14 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.07 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 74.7 mt -111.83 155.76 42.69 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.557 0.694 . . . . 0.0 110.964 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.493 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.85 123.54 10.18 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.656 2.237 . . . . 0.0 112.334 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 54.4 m -39.02 -25.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.493 ' N ' ' O ' ' A' ' 103' ' ' PRO . 10.3 m-85 -98.46 143.78 28.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.863 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -164.53 113.27 1.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.896 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -104.68 43.68 1.08 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.113 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.7 p . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.857 -179.801 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.4 m -60.54 151.78 27.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.962 0.411 . . . . 0.0 110.788 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 90.7 p -104.27 42.59 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.04 122.65 5.09 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.49 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.3 m -136.18 173.09 12.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.836 0.35 . . . . 0.0 110.868 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.8 t -123.41 129.09 50.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.39 61.75 1.3 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.438 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.404 HG23 ' N ' ' A' ' 9' ' ' VAL . 13.0 p -127.16 143.43 40.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.739 0.304 . . . . 0.0 111.158 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.404 ' N ' HG23 ' A' ' 8' ' ' VAL . 73.5 t -117.39 131.23 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.144 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -131.73 97.62 18.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.611 0.72 . . . . 0.0 110.819 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 -1.75 9.0 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.645 2.23 . . . . 0.0 112.365 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -101.12 14.04 33.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.8 mmpt? -117.83 -8.38 10.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -84.31 132.4 31.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.119 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.2 mtmt -126.49 169.48 12.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.552 HD13 ' CZ ' ' A' ' 97' ' ' PHE . 37.3 pt -145.74 133.81 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.144 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.65 146.18 35.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 160.13 172.15 26.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -33.41 16.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.674 2.249 . . . . 0.0 112.366 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.45 -42.05 93.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.469 HD13 ' CD1' ' A' ' 16' ' ' ILE . 8.6 mt -80.43 -25.87 38.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.17 176.63 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.479 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.7 t -89.46 -16.58 30.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.976 0.417 . . . . 0.0 110.917 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.82 47.79 3.86 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.414 HG11 ' CD ' ' A' ' 31' ' ' GLN . 66.1 t -99.81 141.5 16.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.784 0.326 . . . . 0.0 111.156 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -117.64 151.54 37.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.67 152.41 42.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 55.32 40.2 31.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.27 144.37 34.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 14.7 tp -66.4 115.17 6.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.512 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 47.6 mm-40 -120.32 127.06 52.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.867 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -141.45 149.63 41.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.839 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 3.5 p90 -142.18 176.55 8.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 83.9 m -114.21 136.96 52.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.5 t -115.16 105.33 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.158 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -87.74 98.47 11.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.903 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 95.5 p -114.4 30.36 7.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.928 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 87.9 p -76.68 -34.68 58.21 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -76.6 -22.01 54.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.537 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -74.56 -41.34 60.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.075 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.427 ' C ' HD11 ' A' ' 42' ' ' LEU . . . 138.34 -147.04 18.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.482 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.48 HD11 ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -107.18 17.01 23.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.494 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -75.39 151.44 85.42 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.607 0.718 . . . . 0.0 111.112 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 167.56 24.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.26 . . . . 0.0 112.362 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.1 tp -125.88 139.72 53.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.961 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -117.01 146.69 42.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 58.4 t -139.51 134.22 39.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.137 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -140.79 141.12 34.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.859 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 98.9 t -123.32 127.49 74.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.056 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -125.11 124.57 42.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.77 167.87 47.49 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -47.78 0.86 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -71.44 -38.63 71.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.931 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.28 34.93 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.501 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.409 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 8.4 tp -94.44 149.21 21.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.87 0.367 . . . . 0.0 110.903 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.409 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.7 t -115.64 116.25 51.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.146 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -115.63 139.32 24.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.719 0.771 . . . . 0.0 110.851 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 174.74 9.03 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.771 2.314 . . . . 0.0 112.381 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.7 m -140.34 162.13 24.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.9 t30 -117.59 138.54 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.5 p -131.68 119.93 43.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.072 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 92.2 t -138.81 126.32 26.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -79.09 133.29 36.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.813 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -75.29 -46.51 33.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.884 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.15 -23.81 9.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.444 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.4 -44.15 10.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.891 0.376 . . . . 0.0 110.873 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.6 33.94 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.417 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.2 p -150.93 177.59 9.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.329 . . . . 0.0 111.144 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.4 m-70 -145.99 126.62 14.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 35.0 m -86.04 142.49 28.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.111 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.4 t -132.48 108.47 13.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.092 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 27.8 p -97.6 142.31 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.089 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.512 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 8.7 p90 -161.49 175.75 11.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.946 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -150.42 114.27 3.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.639 0.733 . . . . 0.0 111.137 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.483 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 89.09 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.697 2.265 . . . . 0.0 112.329 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 75' ' ' PRO . 44.4 t -35.67 -53.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -122.44 166.64 14.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.953 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -89.69 166.48 13.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.84 179.59 16.12 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.71 86.45 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.691 2.261 . . . . 0.0 112.345 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -76.93 171.66 14.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.1 ttp -143.8 113.25 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.06 96.11 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.084 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 2.0 m -81.46 145.52 30.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 88.7 t -139.29 138.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.094 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -125.92 170.19 11.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.923 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.537 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 8.2 t80 -155.24 110.69 3.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.962 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 61.63 39.77 14.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.115 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 65.52 35.52 7.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.828 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -145.49 105.02 3.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -53.44 118.01 3.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.414 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 47.0 pt -57.18 153.43 25.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.567 0.698 . . . . 0.0 111.163 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 5.15 1.82 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.665 2.244 . . . . 0.0 112.354 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 75.8 mtt85 -118.49 6.32 11.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.528 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -119.8 154.07 54.93 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.612 0.72 . . . . 0.0 110.835 -179.803 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.528 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.76 178.86 24.0 Favored 'Cis proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.717 -1.784 . . . . 0.0 112.318 0.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.552 ' CZ ' HD13 ' A' ' 16' ' ' ILE . 68.7 m-85 -115.5 126.56 54.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.4 ptmt -90.94 107.42 19.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.9 t -117.67 107.82 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.13 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -84.62 97.64 9.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.8 t -69.19 147.39 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.134 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 61.6 mt -112.24 155.51 43.45 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.641 0.734 . . . . 0.0 110.949 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.68 123.93 10.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.723 2.282 . . . . 0.0 112.31 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 103' ' ' PRO . 59.6 m -34.61 -32.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.192 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.488 ' N ' ' O ' ' A' ' 103' ' ' PRO . 15.6 m-85 -100.22 136.06 40.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.21 7.33 16.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.916 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . 41.73 41.44 1.77 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.4 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.799 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.7 m -119.34 176.38 5.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.928 0.394 . . . . 0.0 110.848 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.1 m -151.97 161.82 42.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.853 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 157.64 -148.13 17.19 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.477 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.5 m -66.17 107.07 1.82 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.904 0.383 . . . . 0.0 110.803 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.4 p -94.77 148.31 22.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.839 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.22 -74.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.516 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.9 p -38.1 152.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.836 0.35 . . . . 0.0 111.167 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.1 t -95.71 131.21 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.29 96.21 25.4 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.63 0.729 . . . . 0.0 110.84 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.74 3.11 2.95 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 50.3 m -102.77 -0.29 31.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.0 mmpt? -103.94 -8.82 19.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.411 ' CG1' HG23 ' A' ' 92' ' ' ILE . 2.6 p -85.79 128.18 39.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.411 ' N ' ' HD3' ' A' ' 15' ' ' LYS . 1.2 mppt? -126.83 171.15 11.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.873 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.549 HD12 ' CE2' ' A' ' 97' ' ' PHE . 18.2 pt -144.08 135.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.99 126.58 17.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.3 171.38 38.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -32.58 18.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.637 2.225 . . . . 0.0 112.365 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.9 -36.05 65.41 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.403 HD13 ' CD1' ' A' ' 16' ' ' ILE . 4.7 mt -87.04 -15.5 38.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.851 0.358 . . . . 0.0 110.901 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.67 178.65 3.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.513 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 90.0 p -92.48 -11.77 33.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.96 46.03 3.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.455 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.421 HG13 ' N ' ' A' ' 26' ' ' ARG . 97.8 t -95.69 142.21 14.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 111.092 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.421 ' N ' HG13 ' A' ' 25' ' ' VAL . 95.1 mtt180 -118.55 153.65 33.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.845 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.51 145.36 47.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.072 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.6 mtt180 59.59 42.23 17.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.95 148.35 30.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.126 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -70.5 112.31 6.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 47.1 mm-40 -117.43 128.95 55.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.4 t -148.41 161.16 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.486 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -151.85 -176.08 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.8 m -117.86 128.79 55.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.167 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.2 t -109.34 107.98 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.152 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -88.79 103.93 16.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.943 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.2 p -122.61 27.24 7.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 28.1 t -68.82 -37.32 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.872 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -81.07 -19.87 42.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.543 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -69.71 -37.5 76.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 131.58 -143.12 14.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.449 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.551 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -113.69 19.0 17.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.827 0.346 . . . . 0.0 110.875 -179.906 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.471 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -77.15 151.37 81.42 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.562 0.696 . . . . 0.0 111.153 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.452 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.6 Cg_endo -69.72 167.1 25.37 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 tp -127.29 130.97 50.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -118.57 143.91 46.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.826 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 81.8 t -137.44 124.56 29.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.152 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -115.07 149.04 38.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.462 HG23 ' CG2' ' A' ' 59' ' ' VAL . 48.6 t -123.7 120.59 60.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.211 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -96.68 175.21 6.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.34 159.73 24.17 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.478 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -41.75 4.06 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.689 2.26 . . . . 0.0 112.397 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.22 -14.9 34.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 114.58 36.58 1.28 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.439 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.4 tp -100.27 146.55 26.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 0.0 110.939 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 37.8 t -116.21 123.76 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.204 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.474 ' N ' ' OE1' ' A' ' 57' ' ' GLU . 27.1 mp0 -117.07 140.62 27.29 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.637 0.732 . . . . 0.0 110.853 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 176.96 6.11 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.659 2.239 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.462 ' CG2' HG23 ' A' ' 49' ' ' VAL . 61.8 t -144.29 160.16 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.152 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.45 ' N ' HG11 ' A' ' 59' ' ' VAL . 20.5 t30 -106.79 138.3 43.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 95.9 t -132.77 113.31 20.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 67.1 t -141.15 125.37 17.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -75.15 142.83 43.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -80.24 -43.2 21.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.5 -20.91 13.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.454 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -92.99 -39.44 11.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.887 0.375 . . . . 0.0 110.842 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.43 34.48 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.503 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.4 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 67.9 p -151.74 176.82 11.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.819 0.342 . . . . 0.0 111.146 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.4 ' CD2' ' C ' ' A' ' 68' ' ' THR . 18.4 m-70 -142.96 129.7 20.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.3 m -86.76 137.71 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.486 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 33.1 t -130.11 101.51 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 64.3 p -95.31 144.32 25.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.166 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.499 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 3.9 p90 -163.88 168.32 19.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -146.09 115.99 4.74 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.607 0.718 . . . . 0.0 111.161 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.499 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.0 Cg_endo -69.76 93.42 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.658 2.239 . . . . 0.0 112.357 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 t -34.77 -58.85 0.5 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -120.87 168.76 11.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -86.53 170.24 12.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.47 178.16 15.22 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 93.71 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.705 2.27 . . . . 0.0 112.352 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -94.91 171.55 8.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 ttp -147.72 120.26 8.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.21 96.49 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.415 ' C ' HG23 ' A' ' 85' ' ' VAL . 31.8 t -78.58 150.46 32.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.871 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.415 HG23 ' C ' ' A' ' 84' ' ' SER . 86.2 t -140.86 133.77 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.077 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 39.7 tttt -125.02 170.0 11.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.543 ' CE2' ' HB3' ' A' ' 40' ' ' ALA . 7.5 t80 -157.41 112.81 2.8 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.469 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 59.49 35.57 22.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.141 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 71.4 30.73 2.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -139.16 105.82 5.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.926 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -56.69 112.24 1.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.438 HD13 ' CZ ' ' A' ' 97' ' ' PHE . 44.5 pt -50.46 152.73 3.04 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.641 0.734 . . . . 0.0 111.141 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 4.27 2.33 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.422 ' O ' ' CE1' ' A' ' 97' ' ' PHE . 22.9 mmm180 -114.85 -1.26 13.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.805 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -113.51 154.27 45.56 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.607 0.717 . . . . 0.0 110.863 -179.745 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.1 Cg_endo -69.84 179.67 21.81 Favored 'Cis proline' 0 C--O 1.232 0.191 0 C-N-CA 122.646 -1.814 . . . . 0.0 112.299 0.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.549 ' CE2' HD12 ' A' ' 16' ' ' ILE . 85.9 m-85 -120.87 119.54 32.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.63 116.23 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.51 102.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -85.18 102.31 13.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.39 147.21 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.174 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.2 mt -117.54 154.81 50.76 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.604 0.716 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 123.81 10.46 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.716 2.277 . . . . 0.0 112.338 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.3 m -39.6 -30.33 0.07 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.139 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -108.23 139.72 42.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -108.98 81.6 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -73.46 87.01 1.56 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.855 -179.78 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.444 -0.263 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.3 p -157.79 109.85 2.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.84 0.352 . . . . 0.0 110.838 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 93.2 p -76.65 141.09 41.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -94.72 -67.67 1.02 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.449 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -133.22 92.9 3.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.853 0.359 . . . . 0.0 110.855 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -88.7 42.15 1.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.869 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 53.9 60.36 8.5 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.506 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.4 p -119.0 147.4 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.863 0.363 . . . . 0.0 111.099 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.3 t -102.86 136.3 36.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.083 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.03 97.08 18.87 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.905 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 -2.05 9.54 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.719 2.279 . . . . 0.0 112.295 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 44.5 p -101.71 17.68 22.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.894 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 mmpt? -121.05 -7.37 9.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.881 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -84.66 128.49 38.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.16 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.6 mtpt -124.28 168.08 13.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.936 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.523 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 13.1 pt -144.83 134.79 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.173 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.07 130.58 22.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.041 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.64 168.82 35.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -32.09 19.18 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.298 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.4 -43.78 84.99 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.4 mt -78.33 -26.23 46.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -49.48 172.68 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.487 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.5 m -86.35 -18.62 31.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.822 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -82.83 45.46 3.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.519 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.471 HG11 ' N ' ' A' ' 26' ' ' ARG . 43.9 t -94.95 142.5 13.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.871 0.367 . . . . 0.0 111.102 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.471 ' N ' HG11 ' A' ' 25' ' ' VAL . 49.7 mtm180 -117.79 160.01 22.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -78.2 149.58 33.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.091 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 51.6 mtm-85 55.63 32.04 18.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.85 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.48 HG13 ' N ' ' A' ' 30' ' ' LEU . 61.4 t -121.48 140.02 46.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.11 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.48 ' N ' HG13 ' A' ' 29' ' ' VAL . 8.7 tp -65.8 110.84 2.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.532 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 54.7 mm-40 -113.12 133.12 55.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 22.1 t -146.37 154.35 41.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.535 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.1 p90 -148.13 -178.49 6.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.878 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.5 m -122.22 132.02 54.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.174 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.3 t -112.07 105.12 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.132 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -86.07 98.22 10.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 95.6 p -113.03 25.33 11.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.8 t -72.57 -37.49 68.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -74.39 -20.78 59.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.511 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -73.99 -38.67 64.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.063 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.58 -136.49 8.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.573 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.53 20.0 13.12 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.759 0.314 . . . . 0.0 110.839 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.47 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -76.99 151.67 82.02 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.556 0.693 . . . . 0.0 111.091 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 166.73 26.6 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.381 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.439 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.3 tp -124.72 135.13 52.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -116.9 145.86 43.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.941 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.466 ' CG1' HG12 ' A' ' 59' ' ' VAL . 60.2 t -134.18 147.68 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.125 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -152.07 133.29 14.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 87.6 t -116.92 124.98 73.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.43 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.2 mm? -123.65 121.67 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.946 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.21 172.83 8.81 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.487 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -48.44 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.707 2.271 . . . . 0.0 112.373 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -71.83 -39.2 69.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.84 32.79 0.12 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.506 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.447 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 9.1 tp -91.3 153.32 20.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.807 0.336 . . . . 0.0 110.92 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.447 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.8 t -115.37 130.08 70.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.068 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -133.12 140.85 38.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.699 0.761 . . . . 0.0 110.869 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 170.68 15.95 Favored 'Trans proline' 0 C--N 1.343 0.247 0 C-N-CA 122.617 2.211 . . . . 0.0 112.419 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 ' CG1' ' A' ' 47' ' ' VAL . 67.2 t -141.52 154.66 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -100.35 137.69 38.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.411 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 10.6 p -133.54 116.55 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 82.3 t -138.31 130.29 38.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.134 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -82.3 140.48 33.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -79.95 -45.33 18.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.09 -25.22 8.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -88.11 -41.63 12.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.877 0.37 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.96 34.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 62.3 p -149.35 177.5 9.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.139 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.6 m-70 -145.92 123.73 11.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 65.7 m -85.23 136.47 33.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.166 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.535 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.6 t -129.09 112.71 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.4 p -103.93 146.72 28.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.566 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.9 p90 -165.79 177.44 7.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.986 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.1 m -154.31 113.74 2.47 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.551 0.691 . . . . 0.0 111.109 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.566 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.2 Cg_endo -69.82 93.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.642 2.228 . . . . 0.0 112.333 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 75' ' ' PRO . 31.2 t -34.14 -59.78 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -116.35 167.81 10.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.937 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -83.76 166.26 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.836 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.78 169.31 12.32 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.98 91.24 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.605 2.203 . . . . 0.0 112.276 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -82.97 172.06 13.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 17.6 ttp -140.74 118.72 11.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.846 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 71.8 t -110.26 96.88 5.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.178 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.3 m -81.6 145.08 30.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.924 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.456 HG13 ' N ' ' A' ' 86' ' ' LYS . 98.0 t -138.75 137.29 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.108 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.456 ' N ' HG13 ' A' ' 85' ' ' VAL . 43.1 tttt -123.22 169.1 11.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.899 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.511 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 5.6 t80 -155.59 111.46 3.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.413 ' HB2' ' CB ' ' A' ' 43' ' ' ALA . . . 62.56 37.9 12.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.036 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.419 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 5.6 m-20 66.4 35.34 5.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.817 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -145.78 104.99 3.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -52.26 113.0 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.481 HD12 ' CE2' ' A' ' 97' ' ' PHE . 45.6 pt -51.37 153.14 3.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.604 0.716 . . . . 0.0 111.179 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 4.89 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.696 2.264 . . . . 0.0 112.326 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 20.1 mmt180 -116.98 1.54 12.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.841 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.527 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.09 154.34 48.51 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.661 0.743 . . . . 0.0 110.883 -179.798 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.2 Cg_endo -69.78 177.47 28.8 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.654 -1.811 . . . . 0.0 112.353 -0.022 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.523 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 86.9 m-85 -116.84 146.29 42.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.839 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.03 131.49 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.914 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 69.5 t -134.98 101.62 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.113 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -82.78 94.0 7.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.918 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -71.07 145.22 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.073 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 57.3 mt -118.77 155.82 52.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.634 0.731 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.2 Cg_endo -69.67 116.25 4.46 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.672 2.248 . . . . 0.0 112.408 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 52.1 m -34.01 -33.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.498 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.5 m-85 -81.82 48.09 1.17 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.955 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -90.19 35.93 0.87 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.914 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.23 41.63 0.61 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.105 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.7 m . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.874 -179.787 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 t 65.11 42.93 3.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.867 0.365 . . . . 0.0 110.896 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.6 t -109.71 147.1 33.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.859 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 138.8 178.71 16.57 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.466 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 90.6 p -102.21 115.46 30.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.353 . . . . 0.0 110.824 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.1 m -93.26 43.15 1.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.897 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 56.98 49.94 67.75 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.53 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -130.12 143.94 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.866 0.365 . . . . 0.0 111.094 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.8 t -108.08 135.21 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.194 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -133.79 96.86 16.02 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.652 0.739 . . . . 0.0 110.801 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -1.5 8.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.642 2.228 . . . . 0.0 112.364 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 48.0 m -100.97 12.56 37.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.819 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.1 mmpt? -117.47 -9.16 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.38 135.84 24.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.116 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.405 ' C ' HG23 ' A' ' 16' ' ' ILE . 7.8 mtpm? -132.64 168.0 19.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.561 HD12 ' CZ ' ' A' ' 97' ' ' PHE . 36.8 pt -144.33 135.37 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.98 133.14 26.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.056 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.01 175.36 40.13 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.445 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 -35.35 12.72 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.667 2.245 . . . . 0.0 112.362 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.36 -42.56 83.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.46 HD13 ' CD1' ' A' ' 16' ' ' ILE . 11.8 mt -77.45 -28.33 52.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.943 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.85 176.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 t -92.01 -18.03 24.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.906 0.384 . . . . 0.0 110.839 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.26 48.76 4.09 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.459 HG12 ' N ' ' A' ' 26' ' ' ARG . 59.5 t -94.11 140.56 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.336 . . . . 0.0 111.169 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.459 ' N ' HG12 ' A' ' 25' ' ' VAL . 52.4 mtt180 -118.46 148.63 42.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.51 42.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 44.7 mtp180 54.73 39.19 31.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 30' ' ' LEU . 42.6 t -134.79 143.15 38.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.154 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.456 ' N ' HG12 ' A' ' 29' ' ' VAL . 22.5 tp -66.24 114.43 5.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.973 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.492 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 42.3 mm-40 -117.73 128.3 54.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.2 t -139.86 164.82 28.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.822 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.556 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -157.86 167.89 28.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -107.3 131.19 54.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.468 ' CG2' HG22 ' A' ' 16' ' ' ILE . 58.1 t -111.41 105.27 18.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.083 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -88.5 103.17 15.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.9 p -117.96 26.12 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.817 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.1 t -71.67 -39.05 70.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.861 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -72.99 -22.09 60.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.472 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -72.26 -41.58 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.084 179.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 139.23 -136.67 8.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.596 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.22 18.24 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.839 0.352 . . . . 0.0 110.983 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.37 152.0 83.51 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.568 0.699 . . . . 0.0 111.102 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.81 166.79 26.46 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 0.0 112.272 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.455 HD11 ' CG1' ' A' ' 85' ' ' VAL . 3.5 tp -125.48 139.57 53.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.891 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.4 tt0 -125.27 148.03 48.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.423 HG11 ' N ' ' A' ' 48' ' ' ARG . 40.2 t -140.82 152.12 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.111 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.423 ' N ' HG11 ' A' ' 47' ' ' VAL . 49.4 mtm-85 -153.16 138.53 17.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.893 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.446 HG22 ' CG2' ' A' ' 59' ' ' VAL . 93.4 t -118.31 124.09 72.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.1 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.413 ' N ' HD23 ' A' ' 50' ' ' LEU . 3.2 mm? -113.32 152.34 30.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.927 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.67 168.48 22.7 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.472 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.85 -44.74 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.675 2.25 . . . . 0.0 112.299 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -78.14 -29.67 48.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.37 28.38 0.48 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.476 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.4 tp -88.85 144.37 26.26 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -115.93 117.1 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.108 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -112.94 141.98 26.47 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.7 0.762 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 175.85 7.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.46 ' CG1' ' CG1' ' A' ' 71' ' ' VAL . 23.4 t -144.35 153.63 15.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.092 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.453 ' N ' HG11 ' A' ' 59' ' ' VAL . 13.2 t30 -99.63 139.16 35.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.832 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.1 t -133.26 108.38 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 86.4 t -131.51 129.67 62.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.1 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -84.13 133.65 34.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -74.42 -44.24 52.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.49 -25.2 9.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.3 m-20 -88.42 -44.38 10.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.908 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.33 33.49 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.513 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 73.3 p -147.64 177.13 9.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -145.4 131.56 19.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.3 m -92.81 134.94 34.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.556 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 39.3 t -129.7 106.36 13.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.145 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.7 p -103.67 140.82 37.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.195 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.566 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 15.7 p90 -156.78 -176.02 5.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -156.53 112.2 2.03 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 121.569 0.699 . . . . 0.0 111.081 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.566 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.81 90.22 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.695 2.263 . . . . 0.0 112.359 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 75' ' ' PRO . 27.8 m -33.85 -57.61 0.45 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.934 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -118.73 166.36 12.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -85.34 172.28 11.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.908 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.07 174.15 13.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.472 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.73 89.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.628 2.219 . . . . 0.0 112.386 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -86.25 164.35 17.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 39.7 ttp -137.32 119.02 15.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.8 t -105.07 95.91 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.133 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 41.3 t -80.51 143.26 33.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.455 ' CG1' HD11 ' A' ' 45' ' ' LEU . 87.0 t -139.25 142.98 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.446 ' N ' HG12 ' A' ' 85' ' ' VAL . 14.5 tttp -129.62 168.37 16.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 37' ' ' SER . 4.9 t80 -154.03 114.68 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 59.7 36.06 22.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.127 179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.429 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 0.8 OUTLIER 68.57 35.3 3.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.861 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -147.59 105.17 3.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -50.39 120.13 4.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.401 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 43.7 pt -58.62 153.93 37.94 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.634 0.73 . . . . 0.0 111.105 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 5.72 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.66 2.24 . . . . 0.0 112.39 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -119.81 8.17 11.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.531 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.84 153.71 60.42 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.5 Cg_endo -69.72 177.93 27.06 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.399 -0.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.561 ' CZ ' HD12 ' A' ' 16' ' ' ILE . 52.2 m-85 -115.2 127.96 55.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.929 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.2 ptpt -87.72 110.07 20.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.99 101.64 9.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -83.11 103.64 12.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.5 t -70.22 143.72 14.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -112.26 155.91 42.86 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.584 0.707 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.494 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.77 121.29 7.98 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.688 2.258 . . . . 0.0 112.307 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 33.3 m -35.24 -31.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.188 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.6 m-85 -110.09 161.27 15.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -96.19 109.76 22.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -84.81 41.26 0.85 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.032 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.843 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.382 0 N-CA-C 112.538 -0.225 . . . . 0.0 112.538 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.9 t 53.65 42.25 31.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.892 0.377 . . . . 0.0 110.903 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.5 t -45.42 163.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.44 113.19 0.51 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.525 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 61.8 m -91.47 138.9 31.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.866 0.365 . . . . 0.0 110.842 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 83.5 p -144.84 158.35 43.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.7 65.83 0.48 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.513 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.466 HG21 ' N ' ' A' ' 9' ' ' VAL . 11.5 p -106.79 159.51 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.911 0.386 . . . . 0.0 111.094 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.466 ' N ' HG21 ' A' ' 8' ' ' VAL . 53.5 t -97.78 134.4 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.091 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -128.46 95.33 33.22 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.627 0.727 . . . . 0.0 110.859 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.87 9.2 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.645 2.23 . . . . 0.0 112.37 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.4 p -99.71 9.06 43.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.811 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.9 mmpt? -113.06 -6.64 13.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.889 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -86.5 127.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.422 ' C ' HG22 ' A' ' 16' ' ' ILE . 26.4 mtmm -124.44 168.16 13.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.877 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.516 HD13 ' CE2' ' A' ' 97' ' ' PHE . 25.9 pt -144.07 136.34 22.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.165 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.54 144.96 33.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.094 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.34 177.06 30.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -39.67 6.21 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.689 2.259 . . . . 0.0 112.34 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.61 -30.26 13.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.454 ' CD1' HG13 ' A' ' 16' ' ' ILE . 15.1 mt -95.6 -22.52 17.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.862 0.363 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.47 164.67 5.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p -83.95 14.56 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.924 0.393 . . . . 0.0 110.898 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.9 44.25 1.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.415 HG13 ' NE2' ' A' ' 31' ' ' GLN . 76.3 t -95.65 149.12 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.849 0.357 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 93.0 mtt-85 -124.31 153.63 41.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.4 151.94 40.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 54.47 39.29 30.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.3 t -134.13 144.62 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.3 tp -66.85 113.9 5.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.918 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 48.2 mm-40 -117.43 130.03 56.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 25.0 t -143.74 163.32 33.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.835 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.513 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -154.88 -177.8 6.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.4 m -119.06 131.03 55.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.1 t -111.7 105.07 18.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.11 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -86.5 102.54 14.19 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.448 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.7 p -119.31 29.01 7.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.3 t -76.29 -34.53 59.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.3 mttp -80.17 -16.09 55.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.544 ' HB2' ' CE2' ' A' ' 87' ' ' TYR . . . -79.05 -38.25 36.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.128 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -141.4 12.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.559 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -114.98 19.02 16.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.763 0.316 . . . . 0.0 110.854 -179.908 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.451 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . . . -76.24 151.47 83.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.606 0.717 . . . . 0.0 111.154 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 166.76 26.42 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.262 . . . . 0.0 112.376 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.432 HD13 ' CG1' ' A' ' 85' ' ' VAL . 5.3 tp -126.18 136.54 52.97 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.941 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -121.9 146.38 47.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 84.9 t -138.77 129.11 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.198 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.3 ttm-85 -125.05 140.26 53.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.438 HG21 ' CG2' ' A' ' 59' ' ' VAL . 92.1 t -119.82 116.97 52.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -115.37 125.69 53.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.28 175.23 15.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.465 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.0 Cg_endo -69.73 -43.27 2.79 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.31 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.422 ' HB2' ' NH1' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -75.3 -38.08 60.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.865 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.67 33.24 0.14 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.481 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.449 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 6.4 tp -90.33 155.84 18.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 110.937 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.449 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 91.9 t -117.94 118.65 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -117.38 143.37 31.91 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.679 0.752 . . . . 0.0 110.886 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 168.18 22.32 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.688 2.259 . . . . 0.0 112.359 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.438 ' CG2' HG21 ' A' ' 49' ' ' VAL . 3.5 t -140.59 144.49 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.125 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -93.12 138.41 31.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 9.5 p -133.23 117.97 30.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 80.4 t -135.55 138.44 48.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -89.63 138.54 31.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.865 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -81.45 -46.38 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.58 -25.08 9.3 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.531 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -87.94 -43.63 11.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.821 0.343 . . . . 0.0 110.785 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.56 33.85 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.431 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.547 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.8 p -150.43 177.66 9.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.822 0.344 . . . . 0.0 111.114 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.547 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.9 m-70 -145.7 127.36 15.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 54.6 m -86.38 132.5 33.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.145 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.513 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.1 t -125.58 111.01 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.081 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 61.9 p -102.38 147.02 27.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.108 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.54 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.6 p90 -165.36 173.47 11.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.6 m -149.49 113.87 3.51 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.577 0.703 . . . . 0.0 111.125 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.54 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.79 93.3 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.702 2.268 . . . . 0.0 112.292 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 3.7 m -34.26 -45.52 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.882 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -135.29 170.76 15.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.404 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.1 pp20? -86.2 177.63 7.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.33 173.98 14.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 83.45 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.684 2.256 . . . . 0.0 112.343 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.465 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.8 m-85 -78.43 172.53 13.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.947 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.6 ttp -143.68 115.61 8.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.827 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.1 t -104.36 95.4 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.129 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 33.8 t -77.32 147.26 36.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.432 ' CG1' HD13 ' A' ' 45' ' ' LEU . 49.4 t -139.93 137.44 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.079 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.417 ' N ' HG12 ' A' ' 85' ' ' VAL . 17.3 tttp -128.65 169.36 14.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.544 ' CE2' ' HB2' ' A' ' 40' ' ' ALA . 5.2 t80 -155.0 110.76 3.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.451 ' HB3' ' CB ' ' A' ' 43' ' ' ALA . . . 60.71 39.79 17.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.044 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.408 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 39.3 m-20 67.15 32.66 6.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.968 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -142.55 105.22 4.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -53.79 116.89 2.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.414 ' CG1' ' HB3' ' A' ' 95' ' ' SER . 45.5 pt -56.13 153.12 19.45 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.593 0.711 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 4.69 2.05 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.653 2.235 . . . . 0.0 112.421 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 39.3 mmt180 -117.19 4.53 12.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.909 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.53 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -117.96 153.98 51.24 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.672 0.749 . . . . 0.0 110.873 -179.85 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.8 -178.83 17.64 Favored 'Cis proline' 0 C--N 1.341 0.15 0 C-N-CA 122.756 -1.768 . . . . 0.0 112.303 0.089 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.516 ' CE2' HD13 ' A' ' 16' ' ' ILE . 77.4 m-85 -118.48 125.38 49.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 29.8 pttt -83.52 109.87 17.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 94.7 t -123.36 101.86 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.099 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 12.5 tttp -84.19 94.08 8.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.992 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.404 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 63.4 t -63.39 145.94 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 65.9 mt -111.23 155.95 41.86 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.554 0.692 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.72 122.4 9.09 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.7 2.266 . . . . 0.0 112.33 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -34.12 -35.21 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.461 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 -79.07 142.06 36.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.841 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -124.35 151.05 44.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.895 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -90.76 36.31 0.9 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 98.0 p . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.819 -179.752 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.9 m -117.88 166.83 12.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.902 0.382 . . . . 0.0 110.837 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.2 m -129.39 151.44 50.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.854 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.36 138.83 5.84 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.502 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.5 t 40.88 42.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.824 0.345 . . . . 0.0 110.844 -179.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.8 t -140.37 113.98 8.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.52 63.55 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.548 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.5 p -71.36 156.61 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 111.076 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.8 t -97.42 124.7 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 m-20 -121.15 98.22 47.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.623 0.725 . . . . 0.0 110.862 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.74 2.4 3.55 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.684 2.256 . . . . 0.0 112.389 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 51.0 m -97.43 -6.74 33.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.453 ' HB3' ' CB ' ' A' ' 39' ' ' LYS . 8.0 mmmm -96.48 -7.09 35.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.917 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.464 ' CG1' HG22 ' A' ' 92' ' ' ILE . 2.3 p -89.37 124.12 41.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.423 ' C ' HG22 ' A' ' 16' ' ' ILE . 8.1 mtmp? -127.27 169.15 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.562 HD12 ' CE2' ' A' ' 97' ' ' PHE . 29.9 pt -141.66 133.31 27.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.101 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.79 129.09 22.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 175.51 42.08 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.86 -34.33 14.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.704 2.27 . . . . 0.0 112.28 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.19 -32.5 67.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.469 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.8 mt -91.64 -14.54 29.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.65 -175.12 4.31 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.495 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.8 t -95.61 -15.59 22.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.906 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.03 47.15 3.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.472 HG11 ' N ' ' A' ' 26' ' ' ARG . 55.4 t -97.0 142.39 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 111.197 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.472 ' N ' HG11 ' A' ' 25' ' ' VAL . 66.9 mtt180 -119.4 150.8 39.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.42 152.57 42.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.079 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.4 mtp180 52.81 41.66 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.932 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.9 t -135.14 149.23 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.0 tp -69.41 113.11 6.42 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.459 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 28.9 mm-40 -118.9 126.75 52.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.887 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 35.1 t -142.17 161.87 36.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.878 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.539 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.4 p90 -151.65 -176.16 5.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.918 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 90.1 m -118.27 134.73 54.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.443 ' CG1' HD23 ' A' ' 45' ' ' LEU . 40.4 t -113.85 105.91 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.11 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -90.62 109.85 21.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -126.45 27.76 6.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.8 m -70.13 -36.39 74.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.453 ' CB ' ' HB3' ' A' ' 13' ' ' LYS . 39.4 mtmt -84.44 -7.7 59.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.912 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.504 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -81.88 -34.72 29.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.07 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.26 -139.56 11.14 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.478 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.453 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.75 19.83 14.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.813 0.34 . . . . 0.0 110.864 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.551 ' O ' ' CZ ' ' A' ' 87' ' ' TYR . . . -77.74 150.21 78.53 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.625 0.726 . . . . 0.0 111.042 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.461 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 54.4 Cg_endo -69.75 168.55 21.2 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.68 2.254 . . . . 0.0 112.386 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.443 HD23 ' CG1' ' A' ' 35' ' ' VAL . 7.4 tp -127.52 128.73 46.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -108.75 155.06 21.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.953 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 65.5 t -141.58 135.97 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 -142.37 142.06 32.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.966 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.46 HG21 ' CG1' ' A' ' 59' ' ' VAL . 60.9 t -124.37 131.24 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.158 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.444 ' N ' HD21 ' A' ' 50' ' ' LEU . 4.0 mm? -102.5 179.24 4.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -128.05 153.6 19.48 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.49 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -26.02 27.78 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.695 2.263 . . . . 0.0 112.293 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.36 12.58 10.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.95 27.92 8.05 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 15.0 tp -94.35 145.34 24.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.399 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -115.5 140.71 35.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.158 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -131.29 145.63 58.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.597 0.713 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 172.64 12.3 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.294 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.46 ' CG1' HG21 ' A' ' 49' ' ' VAL . 3.7 m -144.21 159.66 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.142 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -123.04 140.97 52.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.8 p -133.39 117.03 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.142 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.7 t -139.47 132.04 36.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.093 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -80.2 136.21 36.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -75.04 -42.32 57.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.95 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.82 -23.04 15.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -90.44 -43.28 10.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 33.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.509 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.9 p -151.71 177.75 10.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.8 m-70 -141.73 127.05 18.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.939 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.0 m -86.79 139.88 30.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.164 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.539 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.7 t -131.45 107.69 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -95.43 141.46 28.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.544 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.9 p90 -159.44 167.46 28.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.6 m -145.28 113.67 4.82 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.58 0.705 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.544 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.9 Cg_endo -69.69 94.62 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.684 2.256 . . . . 0.0 112.392 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' PRO . 5.7 m -34.16 -55.4 0.5 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -130.33 158.96 38.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.911 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -72.37 172.95 9.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.925 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.82 176.2 14.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 84.06 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.723 2.282 . . . . 0.0 112.312 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -82.68 173.85 11.53 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 ttp -150.77 129.81 12.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.911 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -115.88 97.99 6.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -80.72 132.71 35.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.774 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 99.0 t -128.25 134.55 64.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.145 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -124.11 167.25 14.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.551 ' CZ ' ' O ' ' A' ' 43' ' ' ALA . 11.9 t80 -153.96 105.61 2.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . 66.49 42.65 2.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.13 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.0 33.52 14.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -143.19 105.72 4.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -55.06 112.59 1.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.511 HD13 ' CE2' ' A' ' 97' ' ' PHE . 44.8 pt -50.42 152.99 2.83 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.6 0.714 . . . . 0.0 111.152 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.437 ' HG2' ' NH1' ' A' ' 94' ' ' ARG . 54.5 Cg_endo -69.73 8.3 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.716 2.277 . . . . 0.0 112.368 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . 0.481 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 0.6 OUTLIER -120.7 -2.47 9.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.516 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.3 t -111.56 152.55 44.09 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.675 0.75 . . . . 0.0 110.844 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.516 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.77 175.17 37.64 Favored 'Cis proline' 0 C--O 1.231 0.153 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.317 0.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . 0.562 ' CE2' HD12 ' A' ' 16' ' ' ILE . 82.4 m-85 -115.45 117.7 31.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -77.97 115.56 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.871 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.5 t -128.01 103.91 11.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 24.3 ttpt -83.32 99.27 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.929 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.3 t -68.51 145.67 13.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.118 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.3 mt -112.08 155.32 43.59 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.631 0.729 . . . . 0.0 110.875 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' TYR . 52.9 Cg_endo -69.83 121.7 8.37 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.246 . . . . 0.0 112.319 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.1 m -33.87 -36.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.173 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.446 ' N ' ' O ' ' A' ' 103' ' ' PRO . 31.3 m-85 -86.91 107.94 18.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.986 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -115.35 87.59 2.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.926 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -88.18 41.61 1.01 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.083 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 75.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.843 -179.814 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.6 t . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.826 0.346 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -118.23 94.96 47.82 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.569 0.699 . . . . 0.0 110.883 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -0.11 6.45 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.77 2.313 . . . . 0.0 112.312 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.7 m -99.12 1.87 45.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.852 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -104.65 -6.76 20.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -90.12 129.31 41.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.115 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.27 176.19 8.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.833 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.627 HD11 ' CE1' ' A' ' 97' ' ' PHE . 13.2 pt -145.61 134.59 17.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.158 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.98 120.74 13.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.087 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.52 168.76 40.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -26.48 27.54 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.723 2.282 . . . . 0.0 112.292 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.76 -25.58 70.57 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.484 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.614 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -98.73 -9.98 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.883 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.08 -178.48 14.6 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.528 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.8 m -91.58 -6.93 51.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.905 0.383 . . . . 0.0 110.863 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.4 47.24 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.491 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.661 HG13 ' NE2' ' A' ' 31' ' ' GLN . 88.1 t -98.01 139.85 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 111.105 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.822 ' HB2' HG21 ' A' ' 29' ' ' VAL . 80.8 mtt-85 -121.97 146.23 47.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.826 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.654 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.28 151.82 39.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.085 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.2 mtt180 53.83 37.0 25.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.904 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.822 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.2 t -127.47 148.82 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.169 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.4 tp -71.56 111.38 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.661 ' NE2' HG13 ' A' ' 25' ' ' VAL . 36.5 mm-40 -114.92 127.48 55.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.8 t -144.44 155.86 43.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.532 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.2 p90 -148.02 -178.21 6.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.866 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -121.17 129.88 53.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.505 HG11 ' CD2' ' A' ' 45' ' ' LEU . 47.6 t -108.26 106.37 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -88.98 111.82 22.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.9 p -128.11 24.41 5.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 t -68.36 -34.71 76.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.25 -8.24 57.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.42 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -83.0 -35.33 25.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.12 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.29 -144.07 15.36 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.415 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.744 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -110.43 17.71 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.796 0.332 . . . . 0.0 110.917 -179.906 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.838 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.01 148.65 81.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.579 0.704 . . . . 0.0 111.095 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 167.67 23.77 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.68 2.253 . . . . 0.0 112.317 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.505 ' CD2' HG11 ' A' ' 35' ' ' VAL . 6.9 tp -125.43 127.32 46.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -110.95 148.42 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.92 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 48' ' ' ARG . 35.7 t -139.45 153.9 24.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.411 ' N ' HG12 ' A' ' 47' ' ' VAL . 18.5 mtp85 -157.36 138.04 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.88 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 83' ' ' VAL . 77.2 t -117.98 116.65 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.095 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.98 123.28 49.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.95 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.22 178.56 1.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.499 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.581 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.5 Cg_endo -69.77 -39.2 6.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.628 2.219 . . . . 0.0 112.365 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.21 -28.77 22.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.843 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.9 34.37 0.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.53 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.607 HD21 ' OE2' ' A' ' 57' ' ' GLU . 18.1 tp -83.16 156.45 23.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.898 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 56' ' ' VAL . 12.7 p -119.46 111.72 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.15 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.607 ' OE2' HD21 ' A' ' 55' ' ' LEU . 8.0 mm-40 -112.8 143.5 29.18 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 110.875 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 169.41 19.04 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.676 2.251 . . . . 0.0 112.336 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.5 m -142.65 157.07 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.658 ' O ' HG13 ' A' ' 71' ' ' VAL . 15.9 t-20 -109.63 143.51 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.13 120.82 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 97.8 t -136.08 132.12 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.134 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -87.04 128.75 35.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.911 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -71.37 -42.1 68.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.868 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.14 -20.95 25.44 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.83 -42.74 9.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.47 36.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.496 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 64.7 p -153.11 176.38 11.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.14 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 29.4 m80 -143.92 133.99 24.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.2 m -96.35 132.9 41.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.134 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.2 t -126.37 108.16 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.135 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 51.8 p -98.28 142.26 30.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.106 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.493 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 7.2 p90 -159.73 169.28 24.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -145.04 113.77 4.91 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.64 0.733 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.493 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.73 97.12 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.374 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 75' ' ' PRO . 57.8 p -35.35 -47.98 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLN . . . . . 0.457 HE21 ' HB3' ' A' ' 77' ' ' GLN . 1.5 pt20 -132.08 -175.54 3.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.5 pp20? -101.47 170.27 8.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.5 176.81 14.57 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.533 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 88.07 0.55 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.581 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.4 m-85 -85.21 173.67 10.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.942 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 23.6 ttp -146.62 117.49 7.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.919 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 49' ' ' VAL . 63.0 t -107.56 100.26 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.0 t -84.46 148.48 26.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.8 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.3 t -142.57 138.85 28.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.079 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -126.52 169.27 13.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.829 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.8 t80 -156.45 105.0 2.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.838 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.81 42.04 2.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.058 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 64.0 32.93 12.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.899 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -143.11 105.01 4.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.953 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -54.54 109.5 0.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.584 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.5 pt -47.52 152.95 1.09 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.648 0.737 . . . . 0.0 111.122 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 3.93 2.48 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.629 2.219 . . . . 0.0 112.374 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 39.1 mmt-85 -113.31 -4.15 13.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -111.84 154.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.685 0.755 . . . . 0.0 110.838 -179.787 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.7 -179.97 20.55 Favored 'Cis proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 -1.797 . . . . 0.0 112.353 -0.097 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.627 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.5 m-85 -120.62 118.86 31.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -82.06 105.16 12.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.7 t -116.38 105.21 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 43.8 tttm -82.49 102.55 11.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 38.9 t -70.21 150.73 9.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.113 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.53 153.84 52.16 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.598 0.713 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.87 122.65 9.3 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.681 2.254 . . . . 0.0 112.305 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 53.5 m -34.7 -34.51 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.173 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.458 ' N ' ' O ' ' A' ' 103' ' ' PRO . 64.9 m-85 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.887 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.5 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.76 0.314 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -128.89 95.73 31.08 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -2.73 10.65 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.752 2.301 . . . . 0.0 112.316 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.7 p -98.99 9.31 43.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.796 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -113.79 -7.65 13.23 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.5 p -83.85 125.1 40.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.109 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -120.9 173.66 7.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.593 HG22 HG13 ' A' ' 35' ' ' VAL . 38.1 pt -147.02 137.6 17.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.72 138.22 32.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.084 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.3 168.84 27.0 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -30.97 21.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.668 2.245 . . . . 0.0 112.354 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -52.55 -46.65 58.55 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.483 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.585 HD11 HD12 ' A' ' 16' ' ' ILE . 6.0 mt -76.64 -28.63 56.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.875 0.369 . . . . 0.0 110.982 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -47.62 169.83 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.479 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 69.7 m -87.06 -7.92 57.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -93.7 49.21 2.3 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 20' ' ' GLY . 70.1 t -101.05 142.31 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.772 0.32 . . . . 0.0 111.15 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.493 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.0 mtt180 -118.33 147.89 43.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -67.71 149.61 49.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 56.18 40.73 30.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.493 HG21 ' HB2' ' A' ' 26' ' ' ARG . 53.6 t -133.62 148.11 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.099 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 18.6 tp -68.18 114.52 6.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.423 ' NE2' HG13 ' A' ' 25' ' ' VAL . 44.4 mm-40 -120.64 128.36 52.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.927 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.3 t -144.9 150.69 37.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.548 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 1.4 p90 -139.58 -178.29 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -121.0 133.78 55.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.12 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.593 HG13 HG22 ' A' ' 16' ' ' ILE . 44.6 t -115.34 107.57 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -91.33 106.86 18.81 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.46 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.1 p -117.01 20.4 13.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 50.6 p -63.05 -42.52 99.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? -77.03 -15.06 59.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.498 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -78.6 -32.38 47.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.062 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.01 -140.11 11.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.504 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.68 22.69 12.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.858 0.361 . . . . 0.0 110.949 -179.933 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.763 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.27 151.64 75.48 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.708 . . . . 0.0 111.074 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 167.05 25.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.659 2.239 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.7 tp -125.78 139.06 53.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.981 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -121.24 145.26 48.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.9 t -134.22 141.18 44.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -146.64 130.99 17.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 83' ' ' VAL . 82.0 t -116.21 125.15 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -115.07 144.2 44.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.72 169.7 43.1 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.552 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -31.74 19.91 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.624 2.216 . . . . 0.0 112.369 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -95.36 -27.37 15.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.881 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 133.28 27.46 0.56 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.8 tp -86.79 148.66 25.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.895 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.3 t -110.96 121.54 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.123 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.569 ' OE1' HG12 ' A' ' 49' ' ' VAL . 4.5 mp0 -112.62 142.92 27.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.641 0.734 . . . . 0.0 110.906 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.18 22.24 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.337 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.74 157.55 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -115.32 140.92 48.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.861 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 84.5 t -132.22 107.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.12 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -131.64 119.13 41.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.136 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t0 -76.07 133.47 40.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.859 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -72.37 -43.33 64.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.71 -24.7 10.09 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.437 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -86.99 -39.1 15.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.78 34.21 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.552 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 72.6 p -150.16 176.74 10.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.837 0.351 . . . . 0.0 111.144 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.2 m80 -145.78 131.18 18.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.859 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 21.9 m -91.61 139.58 30.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.548 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 99.3 t -129.59 102.32 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.111 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 46.7 p -92.51 138.81 31.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.173 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -164.01 160.78 22.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 29' ' ' VAL . 84.9 m -137.98 117.27 9.88 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.607 0.718 . . . . 0.0 111.152 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' SER . 53.8 Cg_endo -69.74 90.45 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.689 2.259 . . . . 0.0 112.305 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' PRO . 64.6 p -34.97 -53.6 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.881 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -122.22 158.39 29.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pp20? -79.7 174.95 11.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.948 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.35 177.16 14.89 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.516 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 86.59 0.59 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.623 2.216 . . . . 0.0 112.32 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -79.07 169.75 17.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -145.16 119.08 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.892 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 49' ' ' VAL . 90.1 t -110.89 97.12 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.141 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.4 m -81.4 142.56 32.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 87.2 t -135.61 145.14 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.404 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 23.7 tttt -132.35 168.66 17.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.733 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.1 t80 -154.39 105.74 2.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.969 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.763 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.49 44.39 5.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.186 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.404 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.1 m-20 63.2 33.3 14.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -142.49 105.06 4.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -56.21 111.62 1.01 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.636 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.7 pt -49.24 153.2 1.78 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.59 0.709 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 4.41 2.16 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.664 2.243 . . . . 0.0 112.377 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.419 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 9.4 mtm-85 -116.18 0.09 12.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.544 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -115.21 153.32 47.36 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.644 0.735 . . . . 0.0 110.803 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.544 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.5 Cg_endo -69.76 171.26 54.53 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.35 -0.005 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.636 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.1 m-85 -109.78 140.8 43.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.3 ptmm? -100.75 110.32 22.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 98.9 t -119.44 101.95 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.1 tttm -81.0 101.6 9.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.9 t -73.22 147.66 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.128 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.8 mt -114.96 154.79 47.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 0.0 110.86 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.0 Cg_endo -69.74 124.16 10.82 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.671 2.247 . . . . 0.0 112.346 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.407 ' C ' ' O ' ' A' ' 103' ' ' PRO . 51.5 m -36.34 -30.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.185 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.479 ' N ' ' O ' ' A' ' 103' ' ' PRO . 70.1 m-85 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.882 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.117 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -132.7 95.94 19.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.6 0.714 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 -0.81 7.36 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.705 2.27 . . . . 0.0 112.412 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 55.8 p -99.92 7.62 44.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.932 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.3 mmpt? -112.16 -9.62 13.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.419 ' H ' HG12 ' A' ' 14' ' ' VAL . 1.2 p -84.32 121.77 37.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -118.12 173.68 6.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.718 HG22 HG13 ' A' ' 35' ' ' VAL . 23.1 pt -146.86 135.93 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.185 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.59 156.57 45.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.059 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 143.07 177.02 17.67 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.86 -33.76 15.56 Favored 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.662 2.241 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -53.57 -23.5 20.66 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.538 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.498 HD13 HG13 ' A' ' 16' ' ' ILE . 7.7 mt -109.67 -19.95 13.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.88 0.372 . . . . 0.0 110.925 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -59.83 166.81 9.48 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.6 m -82.6 11.22 6.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.881 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.83 43.4 1.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.409 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.434 HG13 ' CD ' ' A' ' 31' ' ' GLN . 59.7 t -101.97 143.85 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.908 0.385 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -124.68 155.48 39.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.866 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.7 150.32 43.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.7 mtm-85 57.26 37.78 28.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.12 147.76 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.085 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.9 tp -69.0 113.14 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.519 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 51.0 mm-40 -117.76 130.9 56.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.429 ' HB2' HG22 ' A' ' 72' ' ' THR . 36.0 t -144.83 150.89 37.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.875 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.557 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 8.7 p90 -141.52 176.88 8.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 60.5 m -119.43 135.88 54.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.175 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.718 HG13 HG22 ' A' ' 16' ' ' ILE . 46.4 t -113.22 105.97 19.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.056 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -84.93 103.32 13.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.86 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 81.2 p -116.88 25.68 10.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 p -73.68 -29.76 62.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.854 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 30.5 mmtm -90.37 -5.47 56.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.919 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -89.46 -34.68 16.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.65 -140.18 11.6 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.396 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.34 20.98 12.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.798 0.332 . . . . 0.0 110.895 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.758 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.34 151.37 75.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.598 0.713 . . . . 0.0 111.049 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.9 20.14 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.745 2.296 . . . . 0.0 112.373 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.651 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.7 tp -132.0 135.4 46.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.918 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -112.19 152.97 27.75 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 HG11 ' A' ' 59' ' ' VAL . 21.5 t -138.72 132.91 41.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.156 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 48.8 mtm180 -139.11 132.75 30.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' VAL . 81.6 t -117.18 121.28 67.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 10.8 mt -116.94 129.29 55.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.27 175.03 40.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.534 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.442 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.79 -32.62 18.08 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.712 2.275 . . . . 0.0 112.308 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.29 -25.87 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.887 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 130.84 22.86 1.0 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.499 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 16.7 tp -74.08 149.04 41.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 0.0 110.838 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.3 t -113.7 112.93 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -113.15 141.63 26.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.611 0.719 . . . . 0.0 110.893 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 174.88 8.86 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.623 2.215 . . . . 0.0 112.362 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 HG12 ' A' ' 47' ' ' VAL . 8.9 m -144.32 162.83 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.714 ' O ' HG13 ' A' ' 71' ' ' VAL . 16.7 t-20 -119.49 145.02 46.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.896 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.457 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.3 p -132.46 120.48 42.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.141 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.59 122.58 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -82.17 127.23 32.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.926 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -71.76 -47.71 51.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.52 -16.17 24.25 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -95.14 -38.22 10.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.963 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.69 33.97 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.6 p -152.76 176.15 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 111.175 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -145.85 130.7 18.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.968 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.7 m -92.89 139.78 30.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.157 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.714 HG13 ' O ' ' A' ' 60' ' ' ASN . 36.9 t -131.22 108.94 15.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.171 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.429 HG22 ' HB2' ' A' ' 32' ' ' SER . 38.3 p -93.34 146.42 23.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.103 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 9.3 p90 -163.26 166.87 22.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.5 m -144.22 110.64 5.05 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 121.612 0.72 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.73 91.9 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.724 2.283 . . . . 0.0 112.315 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 22.8 t -34.21 -50.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.801 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -129.62 173.61 10.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.888 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.92 170.21 10.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.861 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.73 172.59 13.18 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.461 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 90.85 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.704 2.27 . . . . 0.0 112.367 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.442 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.0 m-85 -85.07 161.65 19.61 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -131.42 112.8 13.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.842 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 49' ' ' VAL . 96.3 t -103.51 95.98 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.8 t -79.34 145.7 33.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.651 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.1 t -143.54 130.13 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.137 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.3 tttt -118.13 169.81 9.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.758 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.3 t80 -156.89 106.12 2.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.707 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.3 40.79 3.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.13 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.99 34.57 11.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.856 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -145.7 105.03 3.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -54.17 114.53 1.65 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.863 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.677 HD11 ' HE1' ' A' ' 97' ' ' PHE . 48.2 pt -52.12 152.81 5.36 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.574 0.702 . . . . 0.0 111.178 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 4.29 2.27 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.701 2.267 . . . . 0.0 112.296 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -116.13 1.33 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.848 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.543 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -115.23 153.83 47.38 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.683 0.754 . . . . 0.0 110.825 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.69 -179.41 18.97 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.392 -0.132 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.709 ' CE2' HD11 ' A' ' 16' ' ' ILE . 85.2 m-85 -119.45 123.38 43.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.912 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 8.5 pttp -83.89 96.77 8.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 86.9 t -102.28 103.99 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.103 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 23.9 ttpt -85.0 102.53 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.87 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.4 t -75.38 143.43 13.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.134 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 33.8 mt -107.79 154.51 40.92 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.52 0.676 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.7 Cg_endo -69.7 122.51 9.2 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.3 m -33.97 -36.21 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.44 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.8 m-85 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.865 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.838 0.352 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.41 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 3.7 t0 -131.85 96.86 19.6 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.799 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 -0.43 6.89 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.676 2.251 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -99.38 6.95 45.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -112.99 -7.2 13.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -86.33 126.93 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -125.57 170.37 11.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.648 HD11 ' CE2' ' A' ' 97' ' ' PHE . 41.1 pt -145.25 137.01 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.173 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.21 143.26 34.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.076 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.0 169.97 24.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.72 -29.71 23.63 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.703 2.268 . . . . 0.0 112.343 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.59 -45.93 94.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.501 HD13 HG13 ' A' ' 16' ' ' ILE . 12.5 mt -73.91 -26.9 60.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.876 0.369 . . . . 0.0 110.933 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -51.16 169.35 0.36 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.501 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.5 p -85.26 -7.78 58.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.914 0.388 . . . . 0.0 110.841 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.67 44.7 2.73 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.508 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.448 HG13 ' CD ' ' A' ' 31' ' ' GLN . 97.7 t -92.15 143.0 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.831 0.348 . . . . 0.0 111.181 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.722 ' HB2' HG21 ' A' ' 29' ' ' VAL . 46.5 mtm180 -118.33 156.17 29.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.52 147.08 44.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 82.5 mtm-85 54.94 35.79 25.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' A' ' 26' ' ' ARG . 23.3 t -121.71 151.84 25.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.126 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.402 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 7.9 tp -75.62 109.33 9.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.47 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 3.1 mm100 -112.72 127.64 56.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 23.1 t -143.85 149.51 37.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.451 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 9.8 p90 -145.85 171.25 15.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -110.68 130.61 55.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.506 HG22 HG22 ' A' ' 16' ' ' ILE . 100.0 t -108.55 107.05 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.126 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -90.56 106.73 18.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 86.8 p -121.87 25.95 8.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.915 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 78.1 p -71.25 -35.85 71.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.861 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -80.02 -14.91 58.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.918 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.29 -38.2 43.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.13 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -138.19 9.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.609 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.19 17.73 13.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.885 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.75 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.92 151.52 84.29 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.525 0.679 . . . . 0.0 111.119 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 166.87 26.0 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.703 2.269 . . . . 0.0 112.362 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -122.92 136.33 54.82 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -119.21 139.47 51.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.885 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 59' ' ' VAL . 48.8 t -130.73 144.44 37.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.079 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 20.1 ttm180 -148.11 141.8 25.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -122.78 122.04 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.138 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -108.13 151.34 26.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.44 167.35 32.5 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.471 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -29.84 23.47 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' NH1' HD13 ' A' ' 55' ' ' LEU . 0.0 OUTLIER -118.18 3.62 12.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.55 62.98 0.5 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.542 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.45 HD13 ' NH1' ' A' ' 53' ' ' ARG . 10.1 tp -120.48 134.75 55.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.872 0.368 . . . . 0.0 110.911 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.1 t -102.78 129.78 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.157 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -134.46 141.43 38.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.655 0.741 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 168.47 21.41 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.689 2.259 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 47' ' ' VAL . 39.7 t -142.64 151.61 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -100.82 138.52 37.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.85 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.488 ' O ' HG13 ' A' ' 61' ' ' VAL . 6.2 p -133.43 112.47 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.181 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 66.1 t -133.4 127.61 54.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -84.08 130.87 34.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -72.21 -46.14 57.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.24 -22.21 11.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -88.6 -40.59 13.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.814 0.34 . . . . 0.0 110.852 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.28 33.99 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.509 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 66.7 p -150.2 175.39 11.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.876 0.369 . . . . 0.0 111.107 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.6 m80 -147.0 125.21 12.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 38.8 m -85.7 141.28 29.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.451 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.0 t -131.13 104.56 9.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.9 p -96.89 135.13 39.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.132 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.503 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.6 p90 -155.4 175.05 14.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.913 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 29' ' ' VAL . 89.7 m -151.71 117.18 3.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.526 0.679 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.503 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.3 Cg_endo -69.77 98.12 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.723 2.282 . . . . 0.0 112.357 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' PRO . 1.5 t -34.32 -60.3 0.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.883 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -127.36 164.19 22.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -72.73 167.36 20.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 132.46 171.08 12.68 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.443 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 92.76 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.678 2.252 . . . . 0.0 112.363 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -87.94 173.99 8.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 18.3 ttp -148.5 117.17 6.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.79 96.64 4.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.101 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -79.0 144.71 34.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.872 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 55.7 t -139.58 135.91 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -126.47 169.62 12.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.9 t80 -155.71 117.9 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.75 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 57.04 31.58 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.126 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.0 t70 74.22 31.74 1.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -141.79 106.69 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -53.73 114.89 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.678 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.4 pt -53.49 152.79 8.37 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.667 0.746 . . . . 0.0 111.136 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 4.47 2.19 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.535 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.7 mmt180 -115.64 0.76 13.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.881 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.527 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -114.72 153.36 46.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.622 0.725 . . . . 0.0 110.855 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.85 178.63 25.01 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.285 0.077 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.678 ' HE1' HD11 ' A' ' 92' ' ' ILE . 81.8 m-85 -117.2 117.73 30.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.897 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -78.49 113.33 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.836 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -128.99 101.95 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.119 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.5 tttm -83.95 102.51 12.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.9 t -67.15 145.67 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.177 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.7 mt -114.03 156.17 44.39 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.8 121.28 7.96 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.687 2.258 . . . . 0.0 112.351 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.429 ' C ' ' O ' ' A' ' 103' ' ' PRO . 54.0 m -35.21 -31.75 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.075 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.496 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.941 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.6 t . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.827 0.346 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.414 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.0 t0 -134.14 96.21 16.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.635 0.731 . . . . 0.0 110.897 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 1.49 4.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.747 2.298 . . . . 0.0 112.305 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 63.7 m -99.2 -5.23 30.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.5 mmpt? -97.9 -7.66 29.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.9 p -86.43 131.17 35.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.193 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mppt? -128.44 172.61 10.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.864 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.614 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 24.2 pt -143.3 134.96 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.122 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.93 128.17 20.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.79 163.59 28.21 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -24.88 29.44 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.664 2.243 . . . . 0.0 112.365 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.77 95.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.614 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.1 mt -84.13 -17.19 40.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.973 0.416 . . . . 0.0 110.968 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.31 176.71 1.31 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.509 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -91.26 -13.29 33.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.986 0.422 . . . . 0.0 110.87 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.47 49.86 3.49 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.521 HG13 ' NE2' ' A' ' 31' ' ' GLN . 74.6 t -99.34 147.15 7.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.798 0.332 . . . . 0.0 111.103 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.508 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.26 144.84 48.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.418 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.76 150.45 44.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 45.7 mtm180 54.65 43.05 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.508 HG21 ' HB2' ' A' ' 26' ' ' ARG . 75.8 t -135.06 147.65 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -69.96 113.93 7.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.945 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.521 ' NE2' HG13 ' A' ' 25' ' ' VAL . 42.4 mm-40 -120.51 129.02 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.8 t -144.75 157.72 44.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.614 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.3 p90 -147.21 179.95 7.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.931 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 58.2 m -120.08 130.82 54.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.142 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 16' ' ' ILE . 61.2 t -110.72 109.07 27.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -89.83 110.39 21.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 25.6 p -125.75 24.73 7.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.757 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 89.0 p -69.64 -33.76 73.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.7 mmmt -86.31 -12.66 48.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.58 -35.3 46.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.133 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.82 -138.86 10.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.566 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.583 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -121.14 19.37 11.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.745 0.307 . . . . 0.0 110.852 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.857 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.86 151.78 79.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.604 0.716 . . . . 0.0 111.103 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 167.16 25.27 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.486 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.4 tp -125.32 136.0 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.911 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -120.94 149.38 42.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.91 150.15 20.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.196 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -148.58 136.16 20.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 83' ' ' VAL . 93.5 t -116.4 124.8 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -123.89 133.73 53.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.53 -179.86 49.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.491 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -45.17 1.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.674 2.25 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.2 -35.24 59.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.889 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.9 31.59 0.26 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.401 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 11.2 tp -85.31 152.04 23.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.917 0.389 . . . . 0.0 110.886 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.401 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 92.4 t -119.25 122.59 69.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -120.25 142.64 34.08 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.56 0.695 . . . . 0.0 110.97 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 169.01 19.94 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.632 2.221 . . . . 0.0 112.33 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.7 m -138.29 167.7 21.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' VAL . 25.5 t-20 -114.34 140.67 48.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 93.1 t -133.32 114.9 21.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.166 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.0 t -140.47 117.55 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -73.63 139.45 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.933 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -78.42 -45.56 21.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.61 -20.7 11.95 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.447 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.95 -39.03 13.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.807 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.59 34.96 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.487 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.8 p -153.27 177.39 10.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 111.072 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -144.8 130.59 19.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.87 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 81.8 m -88.54 140.98 28.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.47 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.0 t -133.04 102.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.146 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 45.2 p -95.09 143.84 26.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.494 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 5.2 p90 -163.35 175.46 10.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.971 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -151.91 116.95 3.07 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.651 0.738 . . . . 0.0 111.121 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.494 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.76 92.92 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.664 2.243 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 75' ' ' PRO . 40.2 t -34.44 -54.7 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.854 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -125.83 171.71 10.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.969 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -84.82 172.81 11.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.52 170.04 12.99 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.5 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.13 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.726 2.284 . . . . 0.0 112.319 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -83.11 168.59 16.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.978 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.5 ttp -139.54 117.95 12.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 49' ' ' VAL . 90.9 t -107.21 97.59 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.128 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 m -81.53 147.44 29.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.832 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.486 ' CG1' HD11 ' A' ' 45' ' ' LEU . 64.5 t -140.94 138.11 34.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.6 tttt -125.27 173.91 8.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.567 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.7 t80 -160.44 110.54 1.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.974 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.857 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.68 38.31 18.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.154 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 68.02 34.02 4.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -144.23 105.02 4.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.875 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -54.39 108.38 0.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.486 HD12 ' HB2' ' A' ' 94' ' ' ARG . 45.8 pt -46.9 153.02 0.87 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.583 0.706 . . . . 0.0 111.144 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.68 2.04 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.668 2.245 . . . . 0.0 112.347 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.486 ' HB2' HD12 ' A' ' 92' ' ' ILE . 84.2 mmt-85 -114.48 -3.73 12.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 0.9 OUTLIER -112.28 154.45 44.43 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.631 0.729 . . . . 0.0 110.848 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.0 Cg_endo -69.72 -178.53 16.86 Favored 'Cis proline' 0 C--N 1.342 0.206 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.38 -0.084 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.614 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 81.2 m-85 -121.25 132.78 55.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 ptmt -93.16 108.31 19.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.7 t -118.59 103.68 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.104 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 106.85 13.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.908 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 41.5 t -76.81 138.08 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.155 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.6 mt -108.64 155.24 40.91 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 121.675 0.75 . . . . 0.0 110.941 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.6 Cg_endo -69.73 122.46 9.14 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.782 2.321 . . . . 0.0 112.296 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 103' ' ' PRO . 91.9 m -34.83 -35.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.084 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.442 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.4 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.0 t . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.853 0.359 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.1 t0 -133.23 96.18 17.66 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.598 0.713 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.7 Cg_endo -69.72 -1.63 8.78 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.682 2.255 . . . . 0.0 112.359 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.5 p -98.11 5.93 48.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.808 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -110.53 -7.74 14.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -86.29 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.106 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.9 mttt -127.21 173.72 9.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.931 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.792 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.4 pt -147.35 135.79 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.4 153.19 46.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.142 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.52 174.6 20.35 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -36.04 11.46 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.671 2.247 . . . . 0.0 112.315 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.28 -32.68 29.87 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.561 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.434 HD13 HG13 ' A' ' 16' ' ' ILE . 13.0 mt -94.4 -21.38 18.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.912 0.387 . . . . 0.0 110.95 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.43 167.96 2.67 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -87.49 13.75 9.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.893 0.378 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.02 44.9 1.37 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.518 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.452 HG13 ' NE2' ' A' ' 31' ' ' GLN . 60.0 t -97.14 145.96 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 111.095 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.464 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.1 mtt85 -120.89 151.65 39.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.887 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -69.56 150.73 46.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.068 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.9 mtp180 55.09 41.55 31.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.464 HG21 ' HB2' ' A' ' 26' ' ' ARG . 59.3 t -133.88 144.33 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.2 tp -68.43 112.99 5.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.452 ' NE2' HG13 ' A' ' 25' ' ' VAL . 54.5 mm-40 -117.47 130.66 56.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.2 t -144.89 149.1 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.54 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.4 p90 -140.08 179.77 6.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.946 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 89.3 m -117.8 131.55 56.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.606 HG11 HD22 ' A' ' 45' ' ' LEU . 92.8 t -110.38 105.47 18.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.096 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' HG22 ' A' ' 68' ' ' THR . 18.9 t70 -89.67 101.76 14.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.858 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 82.6 p -117.33 27.94 8.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.1 t -70.04 -38.13 75.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 37.7 mttp -76.06 -14.88 60.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -81.2 -38.59 26.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.09 -137.44 9.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.532 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.597 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.86 19.91 12.32 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.793 0.33 . . . . 0.0 110.912 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.711 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.18 151.62 81.47 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.585 0.707 . . . . 0.0 111.084 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 166.86 26.18 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.685 2.256 . . . . 0.0 112.322 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.606 HD22 HG11 ' A' ' 35' ' ' VAL . 5.0 tp -129.61 129.37 44.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -108.73 151.71 25.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.9 t -139.53 144.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.084 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -149.64 135.06 18.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.832 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 83' ' ' VAL . 61.5 t -116.73 128.36 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.1 mt -125.12 121.15 33.41 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.949 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.29 174.44 7.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.534 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -43.62 2.52 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.625 2.216 . . . . 0.0 112.381 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.6 -32.2 47.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.1 32.64 0.3 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.46 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.452 HD21 ' OE2' ' A' ' 57' ' ' GLU . 9.4 tp -85.85 149.69 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 0.0 110.874 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -114.38 115.23 48.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.452 ' OE2' HD21 ' A' ' 55' ' ' LEU . 65.3 mm-40 -113.79 142.84 28.42 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 169.58 18.59 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.237 . . . . 0.0 112.299 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.23 167.94 19.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.139 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -123.21 140.6 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 85.5 t -133.21 113.84 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 85.5 t -138.32 119.85 17.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.093 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -75.12 136.58 41.1 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.765 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -75.69 -43.44 47.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.88 -24.9 9.84 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.506 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -86.05 -44.21 12.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.837 0.351 . . . . 0.0 110.898 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.34 33.57 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.493 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.408 HG22 ' HA ' ' A' ' 36' ' ' ASP . 64.0 p -149.92 177.78 9.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.86 0.362 . . . . 0.0 111.078 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.6 m80 -144.99 133.56 22.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 52.4 m -93.02 141.49 28.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.148 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.54 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 66.4 t -131.36 103.28 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.172 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.6 p -95.19 136.86 35.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.131 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.468 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 8.0 p90 -157.41 176.12 13.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.7 m -150.78 115.35 3.24 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.586 0.708 . . . . 0.0 111.122 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.468 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.8 95.04 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.345 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 13.4 t -38.91 -54.79 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.772 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -121.98 169.94 10.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.497 ' C ' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -86.97 173.75 9.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.86 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.11 176.23 15.05 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.488 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 89.15 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.699 2.266 . . . . 0.0 112.279 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.62 163.54 25.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.938 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 16.3 ttp -135.17 113.09 11.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.856 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 49' ' ' VAL . 69.3 t -105.48 97.78 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.116 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.5 t -82.98 144.29 30.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.899 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.573 ' CG1' HD11 ' A' ' 45' ' ' LEU . 55.7 t -139.83 142.37 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.433 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 39.9 tttt -128.29 170.56 12.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.711 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.5 t80 -156.42 109.42 2.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.674 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.27 40.82 11.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.433 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 4.9 m-20 64.31 35.99 9.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.887 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -147.05 105.04 3.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -52.48 117.01 2.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.652 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.5 pt -55.61 153.16 16.06 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.58 0.705 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 4.74 2.01 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 2.251 . . . . 0.0 112.412 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.42 ' HB2' HD12 ' A' ' 92' ' ' ILE . 29.7 mmt85 -117.04 2.96 12.74 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.64 153.98 49.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.637 0.732 . . . . 0.0 110.861 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.69 -179.92 20.38 Favored 'Cis proline' 0 C--O 1.231 0.135 0 C-N-CA 122.663 -1.807 . . . . 0.0 112.37 -0.112 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 16' ' ' ILE . 80.1 m-85 -117.45 128.98 55.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.878 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -93.64 107.34 19.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.9 t -119.43 107.04 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 19.8 ttpt -81.96 105.5 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.885 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.8 152.49 6.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.18 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 68.4 mt -117.55 154.83 50.79 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.575 0.702 . . . . 0.0 110.93 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.7 122.21 8.91 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.692 2.261 . . . . 0.0 112.377 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m -34.83 -32.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.152 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.6 m-85 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.1 t . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.443 ' CG ' ' HG2' ' A' ' 13' ' ' LYS . 8.8 t0 -123.95 95.1 44.71 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.614 0.721 . . . . 0.0 110.897 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 0.78 5.12 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.71 2.273 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 m -100.7 3.67 42.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.443 ' HG2' ' CG ' ' A' ' 10' ' ' ASP . 14.4 mmmt -104.74 -12.12 16.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 36' ' ' ASP . 6.4 p -84.37 133.67 28.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.0 mtmt -135.69 169.94 16.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.616 HG13 HD13 ' A' ' 21' ' ' LEU . 26.3 pt -142.67 137.25 27.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 143.79 33.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.077 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 155.83 178.57 30.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.87 -38.81 7.06 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.656 2.237 . . . . 0.0 112.315 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.27 -24.99 11.0 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.498 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.616 HD13 HG13 ' A' ' 16' ' ' ILE . 3.3 mt -104.41 -22.16 13.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.864 0.364 . . . . 0.0 110.896 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -58.19 176.82 1.84 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.469 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -91.17 11.78 22.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.884 0.374 . . . . 0.0 110.853 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.84 47.03 1.09 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.505 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.5 HG13 ' CD ' ' A' ' 31' ' ' GLN . 72.4 t -98.54 138.29 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.805 0.336 . . . . 0.0 111.11 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.579 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.4 mtt85 -118.76 146.33 44.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.425 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -66.69 151.51 47.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.034 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 56.18 35.6 25.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.579 HG21 ' HB2' ' A' ' 26' ' ' ARG . 76.2 t -128.91 154.4 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.434 ' N ' HG12 ' A' ' 29' ' ' VAL . 12.1 tp -76.19 112.24 12.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.5 ' CD ' HG13 ' A' ' 25' ' ' VAL . 61.8 mm-40 -113.83 127.54 56.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 13.6 t -142.19 154.1 44.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.872 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.569 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.0 p90 -149.54 176.2 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.948 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 96.1 m -114.64 138.01 51.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.146 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 16' ' ' ILE . 52.3 t -117.48 106.97 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.7 t70 -85.78 110.65 19.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.6 p -125.34 25.77 7.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.8 t -75.67 -35.82 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.876 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? -81.6 -18.52 44.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -75.29 -39.98 59.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.139 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.8 -140.66 11.42 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.826 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -116.35 16.97 15.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.785 0.326 . . . . 0.0 110.907 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.757 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.63 151.3 84.85 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.61 0.719 . . . . 0.0 111.063 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.436 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.7 Cg_endo -69.77 167.37 24.65 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.652 2.234 . . . . 0.0 112.297 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.593 HD11 ' CG1' ' A' ' 85' ' ' VAL . 10.8 tp -128.19 131.11 48.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.897 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -111.86 151.53 29.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.82 149.81 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.46 ' HG2' HD23 ' A' ' 50' ' ' LEU . 2.5 ttp-105 -152.61 143.12 22.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 58.3 t -118.69 122.06 68.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.46 HD23 ' HG2' ' A' ' 48' ' ' ARG . 4.0 mm? -110.48 128.92 55.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.59 165.03 52.6 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.502 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.528 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.75 -26.29 27.76 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.743 2.295 . . . . 0.0 112.365 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.09 3.35 9.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.08 65.16 0.52 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.48 148.0 44.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.59 118.64 57.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -120.65 141.69 32.78 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.639 0.733 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 169.21 19.39 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.663 2.242 . . . . 0.0 112.378 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.8 m -144.31 162.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -125.2 141.15 52.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 61' ' ' VAL . 3.6 p -133.52 110.94 15.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 74.7 t -139.79 116.04 9.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -67.45 138.8 56.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -73.18 -41.98 63.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.89 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.21 -22.05 12.59 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.485 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -91.58 -43.05 9.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.357 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.77 34.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.413 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 57.3 p -152.23 177.87 10.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.413 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.1 m-70 -143.76 125.12 14.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.864 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 31.3 m -84.03 139.02 32.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.569 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 73.3 t -131.3 106.71 12.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.5 p -97.07 147.4 24.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.1 p90 -166.02 164.37 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 92.0 m -140.85 112.38 6.88 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.623 0.725 . . . . 0.0 111.129 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.69 100.59 0.82 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.367 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 75' ' ' PRO . 33.3 t -34.86 -57.85 0.53 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -129.86 166.5 19.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.419 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 5.7 pm0 -76.25 172.11 13.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.887 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.92 173.83 13.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.457 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 93.93 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.528 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 6.3 m-85 -90.11 173.91 7.92 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 27.7 ttp -147.61 117.74 7.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.841 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 93.2 t -106.29 100.22 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 12.4 t -84.37 143.49 29.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.81 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 45' ' ' LEU . 84.4 t -141.21 135.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -122.28 171.69 8.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.738 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 12.9 t80 -157.56 112.81 2.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.929 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.757 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.45 32.51 20.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.083 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 73.47 31.4 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.808 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -141.99 105.05 4.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -53.36 107.9 0.28 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.513 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.9 pt -45.93 153.0 0.69 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.609 0.719 . . . . 0.0 111.104 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 4.31 2.26 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.361 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 14.2 mmm180 -113.46 -4.65 13.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.836 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.546 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -112.21 153.98 44.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.659 0.742 . . . . 0.0 110.845 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.546 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.4 Cg_endo -69.65 179.15 22.84 Favored 'Cis proline' 0 C--N 1.341 0.168 0 C-N-CA 122.8 -1.75 . . . . 0.0 112.347 -0.116 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.513 ' HE2' HD11 ' A' ' 92' ' ' ILE . 89.5 m-85 -120.21 114.8 22.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 106.08 9.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.901 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 79.7 t -117.51 106.71 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.078 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -85.91 96.88 9.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.889 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.419 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 47.7 t -63.61 147.28 12.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.065 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.5 mt -113.02 154.05 45.12 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.59 0.709 . . . . 0.0 110.958 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.5 Cg_endo -69.71 124.06 10.73 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.741 2.294 . . . . 0.0 112.345 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.415 ' C ' ' O ' ' A' ' 103' ' ' PRO . 88.6 m -35.58 -32.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.473 ' N ' ' O ' ' A' ' 103' ' ' PRO . 23.0 m-85 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.9 t . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.875 0.369 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.2 t0 -128.08 96.92 30.39 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.58 0.705 . . . . 0.0 110.832 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.5 Cg_endo -69.71 -0.43 6.86 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.687 2.258 . . . . 0.0 112.369 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.2 p -99.67 10.39 41.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.863 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 mmpt? -114.82 -8.78 12.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.898 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.1 p -83.87 123.11 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.166 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -116.69 173.33 6.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.6 HG22 HG13 ' A' ' 35' ' ' VAL . 33.0 pt -147.13 138.82 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.89 138.1 31.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.95 167.59 22.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.541 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.75 -24.93 29.17 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.85 -28.09 65.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.472 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.546 HD11 HD12 ' A' ' 16' ' ' ILE . 6.7 mt -98.13 -19.78 17.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.41 166.37 5.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.7 t -83.29 8.59 13.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.972 0.415 . . . . 0.0 110.922 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.14 51.0 0.73 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.416 HG13 ' NE2' ' A' ' 31' ' ' GLN . 68.7 t -102.08 141.78 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.845 0.355 . . . . 0.0 111.102 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.643 ' HB2' HG21 ' A' ' 29' ' ' VAL . 75.3 mtt85 -118.97 150.75 39.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.74 150.16 48.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.442 ' HB3' ' NH1' ' A' ' 28' ' ' ARG . 12.2 mtp-105 54.91 40.32 31.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.643 HG21 ' HB2' ' A' ' 26' ' ' ARG . 66.4 t -129.9 150.74 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.7 tp -73.94 110.36 8.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.951 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.416 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.3 mm-40 -115.3 127.68 55.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.3 t -143.44 149.48 37.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 1.0 OUTLIER -141.33 -178.38 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 88.4 m -123.21 137.67 54.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.6 HG13 HG22 ' A' ' 16' ' ' ILE . 46.7 t -117.65 107.18 21.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.48 94.74 9.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.875 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.489 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 59.9 p -103.64 20.02 18.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.9 t -68.41 -34.94 76.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.814 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -82.75 -12.24 57.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -83.35 -39.66 20.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.047 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.654 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 135.66 -146.97 18.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.5 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.781 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.07 14.99 24.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.928 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.58 151.32 84.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.619 0.723 . . . . 0.0 111.046 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 169.36 19.1 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.64 2.227 . . . . 0.0 112.377 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.8 tp -124.82 139.47 53.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -112.96 143.4 44.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.548 HG12 HG11 ' A' ' 59' ' ' VAL . 88.9 t -135.72 131.1 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -141.12 143.0 34.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.23 132.38 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.5 mp -120.57 148.46 43.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.09 172.69 36.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.427 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.4 Cg_endo -69.82 -30.75 21.49 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.657 2.238 . . . . 0.0 112.325 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.86 4.78 17.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 105.45 66.5 0.67 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.54 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 26.9 tp -118.36 138.59 52.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.911 0.386 . . . . 0.0 110.91 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.1 t -109.02 108.98 26.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -110.93 143.13 27.66 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.618 0.723 . . . . 0.0 110.875 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 168.02 22.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.655 2.237 . . . . 0.0 112.363 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.548 HG11 HG12 ' A' ' 47' ' ' VAL . 30.0 m -141.83 163.15 19.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.063 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -115.47 141.31 48.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.866 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 86.9 t -132.86 116.31 26.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 76.6 t -138.25 124.74 26.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -80.45 132.75 35.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -72.84 -40.74 65.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 114.42 -27.37 8.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -83.27 -47.27 11.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.846 0.355 . . . . 0.0 110.931 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.28 30.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.529 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.4 p -144.76 177.78 8.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -146.66 132.16 18.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 23.2 m -93.16 141.86 27.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.144 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.484 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 57.8 t -132.85 104.78 7.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.17 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -94.74 139.97 30.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.495 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -159.36 171.54 19.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.863 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 29' ' ' VAL . 29.2 m -147.07 114.97 4.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.567 0.699 . . . . 0.0 111.149 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.495 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.6 Cg_endo -69.73 91.39 0.51 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.346 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.5 t -34.08 -59.64 0.42 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -121.56 158.34 28.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.886 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -77.19 173.67 11.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.07 176.9 14.64 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 86.19 0.58 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.678 2.252 . . . . 0.0 112.387 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.427 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.1 m-85 -83.0 173.59 11.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.5 ttp -149.16 120.83 8.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.0 t -109.43 100.17 10.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.9 t -82.99 145.4 29.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.848 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.3 t -140.52 138.42 36.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.103 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -126.79 172.99 9.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.667 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.5 t80 -160.18 109.47 1.76 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.731 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.0 37.84 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.047 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 67.94 34.18 4.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -144.35 105.07 4.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.59 111.68 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.601 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.0 pt -49.41 153.03 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.683 0.754 . . . . 0.0 111.1 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 3.85 2.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.71 2.273 . . . . 0.0 112.327 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.438 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 19.6 mmm180 -114.08 -2.03 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.862 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.548 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -113.61 153.27 45.86 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.681 0.753 . . . . 0.0 110.849 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.548 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.78 175.83 35.07 Favored 'Cis proline' 0 C--N 1.341 0.151 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.318 0.015 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.601 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.8 m-85 -116.15 118.07 31.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -78.7 107.24 11.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.903 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 96.1 t -119.26 102.92 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.101 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -83.58 100.42 10.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.8 145.09 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.173 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.6 mt -111.69 154.67 43.88 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.589 0.709 . . . . 0.0 110.958 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.9 Cg_endo -69.66 123.33 10.03 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.67 2.246 . . . . 0.0 112.334 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 103' ' ' PRO . 49.7 m -36.11 -30.82 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.171 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.485 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.8 m-85 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.2 t . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.822 0.344 . . . . 0.0 111.124 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.2 t0 -125.88 99.45 32.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.564 0.697 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.6 Cg_endo -69.81 0.37 5.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.66 2.24 . . . . 0.0 112.386 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.7 p -98.7 9.09 44.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.999 0.428 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -114.18 -8.02 12.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.8 p -84.54 123.5 39.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.215 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.4 mtpp -119.66 167.74 11.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.746 HG22 HG13 ' A' ' 35' ' ' VAL . 37.6 pt -144.09 140.06 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.8 165.92 26.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 133.82 176.11 14.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.41 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.65 -41.44 4.42 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.715 2.277 . . . . 0.0 112.321 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -44.77 -35.44 4.32 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.494 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.439 HD11 HD12 ' A' ' 16' ' ' ILE . 8.2 mt -94.43 -26.6 16.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.897 0.379 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -50.86 163.81 0.92 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.479 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.4 m -86.24 22.91 1.67 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.959 0.409 . . . . 0.0 110.904 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.69 38.05 2.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.582 HG13 ' CD ' ' A' ' 31' ' ' GLN . 78.9 t -89.41 144.3 9.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.558 ' HB2' HG21 ' A' ' 29' ' ' VAL . 65.6 mtt180 -121.63 149.8 42.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.486 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.04 150.16 48.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.6 mtt85 55.35 34.83 23.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.876 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 74' ' ' THR . 73.2 t -127.46 146.98 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.7 tp -68.25 111.6 4.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.582 ' CD ' HG13 ' A' ' 25' ' ' VAL . 5.4 mm100 -116.66 126.62 53.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.592 ' HB2' HG22 ' A' ' 72' ' ' THR . 14.3 t -144.45 148.43 34.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.481 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -140.86 177.61 7.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.791 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 82.6 m -118.36 141.17 48.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.215 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.746 HG13 HG22 ' A' ' 16' ' ' ILE . 38.2 t -118.09 109.47 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -92.32 98.23 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.1 p -111.71 21.38 16.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.5 p -67.01 -35.4 79.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.839 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -79.16 -15.89 57.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.61 -38.68 47.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.092 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.49 -138.45 9.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.444 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.84 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.8 16.35 16.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.88 0.371 . . . . 0.0 110.956 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.764 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.78 151.64 84.64 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.581 0.705 . . . . 0.0 111.105 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.487 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.1 Cg_endo -69.77 169.27 19.31 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.622 2.215 . . . . 0.0 112.327 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -127.32 135.4 50.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.961 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -120.42 145.42 47.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 49.7 t -137.49 145.93 28.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.108 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -146.38 138.16 24.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.69 ' O ' HD22 ' A' ' 50' ' ' LEU . 84.8 t -115.41 129.15 72.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.035 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.69 HD22 ' O ' ' A' ' 49' ' ' VAL . 3.3 mm? -126.2 119.52 27.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.85 177.77 3.76 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.531 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.435 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 53.7 Cg_endo -69.7 -41.39 4.39 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.649 2.232 . . . . 0.0 112.4 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.435 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -84.05 -33.66 24.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.976 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.31 33.21 0.15 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.739 HD21 ' OE2' ' A' ' 57' ' ' GLU . 11.1 tp -85.52 155.67 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.887 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.469 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 94.3 t -119.33 111.1 31.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.739 ' OE2' HD21 ' A' ' 55' ' ' LEU . 18.3 mm-40 -106.13 143.15 26.35 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.651 0.738 . . . . 0.0 110.876 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.691 2.261 . . . . 0.0 112.34 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 m -139.98 162.83 24.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 47.1 t30 -118.88 143.6 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.936 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 74.0 t -129.51 116.31 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.518 HG23 ' HB ' ' A' ' 70' ' ' THR . 0.1 OUTLIER -134.98 110.77 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.203 179.87 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -72.15 129.05 37.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -72.73 -44.74 61.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.856 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.11 -24.31 10.09 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -85.87 -46.49 10.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.841 0.353 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.7 30.54 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.537 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.3 p -145.89 177.63 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 111.098 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -147.82 131.41 16.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' THR . . . . . 0.518 ' HB ' HG23 ' A' ' 62' ' ' VAL . 3.4 m -94.78 137.51 33.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.515 HG13 ' O ' ' A' ' 60' ' ' ASN . 35.6 t -127.04 107.35 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.592 HG22 ' HB2' ' A' ' 32' ' ' SER . 35.1 p -92.68 141.06 28.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.193 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -163.94 161.59 22.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.973 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 29' ' ' VAL . 17.3 m -137.38 117.19 10.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.603 0.716 . . . . 0.0 111.117 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.75 94.59 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.349 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 75' ' ' PRO . 43.0 t -35.88 -54.88 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -125.12 168.94 12.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -85.35 173.68 10.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.33 175.42 14.22 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.465 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 90.13 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.702 2.268 . . . . 0.0 112.364 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -81.06 169.75 17.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.947 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 11.2 ttp -145.31 115.73 7.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.5 t -107.58 97.14 5.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -79.83 142.88 34.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 89.5 t -138.05 142.0 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.084 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.437 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 15.5 tttp -130.49 168.05 17.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.941 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.764 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.7 t80 -154.61 115.99 4.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.944 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.644 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.41 33.27 22.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.115 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.437 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 11.6 m-20 71.04 33.5 2.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -144.4 105.34 4.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.891 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -49.99 114.14 1.02 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.84 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.552 HD11 ' HE2' ' A' ' 97' ' ' PHE . 42.1 pt -54.56 153.52 10.35 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.661 0.743 . . . . 0.0 111.113 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.68 4.33 2.22 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.424 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 53.1 mtp85 -114.5 0.29 13.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.908 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.523 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -115.71 153.37 47.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.684 0.754 . . . . 0.0 110.866 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.73 178.01 26.82 Favored 'Cis proline' 0 C--O 1.232 0.18 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.396 -0.047 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.642 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.3 m-85 -117.84 116.47 27.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.0 pttm -81.65 108.8 15.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.02 104.14 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -81.35 103.01 10.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.2 t -71.25 144.61 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 77.2 mt -111.88 154.5 44.09 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.583 0.706 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.495 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.4 Cg_endo -69.69 123.84 10.52 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.724 2.283 . . . . 0.0 112.324 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.9 m -34.12 -33.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.193 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.495 ' N ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m-85 . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.775 0.321 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -130.53 96.64 23.44 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.4 Cg_endo -69.76 0.3 5.85 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.663 2.242 . . . . 0.0 112.347 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 30.8 m -98.46 -7.12 29.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -94.23 -5.15 47.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -90.42 135.73 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.152 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 22.8 mtmt -133.42 168.9 17.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 97' ' ' PHE . 42.2 pt -142.9 139.42 27.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.066 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.72 153.67 43.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.32 171.68 17.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -29.14 24.27 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 0.0 112.372 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.79 -29.43 67.37 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.411 HD13 HG13 ' A' ' 16' ' ' ILE . 5.2 mt -97.04 -26.43 15.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.894 0.378 . . . . 0.0 110.965 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.92 168.33 2.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.564 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.8 p -83.86 18.49 1.99 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.21 40.83 2.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.459 HG13 ' CD ' ' A' ' 31' ' ' GLN . 58.3 t -92.96 147.46 5.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.572 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.0 mtm180 -123.03 157.26 33.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.835 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -75.35 149.48 38.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 42.5 mtt180 54.09 30.27 11.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.572 HG21 ' HB2' ' A' ' 26' ' ' ARG . 19.1 t -119.99 144.48 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.178 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.5 tp -67.81 110.12 3.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.584 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 59.6 mm-40 -113.29 126.95 55.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.923 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -143.2 152.53 41.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.5 p90 -146.39 -176.48 5.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 48.0 m -122.23 135.5 54.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.09 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.664 HG13 HG22 ' A' ' 16' ' ' ILE . 40.1 t -113.15 108.75 26.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -91.47 104.04 16.59 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.913 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.0 p -121.4 30.19 6.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.9 t -73.04 -36.61 66.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.853 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 6.4 mmpt? -79.95 -16.95 54.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.859 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.05 -38.64 63.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.042 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.7 -137.25 9.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.577 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.31 18.91 12.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.868 0.366 . . . . 0.0 110.973 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.733 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.35 151.89 83.5 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.71 . . . . 0.0 111.076 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 166.64 26.92 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.673 2.249 . . . . 0.0 112.338 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.466 ' CD2' HG11 ' A' ' 35' ' ' VAL . 15.4 tp -126.08 134.49 51.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -119.4 147.52 44.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 59' ' ' VAL . 65.6 t -137.3 149.77 25.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -152.26 136.85 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.837 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 83' ' ' VAL . 71.9 t -119.43 126.18 75.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.169 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.7 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.6 mm? -123.58 122.9 39.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.6 -179.36 1.66 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.472 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.74 -47.93 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.14 -37.25 61.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.919 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.24 33.38 0.13 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.464 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.3 tp -85.37 147.96 26.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.915 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.4 t -107.87 126.0 64.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.106 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -127.92 140.35 37.93 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.603 0.716 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 168.65 20.95 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.702 2.268 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 47' ' ' VAL . 44.5 t -139.91 149.33 22.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.191 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.639 ' O ' HG13 ' A' ' 71' ' ' VAL . 29.3 t-20 -98.67 139.18 34.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.82 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 p -131.94 123.48 51.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.196 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.5 t -141.28 129.43 22.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.174 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.22 132.06 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.84 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -73.23 -48.04 38.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.83 -21.04 10.59 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -90.43 -43.97 9.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.8 32.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 63.2 p -151.02 177.73 9.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 111.152 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.0 m80 -146.61 131.07 17.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.846 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 26.2 m -90.21 138.41 31.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.196 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 60' ' ' ASN . 47.4 t -130.37 110.37 18.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.171 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 55.7 p -101.04 145.33 28.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.188 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.584 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.0 p90 -164.91 169.06 16.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -146.29 112.6 4.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.586 0.708 . . . . 0.0 111.089 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.466 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.81 94.39 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.665 2.243 . . . . 0.0 112.383 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.7 t -34.23 -59.43 0.44 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -116.3 168.75 9.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 pm0 -89.21 169.37 11.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.86 177.71 15.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 93.9 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.661 2.241 . . . . 0.0 112.393 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 3.3 m-85 -88.28 172.98 9.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 7.5 ttp -144.43 117.13 8.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 49' ' ' VAL . 81.2 t -108.57 95.69 4.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.134 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.7 t -79.72 147.2 32.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.411 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.8 t -142.54 134.27 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.149 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -121.44 168.64 11.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.989 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.688 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.0 t80 -154.9 106.86 2.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.733 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 65.4 42.22 3.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.072 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 62.96 34.83 13.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -146.32 105.05 3.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -51.2 114.93 1.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.822 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.712 HD11 ' HE1' ' A' ' 97' ' ' PHE . 38.1 pt -53.79 153.26 8.58 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.542 0.687 . . . . 0.0 111.198 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.66 5.83 1.51 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.267 . . . . 0.0 112.361 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.552 ' HB2' HD12 ' A' ' 92' ' ' ILE . 12.1 mmm180 -118.49 3.61 11.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.804 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.522 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -118.48 153.26 51.88 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.724 0.773 . . . . 0.0 110.838 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.81 176.68 31.76 Favored 'Cis proline' 0 C--N 1.343 0.243 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.41 -0.017 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 16' ' ' ILE . 72.8 m-85 -114.86 121.68 43.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.882 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 pttp -80.94 107.71 13.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 57.8 t -119.2 106.43 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.164 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -89.12 99.1 12.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.9 t -65.75 150.69 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 78.1 mt -118.94 154.69 53.19 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.618 0.723 . . . . 0.0 110.932 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.447 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.76 119.08 6.08 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.718 2.279 . . . . 0.0 112.299 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.6 m -39.38 -27.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.447 ' N ' ' O ' ' A' ' 103' ' ' PRO . 4.7 m-85 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.949 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 72.9 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.947 0.403 . . . . 0.0 111.087 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -133.21 98.18 15.76 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.549 0.69 . . . . 0.0 110.863 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.73 -2.02 9.44 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.751 2.301 . . . . 0.0 112.344 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.2 m -100.07 13.87 32.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.827 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -9.03 10.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.79 134.34 27.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.187 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -129.44 174.29 9.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.969 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.822 HD11 ' CE2' ' A' ' 97' ' ' PHE . 27.4 pt -150.01 135.97 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.127 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.3 154.74 44.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.129 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 146.15 178.54 21.67 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.48 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -39.55 6.5 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.711 2.274 . . . . 0.0 112.407 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -47.8 -35.61 12.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.549 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.472 HD13 HG13 ' A' ' 16' ' ' ILE . 9.4 mt -93.48 -27.49 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.88 167.95 1.0 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.1 m -85.57 16.86 3.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.961 0.41 . . . . 0.0 110.91 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.35 40.17 2.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.676 HG13 ' CD ' ' A' ' 31' ' ' GLN . 64.9 t -93.02 139.6 17.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 111.153 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.551 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.74 148.15 45.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.869 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -65.36 154.86 37.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 23.1 mtm180 50.65 41.72 26.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.894 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 27' ' ' ALA . 70.0 t -134.23 151.32 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.2 tp -73.97 111.21 8.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.987 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.676 ' CD ' HG13 ' A' ' 25' ' ' VAL . 65.2 mm-40 -112.01 127.33 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.0 t -141.03 149.98 42.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.559 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.4 p90 -144.62 168.77 19.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.825 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 92.7 m -110.18 130.09 55.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.177 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.584 HG13 HG22 ' A' ' 16' ' ' ILE . 65.2 t -111.41 105.61 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.117 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -87.01 104.72 16.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.775 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 75.7 p -118.72 27.2 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.909 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.9 p -74.22 -37.41 63.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.821 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -73.93 -23.32 59.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.62 -41.28 72.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.092 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.48 -135.19 7.44 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.45 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.548 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.98 19.55 13.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.764 0.316 . . . . 0.0 110.901 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.842 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.65 152.01 80.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.671 0.748 . . . . 0.0 111.047 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 165.94 29.33 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.691 2.26 . . . . 0.0 112.328 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 tp -125.36 136.68 53.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.937 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -121.13 143.4 49.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.33 144.98 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.449 ' HG2' ' CD1' ' A' ' 50' ' ' LEU . 12.7 ttm180 -148.24 144.6 27.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.481 HG12 ' OE1' ' A' ' 57' ' ' GLU . 67.3 t -120.89 130.37 74.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.454 HD13 ' CE ' ' A' ' 82' ' ' MET . 3.8 mp -125.11 134.78 52.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.46 173.88 54.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.444 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.4 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 54.6 Cg_endo -69.72 -44.36 2.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.4 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -79.21 -35.52 41.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.943 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 138.77 31.32 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.436 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.534 HD23 ' OE2' ' A' ' 57' ' ' GLU . 10.7 tp -91.63 150.11 21.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.1 t -110.62 132.12 59.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.098 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.534 ' OE2' HD23 ' A' ' 55' ' ' LEU . 48.0 mp0 -120.02 142.74 33.95 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.631 0.729 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 167.93 23.1 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.346 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.8 m -144.31 164.79 13.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.155 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.552 ' O ' HG13 ' A' ' 71' ' ' VAL . 10.8 t-20 -122.85 142.69 50.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 89.8 t -133.5 103.06 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.2 t -127.96 115.25 38.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.159 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -71.12 135.0 47.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -75.64 -43.09 49.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.22 -26.0 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.487 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -85.66 -40.09 16.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.863 0.363 . . . . 0.0 110.872 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.82 34.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.478 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.2 p -151.47 177.65 10.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.168 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -145.77 131.38 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.842 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 51.9 m -90.84 137.74 32.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.132 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.559 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 40.3 t -133.19 105.72 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.061 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 71.1 p -98.32 142.15 30.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.223 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.564 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 10.0 p90 -156.53 169.89 23.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.964 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.3 m -145.74 110.67 4.48 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.552 0.691 . . . . 0.0 111.233 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.546 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.75 94.52 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.661 2.241 . . . . 0.0 112.372 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 60.6 p -39.38 -27.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLN . . . . . 0.462 ' N ' ' O ' ' A' ' 75' ' ' PRO . 3.2 pt20 -147.74 175.49 10.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.98 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.93 173.28 7.67 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.72 174.76 13.86 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.547 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.71 81.66 0.79 Allowed 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.697 2.265 . . . . 0.0 112.382 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -80.52 147.33 30.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.908 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' MET . . . . . 0.454 ' CE ' HD13 ' A' ' 50' ' ' LEU . 3.1 tmm? -117.61 127.09 53.62 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.03 95.3 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 t -76.1 139.92 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.825 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 64.9 t -138.86 129.8 34.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.158 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.426 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 40.4 tttt -121.6 170.52 9.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.842 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.0 t80 -157.09 107.82 2.31 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.69 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.16 41.82 5.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.113 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.426 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 44.0 m-20 63.22 36.07 12.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -146.15 104.97 3.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -53.75 117.34 3.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.87 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.788 HD11 ' HE1' ' A' ' 97' ' ' PHE . 40.3 pt -55.75 153.57 15.8 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.657 0.741 . . . . 0.0 111.113 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.401 ' HD2' ' HB ' ' A' ' 92' ' ' ILE . 53.8 Cg_endo -69.74 6.2 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.727 2.285 . . . . 0.0 112.377 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.503 ' HB2' HD12 ' A' ' 92' ' ' ILE . 15.0 mmm180 -120.59 5.55 10.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.973 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -119.93 153.37 54.96 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.688 0.756 . . . . 0.0 110.781 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.71 172.95 46.4 Favored 'Cis proline' 0 C--N 1.342 0.21 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.3 -0.029 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.822 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.1 m-85 -110.43 139.82 45.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.824 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 34.0 mttm -100.29 107.3 19.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.1 t -117.06 101.54 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.087 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 39.9 tttp -81.0 97.78 7.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 49.4 t -69.61 144.14 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 42.1 mt -109.56 155.17 41.78 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.573 0.701 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.3 Cg_endo -69.82 123.22 9.86 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.737 2.291 . . . . 0.0 112.368 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.434 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -33.87 -35.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.182 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 103' ' ' PRO . 20.0 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 76.8 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.827 0.346 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 13.7 m-20 -129.43 96.72 26.88 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.648 0.737 . . . . 0.0 110.803 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.76 -1.5 8.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.318 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.8 m -100.39 12.29 37.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.5 mmpt? -116.54 -7.41 11.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -85.85 127.07 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.214 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -121.68 173.28 7.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.913 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.851 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.8 pt -148.47 134.38 11.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.07 152.17 45.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.124 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 149.08 176.58 22.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.495 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -38.65 7.55 Favored 'Trans proline' 0 N--CA 1.466 -0.118 0 C-N-CA 122.709 2.273 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.92 -24.39 13.8 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.554 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.445 HD13 HG13 ' A' ' 16' ' ' ILE . 6.5 mt -105.77 -18.23 14.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.949 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.62 177.85 3.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 97.9 p -92.31 15.0 14.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.36 . . . . 0.0 110.854 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.03 42.88 1.78 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.481 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.495 HG13 ' NE2' ' A' ' 31' ' ' GLN . 75.9 t -96.46 141.13 15.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.884 0.373 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.509 ' HB2' HG21 ' A' ' 29' ' ' VAL . 88.7 mtt180 -121.11 148.84 43.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.45 150.18 48.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 58.7 mtt-85 53.98 41.09 32.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.878 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.6 t -132.85 143.59 39.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.078 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.1 tp -66.82 114.03 5.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.495 ' NE2' HG13 ' A' ' 25' ' ' VAL . 53.7 mm-40 -116.49 134.7 54.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.858 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 28.9 t -146.94 148.98 32.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.492 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 2.5 p90 -142.73 173.14 11.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 73.8 m -112.79 133.32 54.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.192 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.682 HG13 HG22 ' A' ' 16' ' ' ILE . 41.0 t -112.95 106.75 21.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.141 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -88.5 99.41 12.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.502 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.5 p -112.99 26.08 10.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.848 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.4 p -72.62 -38.14 67.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.834 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -76.43 -17.11 59.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.952 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.39 -38.36 41.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.42 -138.79 9.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.574 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.4 20.68 12.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.798 0.332 . . . . 0.0 110.913 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.784 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.05 151.54 76.02 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.567 0.698 . . . . 0.0 111.085 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 166.56 27.19 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.292 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.473 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.4 tp -125.72 135.86 52.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.892 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -116.05 142.33 46.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.844 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.575 HG12 HG11 ' A' ' 59' ' ' VAL . 60.9 t -130.0 142.3 44.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.433 ' HG2' ' CD2' ' A' ' 50' ' ' LEU . 20.2 ttm180 -148.16 142.46 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.474 ' C ' HD22 ' A' ' 50' ' ' LEU . 49.0 t -121.2 133.51 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.162 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.474 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.5 mm? -124.78 133.19 53.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.928 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.13 170.26 53.56 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.504 179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -42.26 3.54 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -82.51 -34.85 27.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.13 31.65 0.19 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.428 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.9 tp -91.7 146.01 24.12 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.97 125.88 67.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.154 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -118.86 141.81 30.76 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.621 0.724 . . . . 0.0 110.932 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 171.5 14.44 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.662 2.241 . . . . 0.0 112.336 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.575 HG11 HG12 ' A' ' 47' ' ' VAL . 21.0 m -142.29 165.77 16.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.502 ' O ' HG13 ' A' ' 71' ' ' VAL . 18.4 t-20 -124.24 143.3 50.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.872 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.472 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.4 p -133.47 118.52 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.116 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 60.1 t -134.91 121.62 34.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.203 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -75.04 137.2 41.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.794 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -80.64 -40.97 24.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.1 -29.73 7.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -82.79 -47.12 12.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.786 0.327 . . . . 0.0 110.87 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.38 30.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.4 p -144.14 177.34 8.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.826 0.346 . . . . 0.0 111.044 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m80 -146.07 127.63 15.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 97.2 m -88.38 138.94 30.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.179 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 60' ' ' ASN . 64.4 t -129.75 109.81 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.146 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -97.68 140.2 32.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.136 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.459 ' CE2' ' HB2' ' A' ' 31' ' ' GLN . 5.9 p90 -159.72 170.69 20.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.93 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 m -146.02 116.15 4.79 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 111.147 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.419 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.2 Cg_endo -69.74 92.97 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.683 2.256 . . . . 0.0 112.36 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 m -35.92 -51.59 0.71 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.848 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -131.78 163.17 28.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.6 170.35 16.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.81 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.77 172.66 13.28 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 84.2 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.37 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -76.54 173.57 11.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.1 ttp -144.95 114.37 7.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.803 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -103.51 96.91 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.125 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.1 t -80.3 139.91 36.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.934 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.473 ' CG1' HD11 ' A' ' 45' ' ' LEU . 51.5 t -136.11 140.59 43.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.453 ' HE3' ' N ' ' A' ' 90' ' ' GLU . 18.2 tttp -128.61 169.22 14.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.919 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.739 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.0 t80 -153.86 107.7 3.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.959 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.784 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.65 43.02 5.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.092 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.445 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 32.8 m-20 62.65 36.95 13.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.453 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 14.9 mt-10 -147.58 105.05 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -52.58 118.32 3.53 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.726 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.2 pt -57.75 153.07 33.29 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.646 0.736 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 4.34 2.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.711 2.274 . . . . 0.0 112.362 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HB2' HD12 ' A' ' 92' ' ' ILE . 73.9 mtp85 -116.94 4.93 12.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -117.8 153.72 50.91 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.722 0.772 . . . . 0.0 110.827 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.71 178.36 25.6 Favored 'Cis proline' 0 C--N 1.342 0.211 0 C-N-CA 122.743 -1.774 . . . . 0.0 112.383 -0.05 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.851 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.0 m-85 -115.56 119.92 37.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 ptpt -79.7 100.0 7.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 90.9 t -108.35 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.0 ttpm? -83.2 98.61 9.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.934 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.35 145.34 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.121 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 82.0 mt -110.35 154.3 43.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.614 0.721 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.71 124.22 10.89 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.707 2.271 . . . . 0.0 112.289 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.423 ' C ' ' O ' ' A' ' 103' ' ' PRO . 77.9 m -34.73 -32.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 67.1 m-85 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.9 t . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.883 0.373 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 15.5 m-20 -125.76 98.11 34.68 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.546 0.689 . . . . 0.0 110.851 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.7 Cg_endo -69.77 -1.87 9.22 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.689 2.26 . . . . 0.0 112.321 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.4 ' HA ' ' CD ' ' A' ' 93' ' ' PRO . 53.3 p -101.66 14.48 31.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.893 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.432 ' NZ ' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -117.59 -9.62 10.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.883 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.79 134.66 27.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HD3' ' CZ ' ' A' ' 94' ' ' ARG . 14.0 mmmt -127.67 173.27 10.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.519 HG22 HG13 ' A' ' 35' ' ' VAL . 26.5 pt -148.55 134.82 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.166 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.63 130.13 22.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.181 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.84 170.04 34.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -35.9 11.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.66 2.24 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.35 -42.77 50.72 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.446 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.469 HD11 ' CD2' ' A' ' 33' ' ' PHE . 5.1 mt -80.78 -20.03 43.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.906 0.384 . . . . 0.0 110.929 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.81 174.21 0.48 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 91.2 p -89.47 -13.89 36.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.932 0.396 . . . . 0.0 110.833 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -90.43 52.14 3.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.469 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 79.4 t -99.94 143.61 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.852 0.358 . . . . 0.0 111.09 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.689 ' HB2' HG21 ' A' ' 29' ' ' VAL . 48.6 mtt85 -118.43 148.59 42.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.928 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.563 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.22 152.56 45.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.159 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 54.45 35.15 22.54 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.689 HG21 ' HB2' ' A' ' 26' ' ' ARG . 98.5 t -127.1 149.47 32.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.068 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -71.87 112.01 7.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.942 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.536 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 40.5 mm-40 -116.28 126.79 54.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.8 t -143.46 163.0 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.553 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 2.0 p90 -155.07 -176.96 6.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.1 m -120.87 129.79 53.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.106 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.519 HG13 HG22 ' A' ' 16' ' ' ILE . 55.5 t -108.68 105.74 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.069 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -86.54 98.91 11.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.842 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 87' ' ' TYR . 97.5 p -113.18 31.19 6.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.1 t -73.48 -40.99 63.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -73.87 -24.79 59.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.933 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.727 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.1 -32.86 72.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.103 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.573 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 126.26 -147.47 16.75 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.475 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.845 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -106.64 18.41 21.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.803 0.335 . . . . 0.0 110.92 -179.914 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.746 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.21 151.61 85.86 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.583 0.706 . . . . 0.0 111.078 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 167.49 24.28 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.681 2.254 . . . . 0.0 112.297 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 tp -122.96 144.49 49.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -130.25 143.79 50.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.901 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.513 ' CG1' HG11 ' A' ' 59' ' ' VAL . 46.1 t -136.71 153.74 30.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.416 ' N ' HG12 ' A' ' 47' ' ' VAL . 39.2 mtt180 -155.71 145.19 21.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.4 t -125.72 125.96 69.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.156 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.39 126.54 49.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.65 176.98 23.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.471 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -49.24 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.641 2.227 . . . . 0.0 112.372 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -72.56 -37.24 68.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.98 37.37 0.11 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.444 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.41 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 8.7 tp -91.32 150.65 21.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.877 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.41 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.5 t -114.95 126.72 72.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -127.16 141.63 41.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.653 0.74 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.84 168.03 22.84 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.704 2.27 . . . . 0.0 112.327 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' CG1' ' A' ' 47' ' ' VAL . 44.0 t -138.41 149.8 24.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -96.37 137.87 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.565 ' O ' HG13 ' A' ' 61' ' ' VAL . 13.3 p -133.51 114.36 20.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 84.9 t -135.56 123.56 37.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -77.01 134.63 38.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -76.88 -42.06 41.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.57 9.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.548 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.408 ' CG ' ' N ' ' A' ' 67' ' ' GLY . 0.6 OUTLIER -83.75 -46.96 11.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 0.0 110.891 -179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.408 ' N ' ' CG ' ' A' ' 66' ' ' ASP . . . 164.03 30.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.444 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.5 p -144.54 177.77 8.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.767 0.318 . . . . 0.0 111.155 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.6 m-70 -147.19 124.92 11.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.1 m -83.24 139.7 32.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.159 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.553 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 60.5 t -131.45 106.27 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.4 p -100.18 145.49 27.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -165.45 174.32 10.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.2 m -152.05 114.11 2.92 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 121.53 0.681 . . . . 0.0 111.123 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 94.38 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 0.0 112.357 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.7 m -38.04 -49.64 1.3 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -127.13 158.26 37.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -78.54 170.52 16.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.52 175.09 13.88 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.465 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 83.24 0.7 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.646 2.231 . . . . 0.0 112.315 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -77.99 171.84 14.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 19.2 ttp -143.74 119.03 10.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 91.6 t -104.21 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.0 t -84.22 138.14 33.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 91.1 t -133.86 141.42 44.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.14 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.412 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 28.3 tttt -130.51 168.42 17.08 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.746 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.6 t80 -153.54 108.7 3.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.711 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.88 42.58 7.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.412 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.2 m-20 63.18 35.31 12.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -145.63 104.99 3.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -51.75 121.79 7.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.728 HD11 ' CE2' ' A' ' 97' ' ' PHE . 33.5 pt -59.74 153.25 53.71 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.673 0.749 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.4 ' CD ' ' HA ' ' A' ' 12' ' ' SER . 54.1 Cg_endo -69.8 6.02 1.49 Allowed 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.565 2.176 . . . . 0.0 112.419 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.541 ' HB2' HD12 ' A' ' 92' ' ' ILE . 11.9 mtt85 -121.55 9.57 10.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.41 153.54 58.89 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.747 0.784 . . . . 0.0 110.832 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.8 Cg_endo -69.88 176.78 31.57 Favored 'Cis proline' 0 C--N 1.343 0.253 0 C-N-CA 122.6 -1.834 . . . . 0.0 112.325 0.107 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 92' ' ' ILE . 84.8 m-85 -113.99 132.02 56.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.4 ptmm? -87.28 111.65 21.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.2 t -123.49 101.66 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -84.99 100.05 11.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 81.5 t -71.23 148.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.132 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 60.4 mt -113.86 155.5 45.12 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 0.0 110.908 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.6 Cg_endo -69.71 121.63 8.32 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.69 2.26 . . . . 0.0 112.378 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 103' ' ' PRO . 99.5 m -33.96 -34.94 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.139 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.468 ' N ' ' O ' ' A' ' 103' ' ' PRO . 26.7 m-85 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.5 t . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.828 0.347 . . . . 0.0 111.124 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -129.88 95.42 28.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 0.0 110.878 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 -0.79 7.47 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.668 2.245 . . . . 0.0 112.385 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.8 m -98.7 2.1 46.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.819 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -108.48 -7.16 15.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.416 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -88.86 123.93 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.157 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -123.21 174.46 7.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.757 HG22 HG13 ' A' ' 35' ' ' VAL . 20.5 pt -145.59 133.45 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.09 135.69 29.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.99 170.46 35.2 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.444 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -31.64 20.27 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.349 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.89 -42.6 98.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.661 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.8 mt -77.39 -23.72 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.82 173.85 0.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.445 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.5 m -87.16 -11.84 48.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.96 0.409 . . . . 0.0 110.859 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.28 45.33 3.26 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.432 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -93.19 146.49 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 0.0 111.138 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.781 ' HB2' HG21 ' A' ' 29' ' ' VAL . 28.7 mtm-85 -121.27 151.32 40.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.839 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.479 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -70.72 147.07 49.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.063 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.0 mtm-85 56.32 33.68 22.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.781 HG21 ' HB2' ' A' ' 26' ' ' ARG . 85.8 t -123.74 143.8 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.2 tp -68.0 111.05 4.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.968 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.435 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 52.3 mm-40 -114.13 130.45 56.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 38.6 t -145.48 148.76 33.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.867 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.661 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.9 p90 -140.66 -178.22 5.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 98.8 m -119.92 129.13 54.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.757 HG13 HG22 ' A' ' 16' ' ' ILE . 55.4 t -108.94 106.11 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.144 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -87.57 107.19 18.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 84.5 p -123.12 22.09 9.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.877 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.3 t -66.78 -35.96 81.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.886 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.4 mmtm -83.1 -8.64 59.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -82.91 -34.32 26.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.149 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.15 -135.48 8.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.514 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.51 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -122.77 22.1 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.857 0.361 . . . . 0.0 110.945 -179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.819 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.25 151.71 75.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.579 0.704 . . . . 0.0 111.071 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.441 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.3 Cg_endo -69.77 166.52 27.31 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.39 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.4 tp -124.26 134.88 53.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -119.41 147.06 44.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.3 t -136.97 150.38 26.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.149 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 18.6 mtt-85 -154.23 133.37 12.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.619 ' C ' HD22 ' A' ' 50' ' ' LEU . 62.0 t -112.91 128.61 69.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.141 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.619 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -124.44 127.45 47.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.971 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.72 179.71 37.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.479 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.517 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.84 -37.95 8.28 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.669 2.246 . . . . 0.0 112.316 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.62 -31.27 21.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.913 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.06 30.19 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.8 tp -81.75 147.51 29.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.936 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.3 t -110.41 105.63 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.128 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -96.46 144.91 28.66 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.671 0.748 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 168.12 22.52 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.717 2.278 . . . . 0.0 112.317 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.5 m -142.75 167.45 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -125.05 141.74 51.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.5 t -132.84 111.03 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.169 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 90.3 t -138.93 115.42 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.146 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 65' ' ' GLY . 10.2 t70 -72.51 139.9 47.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.884 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -77.68 -43.25 31.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.46 ' N ' ' OD1' ' A' ' 63' ' ' ASP . . . 115.38 -20.07 14.19 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.473 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -91.61 -41.73 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.876 0.37 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.13 33.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.433 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.0 p -149.34 177.33 9.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.796 0.331 . . . . 0.0 111.158 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -146.94 125.06 12.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 34.5 m -84.53 140.4 31.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.083 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.539 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 67.3 t -131.03 103.78 8.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.139 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.0 p -93.44 139.29 30.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.2 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.498 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.1 p90 -159.9 169.15 24.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.927 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -147.14 115.66 4.32 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.631 0.729 . . . . 0.0 111.104 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.498 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.74 99.01 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.255 . . . . 0.0 112.331 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 75' ' ' PRO . 32.5 t -35.6 -54.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.859 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -128.77 177.55 6.98 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.18 166.35 14.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.99 173.14 13.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.555 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 92.49 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.366 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.517 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.3 m-85 -92.0 151.97 20.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' MET . . . . . 0.455 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.7 tmm? -119.91 129.19 54.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.873 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.45 95.84 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.159 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -79.24 139.06 38.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 61.5 t -136.92 134.22 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.425 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 42.7 tttt -123.25 167.18 14.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.819 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 10.9 t80 -154.5 105.55 2.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.808 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.8 42.96 4.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.09 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.425 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 13.2 m-20 63.35 32.94 14.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -142.69 105.11 4.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -56.98 111.79 1.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.718 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.3 pt -49.5 152.86 2.12 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 111.097 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 4.11 2.41 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.651 2.234 . . . . 0.0 112.365 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 49.7 mtt85 -115.04 -1.28 13.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -113.37 153.83 45.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.672 0.748 . . . . 0.0 110.863 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.3 Cg_endo -69.74 177.96 27.02 Favored 'Cis proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.351 -0.053 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.724 ' CE2' HD11 ' A' ' 16' ' ' ILE . 79.9 m-85 -116.93 140.83 49.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -100.2 111.46 23.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -121.52 103.45 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.078 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.3 tttp -81.91 103.25 11.44 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.61 143.14 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.07 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 74.7 mt -111.83 155.76 42.69 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.557 0.694 . . . . 0.0 110.964 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.493 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.85 123.54 10.18 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.656 2.237 . . . . 0.0 112.334 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 54.4 m -39.02 -25.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.493 ' N ' ' O ' ' A' ' 103' ' ' PRO . 10.3 m-85 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.5 t . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.843 0.354 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 17.9 m-20 -131.73 97.62 18.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.611 0.72 . . . . 0.0 110.819 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.2 Cg_endo -69.76 -1.75 9.0 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.645 2.23 . . . . 0.0 112.365 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -101.12 14.04 33.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.8 mmpt? -117.83 -8.38 10.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -84.31 132.4 31.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.119 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.2 mtmt -126.49 169.48 12.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.885 HD11 ' CE2' ' A' ' 97' ' ' PHE . 37.3 pt -145.74 133.81 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.144 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.65 146.18 35.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 160.13 172.15 26.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -33.41 16.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.674 2.249 . . . . 0.0 112.366 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.431 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -57.45 -42.05 93.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.474 HD11 ' CD2' ' A' ' 33' ' ' PHE . 8.6 mt -80.43 -25.87 38.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.17 176.63 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.479 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.7 t -89.46 -16.58 30.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.976 0.417 . . . . 0.0 110.917 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.82 47.79 3.86 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.431 HG21 ' O ' ' A' ' 20' ' ' GLY . 66.1 t -99.81 141.5 16.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.784 0.326 . . . . 0.0 111.156 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -117.64 151.54 37.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.67 152.41 42.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 55.32 40.2 31.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.27 144.37 34.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 14.7 tp -66.4 115.17 6.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 47.6 mm-40 -120.32 127.06 52.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.867 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . 0.473 ' HB2' HG22 ' A' ' 72' ' ' THR . 32.5 t -141.45 149.63 41.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.839 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.474 ' CD2' HD11 ' A' ' 21' ' ' LEU . 3.5 p90 -142.18 176.55 8.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 83.9 m -114.21 136.96 52.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.725 HG13 HG22 ' A' ' 16' ' ' ILE . 41.5 t -115.16 105.33 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.158 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -87.74 98.47 11.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.903 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 95.5 p -114.4 30.36 7.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.928 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 87.9 p -76.68 -34.68 58.21 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -76.6 -22.01 54.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.56 -41.34 60.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.075 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.593 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 138.34 -147.04 18.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.482 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.838 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -107.18 17.01 23.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.845 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.39 151.44 85.42 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.607 0.718 . . . . 0.0 111.112 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 167.56 24.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.26 . . . . 0.0 112.362 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.491 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.1 tp -125.88 139.72 53.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.961 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 85' ' ' VAL . 1.9 mp0 -117.01 146.69 42.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.623 HG12 HG11 ' A' ' 59' ' ' VAL . 58.4 t -139.51 134.22 39.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.137 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -140.79 141.12 34.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.859 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.667 ' C ' HD22 ' A' ' 50' ' ' LEU . 98.9 t -123.32 127.49 74.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.056 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.667 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -125.11 124.57 42.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.77 167.87 47.49 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -47.78 0.86 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -71.44 -38.63 71.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.931 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.28 34.93 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.501 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.446 HD21 ' OE2' ' A' ' 57' ' ' GLU . 8.4 tp -94.44 149.21 21.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.87 0.367 . . . . 0.0 110.903 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.7 t -115.64 116.25 51.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.146 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.446 ' OE2' HD21 ' A' ' 55' ' ' LEU . 30.2 mm-40 -115.63 139.32 24.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.719 0.771 . . . . 0.0 110.851 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 174.74 9.03 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.771 2.314 . . . . 0.0 112.381 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.623 HG11 HG12 ' A' ' 47' ' ' VAL . 13.7 m -140.34 162.13 24.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.079 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' O ' HG13 ' A' ' 71' ' ' VAL . 23.7 t-20 -117.59 138.54 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.5 p -131.68 119.93 43.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.072 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 92.2 t -138.81 126.32 26.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -79.09 133.29 36.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.813 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -75.29 -46.51 33.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.884 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.15 -23.81 9.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.444 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.4 -44.15 10.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.891 0.376 . . . . 0.0 110.873 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.6 33.94 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.417 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.2 p -150.93 177.59 9.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.329 . . . . 0.0 111.144 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.6 m80 -145.99 126.62 14.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 35.0 m -86.04 142.49 28.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.111 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.404 HG13 ' O ' ' A' ' 60' ' ' ASN . 95.4 t -132.48 108.47 13.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.092 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.473 HG22 ' HB2' ' A' ' 32' ' ' SER . 27.8 p -97.6 142.31 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.089 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 8.7 p90 -161.49 175.75 11.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.946 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -150.42 114.27 3.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.639 0.733 . . . . 0.0 111.137 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 89.09 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.697 2.265 . . . . 0.0 112.329 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 75' ' ' PRO . 44.4 t -35.67 -53.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -122.44 166.64 14.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.953 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -89.69 166.48 13.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.84 179.59 16.12 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.71 86.45 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.691 2.261 . . . . 0.0 112.345 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -76.93 171.66 14.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.1 ttp -143.8 113.25 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 49' ' ' VAL . 85.1 t -109.06 96.11 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.084 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 2.0 m -81.46 145.52 30.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.491 ' CG1' HD11 ' A' ' 45' ' ' LEU . 88.7 t -139.29 138.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.094 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -125.92 170.19 11.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.923 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.845 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.2 t80 -155.24 110.69 3.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.962 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.687 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 61.63 39.77 14.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.115 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 65.52 35.52 7.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.828 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -145.49 105.02 3.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -53.44 118.01 3.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.684 HD11 ' HE1' ' A' ' 97' ' ' PHE . 47.0 pt -57.18 153.43 25.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.567 0.698 . . . . 0.0 111.163 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 5.15 1.82 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.665 2.244 . . . . 0.0 112.354 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 75.8 mtt85 -118.49 6.32 11.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.54 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -119.8 154.07 54.93 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.612 0.72 . . . . 0.0 110.835 -179.803 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.76 178.86 24.0 Favored 'Cis proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.717 -1.784 . . . . 0.0 112.318 0.016 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.885 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.7 m-85 -115.5 126.56 54.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.4 ptmt -90.94 107.42 19.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.9 t -117.67 107.82 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.13 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -84.62 97.64 9.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.8 t -69.19 147.39 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.134 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 61.6 mt -112.24 155.51 43.45 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.641 0.734 . . . . 0.0 110.949 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.68 123.93 10.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.723 2.282 . . . . 0.0 112.31 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 103' ' ' PRO . 59.6 m -34.61 -32.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.192 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.488 ' N ' ' O ' ' A' ' 103' ' ' PRO . 15.6 m-85 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.964 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.885 0.374 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.407 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.1 m-20 -130.29 96.21 25.4 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.63 0.729 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.9 Cg_endo -69.74 3.11 2.95 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 50.3 m -102.77 -0.29 31.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.0 mmpt? -103.94 -8.82 19.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -85.79 128.18 39.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 15' ' ' LYS . 1.2 mppt? -126.83 171.15 11.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.873 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 35' ' ' VAL . 18.2 pt -144.08 135.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.99 126.58 17.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.3 171.38 38.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -32.58 18.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.637 2.225 . . . . 0.0 112.365 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.9 -36.05 65.41 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.618 HD13 HG13 ' A' ' 16' ' ' ILE . 4.7 mt -87.04 -15.5 38.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.851 0.358 . . . . 0.0 110.901 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.67 178.65 3.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.513 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 90.0 p -92.48 -11.77 33.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.96 46.03 3.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.455 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 97.8 t -95.69 142.21 14.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 111.092 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -118.55 153.65 33.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.845 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.51 145.36 47.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.072 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.6 mtt180 59.59 42.23 17.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.95 148.35 30.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.126 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -70.5 112.31 6.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.513 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.1 mm-40 -117.43 128.95 55.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.4 t -148.41 161.16 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.494 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -151.85 -176.08 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.8 m -117.86 128.79 55.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.167 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 16' ' ' ILE . 86.2 t -109.34 107.98 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.152 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -88.79 103.93 16.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.943 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.2 p -122.61 27.24 7.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 28.1 t -68.82 -37.32 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.872 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -81.07 -19.87 42.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.436 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.71 -37.5 76.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 131.58 -143.12 14.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.449 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.551 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -113.69 19.0 17.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.827 0.346 . . . . 0.0 110.875 -179.906 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.721 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.15 151.37 81.42 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.562 0.696 . . . . 0.0 111.153 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.452 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.6 Cg_endo -69.72 167.1 25.37 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.501 HD22 HG11 ' A' ' 35' ' ' VAL . 11.0 tp -127.29 130.97 50.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.901 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -118.57 143.91 46.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.826 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 85' ' ' VAL . 81.8 t -137.44 124.56 29.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.152 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -115.07 149.04 38.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.503 HG23 ' CG2' ' A' ' 59' ' ' VAL . 48.6 t -123.7 120.59 60.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.211 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 50' ' ' LEU . 2.5 mm? -96.68 175.21 6.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.34 159.73 24.17 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.478 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -41.75 4.06 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.689 2.26 . . . . 0.0 112.397 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.22 -14.9 34.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 114.58 36.58 1.28 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.439 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.563 HD23 ' OE2' ' A' ' 57' ' ' GLU . 11.4 tp -100.27 146.55 26.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 0.0 110.939 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 37.8 t -116.21 123.76 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.204 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.563 ' OE2' HD23 ' A' ' 55' ' ' LEU . 27.1 mp0 -117.07 140.62 27.29 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.637 0.732 . . . . 0.0 110.853 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 176.96 6.11 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.659 2.239 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.539 HG12 ' N ' ' A' ' 60' ' ' ASN . 61.8 t -144.29 160.16 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.152 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.539 ' N ' HG12 ' A' ' 59' ' ' VAL . 20.5 t30 -106.79 138.3 43.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 95.9 t -132.77 113.31 20.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 67.1 t -141.15 125.37 17.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -75.15 142.83 43.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -80.24 -43.2 21.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.5 -20.91 13.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.454 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -92.99 -39.44 11.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.887 0.375 . . . . 0.0 110.842 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.43 34.48 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.503 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 67.9 p -151.74 176.82 11.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.819 0.342 . . . . 0.0 111.146 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.6 m80 -142.96 129.7 20.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.3 m -86.76 137.71 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.494 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 33.1 t -130.11 101.51 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 64.3 p -95.31 144.32 25.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.166 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.491 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 3.9 p90 -163.88 168.32 19.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -146.09 115.99 4.74 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.607 0.718 . . . . 0.0 111.161 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.491 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.0 Cg_endo -69.76 93.42 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.658 2.239 . . . . 0.0 112.357 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 t -34.77 -58.85 0.5 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -120.87 168.76 11.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -86.53 170.24 12.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.47 178.16 15.22 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 93.71 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.705 2.27 . . . . 0.0 112.352 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -94.91 171.55 8.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 ttp -147.72 120.26 8.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.21 96.49 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.8 t -78.58 150.46 32.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 47' ' ' VAL . 86.2 t -140.86 133.77 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.077 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 39.7 tttt -125.02 170.0 11.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.5 t80 -157.41 112.81 2.8 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.721 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.49 35.57 22.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.141 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 71.4 30.73 2.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -139.16 105.82 5.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.926 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -56.69 112.24 1.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.621 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.5 pt -50.46 152.73 3.04 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.641 0.734 . . . . 0.0 111.141 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 4.27 2.33 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.55 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.9 mmm180 -114.85 -1.26 13.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.805 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -113.51 154.27 45.56 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.607 0.717 . . . . 0.0 110.863 -179.745 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.1 Cg_endo -69.84 179.67 21.81 Favored 'Cis proline' 0 C--O 1.232 0.191 0 C-N-CA 122.646 -1.814 . . . . 0.0 112.299 0.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.621 ' HE2' HD11 ' A' ' 92' ' ' ILE . 85.9 m-85 -120.87 119.54 32.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.63 116.23 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.51 102.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -85.18 102.31 13.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.39 147.21 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.174 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.2 mt -117.54 154.81 50.76 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.604 0.716 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 123.81 10.46 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.716 2.277 . . . . 0.0 112.338 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.3 m -39.6 -30.33 0.07 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.139 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 -179.885 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.3 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.843 0.354 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.03 97.08 18.87 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.905 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 -2.05 9.54 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.719 2.279 . . . . 0.0 112.295 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 44.5 p -101.71 17.68 22.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.894 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 mmpt? -121.05 -7.37 9.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.881 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -84.66 128.49 38.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.16 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.6 mtpt -124.28 168.08 13.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.936 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.743 HG22 HG13 ' A' ' 35' ' ' VAL . 13.1 pt -144.83 134.79 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.173 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.07 130.58 22.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.041 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.64 168.82 35.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -32.09 19.18 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.298 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.4 -43.78 84.99 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.528 HD13 HG13 ' A' ' 16' ' ' ILE . 4.4 mt -78.33 -26.23 46.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 110.922 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -49.48 172.68 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.487 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.5 m -86.35 -18.62 31.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.822 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -82.83 45.46 3.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.519 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 ' CD ' ' A' ' 31' ' ' GLN . 43.9 t -94.95 142.5 13.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.871 0.367 . . . . 0.0 111.102 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.835 ' HB2' HG21 ' A' ' 29' ' ' VAL . 49.7 mtm180 -117.79 160.01 22.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.576 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -78.2 149.58 33.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.091 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 51.6 mtm-85 55.63 32.04 18.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.85 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.835 HG21 ' HB2' ' A' ' 26' ' ' ARG . 61.4 t -121.48 140.02 46.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.11 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.7 tp -65.8 110.84 2.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 54.7 mm-40 -113.12 133.12 55.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 22.1 t -146.37 154.35 41.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.544 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.1 p90 -148.13 -178.49 6.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.878 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.5 m -122.22 132.02 54.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.174 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.743 HG13 HG22 ' A' ' 16' ' ' ILE . 45.3 t -112.07 105.12 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -86.07 98.22 10.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.474 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 95.6 p -113.03 25.33 11.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.8 t -72.57 -37.49 68.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -74.39 -20.78 59.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.99 -38.67 64.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.063 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.58 -136.49 8.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.573 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.53 20.0 13.12 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.759 0.314 . . . . 0.0 110.839 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.747 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.99 151.67 82.02 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.556 0.693 . . . . 0.0 111.091 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 166.73 26.6 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.381 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -124.72 135.13 52.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -116.9 145.86 43.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.941 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 59' ' ' VAL . 60.2 t -134.18 147.68 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.125 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -152.07 133.29 14.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.687 HG23 ' CG2' ' A' ' 59' ' ' VAL . 87.6 t -116.92 124.98 73.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.623 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.2 mm? -123.65 121.67 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.946 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.21 172.83 8.81 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.487 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.71 -48.44 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.707 2.271 . . . . 0.0 112.373 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -71.83 -39.2 69.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.84 32.79 0.12 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.506 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.457 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 9.1 tp -91.3 153.32 20.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.807 0.336 . . . . 0.0 110.92 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.457 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.8 t -115.37 130.08 70.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.068 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -133.12 140.85 38.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.699 0.761 . . . . 0.0 110.869 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 170.68 15.95 Favored 'Trans proline' 0 C--N 1.343 0.247 0 C-N-CA 122.617 2.211 . . . . 0.0 112.419 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 47' ' ' VAL . 67.2 t -141.52 154.66 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.721 ' O ' HG13 ' A' ' 71' ' ' VAL . 9.4 t-20 -100.35 137.69 38.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.599 ' O ' HG13 ' A' ' 61' ' ' VAL . 10.6 p -133.54 116.55 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 82.3 t -138.31 130.29 38.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.134 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -82.3 140.48 33.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -79.95 -45.33 18.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.09 -25.22 8.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -88.11 -41.63 12.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.877 0.37 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.96 34.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 62.3 p -149.35 177.5 9.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.139 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.6 m-70 -145.92 123.73 11.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 65.7 m -85.23 136.47 33.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.166 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.721 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.6 t -129.09 112.71 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.4 p -103.93 146.72 28.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.9 p90 -165.79 177.44 7.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.986 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.1 m -154.31 113.74 2.47 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.551 0.691 . . . . 0.0 111.109 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.2 Cg_endo -69.82 93.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.642 2.228 . . . . 0.0 112.333 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 75' ' ' PRO . 31.2 t -34.14 -59.78 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -116.35 167.81 10.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.937 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -83.76 166.26 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.836 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.78 169.31 12.32 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.98 91.24 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.605 2.203 . . . . 0.0 112.276 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.415 ' CD1' ' HD3' ' A' ' 52' ' ' PRO . 4.3 m-85 -82.97 172.06 13.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 17.6 ttp -140.74 118.72 11.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.846 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 49' ' ' VAL . 71.8 t -110.26 96.88 5.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.178 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.3 m -81.6 145.08 30.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.924 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 98.0 t -138.75 137.29 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.108 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 43.1 tttt -123.22 169.1 11.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.899 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.747 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.6 t80 -155.59 111.46 3.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.666 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.56 37.9 12.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.036 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.418 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 5.6 m-20 66.4 35.34 5.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.817 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -145.78 104.99 3.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -52.26 113.0 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.622 HD11 ' CE2' ' A' ' 97' ' ' PHE . 45.6 pt -51.37 153.14 3.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.604 0.716 . . . . 0.0 111.179 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 4.89 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.696 2.264 . . . . 0.0 112.326 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.508 ' HB2' HD12 ' A' ' 92' ' ' ILE . 20.1 mmt180 -116.98 1.54 12.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.841 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.538 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.09 154.34 48.51 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.661 0.743 . . . . 0.0 110.883 -179.798 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.2 Cg_endo -69.78 177.47 28.8 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.654 -1.811 . . . . 0.0 112.353 -0.022 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.622 ' CE2' HD11 ' A' ' 92' ' ' ILE . 86.9 m-85 -116.84 146.29 42.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.839 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.03 131.49 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.914 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 69.5 t -134.98 101.62 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.113 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -82.78 94.0 7.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.918 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -71.07 145.22 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.073 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 57.3 mt -118.77 155.82 52.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.634 0.731 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.2 Cg_endo -69.67 116.25 4.46 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.672 2.248 . . . . 0.0 112.408 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 52.1 m -34.01 -33.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.498 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.5 m-85 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.955 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.798 0.332 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -133.79 96.86 16.02 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.652 0.739 . . . . 0.0 110.801 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -1.5 8.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.642 2.228 . . . . 0.0 112.364 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 48.0 m -100.97 12.56 37.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.819 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.1 mmpt? -117.47 -9.16 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.413 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -82.38 135.84 24.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.8 mtpm? -132.64 168.0 19.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.819 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.815 HD11 ' CE2' ' A' ' 97' ' ' PHE . 36.8 pt -144.33 135.37 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.98 133.14 26.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.056 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.01 175.36 40.13 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.445 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 -35.35 12.72 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.667 2.245 . . . . 0.0 112.362 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.36 -42.56 83.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.534 HD13 HG13 ' A' ' 16' ' ' ILE . 11.8 mt -77.45 -28.33 52.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.943 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.85 176.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 t -92.01 -18.03 24.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.906 0.384 . . . . 0.0 110.839 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.26 48.76 4.09 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.11 140.56 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.336 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 52.4 mtt180 -118.46 148.63 42.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.51 42.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 44.7 mtp180 54.73 39.19 31.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.6 t -134.79 143.15 38.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.154 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 22.5 tp -66.24 114.43 5.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.973 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.511 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 42.3 mm-40 -117.73 128.3 54.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.2 t -139.86 164.82 28.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.822 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.564 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -157.86 167.89 28.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -107.3 131.19 54.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.603 HG13 HG22 ' A' ' 16' ' ' ILE . 58.1 t -111.41 105.27 18.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.083 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -88.5 103.17 15.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.9 p -117.96 26.12 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.817 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.1 t -71.67 -39.05 70.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.861 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -72.99 -22.09 60.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.26 -41.58 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.084 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 139.23 -136.67 8.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.596 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.22 18.24 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.839 0.352 . . . . 0.0 110.983 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.683 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.37 152.0 83.51 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.568 0.699 . . . . 0.0 111.102 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.81 166.79 26.46 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 0.0 112.272 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.5 tp -125.48 139.57 53.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.483 ' O ' HG13 ' A' ' 85' ' ' VAL . 12.4 tt0 -125.27 148.03 48.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 85' ' ' VAL . 40.2 t -140.82 152.12 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.111 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 49.4 mtm-85 -153.16 138.53 17.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 83' ' ' VAL . 93.4 t -118.31 124.09 72.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.1 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.51 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.2 mm? -113.32 152.34 30.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.927 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.67 168.48 22.7 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.472 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.85 -44.74 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.675 2.25 . . . . 0.0 112.299 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -78.14 -29.67 48.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.37 28.38 0.48 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.476 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.4 tp -88.85 144.37 26.26 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -115.93 117.1 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.108 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -112.94 141.98 26.47 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.7 0.762 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 175.85 7.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG13 ' A' ' 71' ' ' VAL . 23.4 t -144.35 153.63 15.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.092 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 27.3 t-20 -99.63 139.16 35.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.832 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.1 t -133.26 108.38 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 86.4 t -131.51 129.67 62.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.1 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -84.13 133.65 34.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -74.42 -44.24 52.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.49 -25.2 9.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.3 m-20 -88.42 -44.38 10.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.908 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.33 33.49 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.513 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 73.3 p -147.64 177.13 9.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 41.3 m80 -145.4 131.56 19.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.3 m -92.81 134.94 34.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.57 HG13 ' O ' ' A' ' 60' ' ' ASN . 39.3 t -129.7 106.36 13.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.145 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.7 p -103.67 140.82 37.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.195 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.557 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 15.7 p90 -156.78 -176.02 5.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -156.53 112.2 2.03 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 121.569 0.699 . . . . 0.0 111.081 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.557 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.81 90.22 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.695 2.263 . . . . 0.0 112.359 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 75' ' ' PRO . 27.8 m -33.85 -57.61 0.45 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.934 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -118.73 166.36 12.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -85.34 172.28 11.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.908 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.07 174.15 13.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.472 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.73 89.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.628 2.219 . . . . 0.0 112.386 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -86.25 164.35 17.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 39.7 ttp -137.32 119.02 15.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 49' ' ' VAL . 92.8 t -105.07 95.91 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.133 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 41.3 t -80.51 143.26 33.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 46' ' ' GLU . 87.0 t -139.25 142.98 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.45 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 14.5 tttp -129.62 168.37 16.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.616 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.9 t80 -154.03 114.68 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.683 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.7 36.06 22.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.127 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.45 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 0.8 OUTLIER 68.57 35.3 3.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.861 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.409 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 28.6 mt-10 -147.59 105.17 3.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -50.39 120.13 4.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.681 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.7 pt -58.62 153.93 37.94 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.634 0.73 . . . . 0.0 111.105 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 5.72 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.66 2.24 . . . . 0.0 112.39 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -119.81 8.17 11.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.84 153.71 60.42 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.5 Cg_endo -69.72 177.93 27.06 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.399 -0.05 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.815 ' CE2' HD11 ' A' ' 16' ' ' ILE . 52.2 m-85 -115.2 127.96 55.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.929 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.2 ptpt -87.72 110.07 20.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.99 101.64 9.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -83.11 103.64 12.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.5 t -70.22 143.72 14.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -112.26 155.91 42.86 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.584 0.707 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.494 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.77 121.29 7.98 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.688 2.258 . . . . 0.0 112.307 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 33.3 m -35.24 -31.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.188 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.6 m-85 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -128.46 95.33 33.22 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.627 0.727 . . . . 0.0 110.859 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.87 9.2 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.645 2.23 . . . . 0.0 112.37 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.4 p -99.71 9.06 43.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.811 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.9 mmpt? -113.06 -6.64 13.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.889 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -86.5 127.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.4 mtmm -124.44 168.16 13.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.738 HD11 ' CE2' ' A' ' 97' ' ' PHE . 25.9 pt -144.07 136.34 22.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.165 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.54 144.96 33.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.094 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.34 177.06 30.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -39.67 6.21 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.689 2.259 . . . . 0.0 112.34 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.61 -30.26 13.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.45 HD13 HG13 ' A' ' 16' ' ' ILE . 15.1 mt -95.6 -22.52 17.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.862 0.363 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.47 164.67 5.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p -83.95 14.56 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.924 0.393 . . . . 0.0 110.898 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.9 44.25 1.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.457 HG13 ' NE2' ' A' ' 31' ' ' GLN . 76.3 t -95.65 149.12 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.849 0.357 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 93.0 mtt-85 -124.31 153.63 41.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.4 151.94 40.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 54.47 39.29 30.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.3 t -134.13 144.62 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.3 tp -66.85 113.9 5.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.918 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 48.2 mm-40 -117.43 130.03 56.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 25.0 t -143.74 163.32 33.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.835 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.522 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -154.88 -177.8 6.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.4 m -119.06 131.03 55.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.629 HG13 HG22 ' A' ' 16' ' ' ILE . 59.1 t -111.7 105.07 18.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.11 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -86.5 102.54 14.19 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.456 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.7 p -119.31 29.01 7.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.3 t -76.29 -34.53 59.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.3 mttp -80.17 -16.09 55.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -79.05 -38.25 36.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.128 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -141.4 12.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.559 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -114.98 19.02 16.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.763 0.316 . . . . 0.0 110.854 -179.908 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.8 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.24 151.47 83.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.606 0.717 . . . . 0.0 111.154 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 166.76 26.42 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.262 . . . . 0.0 112.376 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -126.18 136.54 52.97 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -121.9 146.38 47.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.778 ' CG1' HG11 ' A' ' 59' ' ' VAL . 84.9 t -138.77 129.11 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.198 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.3 ttm-85 -125.05 140.26 53.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.464 HG23 HG22 ' A' ' 59' ' ' VAL . 92.1 t -119.82 116.97 52.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.463 HD11 HG22 ' A' ' 56' ' ' VAL . 2.0 mm? -115.37 125.69 53.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.28 175.23 15.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.0 Cg_endo -69.73 -43.27 2.79 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.31 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.421 ' HB2' ' NH1' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -75.3 -38.08 60.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.865 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.67 33.24 0.14 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.481 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.459 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 6.4 tp -90.33 155.84 18.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 110.937 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 HD11 ' A' ' 50' ' ' LEU . 91.9 t -117.94 118.65 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -117.38 143.37 31.91 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.679 0.752 . . . . 0.0 110.886 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 168.18 22.32 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.688 2.259 . . . . 0.0 112.359 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.778 HG11 ' CG1' ' A' ' 47' ' ' VAL . 3.5 t -140.59 144.49 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.125 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.681 ' O ' HG13 ' A' ' 71' ' ' VAL . 26.2 t-20 -93.12 138.41 31.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.504 ' O ' HG13 ' A' ' 61' ' ' VAL . 9.5 p -133.23 117.97 30.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 80.4 t -135.55 138.44 48.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -89.63 138.54 31.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.865 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.45 -46.38 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.58 -25.08 9.3 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.531 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -87.94 -43.63 11.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.821 0.343 . . . . 0.0 110.785 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.56 33.85 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.431 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 70.8 p -150.43 177.66 9.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.822 0.344 . . . . 0.0 111.114 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -145.7 127.36 15.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 54.6 m -86.38 132.5 33.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.145 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.1 t -125.58 111.01 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.081 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 61.9 p -102.38 147.02 27.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.108 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 6.6 p90 -165.36 173.47 11.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.6 m -149.49 113.87 3.51 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.577 0.703 . . . . 0.0 111.125 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.79 93.3 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.702 2.268 . . . . 0.0 112.292 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 3.7 m -34.26 -45.52 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.882 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -135.29 170.76 15.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.412 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.1 pp20? -86.2 177.63 7.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.33 173.98 14.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 83.45 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.684 2.256 . . . . 0.0 112.343 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.8 m-85 -78.43 172.53 13.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.947 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.6 ttp -143.68 115.61 8.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.827 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.1 t -104.36 95.4 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.129 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 33.8 t -77.32 147.26 36.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.4 t -139.93 137.44 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.079 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.427 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 17.3 tttp -128.65 169.36 14.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.8 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.2 t80 -155.0 110.76 3.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.741 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.71 39.79 17.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.044 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.427 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 39.3 m-20 67.15 32.66 6.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.968 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -142.55 105.22 4.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -53.79 116.89 2.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.663 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.5 pt -56.13 153.12 19.45 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.593 0.711 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 4.69 2.05 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.653 2.235 . . . . 0.0 112.421 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.463 ' HB2' HD12 ' A' ' 92' ' ' ILE . 39.3 mmt180 -117.19 4.53 12.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.909 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -117.96 153.98 51.24 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.672 0.749 . . . . 0.0 110.873 -179.85 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.8 -178.83 17.64 Favored 'Cis proline' 0 C--N 1.341 0.15 0 C-N-CA 122.756 -1.768 . . . . 0.0 112.303 0.089 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.738 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.4 m-85 -118.48 125.38 49.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 29.8 pttt -83.52 109.87 17.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 94.7 t -123.36 101.86 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.099 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 12.5 tttp -84.19 94.08 8.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.992 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.412 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 63.4 t -63.39 145.94 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 65.9 mt -111.23 155.95 41.86 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.554 0.692 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.72 122.4 9.09 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.7 2.266 . . . . 0.0 112.33 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -34.12 -35.21 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.461 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.841 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.8 t . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.794 0.33 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 m-20 -121.15 98.22 47.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.623 0.725 . . . . 0.0 110.862 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.74 2.4 3.55 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.684 2.256 . . . . 0.0 112.389 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 51.0 m -97.43 -6.74 33.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 39' ' ' LYS . 8.0 mmmm -96.48 -7.09 35.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.917 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -89.37 124.12 41.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -127.27 169.15 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.536 HG13 HD13 ' A' ' 21' ' ' LEU . 29.9 pt -141.66 133.31 27.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.101 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.79 129.09 22.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 175.51 42.08 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.86 -34.33 14.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.704 2.27 . . . . 0.0 112.28 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.19 -32.5 67.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.469 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.536 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -91.64 -14.54 29.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.65 -175.12 4.31 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.495 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.8 t -95.61 -15.59 22.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.906 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.03 47.15 3.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.478 HG13 ' NE2' ' A' ' 31' ' ' GLN . 55.4 t -97.0 142.39 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 111.197 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 66.9 mtt180 -119.4 150.8 39.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.42 152.57 42.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.079 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.4 mtp180 52.81 41.66 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.932 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.9 t -135.14 149.23 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.0 tp -69.41 113.11 6.42 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.48 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 28.9 mm-40 -118.9 126.75 52.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.887 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 35.1 t -142.17 161.87 36.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.878 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.55 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.4 p90 -151.65 -176.16 5.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.918 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 90.1 m -118.27 134.73 54.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.517 HG11 ' CD2' ' A' ' 45' ' ' LEU . 40.4 t -113.85 105.91 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.11 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -90.62 109.85 21.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -126.45 27.76 6.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.8 m -70.13 -36.39 74.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.468 ' CB ' ' HB3' ' A' ' 13' ' ' LYS . 39.4 mtmt -84.44 -7.7 59.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.912 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.402 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -81.88 -34.72 29.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.07 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.26 -139.56 11.14 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.478 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.809 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.75 19.83 14.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.813 0.34 . . . . 0.0 110.864 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.908 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.74 150.21 78.53 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.625 0.726 . . . . 0.0 111.042 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.461 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 54.4 Cg_endo -69.75 168.55 21.2 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.68 2.254 . . . . 0.0 112.386 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.517 ' CD2' HG11 ' A' ' 35' ' ' VAL . 7.4 tp -127.52 128.73 46.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -108.75 155.06 21.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.953 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.671 HG12 HG11 ' A' ' 59' ' ' VAL . 65.5 t -141.58 135.97 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 -142.37 142.06 32.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.966 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -124.37 131.24 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.158 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -102.5 179.24 4.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -128.05 153.6 19.48 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.49 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -26.02 27.78 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.695 2.263 . . . . 0.0 112.293 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.36 12.58 10.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.95 27.92 8.05 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 15.0 tp -94.35 145.34 24.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.399 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -115.5 140.71 35.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.158 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -131.29 145.63 58.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.597 0.713 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 172.64 12.3 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.294 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.671 HG11 HG12 ' A' ' 47' ' ' VAL . 3.7 m -144.21 159.66 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.142 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 11.5 t-20 -123.04 140.97 52.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.8 p -133.39 117.03 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.142 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.7 t -139.47 132.04 36.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.093 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -80.2 136.21 36.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -75.04 -42.32 57.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.95 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.82 -23.04 15.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -90.44 -43.28 10.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 33.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.509 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 70.9 p -151.71 177.75 10.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.3 m80 -141.73 127.05 18.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.939 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.0 m -86.79 139.88 30.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.164 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.585 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.7 t -131.45 107.69 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -95.43 141.46 28.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.537 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.9 p90 -159.44 167.46 28.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.6 m -145.28 113.67 4.82 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.58 0.705 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.537 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.9 Cg_endo -69.69 94.62 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.684 2.256 . . . . 0.0 112.392 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' PRO . 5.7 m -34.16 -55.4 0.5 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -130.33 158.96 38.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.911 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -72.37 172.95 9.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.925 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.82 176.2 14.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 84.06 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.723 2.282 . . . . 0.0 112.312 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -82.68 173.85 11.53 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 ttp -150.77 129.81 12.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.911 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -115.88 97.99 6.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -80.72 132.71 35.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.774 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 99.0 t -128.25 134.55 64.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.145 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -124.11 167.25 14.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.908 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.9 t80 -153.96 105.61 2.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.826 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.49 42.65 2.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.13 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.0 33.52 14.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -143.19 105.72 4.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -55.06 112.59 1.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.65 HD11 ' CE2' ' A' ' 97' ' ' PHE . 44.8 pt -50.42 152.99 2.83 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.6 0.714 . . . . 0.0 111.152 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.441 ' HG2' ' NH1' ' A' ' 94' ' ' ARG . 54.5 Cg_endo -69.73 8.3 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.716 2.277 . . . . 0.0 112.368 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.501 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 0.6 OUTLIER -120.7 -2.47 9.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.526 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.3 t -111.56 152.55 44.09 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.675 0.75 . . . . 0.0 110.844 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.526 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.77 175.17 37.64 Favored 'Cis proline' 0 C--O 1.231 0.153 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.317 0.017 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.65 ' CE2' HD11 ' A' ' 92' ' ' ILE . 82.4 m-85 -115.45 117.7 31.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -77.97 115.56 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.871 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.5 t -128.01 103.91 11.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 24.3 ttpt -83.32 99.27 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.929 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.3 t -68.51 145.67 13.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.118 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.3 mt -112.08 155.32 43.59 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.631 0.729 . . . . 0.0 110.875 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' TYR . 52.9 Cg_endo -69.83 121.7 8.37 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.246 . . . . 0.0 112.319 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.1 m -33.87 -36.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.173 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.446 ' N ' ' O ' ' A' ' 103' ' ' PRO . 31.3 m-85 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.986 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 112.494 -0.243 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.8 t -90.03 114.92 26.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.959 0.409 . . . . 0.0 110.818 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 84.2 p -145.55 135.8 23.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.874 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 118.62 148.82 8.53 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.495 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 t -125.1 96.89 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.888 0.375 . . . . 0.0 110.891 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.9 t -148.47 145.95 28.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.827 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.33 50.32 0.89 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.423 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.433 HG22 ' N ' ' A' ' 9' ' ' VAL . 13.4 p -93.08 155.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.933 0.397 . . . . 0.0 111.12 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.433 ' N ' HG22 ' A' ' 8' ' ' VAL . 52.6 t -98.25 125.66 51.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.211 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -118.23 94.96 47.82 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.569 0.699 . . . . 0.0 110.883 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -0.11 6.45 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.77 2.313 . . . . 0.0 112.312 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.7 m -99.12 1.87 45.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.852 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -104.65 -6.76 20.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -90.12 129.31 41.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.115 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.27 176.19 8.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.833 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.627 HD11 ' CE1' ' A' ' 97' ' ' PHE . 13.2 pt -145.61 134.59 17.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.158 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.98 120.74 13.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.087 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.52 168.76 40.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -26.48 27.54 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.723 2.282 . . . . 0.0 112.292 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.76 -25.58 70.57 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.484 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.614 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -98.73 -9.98 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.883 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.08 -178.48 14.6 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.528 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.8 m -91.58 -6.93 51.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.905 0.383 . . . . 0.0 110.863 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.4 47.24 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.491 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.661 HG13 ' NE2' ' A' ' 31' ' ' GLN . 88.1 t -98.01 139.85 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 111.105 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.822 ' HB2' HG21 ' A' ' 29' ' ' VAL . 80.8 mtt-85 -121.97 146.23 47.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.826 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.654 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.28 151.82 39.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.085 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.2 mtt180 53.83 37.0 25.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.904 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.822 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.2 t -127.47 148.82 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.169 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.4 tp -71.56 111.38 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.661 ' NE2' HG13 ' A' ' 25' ' ' VAL . 36.5 mm-40 -114.92 127.48 55.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.8 t -144.44 155.86 43.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.532 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.2 p90 -148.02 -178.21 6.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.866 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -121.17 129.88 53.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.505 HG11 ' CD2' ' A' ' 45' ' ' LEU . 47.6 t -108.26 106.37 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -88.98 111.82 22.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.9 p -128.11 24.41 5.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 t -68.36 -34.71 76.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.25 -8.24 57.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.42 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -83.0 -35.33 25.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.12 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.29 -144.07 15.36 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.415 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.744 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -110.43 17.71 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.796 0.332 . . . . 0.0 110.917 -179.906 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.838 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.01 148.65 81.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.579 0.704 . . . . 0.0 111.095 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 167.67 23.77 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.68 2.253 . . . . 0.0 112.317 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.505 ' CD2' HG11 ' A' ' 35' ' ' VAL . 6.9 tp -125.43 127.32 46.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -110.95 148.42 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.92 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 48' ' ' ARG . 35.7 t -139.45 153.9 24.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.411 ' N ' HG12 ' A' ' 47' ' ' VAL . 18.5 mtp85 -157.36 138.04 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.88 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 83' ' ' VAL . 77.2 t -117.98 116.65 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.095 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.98 123.28 49.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.95 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.22 178.56 1.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.499 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.581 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.5 Cg_endo -69.77 -39.2 6.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.628 2.219 . . . . 0.0 112.365 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.21 -28.77 22.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.843 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.9 34.37 0.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.53 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.607 HD21 ' OE2' ' A' ' 57' ' ' GLU . 18.1 tp -83.16 156.45 23.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.898 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 56' ' ' VAL . 12.7 p -119.46 111.72 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.15 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.607 ' OE2' HD21 ' A' ' 55' ' ' LEU . 8.0 mm-40 -112.8 143.5 29.18 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 110.875 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 169.41 19.04 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.676 2.251 . . . . 0.0 112.336 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.5 m -142.65 157.07 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.658 ' O ' HG13 ' A' ' 71' ' ' VAL . 15.9 t-20 -109.63 143.51 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.13 120.82 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 97.8 t -136.08 132.12 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.134 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -87.04 128.75 35.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.911 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -71.37 -42.1 68.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.868 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.14 -20.95 25.44 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.83 -42.74 9.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.47 36.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.496 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 64.7 p -153.11 176.38 11.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.14 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 29.4 m80 -143.92 133.99 24.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.2 m -96.35 132.9 41.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.134 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.2 t -126.37 108.16 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.135 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 51.8 p -98.28 142.26 30.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.106 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.493 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 7.2 p90 -159.73 169.28 24.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -145.04 113.77 4.91 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.64 0.733 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.493 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.73 97.12 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.374 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 75' ' ' PRO . 57.8 p -35.35 -47.98 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLN . . . . . 0.457 HE21 ' HB3' ' A' ' 77' ' ' GLN . 1.5 pt20 -132.08 -175.54 3.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.5 pp20? -101.47 170.27 8.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.5 176.81 14.57 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.533 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 88.07 0.55 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.581 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.4 m-85 -85.21 173.67 10.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.942 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 23.6 ttp -146.62 117.49 7.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.919 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 49' ' ' VAL . 63.0 t -107.56 100.26 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.0 t -84.46 148.48 26.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.8 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.3 t -142.57 138.85 28.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.079 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -126.52 169.27 13.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.829 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.8 t80 -156.45 105.0 2.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.838 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.81 42.04 2.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.058 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 64.0 32.93 12.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.899 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -143.11 105.01 4.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.953 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -54.54 109.5 0.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.584 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.5 pt -47.52 152.95 1.09 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.648 0.737 . . . . 0.0 111.122 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 3.93 2.48 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.629 2.219 . . . . 0.0 112.374 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 39.1 mmt-85 -113.31 -4.15 13.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -111.84 154.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.685 0.755 . . . . 0.0 110.838 -179.787 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.7 -179.97 20.55 Favored 'Cis proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 -1.797 . . . . 0.0 112.353 -0.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.627 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.5 m-85 -120.62 118.86 31.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -82.06 105.16 12.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.7 t -116.38 105.21 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 43.8 tttm -82.49 102.55 11.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 38.9 t -70.21 150.73 9.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.113 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.53 153.84 52.16 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.598 0.713 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.87 122.65 9.3 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.681 2.254 . . . . 0.0 112.305 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 53.5 m -34.7 -34.51 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.173 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.458 ' N ' ' O ' ' A' ' 103' ' ' PRO . 64.9 m-85 -97.86 120.0 37.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -85.96 120.43 27.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.7 78.85 8.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.846 -179.787 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 3' ' ' SER . 82.1 p -130.17 167.05 19.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.855 0.359 . . . . 0.0 110.884 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 2' ' ' SER . 78.7 p 36.77 42.26 0.21 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.871 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -77.74 -98.09 0.2 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.1 t -82.33 109.89 17.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.902 0.382 . . . . 0.0 110.845 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 87.7 p -163.6 155.1 16.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.46 83.41 0.16 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.428 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.89 148.71 27.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.889 0.376 . . . . 0.0 111.16 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.5 t -92.61 130.28 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.152 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -128.89 95.73 31.08 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -2.73 10.65 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.752 2.301 . . . . 0.0 112.316 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.7 p -98.99 9.31 43.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.796 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -113.79 -7.65 13.23 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.5 p -83.85 125.1 40.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.109 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -120.9 173.66 7.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.593 HG22 HG13 ' A' ' 35' ' ' VAL . 38.1 pt -147.02 137.6 17.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.72 138.22 32.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.084 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.3 168.84 27.0 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -30.97 21.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.668 2.245 . . . . 0.0 112.354 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -52.55 -46.65 58.55 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.483 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.585 HD11 HD12 ' A' ' 16' ' ' ILE . 6.0 mt -76.64 -28.63 56.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.875 0.369 . . . . 0.0 110.982 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -47.62 169.83 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.479 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 69.7 m -87.06 -7.92 57.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -93.7 49.21 2.3 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 20' ' ' GLY . 70.1 t -101.05 142.31 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.772 0.32 . . . . 0.0 111.15 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.493 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.0 mtt180 -118.33 147.89 43.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -67.71 149.61 49.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 56.18 40.73 30.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.493 HG21 ' HB2' ' A' ' 26' ' ' ARG . 53.6 t -133.62 148.11 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.099 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 18.6 tp -68.18 114.52 6.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.423 ' NE2' HG13 ' A' ' 25' ' ' VAL . 44.4 mm-40 -120.64 128.36 52.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.927 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.3 t -144.9 150.69 37.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.548 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 1.4 p90 -139.58 -178.29 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -121.0 133.78 55.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.12 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.593 HG13 HG22 ' A' ' 16' ' ' ILE . 44.6 t -115.34 107.57 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -91.33 106.86 18.81 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.46 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.1 p -117.01 20.4 13.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 50.6 p -63.05 -42.52 99.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? -77.03 -15.06 59.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.498 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -78.6 -32.38 47.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.062 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.01 -140.11 11.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.504 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.68 22.69 12.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.858 0.361 . . . . 0.0 110.949 -179.933 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.763 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.27 151.64 75.48 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.708 . . . . 0.0 111.074 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 167.05 25.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.659 2.239 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.7 tp -125.78 139.06 53.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.981 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -121.24 145.26 48.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.9 t -134.22 141.18 44.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -146.64 130.99 17.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 83' ' ' VAL . 82.0 t -116.21 125.15 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -115.07 144.2 44.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.72 169.7 43.1 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.552 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -31.74 19.91 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.624 2.216 . . . . 0.0 112.369 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -95.36 -27.37 15.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.881 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 133.28 27.46 0.56 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.8 tp -86.79 148.66 25.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.895 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.3 t -110.96 121.54 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.123 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.569 ' OE1' HG12 ' A' ' 49' ' ' VAL . 4.5 mp0 -112.62 142.92 27.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.641 0.734 . . . . 0.0 110.906 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.18 22.24 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.337 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.74 157.55 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -115.32 140.92 48.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.861 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 84.5 t -132.22 107.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.12 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -131.64 119.13 41.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.136 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t0 -76.07 133.47 40.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.859 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -72.37 -43.33 64.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.71 -24.7 10.09 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.437 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -86.99 -39.1 15.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.78 34.21 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.552 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 72.6 p -150.16 176.74 10.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.837 0.351 . . . . 0.0 111.144 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.2 m80 -145.78 131.18 18.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.859 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 21.9 m -91.61 139.58 30.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.548 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 99.3 t -129.59 102.32 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.111 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 46.7 p -92.51 138.81 31.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.173 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -164.01 160.78 22.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 29' ' ' VAL . 84.9 m -137.98 117.27 9.88 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.607 0.718 . . . . 0.0 111.152 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' SER . 53.8 Cg_endo -69.74 90.45 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.689 2.259 . . . . 0.0 112.305 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' PRO . 64.6 p -34.97 -53.6 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.881 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -122.22 158.39 29.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pp20? -79.7 174.95 11.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.948 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.35 177.16 14.89 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.516 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 86.59 0.59 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.623 2.216 . . . . 0.0 112.32 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -79.07 169.75 17.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -145.16 119.08 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.892 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 49' ' ' VAL . 90.1 t -110.89 97.12 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.141 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.4 m -81.4 142.56 32.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 87.2 t -135.61 145.14 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.404 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 23.7 tttt -132.35 168.66 17.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.733 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.1 t80 -154.39 105.74 2.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.969 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.763 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.49 44.39 5.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.186 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.404 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.1 m-20 63.2 33.3 14.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -142.49 105.06 4.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -56.21 111.62 1.01 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.636 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.7 pt -49.24 153.2 1.78 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.59 0.709 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 4.41 2.16 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.664 2.243 . . . . 0.0 112.377 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.419 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 9.4 mtm-85 -116.18 0.09 12.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.544 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -115.21 153.32 47.36 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.644 0.735 . . . . 0.0 110.803 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.544 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.5 Cg_endo -69.76 171.26 54.53 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.35 -0.005 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.636 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.1 m-85 -109.78 140.8 43.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.3 ptmm? -100.75 110.32 22.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 98.9 t -119.44 101.95 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.1 tttm -81.0 101.6 9.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.9 t -73.22 147.66 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.128 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.8 mt -114.96 154.79 47.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 0.0 110.86 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.0 Cg_endo -69.74 124.16 10.82 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.671 2.247 . . . . 0.0 112.346 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.407 ' C ' ' O ' ' A' ' 103' ' ' PRO . 51.5 m -36.34 -30.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.185 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.479 ' N ' ' O ' ' A' ' 103' ' ' PRO . 70.1 m-85 -102.17 143.56 31.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.882 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.9 p-10 -109.06 121.79 45.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.916 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.419 ' O ' ' C ' ' A' ' 108' ' ' SER . . . -111.66 78.73 1.14 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 107' ' ' ALA . 1.5 t . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.78 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 96.0 p -159.99 125.94 4.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.855 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 m -61.21 148.54 40.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.845 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.4 -129.37 2.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.557 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.6 t -94.64 138.55 32.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.948 0.404 . . . . 0.0 110.781 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -69.48 90.54 0.54 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.08 69.4 0.27 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.486 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.84 143.63 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.897 0.38 . . . . 0.0 111.1 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.33 133.88 51.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.117 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -132.7 95.94 19.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.6 0.714 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 -0.81 7.36 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.705 2.27 . . . . 0.0 112.412 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 55.8 p -99.92 7.62 44.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.932 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.3 mmpt? -112.16 -9.62 13.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.419 ' H ' HG12 ' A' ' 14' ' ' VAL . 1.2 p -84.32 121.77 37.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -118.12 173.68 6.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.718 HG22 HG13 ' A' ' 35' ' ' VAL . 23.1 pt -146.86 135.93 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.185 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.59 156.57 45.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.059 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 143.07 177.02 17.67 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.86 -33.76 15.56 Favored 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.662 2.241 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -53.57 -23.5 20.66 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.538 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.498 HD13 HG13 ' A' ' 16' ' ' ILE . 7.7 mt -109.67 -19.95 13.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.88 0.372 . . . . 0.0 110.925 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -59.83 166.81 9.48 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.6 m -82.6 11.22 6.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.881 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.83 43.4 1.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.409 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.434 HG13 ' CD ' ' A' ' 31' ' ' GLN . 59.7 t -101.97 143.85 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.908 0.385 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -124.68 155.48 39.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.866 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.7 150.32 43.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.7 mtm-85 57.26 37.78 28.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.12 147.76 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.085 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.9 tp -69.0 113.14 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.519 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 51.0 mm-40 -117.76 130.9 56.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.429 ' HB2' HG22 ' A' ' 72' ' ' THR . 36.0 t -144.83 150.89 37.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.875 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.557 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 8.7 p90 -141.52 176.88 8.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 60.5 m -119.43 135.88 54.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.175 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.718 HG13 HG22 ' A' ' 16' ' ' ILE . 46.4 t -113.22 105.97 19.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.056 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -84.93 103.32 13.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.86 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 81.2 p -116.88 25.68 10.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 p -73.68 -29.76 62.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.854 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 30.5 mmtm -90.37 -5.47 56.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.919 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -89.46 -34.68 16.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.65 -140.18 11.6 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.396 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.34 20.98 12.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.798 0.332 . . . . 0.0 110.895 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.758 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.34 151.37 75.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.598 0.713 . . . . 0.0 111.049 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.9 20.14 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.745 2.296 . . . . 0.0 112.373 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.651 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.7 tp -132.0 135.4 46.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.918 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -112.19 152.97 27.75 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 HG11 ' A' ' 59' ' ' VAL . 21.5 t -138.72 132.91 41.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.156 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 48.8 mtm180 -139.11 132.75 30.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' VAL . 81.6 t -117.18 121.28 67.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 10.8 mt -116.94 129.29 55.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.27 175.03 40.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.534 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.442 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.79 -32.62 18.08 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.712 2.275 . . . . 0.0 112.308 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.29 -25.87 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.887 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 130.84 22.86 1.0 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.499 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 16.7 tp -74.08 149.04 41.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 0.0 110.838 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.3 t -113.7 112.93 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -113.15 141.63 26.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.611 0.719 . . . . 0.0 110.893 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 174.88 8.86 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.623 2.215 . . . . 0.0 112.362 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 HG12 ' A' ' 47' ' ' VAL . 8.9 m -144.32 162.83 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.714 ' O ' HG13 ' A' ' 71' ' ' VAL . 16.7 t-20 -119.49 145.02 46.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.896 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.457 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.3 p -132.46 120.48 42.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.141 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.59 122.58 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -82.17 127.23 32.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.926 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -71.76 -47.71 51.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.52 -16.17 24.25 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -95.14 -38.22 10.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.963 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.69 33.97 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.6 p -152.76 176.15 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 111.175 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -145.85 130.7 18.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.968 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.7 m -92.89 139.78 30.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.157 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.714 HG13 ' O ' ' A' ' 60' ' ' ASN . 36.9 t -131.22 108.94 15.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.171 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.429 HG22 ' HB2' ' A' ' 32' ' ' SER . 38.3 p -93.34 146.42 23.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.103 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 9.3 p90 -163.26 166.87 22.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.5 m -144.22 110.64 5.05 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 121.612 0.72 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.73 91.9 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.724 2.283 . . . . 0.0 112.315 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 22.8 t -34.21 -50.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.801 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -129.62 173.61 10.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.888 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.92 170.21 10.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.861 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.73 172.59 13.18 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.461 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 90.85 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.704 2.27 . . . . 0.0 112.367 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.442 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.0 m-85 -85.07 161.65 19.61 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -131.42 112.8 13.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.842 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 49' ' ' VAL . 96.3 t -103.51 95.98 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.8 t -79.34 145.7 33.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.651 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.1 t -143.54 130.13 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.137 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.3 tttt -118.13 169.81 9.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.758 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.3 t80 -156.89 106.12 2.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.707 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.3 40.79 3.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.13 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.99 34.57 11.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.856 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -145.7 105.03 3.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -54.17 114.53 1.65 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.863 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.677 HD11 ' HE1' ' A' ' 97' ' ' PHE . 48.2 pt -52.12 152.81 5.36 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.574 0.702 . . . . 0.0 111.178 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 4.29 2.27 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.701 2.267 . . . . 0.0 112.296 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -116.13 1.33 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.848 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.543 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -115.23 153.83 47.38 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.683 0.754 . . . . 0.0 110.825 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.69 -179.41 18.97 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.392 -0.132 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.709 ' CE2' HD11 ' A' ' 16' ' ' ILE . 85.2 m-85 -119.45 123.38 43.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.912 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 8.5 pttp -83.89 96.77 8.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 86.9 t -102.28 103.99 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.103 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 23.9 ttpt -85.0 102.53 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.87 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.4 t -75.38 143.43 13.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.134 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 33.8 mt -107.79 154.51 40.92 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.52 0.676 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.7 Cg_endo -69.7 122.51 9.2 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.3 m -33.97 -36.21 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.44 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.8 m-85 -76.21 139.1 41.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.865 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -155.7 116.94 3.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -101.73 80.51 2.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.139 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.802 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 87.8 p 41.72 41.89 1.92 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.874 0.369 . . . . 0.0 110.906 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.6 m -79.2 92.18 5.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.864 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -46.6 139.62 7.21 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.465 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 95.2 p -165.41 135.02 3.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.788 0.328 . . . . 0.0 110.851 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 97.8 p -124.81 148.77 47.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 67.97 90.07 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.497 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -137.19 139.62 43.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.368 . . . . 0.0 111.131 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.3 t -120.9 134.46 64.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.156 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.41 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 3.7 t0 -131.85 96.86 19.6 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.799 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 -0.43 6.89 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.676 2.251 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -99.38 6.95 45.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -112.99 -7.2 13.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -86.33 126.93 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -125.57 170.37 11.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.648 HD11 ' CE2' ' A' ' 97' ' ' PHE . 41.1 pt -145.25 137.01 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.173 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.21 143.26 34.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.076 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.0 169.97 24.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.72 -29.71 23.63 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.703 2.268 . . . . 0.0 112.343 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.59 -45.93 94.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.501 HD13 HG13 ' A' ' 16' ' ' ILE . 12.5 mt -73.91 -26.9 60.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.876 0.369 . . . . 0.0 110.933 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -51.16 169.35 0.36 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.501 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.5 p -85.26 -7.78 58.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.914 0.388 . . . . 0.0 110.841 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.67 44.7 2.73 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.508 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.448 HG13 ' CD ' ' A' ' 31' ' ' GLN . 97.7 t -92.15 143.0 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.831 0.348 . . . . 0.0 111.181 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.722 ' HB2' HG21 ' A' ' 29' ' ' VAL . 46.5 mtm180 -118.33 156.17 29.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.52 147.08 44.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 82.5 mtm-85 54.94 35.79 25.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' A' ' 26' ' ' ARG . 23.3 t -121.71 151.84 25.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.126 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.402 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 7.9 tp -75.62 109.33 9.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.47 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 3.1 mm100 -112.72 127.64 56.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 23.1 t -143.85 149.51 37.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.451 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 9.8 p90 -145.85 171.25 15.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -110.68 130.61 55.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.506 HG22 HG22 ' A' ' 16' ' ' ILE . 100.0 t -108.55 107.05 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.126 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -90.56 106.73 18.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 86.8 p -121.87 25.95 8.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.915 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 78.1 p -71.25 -35.85 71.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.861 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -80.02 -14.91 58.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.918 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.29 -38.2 43.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.13 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -138.19 9.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.609 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.19 17.73 13.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.885 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.75 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.92 151.52 84.29 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.525 0.679 . . . . 0.0 111.119 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 166.87 26.0 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.703 2.269 . . . . 0.0 112.362 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -122.92 136.33 54.82 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -119.21 139.47 51.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.885 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 59' ' ' VAL . 48.8 t -130.73 144.44 37.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.079 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 20.1 ttm180 -148.11 141.8 25.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -122.78 122.04 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.138 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -108.13 151.34 26.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.44 167.35 32.5 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.471 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -29.84 23.47 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' NH1' HD13 ' A' ' 55' ' ' LEU . 0.0 OUTLIER -118.18 3.62 12.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.55 62.98 0.5 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.542 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.45 HD13 ' NH1' ' A' ' 53' ' ' ARG . 10.1 tp -120.48 134.75 55.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.872 0.368 . . . . 0.0 110.911 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.1 t -102.78 129.78 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.157 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -134.46 141.43 38.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.655 0.741 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 168.47 21.41 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.689 2.259 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 47' ' ' VAL . 39.7 t -142.64 151.61 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -100.82 138.52 37.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.85 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.488 ' O ' HG13 ' A' ' 61' ' ' VAL . 6.2 p -133.43 112.47 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.181 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 66.1 t -133.4 127.61 54.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -84.08 130.87 34.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -72.21 -46.14 57.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.24 -22.21 11.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -88.6 -40.59 13.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.814 0.34 . . . . 0.0 110.852 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.28 33.99 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.509 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 66.7 p -150.2 175.39 11.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.876 0.369 . . . . 0.0 111.107 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.6 m80 -147.0 125.21 12.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 38.8 m -85.7 141.28 29.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.451 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.0 t -131.13 104.56 9.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.9 p -96.89 135.13 39.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.132 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.503 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.6 p90 -155.4 175.05 14.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.913 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 29' ' ' VAL . 89.7 m -151.71 117.18 3.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.526 0.679 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.503 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.3 Cg_endo -69.77 98.12 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.723 2.282 . . . . 0.0 112.357 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' PRO . 1.5 t -34.32 -60.3 0.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.883 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -127.36 164.19 22.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -72.73 167.36 20.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 132.46 171.08 12.68 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.443 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 92.76 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.678 2.252 . . . . 0.0 112.363 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -87.94 173.99 8.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 18.3 ttp -148.5 117.17 6.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.79 96.64 4.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.101 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -79.0 144.71 34.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.872 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 55.7 t -139.58 135.91 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -126.47 169.62 12.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.9 t80 -155.71 117.9 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.75 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 57.04 31.58 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.126 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.0 t70 74.22 31.74 1.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -141.79 106.69 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -53.73 114.89 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.678 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.4 pt -53.49 152.79 8.37 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.667 0.746 . . . . 0.0 111.136 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 4.47 2.19 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.535 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.7 mmt180 -115.64 0.76 13.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.881 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.527 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -114.72 153.36 46.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.622 0.725 . . . . 0.0 110.855 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.85 178.63 25.01 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.285 0.077 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.678 ' HE1' HD11 ' A' ' 92' ' ' ILE . 81.8 m-85 -117.2 117.73 30.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.897 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -78.49 113.33 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.836 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -128.99 101.95 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.119 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.5 tttm -83.95 102.51 12.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.9 t -67.15 145.67 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.177 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.7 mt -114.03 156.17 44.39 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.8 121.28 7.96 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.687 2.258 . . . . 0.0 112.351 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.429 ' C ' ' O ' ' A' ' 103' ' ' PRO . 54.0 m -35.21 -31.75 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.075 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.496 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 -112.34 167.64 10.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.941 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -124.59 172.72 9.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.903 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -117.33 41.67 2.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.085 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 58.3 m . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.772 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.7 p -117.28 166.59 12.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.844 0.354 . . . . 0.0 110.89 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.4 m -70.11 108.91 4.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.902 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.7 -174.84 4.21 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.7 t 41.49 41.76 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.877 0.37 . . . . 0.0 110.883 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.5 m -104.35 120.05 40.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.846 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.97 95.34 0.69 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.533 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.459 HG22 ' N ' ' A' ' 9' ' ' VAL . 11.7 p -123.43 158.41 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.869 0.366 . . . . 0.0 111.077 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.459 ' N ' HG22 ' A' ' 8' ' ' VAL . 53.6 t -97.54 132.84 41.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.414 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.0 t0 -134.14 96.21 16.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.635 0.731 . . . . 0.0 110.897 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 1.49 4.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.747 2.298 . . . . 0.0 112.305 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 63.7 m -99.2 -5.23 30.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.5 mmpt? -97.9 -7.66 29.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.9 p -86.43 131.17 35.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.193 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mppt? -128.44 172.61 10.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.864 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.614 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 24.2 pt -143.3 134.96 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.122 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.93 128.17 20.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.79 163.59 28.21 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -24.88 29.44 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.664 2.243 . . . . 0.0 112.365 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.77 95.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.614 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.1 mt -84.13 -17.19 40.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.973 0.416 . . . . 0.0 110.968 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.31 176.71 1.31 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.509 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -91.26 -13.29 33.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.986 0.422 . . . . 0.0 110.87 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.47 49.86 3.49 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.521 HG13 ' NE2' ' A' ' 31' ' ' GLN . 74.6 t -99.34 147.15 7.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.798 0.332 . . . . 0.0 111.103 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.508 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.26 144.84 48.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.418 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.76 150.45 44.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 45.7 mtm180 54.65 43.05 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.508 HG21 ' HB2' ' A' ' 26' ' ' ARG . 75.8 t -135.06 147.65 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -69.96 113.93 7.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.945 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.521 ' NE2' HG13 ' A' ' 25' ' ' VAL . 42.4 mm-40 -120.51 129.02 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.8 t -144.75 157.72 44.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.614 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.3 p90 -147.21 179.95 7.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.931 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 58.2 m -120.08 130.82 54.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.142 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 16' ' ' ILE . 61.2 t -110.72 109.07 27.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -89.83 110.39 21.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 25.6 p -125.75 24.73 7.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.757 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 89.0 p -69.64 -33.76 73.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.7 mmmt -86.31 -12.66 48.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.58 -35.3 46.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.133 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.82 -138.86 10.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.566 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.583 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -121.14 19.37 11.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.745 0.307 . . . . 0.0 110.852 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.857 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.86 151.78 79.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.604 0.716 . . . . 0.0 111.103 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 167.16 25.27 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.486 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.4 tp -125.32 136.0 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.911 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -120.94 149.38 42.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.91 150.15 20.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.196 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -148.58 136.16 20.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 83' ' ' VAL . 93.5 t -116.4 124.8 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -123.89 133.73 53.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.53 -179.86 49.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.491 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -45.17 1.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.674 2.25 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.2 -35.24 59.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.889 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.9 31.59 0.26 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.401 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 11.2 tp -85.31 152.04 23.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.917 0.389 . . . . 0.0 110.886 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.401 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 92.4 t -119.25 122.59 69.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -120.25 142.64 34.08 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.56 0.695 . . . . 0.0 110.97 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 169.01 19.94 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.632 2.221 . . . . 0.0 112.33 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.7 m -138.29 167.7 21.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' VAL . 25.5 t-20 -114.34 140.67 48.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 93.1 t -133.32 114.9 21.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.166 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.0 t -140.47 117.55 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -73.63 139.45 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.933 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -78.42 -45.56 21.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.61 -20.7 11.95 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.447 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.95 -39.03 13.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.807 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.59 34.96 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.487 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.8 p -153.27 177.39 10.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 111.072 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -144.8 130.59 19.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.87 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 81.8 m -88.54 140.98 28.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.47 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.0 t -133.04 102.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.146 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 45.2 p -95.09 143.84 26.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.494 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 5.2 p90 -163.35 175.46 10.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.971 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -151.91 116.95 3.07 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.651 0.738 . . . . 0.0 111.121 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.494 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.76 92.92 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.664 2.243 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 75' ' ' PRO . 40.2 t -34.44 -54.7 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.854 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -125.83 171.71 10.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.969 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -84.82 172.81 11.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.52 170.04 12.99 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.5 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.13 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.726 2.284 . . . . 0.0 112.319 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -83.11 168.59 16.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.978 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.5 ttp -139.54 117.95 12.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 49' ' ' VAL . 90.9 t -107.21 97.59 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.128 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 m -81.53 147.44 29.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.832 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.486 ' CG1' HD11 ' A' ' 45' ' ' LEU . 64.5 t -140.94 138.11 34.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.6 tttt -125.27 173.91 8.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.567 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.7 t80 -160.44 110.54 1.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.974 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.857 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.68 38.31 18.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.154 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 68.02 34.02 4.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -144.23 105.02 4.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.875 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -54.39 108.38 0.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.486 HD12 ' HB2' ' A' ' 94' ' ' ARG . 45.8 pt -46.9 153.02 0.87 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.583 0.706 . . . . 0.0 111.144 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.68 2.04 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.668 2.245 . . . . 0.0 112.347 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.486 ' HB2' HD12 ' A' ' 92' ' ' ILE . 84.2 mmt-85 -114.48 -3.73 12.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 0.9 OUTLIER -112.28 154.45 44.43 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.631 0.729 . . . . 0.0 110.848 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.0 Cg_endo -69.72 -178.53 16.86 Favored 'Cis proline' 0 C--N 1.342 0.206 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.38 -0.084 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.614 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 81.2 m-85 -121.25 132.78 55.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 ptmt -93.16 108.31 19.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.7 t -118.59 103.68 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.104 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 106.85 13.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.908 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 41.5 t -76.81 138.08 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.155 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.6 mt -108.64 155.24 40.91 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 121.675 0.75 . . . . 0.0 110.941 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.6 Cg_endo -69.73 122.46 9.14 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.782 2.321 . . . . 0.0 112.296 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 103' ' ' PRO . 91.9 m -34.83 -35.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.084 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.442 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.4 m-85 -93.84 147.34 23.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.53 38.21 2.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.862 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.98 93.26 1.35 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.014 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 23.6 t . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.894 -179.88 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.8 m -81.98 164.43 21.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.835 0.35 . . . . 0.0 110.859 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.9 p -75.22 -52.95 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.852 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 144.67 -137.04 6.98 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.54 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m -118.19 168.89 10.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 110.851 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.7 t -122.93 171.71 9.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.35 -65.93 0.36 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.503 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -62.93 163.07 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.866 0.365 . . . . 0.0 111.106 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.0 t -120.62 135.65 60.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.1 t0 -133.23 96.18 17.66 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.598 0.713 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.7 Cg_endo -69.72 -1.63 8.78 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.682 2.255 . . . . 0.0 112.359 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.5 p -98.11 5.93 48.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.808 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -110.53 -7.74 14.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -86.29 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.106 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.9 mttt -127.21 173.72 9.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.931 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.792 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.4 pt -147.35 135.79 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.4 153.19 46.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.142 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.52 174.6 20.35 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -36.04 11.46 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.671 2.247 . . . . 0.0 112.315 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.28 -32.68 29.87 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.561 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.434 HD13 HG13 ' A' ' 16' ' ' ILE . 13.0 mt -94.4 -21.38 18.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.912 0.387 . . . . 0.0 110.95 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.43 167.96 2.67 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -87.49 13.75 9.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.893 0.378 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.02 44.9 1.37 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.518 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.452 HG13 ' NE2' ' A' ' 31' ' ' GLN . 60.0 t -97.14 145.96 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 111.095 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.464 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.1 mtt85 -120.89 151.65 39.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.887 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -69.56 150.73 46.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.068 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.9 mtp180 55.09 41.55 31.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.464 HG21 ' HB2' ' A' ' 26' ' ' ARG . 59.3 t -133.88 144.33 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.2 tp -68.43 112.99 5.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.452 ' NE2' HG13 ' A' ' 25' ' ' VAL . 54.5 mm-40 -117.47 130.66 56.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.2 t -144.89 149.1 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.54 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.4 p90 -140.08 179.77 6.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.946 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 89.3 m -117.8 131.55 56.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.606 HG11 HD22 ' A' ' 45' ' ' LEU . 92.8 t -110.38 105.47 18.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.096 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' HG22 ' A' ' 68' ' ' THR . 18.9 t70 -89.67 101.76 14.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.858 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 82.6 p -117.33 27.94 8.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.1 t -70.04 -38.13 75.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 37.7 mttp -76.06 -14.88 60.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -81.2 -38.59 26.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.09 -137.44 9.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.532 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.597 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.86 19.91 12.32 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.793 0.33 . . . . 0.0 110.912 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.711 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.18 151.62 81.47 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.585 0.707 . . . . 0.0 111.084 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 166.86 26.18 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.685 2.256 . . . . 0.0 112.322 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.606 HD22 HG11 ' A' ' 35' ' ' VAL . 5.0 tp -129.61 129.37 44.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -108.73 151.71 25.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.9 t -139.53 144.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.084 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -149.64 135.06 18.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.832 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 83' ' ' VAL . 61.5 t -116.73 128.36 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.1 mt -125.12 121.15 33.41 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.949 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.29 174.44 7.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.534 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -43.62 2.52 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.625 2.216 . . . . 0.0 112.381 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.6 -32.2 47.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.1 32.64 0.3 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.46 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.452 HD21 ' OE2' ' A' ' 57' ' ' GLU . 9.4 tp -85.85 149.69 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 0.0 110.874 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -114.38 115.23 48.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.452 ' OE2' HD21 ' A' ' 55' ' ' LEU . 65.3 mm-40 -113.79 142.84 28.42 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 169.58 18.59 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.237 . . . . 0.0 112.299 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.23 167.94 19.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.139 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -123.21 140.6 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 85.5 t -133.21 113.84 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 85.5 t -138.32 119.85 17.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.093 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -75.12 136.58 41.1 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.765 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -75.69 -43.44 47.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.88 -24.9 9.84 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.506 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -86.05 -44.21 12.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.837 0.351 . . . . 0.0 110.898 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.34 33.57 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.493 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.408 HG22 ' HA ' ' A' ' 36' ' ' ASP . 64.0 p -149.92 177.78 9.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.86 0.362 . . . . 0.0 111.078 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.6 m80 -144.99 133.56 22.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 52.4 m -93.02 141.49 28.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.148 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.54 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 66.4 t -131.36 103.28 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.172 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.6 p -95.19 136.86 35.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.131 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.468 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 8.0 p90 -157.41 176.12 13.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.7 m -150.78 115.35 3.24 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.586 0.708 . . . . 0.0 111.122 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.468 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.8 95.04 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.345 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 13.4 t -38.91 -54.79 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.772 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -121.98 169.94 10.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.497 ' C ' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -86.97 173.75 9.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.86 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.11 176.23 15.05 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.488 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 89.15 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.699 2.266 . . . . 0.0 112.279 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.62 163.54 25.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.938 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 16.3 ttp -135.17 113.09 11.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.856 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 49' ' ' VAL . 69.3 t -105.48 97.78 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.116 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.5 t -82.98 144.29 30.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.899 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.573 ' CG1' HD11 ' A' ' 45' ' ' LEU . 55.7 t -139.83 142.37 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.433 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 39.9 tttt -128.29 170.56 12.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.711 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.5 t80 -156.42 109.42 2.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.674 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.27 40.82 11.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.433 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 4.9 m-20 64.31 35.99 9.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.887 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -147.05 105.04 3.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -52.48 117.01 2.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.652 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.5 pt -55.61 153.16 16.06 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.58 0.705 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 4.74 2.01 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 2.251 . . . . 0.0 112.412 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.42 ' HB2' HD12 ' A' ' 92' ' ' ILE . 29.7 mmt85 -117.04 2.96 12.74 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.64 153.98 49.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.637 0.732 . . . . 0.0 110.861 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.69 -179.92 20.38 Favored 'Cis proline' 0 C--O 1.231 0.135 0 C-N-CA 122.663 -1.807 . . . . 0.0 112.37 -0.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 16' ' ' ILE . 80.1 m-85 -117.45 128.98 55.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.878 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -93.64 107.34 19.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.9 t -119.43 107.04 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 19.8 ttpt -81.96 105.5 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.885 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.8 152.49 6.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.18 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 68.4 mt -117.55 154.83 50.79 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.575 0.702 . . . . 0.0 110.93 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.7 122.21 8.91 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.692 2.261 . . . . 0.0 112.377 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m -34.83 -32.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.152 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.6 m-85 -90.05 38.71 0.93 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 7.5 t70 -81.82 123.62 28.96 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.894 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -108.41 78.53 1.17 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.84 -179.794 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 m -67.61 -56.87 7.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.818 0.342 . . . . 0.0 110.78 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 44.5 m -74.78 86.36 2.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -128.03 -123.24 2.58 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.527 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -94.96 164.58 12.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 110.888 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.1 t -46.02 -60.54 2.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.65 66.98 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.509 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 30.7 m -69.18 165.35 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 111.024 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.1 t -99.18 134.04 39.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.211 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.443 ' CG ' ' HG2' ' A' ' 13' ' ' LYS . 8.8 t0 -123.95 95.1 44.71 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.614 0.721 . . . . 0.0 110.897 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 0.78 5.12 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.71 2.273 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 m -100.7 3.67 42.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.443 ' HG2' ' CG ' ' A' ' 10' ' ' ASP . 14.4 mmmt -104.74 -12.12 16.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 36' ' ' ASP . 6.4 p -84.37 133.67 28.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.0 mtmt -135.69 169.94 16.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.616 HG13 HD13 ' A' ' 21' ' ' LEU . 26.3 pt -142.67 137.25 27.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 143.79 33.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.077 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 155.83 178.57 30.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.87 -38.81 7.06 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.656 2.237 . . . . 0.0 112.315 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.27 -24.99 11.0 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.498 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.616 HD13 HG13 ' A' ' 16' ' ' ILE . 3.3 mt -104.41 -22.16 13.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.864 0.364 . . . . 0.0 110.896 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -58.19 176.82 1.84 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.469 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -91.17 11.78 22.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.884 0.374 . . . . 0.0 110.853 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.84 47.03 1.09 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.505 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.5 HG13 ' CD ' ' A' ' 31' ' ' GLN . 72.4 t -98.54 138.29 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.805 0.336 . . . . 0.0 111.11 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.579 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.4 mtt85 -118.76 146.33 44.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.425 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -66.69 151.51 47.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.034 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 56.18 35.6 25.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.579 HG21 ' HB2' ' A' ' 26' ' ' ARG . 76.2 t -128.91 154.4 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.434 ' N ' HG12 ' A' ' 29' ' ' VAL . 12.1 tp -76.19 112.24 12.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.5 ' CD ' HG13 ' A' ' 25' ' ' VAL . 61.8 mm-40 -113.83 127.54 56.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 13.6 t -142.19 154.1 44.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.872 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.569 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.0 p90 -149.54 176.2 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.948 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 96.1 m -114.64 138.01 51.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.146 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 16' ' ' ILE . 52.3 t -117.48 106.97 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.7 t70 -85.78 110.65 19.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.6 p -125.34 25.77 7.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.8 t -75.67 -35.82 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.876 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? -81.6 -18.52 44.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -75.29 -39.98 59.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.139 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.8 -140.66 11.42 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.826 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -116.35 16.97 15.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.785 0.326 . . . . 0.0 110.907 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.757 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.63 151.3 84.85 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.61 0.719 . . . . 0.0 111.063 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.436 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.7 Cg_endo -69.77 167.37 24.65 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.652 2.234 . . . . 0.0 112.297 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.593 HD11 ' CG1' ' A' ' 85' ' ' VAL . 10.8 tp -128.19 131.11 48.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.897 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -111.86 151.53 29.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.82 149.81 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.46 ' HG2' HD23 ' A' ' 50' ' ' LEU . 2.5 ttp-105 -152.61 143.12 22.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 58.3 t -118.69 122.06 68.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.46 HD23 ' HG2' ' A' ' 48' ' ' ARG . 4.0 mm? -110.48 128.92 55.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.59 165.03 52.6 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.502 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.528 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.75 -26.29 27.76 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.743 2.295 . . . . 0.0 112.365 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.09 3.35 9.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.08 65.16 0.52 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.48 148.0 44.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.59 118.64 57.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -120.65 141.69 32.78 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.639 0.733 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 169.21 19.39 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.663 2.242 . . . . 0.0 112.378 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.8 m -144.31 162.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -125.2 141.15 52.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 61' ' ' VAL . 3.6 p -133.52 110.94 15.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 74.7 t -139.79 116.04 9.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -67.45 138.8 56.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -73.18 -41.98 63.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.89 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.21 -22.05 12.59 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.485 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -91.58 -43.05 9.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.357 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.77 34.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.413 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 57.3 p -152.23 177.87 10.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.413 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.1 m-70 -143.76 125.12 14.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.864 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 31.3 m -84.03 139.02 32.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.569 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 73.3 t -131.3 106.71 12.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.5 p -97.07 147.4 24.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.1 p90 -166.02 164.37 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 92.0 m -140.85 112.38 6.88 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.623 0.725 . . . . 0.0 111.129 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.69 100.59 0.82 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.367 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 75' ' ' PRO . 33.3 t -34.86 -57.85 0.53 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -129.86 166.5 19.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.419 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 5.7 pm0 -76.25 172.11 13.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.887 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.92 173.83 13.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.457 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 93.93 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.528 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 6.3 m-85 -90.11 173.91 7.92 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 27.7 ttp -147.61 117.74 7.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.841 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 93.2 t -106.29 100.22 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 12.4 t -84.37 143.49 29.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.81 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 45' ' ' LEU . 84.4 t -141.21 135.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -122.28 171.69 8.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.738 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 12.9 t80 -157.56 112.81 2.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.929 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.757 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.45 32.51 20.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.083 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 73.47 31.4 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.808 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -141.99 105.05 4.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -53.36 107.9 0.28 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.513 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.9 pt -45.93 153.0 0.69 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.609 0.719 . . . . 0.0 111.104 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 4.31 2.26 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.361 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 14.2 mmm180 -113.46 -4.65 13.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.836 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.546 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -112.21 153.98 44.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.659 0.742 . . . . 0.0 110.845 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.546 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.4 Cg_endo -69.65 179.15 22.84 Favored 'Cis proline' 0 C--N 1.341 0.168 0 C-N-CA 122.8 -1.75 . . . . 0.0 112.347 -0.116 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.513 ' HE2' HD11 ' A' ' 92' ' ' ILE . 89.5 m-85 -120.21 114.8 22.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 106.08 9.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.901 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 79.7 t -117.51 106.71 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.078 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -85.91 96.88 9.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.889 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.419 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 47.7 t -63.61 147.28 12.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.065 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.5 mt -113.02 154.05 45.12 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.59 0.709 . . . . 0.0 110.958 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.5 Cg_endo -69.71 124.06 10.73 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.741 2.294 . . . . 0.0 112.345 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.415 ' C ' ' O ' ' A' ' 103' ' ' PRO . 88.6 m -35.58 -32.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.473 ' N ' ' O ' ' A' ' 103' ' ' PRO . 23.0 m-85 -101.28 154.81 18.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -125.05 36.42 4.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.796 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -79.87 43.45 0.59 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.828 -179.725 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.0 p -141.14 170.91 14.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.888 0.375 . . . . 0.0 110.849 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 66.4 m -99.47 145.0 27.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.839 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.47 162.21 47.35 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.6 m -96.49 147.69 23.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -123.9 113.54 18.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.809 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 159.22 -42.06 0.48 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.457 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 3.8 p -85.45 138.26 19.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 111.15 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.9 t -103.77 130.47 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.2 t0 -128.08 96.92 30.39 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.58 0.705 . . . . 0.0 110.832 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.5 Cg_endo -69.71 -0.43 6.86 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.687 2.258 . . . . 0.0 112.369 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.2 p -99.67 10.39 41.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.863 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 mmpt? -114.82 -8.78 12.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.898 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.1 p -83.87 123.11 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.166 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -116.69 173.33 6.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.6 HG22 HG13 ' A' ' 35' ' ' VAL . 33.0 pt -147.13 138.82 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.89 138.1 31.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.95 167.59 22.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.541 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.75 -24.93 29.17 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.85 -28.09 65.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.472 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.546 HD11 HD12 ' A' ' 16' ' ' ILE . 6.7 mt -98.13 -19.78 17.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.41 166.37 5.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.7 t -83.29 8.59 13.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.972 0.415 . . . . 0.0 110.922 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.14 51.0 0.73 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.416 HG13 ' NE2' ' A' ' 31' ' ' GLN . 68.7 t -102.08 141.78 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.845 0.355 . . . . 0.0 111.102 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.643 ' HB2' HG21 ' A' ' 29' ' ' VAL . 75.3 mtt85 -118.97 150.75 39.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.74 150.16 48.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.442 ' HB3' ' NH1' ' A' ' 28' ' ' ARG . 12.2 mtp-105 54.91 40.32 31.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.643 HG21 ' HB2' ' A' ' 26' ' ' ARG . 66.4 t -129.9 150.74 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.7 tp -73.94 110.36 8.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.951 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.416 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.3 mm-40 -115.3 127.68 55.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.3 t -143.44 149.48 37.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 1.0 OUTLIER -141.33 -178.38 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 88.4 m -123.21 137.67 54.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.6 HG13 HG22 ' A' ' 16' ' ' ILE . 46.7 t -117.65 107.18 21.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.48 94.74 9.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.875 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.489 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 59.9 p -103.64 20.02 18.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.9 t -68.41 -34.94 76.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.814 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -82.75 -12.24 57.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -83.35 -39.66 20.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.047 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.654 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 135.66 -146.97 18.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.5 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.781 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.07 14.99 24.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.928 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.58 151.32 84.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.619 0.723 . . . . 0.0 111.046 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 169.36 19.1 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.64 2.227 . . . . 0.0 112.377 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.8 tp -124.82 139.47 53.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -112.96 143.4 44.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.548 HG12 HG11 ' A' ' 59' ' ' VAL . 88.9 t -135.72 131.1 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -141.12 143.0 34.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.23 132.38 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.5 mp -120.57 148.46 43.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.09 172.69 36.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.427 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.4 Cg_endo -69.82 -30.75 21.49 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.657 2.238 . . . . 0.0 112.325 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.86 4.78 17.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 105.45 66.5 0.67 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.54 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 26.9 tp -118.36 138.59 52.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.911 0.386 . . . . 0.0 110.91 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.1 t -109.02 108.98 26.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -110.93 143.13 27.66 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.618 0.723 . . . . 0.0 110.875 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 168.02 22.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.655 2.237 . . . . 0.0 112.363 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.548 HG11 HG12 ' A' ' 47' ' ' VAL . 30.0 m -141.83 163.15 19.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.063 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -115.47 141.31 48.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.866 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 86.9 t -132.86 116.31 26.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 76.6 t -138.25 124.74 26.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -80.45 132.75 35.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -72.84 -40.74 65.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 114.42 -27.37 8.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -83.27 -47.27 11.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.846 0.355 . . . . 0.0 110.931 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.28 30.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.529 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.4 p -144.76 177.78 8.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -146.66 132.16 18.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 23.2 m -93.16 141.86 27.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.144 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.484 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 57.8 t -132.85 104.78 7.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.17 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -94.74 139.97 30.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.495 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -159.36 171.54 19.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.863 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 29' ' ' VAL . 29.2 m -147.07 114.97 4.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.567 0.699 . . . . 0.0 111.149 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.495 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.6 Cg_endo -69.73 91.39 0.51 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.346 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.5 t -34.08 -59.64 0.42 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -121.56 158.34 28.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.886 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -77.19 173.67 11.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.07 176.9 14.64 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 86.19 0.58 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.678 2.252 . . . . 0.0 112.387 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.427 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.1 m-85 -83.0 173.59 11.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.5 ttp -149.16 120.83 8.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.0 t -109.43 100.17 10.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.9 t -82.99 145.4 29.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.848 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.3 t -140.52 138.42 36.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.103 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -126.79 172.99 9.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.667 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.5 t80 -160.18 109.47 1.76 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.731 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.0 37.84 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.047 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 67.94 34.18 4.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -144.35 105.07 4.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.59 111.68 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.601 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.0 pt -49.41 153.03 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.683 0.754 . . . . 0.0 111.1 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 3.85 2.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.71 2.273 . . . . 0.0 112.327 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.438 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 19.6 mmm180 -114.08 -2.03 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.862 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.548 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -113.61 153.27 45.86 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.681 0.753 . . . . 0.0 110.849 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.548 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.78 175.83 35.07 Favored 'Cis proline' 0 C--N 1.341 0.151 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.318 0.015 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.601 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.8 m-85 -116.15 118.07 31.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -78.7 107.24 11.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.903 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 96.1 t -119.26 102.92 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.101 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -83.58 100.42 10.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.8 145.09 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.173 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.6 mt -111.69 154.67 43.88 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.589 0.709 . . . . 0.0 110.958 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.9 Cg_endo -69.66 123.33 10.03 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.67 2.246 . . . . 0.0 112.334 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 103' ' ' PRO . 49.7 m -36.11 -30.82 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.171 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.485 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.8 m-85 -83.18 140.07 32.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.68 96.26 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.838 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.91 44.03 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 61.0 p . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.903 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.248 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 t -157.89 161.48 38.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.931 0.396 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -53.58 113.06 1.04 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.876 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -39.2 113.16 0.28 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.471 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 95.7 p -106.06 119.16 38.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 110.807 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.5 t -118.69 107.37 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.898 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.442 ' O ' ' C ' ' A' ' 8' ' ' VAL . . . -150.71 -68.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.503 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' A' ' 7' ' ' GLY . 28.3 t -33.97 135.73 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.855 0.36 . . . . 0.0 111.129 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.2 t -82.15 125.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.2 t0 -125.88 99.45 32.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.564 0.697 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.6 Cg_endo -69.81 0.37 5.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.66 2.24 . . . . 0.0 112.386 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.7 p -98.7 9.09 44.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.999 0.428 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -114.18 -8.02 12.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.8 p -84.54 123.5 39.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.215 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.4 mtpp -119.66 167.74 11.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.746 HG22 HG13 ' A' ' 35' ' ' VAL . 37.6 pt -144.09 140.06 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.8 165.92 26.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 133.82 176.11 14.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.41 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.65 -41.44 4.42 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.715 2.277 . . . . 0.0 112.321 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -44.77 -35.44 4.32 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.494 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.439 HD11 HD12 ' A' ' 16' ' ' ILE . 8.2 mt -94.43 -26.6 16.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.897 0.379 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -50.86 163.81 0.92 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.479 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.4 m -86.24 22.91 1.67 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.959 0.409 . . . . 0.0 110.904 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.69 38.05 2.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.582 HG13 ' CD ' ' A' ' 31' ' ' GLN . 78.9 t -89.41 144.3 9.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.558 ' HB2' HG21 ' A' ' 29' ' ' VAL . 65.6 mtt180 -121.63 149.8 42.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.486 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.04 150.16 48.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.6 mtt85 55.35 34.83 23.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.876 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 74' ' ' THR . 73.2 t -127.46 146.98 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.7 tp -68.25 111.6 4.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.582 ' CD ' HG13 ' A' ' 25' ' ' VAL . 5.4 mm100 -116.66 126.62 53.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.592 ' HB2' HG22 ' A' ' 72' ' ' THR . 14.3 t -144.45 148.43 34.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.481 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -140.86 177.61 7.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.791 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 82.6 m -118.36 141.17 48.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.215 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.746 HG13 HG22 ' A' ' 16' ' ' ILE . 38.2 t -118.09 109.47 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -92.32 98.23 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.1 p -111.71 21.38 16.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.5 p -67.01 -35.4 79.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.839 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -79.16 -15.89 57.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.61 -38.68 47.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.092 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.49 -138.45 9.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.444 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.84 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.8 16.35 16.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.88 0.371 . . . . 0.0 110.956 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.764 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.78 151.64 84.64 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.581 0.705 . . . . 0.0 111.105 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.487 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.1 Cg_endo -69.77 169.27 19.31 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.622 2.215 . . . . 0.0 112.327 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -127.32 135.4 50.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.961 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -120.42 145.42 47.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 49.7 t -137.49 145.93 28.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.108 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -146.38 138.16 24.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.69 ' O ' HD22 ' A' ' 50' ' ' LEU . 84.8 t -115.41 129.15 72.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.035 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.69 HD22 ' O ' ' A' ' 49' ' ' VAL . 3.3 mm? -126.2 119.52 27.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.85 177.77 3.76 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.531 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.435 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 53.7 Cg_endo -69.7 -41.39 4.39 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.649 2.232 . . . . 0.0 112.4 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.435 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -84.05 -33.66 24.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.976 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.31 33.21 0.15 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.739 HD21 ' OE2' ' A' ' 57' ' ' GLU . 11.1 tp -85.52 155.67 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.887 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.469 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 94.3 t -119.33 111.1 31.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.739 ' OE2' HD21 ' A' ' 55' ' ' LEU . 18.3 mm-40 -106.13 143.15 26.35 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.651 0.738 . . . . 0.0 110.876 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.691 2.261 . . . . 0.0 112.34 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 m -139.98 162.83 24.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 47.1 t30 -118.88 143.6 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.936 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 74.0 t -129.51 116.31 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.518 HG23 ' HB ' ' A' ' 70' ' ' THR . 0.1 OUTLIER -134.98 110.77 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.203 179.87 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -72.15 129.05 37.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -72.73 -44.74 61.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.856 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.11 -24.31 10.09 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -85.87 -46.49 10.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.841 0.353 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.7 30.54 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.537 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 60.3 p -145.89 177.63 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 111.098 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -147.82 131.41 16.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' THR . . . . . 0.518 ' HB ' HG23 ' A' ' 62' ' ' VAL . 3.4 m -94.78 137.51 33.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.515 HG13 ' O ' ' A' ' 60' ' ' ASN . 35.6 t -127.04 107.35 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.592 HG22 ' HB2' ' A' ' 32' ' ' SER . 35.1 p -92.68 141.06 28.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.193 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -163.94 161.59 22.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.973 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 29' ' ' VAL . 17.3 m -137.38 117.19 10.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.603 0.716 . . . . 0.0 111.117 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.75 94.59 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.349 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 75' ' ' PRO . 43.0 t -35.88 -54.88 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -125.12 168.94 12.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -85.35 173.68 10.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.33 175.42 14.22 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.465 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 90.13 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.702 2.268 . . . . 0.0 112.364 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -81.06 169.75 17.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.947 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 11.2 ttp -145.31 115.73 7.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.5 t -107.58 97.14 5.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -79.83 142.88 34.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 89.5 t -138.05 142.0 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.084 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.437 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 15.5 tttp -130.49 168.05 17.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.941 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.764 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.7 t80 -154.61 115.99 4.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.944 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.644 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.41 33.27 22.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.115 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.437 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 11.6 m-20 71.04 33.5 2.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -144.4 105.34 4.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.891 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -49.99 114.14 1.02 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.84 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.552 HD11 ' HE2' ' A' ' 97' ' ' PHE . 42.1 pt -54.56 153.52 10.35 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.661 0.743 . . . . 0.0 111.113 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.68 4.33 2.22 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.424 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 53.1 mtp85 -114.5 0.29 13.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.908 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.523 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -115.71 153.37 47.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.684 0.754 . . . . 0.0 110.866 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.73 178.01 26.82 Favored 'Cis proline' 0 C--O 1.232 0.18 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.396 -0.047 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.642 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.3 m-85 -117.84 116.47 27.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.0 pttm -81.65 108.8 15.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.02 104.14 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -81.35 103.01 10.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.2 t -71.25 144.61 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 77.2 mt -111.88 154.5 44.09 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.583 0.706 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.495 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.4 Cg_endo -69.69 123.84 10.52 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.724 2.283 . . . . 0.0 112.324 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.9 m -34.12 -33.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.193 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.495 ' N ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m-85 -95.09 126.65 40.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -92.05 121.5 33.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.934 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -68.02 81.87 0.21 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.5 m . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.459 -0.256 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.6 m -151.87 164.34 37.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.36 . . . . 0.0 110.9 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 t -97.1 123.5 40.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.905 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.45 155.63 7.31 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.2 t -95.43 135.88 36.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.919 0.39 . . . . 0.0 110.873 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.2 p -94.62 162.97 13.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.818 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -150.6 74.0 0.27 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.53 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.35 141.42 44.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.943 0.401 . . . . 0.0 111.086 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -107.52 133.73 51.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -130.53 96.64 23.44 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.4 Cg_endo -69.76 0.3 5.85 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.663 2.242 . . . . 0.0 112.347 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 30.8 m -98.46 -7.12 29.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -94.23 -5.15 47.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -90.42 135.73 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.152 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 22.8 mtmt -133.42 168.9 17.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 97' ' ' PHE . 42.2 pt -142.9 139.42 27.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.066 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.72 153.67 43.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.32 171.68 17.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -29.14 24.27 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 0.0 112.372 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.79 -29.43 67.37 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.411 HD13 HG13 ' A' ' 16' ' ' ILE . 5.2 mt -97.04 -26.43 15.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.894 0.378 . . . . 0.0 110.965 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.92 168.33 2.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.564 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.8 p -83.86 18.49 1.99 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.21 40.83 2.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.459 HG13 ' CD ' ' A' ' 31' ' ' GLN . 58.3 t -92.96 147.46 5.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.572 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.0 mtm180 -123.03 157.26 33.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.835 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -75.35 149.48 38.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 42.5 mtt180 54.09 30.27 11.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.572 HG21 ' HB2' ' A' ' 26' ' ' ARG . 19.1 t -119.99 144.48 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.178 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.5 tp -67.81 110.12 3.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.584 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 59.6 mm-40 -113.29 126.95 55.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.923 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -143.2 152.53 41.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.5 p90 -146.39 -176.48 5.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 48.0 m -122.23 135.5 54.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.09 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.664 HG13 HG22 ' A' ' 16' ' ' ILE . 40.1 t -113.15 108.75 26.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -91.47 104.04 16.59 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.913 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.0 p -121.4 30.19 6.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.9 t -73.04 -36.61 66.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.853 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 6.4 mmpt? -79.95 -16.95 54.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.859 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.05 -38.64 63.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.042 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.7 -137.25 9.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.577 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.31 18.91 12.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.868 0.366 . . . . 0.0 110.973 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.733 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.35 151.89 83.5 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.71 . . . . 0.0 111.076 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 166.64 26.92 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.673 2.249 . . . . 0.0 112.338 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.466 ' CD2' HG11 ' A' ' 35' ' ' VAL . 15.4 tp -126.08 134.49 51.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -119.4 147.52 44.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 59' ' ' VAL . 65.6 t -137.3 149.77 25.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -152.26 136.85 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.837 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 83' ' ' VAL . 71.9 t -119.43 126.18 75.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.169 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.7 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.6 mm? -123.58 122.9 39.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.6 -179.36 1.66 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.472 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.74 -47.93 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.14 -37.25 61.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.919 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.24 33.38 0.13 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.464 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.3 tp -85.37 147.96 26.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.915 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.4 t -107.87 126.0 64.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.106 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -127.92 140.35 37.93 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.603 0.716 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 168.65 20.95 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.702 2.268 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 47' ' ' VAL . 44.5 t -139.91 149.33 22.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.191 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.639 ' O ' HG13 ' A' ' 71' ' ' VAL . 29.3 t-20 -98.67 139.18 34.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.82 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 p -131.94 123.48 51.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.196 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.5 t -141.28 129.43 22.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.174 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.22 132.06 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.84 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -73.23 -48.04 38.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.83 -21.04 10.59 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -90.43 -43.97 9.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.8 32.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 63.2 p -151.02 177.73 9.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 111.152 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.0 m80 -146.61 131.07 17.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.846 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 26.2 m -90.21 138.41 31.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.196 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 60' ' ' ASN . 47.4 t -130.37 110.37 18.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.171 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 55.7 p -101.04 145.33 28.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.188 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.584 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.0 p90 -164.91 169.06 16.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -146.29 112.6 4.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.586 0.708 . . . . 0.0 111.089 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.466 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.81 94.39 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.665 2.243 . . . . 0.0 112.383 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.7 t -34.23 -59.43 0.44 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -116.3 168.75 9.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 pm0 -89.21 169.37 11.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.86 177.71 15.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 93.9 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.661 2.241 . . . . 0.0 112.393 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 3.3 m-85 -88.28 172.98 9.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 7.5 ttp -144.43 117.13 8.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 49' ' ' VAL . 81.2 t -108.57 95.69 4.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.134 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.7 t -79.72 147.2 32.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.411 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.8 t -142.54 134.27 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.149 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -121.44 168.64 11.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.989 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.688 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.0 t80 -154.9 106.86 2.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.733 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 65.4 42.22 3.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.072 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 62.96 34.83 13.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -146.32 105.05 3.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -51.2 114.93 1.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.822 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.712 HD11 ' HE1' ' A' ' 97' ' ' PHE . 38.1 pt -53.79 153.26 8.58 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.542 0.687 . . . . 0.0 111.198 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.66 5.83 1.51 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.267 . . . . 0.0 112.361 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.552 ' HB2' HD12 ' A' ' 92' ' ' ILE . 12.1 mmm180 -118.49 3.61 11.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.804 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.522 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -118.48 153.26 51.88 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.724 0.773 . . . . 0.0 110.838 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.81 176.68 31.76 Favored 'Cis proline' 0 C--N 1.343 0.243 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.41 -0.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 16' ' ' ILE . 72.8 m-85 -114.86 121.68 43.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.882 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 pttp -80.94 107.71 13.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 57.8 t -119.2 106.43 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.164 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -89.12 99.1 12.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.9 t -65.75 150.69 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 78.1 mt -118.94 154.69 53.19 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.618 0.723 . . . . 0.0 110.932 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.562 ' CG ' ' HB2' ' A' ' 107' ' ' ALA . 53.1 Cg_endo -69.76 119.08 6.08 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.718 2.279 . . . . 0.0 112.299 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.6 m -39.38 -27.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 107' ' ' ALA . 4.7 m-85 -82.25 38.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.949 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 105' ' ' TYR . 0.9 OUTLIER 36.44 29.37 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.813 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.562 ' HB2' ' CG ' ' A' ' 103' ' ' PRO . . . 44.81 49.33 8.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 37.3 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.77 -179.705 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.5 m 54.65 44.94 27.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.864 0.364 . . . . 0.0 110.886 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.3 p -144.02 140.56 29.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.858 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.49 144.46 7.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.498 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -69.11 169.45 11.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.876 0.37 . . . . 0.0 110.857 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 m -123.39 116.56 23.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.902 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.61 89.56 1.07 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.485 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.54 153.59 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.356 . . . . 0.0 111.128 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 72.9 t -101.22 131.3 49.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -133.21 98.18 15.76 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.549 0.69 . . . . 0.0 110.863 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.73 -2.02 9.44 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.751 2.301 . . . . 0.0 112.344 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.2 m -100.07 13.87 32.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.827 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -9.03 10.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.79 134.34 27.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.187 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -129.44 174.29 9.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.969 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.822 HD11 ' CE2' ' A' ' 97' ' ' PHE . 27.4 pt -150.01 135.97 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.127 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.3 154.74 44.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.129 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 146.15 178.54 21.67 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.48 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -39.55 6.5 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.711 2.274 . . . . 0.0 112.407 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -47.8 -35.61 12.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.549 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.472 HD13 HG13 ' A' ' 16' ' ' ILE . 9.4 mt -93.48 -27.49 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.88 167.95 1.0 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.1 m -85.57 16.86 3.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.961 0.41 . . . . 0.0 110.91 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.35 40.17 2.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.676 HG13 ' CD ' ' A' ' 31' ' ' GLN . 64.9 t -93.02 139.6 17.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 111.153 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.551 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.74 148.15 45.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.869 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -65.36 154.86 37.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 23.1 mtm180 50.65 41.72 26.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.894 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 27' ' ' ALA . 70.0 t -134.23 151.32 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.2 tp -73.97 111.21 8.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.987 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.676 ' CD ' HG13 ' A' ' 25' ' ' VAL . 65.2 mm-40 -112.01 127.33 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.0 t -141.03 149.98 42.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.559 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.4 p90 -144.62 168.77 19.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.825 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 92.7 m -110.18 130.09 55.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.177 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.584 HG13 HG22 ' A' ' 16' ' ' ILE . 65.2 t -111.41 105.61 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.117 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -87.01 104.72 16.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.775 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 75.7 p -118.72 27.2 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.909 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.9 p -74.22 -37.41 63.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.821 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -73.93 -23.32 59.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.62 -41.28 72.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.092 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.48 -135.19 7.44 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.45 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.548 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.98 19.55 13.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.764 0.316 . . . . 0.0 110.901 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.842 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.65 152.01 80.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.671 0.748 . . . . 0.0 111.047 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 165.94 29.33 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.691 2.26 . . . . 0.0 112.328 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 tp -125.36 136.68 53.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.937 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -121.13 143.4 49.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.33 144.98 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.449 ' HG2' ' CD1' ' A' ' 50' ' ' LEU . 12.7 ttm180 -148.24 144.6 27.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.481 HG12 ' OE1' ' A' ' 57' ' ' GLU . 67.3 t -120.89 130.37 74.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.454 HD13 ' CE ' ' A' ' 82' ' ' MET . 3.8 mp -125.11 134.78 52.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.46 173.88 54.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.444 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.4 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 54.6 Cg_endo -69.72 -44.36 2.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.4 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -79.21 -35.52 41.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.943 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 138.77 31.32 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.436 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.534 HD23 ' OE2' ' A' ' 57' ' ' GLU . 10.7 tp -91.63 150.11 21.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.1 t -110.62 132.12 59.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.098 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.534 ' OE2' HD23 ' A' ' 55' ' ' LEU . 48.0 mp0 -120.02 142.74 33.95 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.631 0.729 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 167.93 23.1 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.346 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.8 m -144.31 164.79 13.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.155 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.552 ' O ' HG13 ' A' ' 71' ' ' VAL . 10.8 t-20 -122.85 142.69 50.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 89.8 t -133.5 103.06 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.2 t -127.96 115.25 38.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.159 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -71.12 135.0 47.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -75.64 -43.09 49.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.22 -26.0 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.487 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -85.66 -40.09 16.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.863 0.363 . . . . 0.0 110.872 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.82 34.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.478 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.2 p -151.47 177.65 10.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.168 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -145.77 131.38 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.842 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 51.9 m -90.84 137.74 32.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.132 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.559 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 40.3 t -133.19 105.72 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.061 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 71.1 p -98.32 142.15 30.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.223 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.564 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 10.0 p90 -156.53 169.89 23.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.964 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.3 m -145.74 110.67 4.48 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.552 0.691 . . . . 0.0 111.233 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.546 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.75 94.52 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.661 2.241 . . . . 0.0 112.372 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 60.6 p -39.38 -27.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLN . . . . . 0.462 ' N ' ' O ' ' A' ' 75' ' ' PRO . 3.2 pt20 -147.74 175.49 10.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.98 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.93 173.28 7.67 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.72 174.76 13.86 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.547 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.71 81.66 0.79 Allowed 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.697 2.265 . . . . 0.0 112.382 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -80.52 147.33 30.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.908 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' MET . . . . . 0.454 ' CE ' HD13 ' A' ' 50' ' ' LEU . 3.1 tmm? -117.61 127.09 53.62 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.03 95.3 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 t -76.1 139.92 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.825 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 64.9 t -138.86 129.8 34.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.158 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.426 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 40.4 tttt -121.6 170.52 9.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.842 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.0 t80 -157.09 107.82 2.31 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.69 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.16 41.82 5.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.113 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.426 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 44.0 m-20 63.22 36.07 12.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -146.15 104.97 3.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -53.75 117.34 3.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.87 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.788 HD11 ' HE1' ' A' ' 97' ' ' PHE . 40.3 pt -55.75 153.57 15.8 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.657 0.741 . . . . 0.0 111.113 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.401 ' HD2' ' HB ' ' A' ' 92' ' ' ILE . 53.8 Cg_endo -69.74 6.2 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.727 2.285 . . . . 0.0 112.377 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.503 ' HB2' HD12 ' A' ' 92' ' ' ILE . 15.0 mmm180 -120.59 5.55 10.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.973 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -119.93 153.37 54.96 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.688 0.756 . . . . 0.0 110.781 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.71 172.95 46.4 Favored 'Cis proline' 0 C--N 1.342 0.21 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.3 -0.029 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.822 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.1 m-85 -110.43 139.82 45.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.824 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 34.0 mttm -100.29 107.3 19.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.1 t -117.06 101.54 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.087 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 39.9 tttp -81.0 97.78 7.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 49.4 t -69.61 144.14 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 42.1 mt -109.56 155.17 41.78 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.573 0.701 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.3 Cg_endo -69.82 123.22 9.86 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.737 2.291 . . . . 0.0 112.368 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.434 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -33.87 -35.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.182 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 103' ' ' PRO . 20.0 m-85 -105.45 159.45 15.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -118.96 96.38 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.867 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -124.55 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.122 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 12.7 t . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.875 -179.77 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.439 -0.265 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.4 t -161.15 134.54 6.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.967 0.413 . . . . 0.0 110.752 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.7 m -151.24 142.51 23.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.49 -160.64 25.52 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.439 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.9 t -135.2 155.77 50.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.852 0.358 . . . . 0.0 110.849 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 95.1 p -83.0 40.0 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.49 -63.41 2.36 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.434 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.423 HG22 ' N ' ' A' ' 9' ' ' VAL . 11.8 p -42.99 155.74 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.152 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.423 ' N ' HG22 ' A' ' 8' ' ' VAL . 76.8 t -95.68 132.16 40.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 13.7 m-20 -129.43 96.72 26.88 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.648 0.737 . . . . 0.0 110.803 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.76 -1.5 8.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.318 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.8 m -100.39 12.29 37.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.5 mmpt? -116.54 -7.41 11.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -85.85 127.07 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.214 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -121.68 173.28 7.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.913 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.851 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.8 pt -148.47 134.38 11.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.07 152.17 45.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.124 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 149.08 176.58 22.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.495 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -38.65 7.55 Favored 'Trans proline' 0 N--CA 1.466 -0.118 0 C-N-CA 122.709 2.273 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.92 -24.39 13.8 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.554 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.445 HD13 HG13 ' A' ' 16' ' ' ILE . 6.5 mt -105.77 -18.23 14.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.949 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.62 177.85 3.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 97.9 p -92.31 15.0 14.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.36 . . . . 0.0 110.854 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.03 42.88 1.78 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.481 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.495 HG13 ' NE2' ' A' ' 31' ' ' GLN . 75.9 t -96.46 141.13 15.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.884 0.373 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.509 ' HB2' HG21 ' A' ' 29' ' ' VAL . 88.7 mtt180 -121.11 148.84 43.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.45 150.18 48.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 58.7 mtt-85 53.98 41.09 32.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.878 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.6 t -132.85 143.59 39.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.078 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.1 tp -66.82 114.03 5.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.495 ' NE2' HG13 ' A' ' 25' ' ' VAL . 53.7 mm-40 -116.49 134.7 54.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.858 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 28.9 t -146.94 148.98 32.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.492 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 2.5 p90 -142.73 173.14 11.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 73.8 m -112.79 133.32 54.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.192 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.682 HG13 HG22 ' A' ' 16' ' ' ILE . 41.0 t -112.95 106.75 21.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.141 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -88.5 99.41 12.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.502 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.5 p -112.99 26.08 10.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.848 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.4 p -72.62 -38.14 67.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.834 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -76.43 -17.11 59.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.952 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.39 -38.36 41.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.42 -138.79 9.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.574 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.4 20.68 12.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.798 0.332 . . . . 0.0 110.913 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.784 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.05 151.54 76.02 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.567 0.698 . . . . 0.0 111.085 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 166.56 27.19 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.292 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.473 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.4 tp -125.72 135.86 52.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.892 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -116.05 142.33 46.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.844 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.575 HG12 HG11 ' A' ' 59' ' ' VAL . 60.9 t -130.0 142.3 44.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.433 ' HG2' ' CD2' ' A' ' 50' ' ' LEU . 20.2 ttm180 -148.16 142.46 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.474 ' C ' HD22 ' A' ' 50' ' ' LEU . 49.0 t -121.2 133.51 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.162 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.474 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.5 mm? -124.78 133.19 53.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.928 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.13 170.26 53.56 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.504 179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -42.26 3.54 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -82.51 -34.85 27.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.13 31.65 0.19 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.428 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.9 tp -91.7 146.01 24.12 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.97 125.88 67.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.154 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -118.86 141.81 30.76 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.621 0.724 . . . . 0.0 110.932 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 171.5 14.44 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.662 2.241 . . . . 0.0 112.336 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.575 HG11 HG12 ' A' ' 47' ' ' VAL . 21.0 m -142.29 165.77 16.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.502 ' O ' HG13 ' A' ' 71' ' ' VAL . 18.4 t-20 -124.24 143.3 50.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.872 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.472 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.4 p -133.47 118.52 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.116 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 60.1 t -134.91 121.62 34.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.203 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -75.04 137.2 41.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.794 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -80.64 -40.97 24.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.1 -29.73 7.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -82.79 -47.12 12.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.786 0.327 . . . . 0.0 110.87 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.38 30.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.4 p -144.14 177.34 8.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.826 0.346 . . . . 0.0 111.044 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m80 -146.07 127.63 15.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 97.2 m -88.38 138.94 30.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.179 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 60' ' ' ASN . 64.4 t -129.75 109.81 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.146 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -97.68 140.2 32.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.136 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.459 ' CE2' ' HB2' ' A' ' 31' ' ' GLN . 5.9 p90 -159.72 170.69 20.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.93 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 m -146.02 116.15 4.79 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 111.147 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.419 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.2 Cg_endo -69.74 92.97 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.683 2.256 . . . . 0.0 112.36 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 m -35.92 -51.59 0.71 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.848 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -131.78 163.17 28.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.6 170.35 16.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.81 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.77 172.66 13.28 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 84.2 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.37 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -76.54 173.57 11.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.1 ttp -144.95 114.37 7.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.803 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -103.51 96.91 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.125 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.1 t -80.3 139.91 36.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.934 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.473 ' CG1' HD11 ' A' ' 45' ' ' LEU . 51.5 t -136.11 140.59 43.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.453 ' HE3' ' N ' ' A' ' 90' ' ' GLU . 18.2 tttp -128.61 169.22 14.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.919 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.739 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.0 t80 -153.86 107.7 3.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.959 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.784 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.65 43.02 5.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.092 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.445 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 32.8 m-20 62.65 36.95 13.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.453 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 14.9 mt-10 -147.58 105.05 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -52.58 118.32 3.53 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.726 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.2 pt -57.75 153.07 33.29 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.646 0.736 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 4.34 2.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.711 2.274 . . . . 0.0 112.362 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HB2' HD12 ' A' ' 92' ' ' ILE . 73.9 mtp85 -116.94 4.93 12.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -117.8 153.72 50.91 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.722 0.772 . . . . 0.0 110.827 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.71 178.36 25.6 Favored 'Cis proline' 0 C--N 1.342 0.211 0 C-N-CA 122.743 -1.774 . . . . 0.0 112.383 -0.05 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.851 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.0 m-85 -115.56 119.92 37.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 ptpt -79.7 100.0 7.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 90.9 t -108.35 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.0 ttpm? -83.2 98.61 9.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.934 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.35 145.34 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.121 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 82.0 mt -110.35 154.3 43.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.614 0.721 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.71 124.22 10.89 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.707 2.271 . . . . 0.0 112.289 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.423 ' C ' ' O ' ' A' ' 103' ' ' PRO . 77.9 m -34.73 -32.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 67.1 m-85 -109.09 168.26 9.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -120.47 151.68 39.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.25 79.43 7.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.08 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 32.6 p . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.821 -179.785 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 t -81.15 100.5 9.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.861 0.362 . . . . 0.0 110.891 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.4 m -92.43 92.66 8.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.853 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.2 141.64 6.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 t -64.47 105.95 1.04 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.889 0.376 . . . . 0.0 110.85 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 m -110.09 150.81 28.04 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.903 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.41 52.0 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.455 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.0 p -104.31 145.83 12.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.9 t -106.98 125.31 63.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.181 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 15.5 m-20 -125.76 98.11 34.68 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.546 0.689 . . . . 0.0 110.851 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.7 Cg_endo -69.77 -1.87 9.22 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.689 2.26 . . . . 0.0 112.321 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.4 ' HA ' ' CD ' ' A' ' 93' ' ' PRO . 53.3 p -101.66 14.48 31.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.893 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.432 ' NZ ' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -117.59 -9.62 10.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.883 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.79 134.66 27.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HD3' ' CZ ' ' A' ' 94' ' ' ARG . 14.0 mmmt -127.67 173.27 10.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.519 HG22 HG13 ' A' ' 35' ' ' VAL . 26.5 pt -148.55 134.82 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.166 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.63 130.13 22.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.181 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.84 170.04 34.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -35.9 11.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.66 2.24 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.35 -42.77 50.72 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.446 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.469 HD11 ' CD2' ' A' ' 33' ' ' PHE . 5.1 mt -80.78 -20.03 43.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.906 0.384 . . . . 0.0 110.929 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.81 174.21 0.48 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 91.2 p -89.47 -13.89 36.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.932 0.396 . . . . 0.0 110.833 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -90.43 52.14 3.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.469 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 79.4 t -99.94 143.61 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.852 0.358 . . . . 0.0 111.09 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.689 ' HB2' HG21 ' A' ' 29' ' ' VAL . 48.6 mtt85 -118.43 148.59 42.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.928 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.563 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.22 152.56 45.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.159 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 54.45 35.15 22.54 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.689 HG21 ' HB2' ' A' ' 26' ' ' ARG . 98.5 t -127.1 149.47 32.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.068 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -71.87 112.01 7.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.942 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.536 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 40.5 mm-40 -116.28 126.79 54.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.8 t -143.46 163.0 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.553 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 2.0 p90 -155.07 -176.96 6.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.1 m -120.87 129.79 53.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.106 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.519 HG13 HG22 ' A' ' 16' ' ' ILE . 55.5 t -108.68 105.74 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.069 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -86.54 98.91 11.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.842 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 87' ' ' TYR . 97.5 p -113.18 31.19 6.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.1 t -73.48 -40.99 63.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -73.87 -24.79 59.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.933 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.727 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.1 -32.86 72.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.103 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.573 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 126.26 -147.47 16.75 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.475 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.845 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -106.64 18.41 21.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.803 0.335 . . . . 0.0 110.92 -179.914 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.746 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.21 151.61 85.86 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.583 0.706 . . . . 0.0 111.078 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 167.49 24.28 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.681 2.254 . . . . 0.0 112.297 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 tp -122.96 144.49 49.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -130.25 143.79 50.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.901 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.513 ' CG1' HG11 ' A' ' 59' ' ' VAL . 46.1 t -136.71 153.74 30.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.416 ' N ' HG12 ' A' ' 47' ' ' VAL . 39.2 mtt180 -155.71 145.19 21.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.4 t -125.72 125.96 69.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.156 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.39 126.54 49.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.65 176.98 23.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.471 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -49.24 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.641 2.227 . . . . 0.0 112.372 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -72.56 -37.24 68.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.98 37.37 0.11 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.444 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.41 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 8.7 tp -91.32 150.65 21.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.877 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.41 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.5 t -114.95 126.72 72.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -127.16 141.63 41.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.653 0.74 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.84 168.03 22.84 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.704 2.27 . . . . 0.0 112.327 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' CG1' ' A' ' 47' ' ' VAL . 44.0 t -138.41 149.8 24.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -96.37 137.87 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.565 ' O ' HG13 ' A' ' 61' ' ' VAL . 13.3 p -133.51 114.36 20.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 84.9 t -135.56 123.56 37.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -77.01 134.63 38.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -76.88 -42.06 41.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.57 9.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.548 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.408 ' CG ' ' N ' ' A' ' 67' ' ' GLY . 0.6 OUTLIER -83.75 -46.96 11.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 0.0 110.891 -179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.408 ' N ' ' CG ' ' A' ' 66' ' ' ASP . . . 164.03 30.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.444 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.5 p -144.54 177.77 8.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.767 0.318 . . . . 0.0 111.155 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.6 m-70 -147.19 124.92 11.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.1 m -83.24 139.7 32.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.159 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.553 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 60.5 t -131.45 106.27 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.4 p -100.18 145.49 27.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -165.45 174.32 10.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.2 m -152.05 114.11 2.92 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 121.53 0.681 . . . . 0.0 111.123 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 94.38 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 0.0 112.357 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.7 m -38.04 -49.64 1.3 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -127.13 158.26 37.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -78.54 170.52 16.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.52 175.09 13.88 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.465 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 83.24 0.7 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.646 2.231 . . . . 0.0 112.315 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -77.99 171.84 14.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 19.2 ttp -143.74 119.03 10.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 91.6 t -104.21 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.0 t -84.22 138.14 33.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 91.1 t -133.86 141.42 44.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.14 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.412 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 28.3 tttt -130.51 168.42 17.08 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.746 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.6 t80 -153.54 108.7 3.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.711 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.88 42.58 7.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.412 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.2 m-20 63.18 35.31 12.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -145.63 104.99 3.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -51.75 121.79 7.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.728 HD11 ' CE2' ' A' ' 97' ' ' PHE . 33.5 pt -59.74 153.25 53.71 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.673 0.749 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.4 ' CD ' ' HA ' ' A' ' 12' ' ' SER . 54.1 Cg_endo -69.8 6.02 1.49 Allowed 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.565 2.176 . . . . 0.0 112.419 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.541 ' HB2' HD12 ' A' ' 92' ' ' ILE . 11.9 mtt85 -121.55 9.57 10.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.41 153.54 58.89 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.747 0.784 . . . . 0.0 110.832 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.8 Cg_endo -69.88 176.78 31.57 Favored 'Cis proline' 0 C--N 1.343 0.253 0 C-N-CA 122.6 -1.834 . . . . 0.0 112.325 0.107 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 92' ' ' ILE . 84.8 m-85 -113.99 132.02 56.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.4 ptmm? -87.28 111.65 21.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.2 t -123.49 101.66 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -84.99 100.05 11.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 81.5 t -71.23 148.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.132 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 60.4 mt -113.86 155.5 45.12 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 0.0 110.908 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.6 Cg_endo -69.71 121.63 8.32 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.69 2.26 . . . . 0.0 112.378 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 103' ' ' PRO . 99.5 m -33.96 -34.94 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.139 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.468 ' N ' ' O ' ' A' ' 103' ' ' PRO . 26.7 m-85 -106.61 156.39 18.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.95 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -113.94 96.88 6.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -68.06 82.92 0.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 60.2 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 -179.8 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.431 -0.268 . . . . 0.0 112.431 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 m -68.94 122.98 19.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.871 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 4' ' ' GLY . 15.1 t -109.23 163.29 13.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.838 -179.784 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 3' ' ' SER . . . -35.82 131.83 0.75 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.445 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' SER . 16.5 m -103.65 108.31 19.54 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.91 0.386 . . . . 0.0 110.903 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 5' ' ' SER . 2.7 m 34.65 42.14 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.841 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 83.39 108.38 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.469 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.2 m -74.59 152.42 6.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.145 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.5 t -107.93 136.76 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.124 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -129.88 95.42 28.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 0.0 110.878 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 -0.79 7.47 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.668 2.245 . . . . 0.0 112.385 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.8 m -98.7 2.1 46.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.819 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -108.48 -7.16 15.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.416 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -88.86 123.93 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.157 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -123.21 174.46 7.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.757 HG22 HG13 ' A' ' 35' ' ' VAL . 20.5 pt -145.59 133.45 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.09 135.69 29.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.99 170.46 35.2 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.444 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -31.64 20.27 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.349 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.89 -42.6 98.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.661 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.8 mt -77.39 -23.72 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.82 173.85 0.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.445 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.5 m -87.16 -11.84 48.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.96 0.409 . . . . 0.0 110.859 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.28 45.33 3.26 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.432 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -93.19 146.49 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 0.0 111.138 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.781 ' HB2' HG21 ' A' ' 29' ' ' VAL . 28.7 mtm-85 -121.27 151.32 40.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.839 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.479 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -70.72 147.07 49.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.063 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.0 mtm-85 56.32 33.68 22.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.781 HG21 ' HB2' ' A' ' 26' ' ' ARG . 85.8 t -123.74 143.8 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.2 tp -68.0 111.05 4.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.968 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.435 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 52.3 mm-40 -114.13 130.45 56.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 38.6 t -145.48 148.76 33.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.867 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.661 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.9 p90 -140.66 -178.22 5.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 98.8 m -119.92 129.13 54.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.757 HG13 HG22 ' A' ' 16' ' ' ILE . 55.4 t -108.94 106.11 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.144 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -87.57 107.19 18.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 84.5 p -123.12 22.09 9.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.877 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.3 t -66.78 -35.96 81.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.886 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.4 mmtm -83.1 -8.64 59.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -82.91 -34.32 26.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.149 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.15 -135.48 8.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.514 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.51 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -122.77 22.1 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.857 0.361 . . . . 0.0 110.945 -179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.819 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.25 151.71 75.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.579 0.704 . . . . 0.0 111.071 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.441 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.3 Cg_endo -69.77 166.52 27.31 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.39 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.4 tp -124.26 134.88 53.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -119.41 147.06 44.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.3 t -136.97 150.38 26.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.149 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 18.6 mtt-85 -154.23 133.37 12.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.619 ' C ' HD22 ' A' ' 50' ' ' LEU . 62.0 t -112.91 128.61 69.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.141 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.619 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -124.44 127.45 47.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.971 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.72 179.71 37.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.479 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.517 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.84 -37.95 8.28 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.669 2.246 . . . . 0.0 112.316 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.62 -31.27 21.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.913 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.06 30.19 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.8 tp -81.75 147.51 29.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.936 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.3 t -110.41 105.63 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.128 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -96.46 144.91 28.66 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.671 0.748 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 168.12 22.52 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.717 2.278 . . . . 0.0 112.317 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.5 m -142.75 167.45 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -125.05 141.74 51.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.5 t -132.84 111.03 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.169 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 90.3 t -138.93 115.42 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.146 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 65' ' ' GLY . 10.2 t70 -72.51 139.9 47.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.884 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -77.68 -43.25 31.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.46 ' N ' ' OD1' ' A' ' 63' ' ' ASP . . . 115.38 -20.07 14.19 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.473 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -91.61 -41.73 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.876 0.37 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.13 33.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.433 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.0 p -149.34 177.33 9.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.796 0.331 . . . . 0.0 111.158 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -146.94 125.06 12.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 34.5 m -84.53 140.4 31.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.083 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.539 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 67.3 t -131.03 103.78 8.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.139 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.0 p -93.44 139.29 30.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.2 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.498 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.1 p90 -159.9 169.15 24.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.927 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -147.14 115.66 4.32 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.631 0.729 . . . . 0.0 111.104 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.498 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.74 99.01 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.255 . . . . 0.0 112.331 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 75' ' ' PRO . 32.5 t -35.6 -54.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.859 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -128.77 177.55 6.98 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.18 166.35 14.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.99 173.14 13.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.555 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 92.49 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.366 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.517 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.3 m-85 -92.0 151.97 20.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' MET . . . . . 0.455 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.7 tmm? -119.91 129.19 54.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.873 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.45 95.84 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.159 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -79.24 139.06 38.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 61.5 t -136.92 134.22 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.425 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 42.7 tttt -123.25 167.18 14.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.819 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 10.9 t80 -154.5 105.55 2.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.808 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.8 42.96 4.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.09 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.425 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 13.2 m-20 63.35 32.94 14.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -142.69 105.11 4.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -56.98 111.79 1.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.718 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.3 pt -49.5 152.86 2.12 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 111.097 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 4.11 2.41 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.651 2.234 . . . . 0.0 112.365 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 49.7 mtt85 -115.04 -1.28 13.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -113.37 153.83 45.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.672 0.748 . . . . 0.0 110.863 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.3 Cg_endo -69.74 177.96 27.02 Favored 'Cis proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.351 -0.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.724 ' CE2' HD11 ' A' ' 16' ' ' ILE . 79.9 m-85 -116.93 140.83 49.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -100.2 111.46 23.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -121.52 103.45 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.078 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.3 tttp -81.91 103.25 11.44 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.61 143.14 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.07 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 74.7 mt -111.83 155.76 42.69 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.557 0.694 . . . . 0.0 110.964 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.493 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.85 123.54 10.18 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.656 2.237 . . . . 0.0 112.334 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 54.4 m -39.02 -25.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.493 ' N ' ' O ' ' A' ' 103' ' ' PRO . 10.3 m-85 -98.46 143.78 28.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.863 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -164.53 113.27 1.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.896 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -104.68 43.68 1.08 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.113 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.7 p . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.857 -179.801 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.4 m -60.54 151.78 27.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.962 0.411 . . . . 0.0 110.788 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 90.7 p -104.27 42.59 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.04 122.65 5.09 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.49 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.3 m -136.18 173.09 12.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.836 0.35 . . . . 0.0 110.868 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.8 t -123.41 129.09 50.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.39 61.75 1.3 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.438 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.0 p -127.16 143.43 40.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.739 0.304 . . . . 0.0 111.158 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.5 t -117.39 131.23 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.144 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 17.9 m-20 -131.73 97.62 18.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.611 0.72 . . . . 0.0 110.819 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.2 Cg_endo -69.76 -1.75 9.0 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.645 2.23 . . . . 0.0 112.365 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -101.12 14.04 33.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.8 mmpt? -117.83 -8.38 10.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -84.31 132.4 31.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.119 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.2 mtmt -126.49 169.48 12.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.885 HD11 ' CE2' ' A' ' 97' ' ' PHE . 37.3 pt -145.74 133.81 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.144 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.65 146.18 35.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 160.13 172.15 26.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -33.41 16.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.674 2.249 . . . . 0.0 112.366 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.431 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -57.45 -42.05 93.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.474 HD11 ' CD2' ' A' ' 33' ' ' PHE . 8.6 mt -80.43 -25.87 38.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.17 176.63 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.479 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.7 t -89.46 -16.58 30.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.976 0.417 . . . . 0.0 110.917 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.82 47.79 3.86 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.431 HG21 ' O ' ' A' ' 20' ' ' GLY . 66.1 t -99.81 141.5 16.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.784 0.326 . . . . 0.0 111.156 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -117.64 151.54 37.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.67 152.41 42.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 55.32 40.2 31.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.27 144.37 34.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 14.7 tp -66.4 115.17 6.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 47.6 mm-40 -120.32 127.06 52.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.867 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . 0.473 ' HB2' HG22 ' A' ' 72' ' ' THR . 32.5 t -141.45 149.63 41.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.839 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.474 ' CD2' HD11 ' A' ' 21' ' ' LEU . 3.5 p90 -142.18 176.55 8.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 83.9 m -114.21 136.96 52.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.725 HG13 HG22 ' A' ' 16' ' ' ILE . 41.5 t -115.16 105.33 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.158 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -87.74 98.47 11.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.903 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 95.5 p -114.4 30.36 7.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.928 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 87.9 p -76.68 -34.68 58.21 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -76.6 -22.01 54.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.56 -41.34 60.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.075 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.593 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 138.34 -147.04 18.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.482 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.838 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -107.18 17.01 23.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.845 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.39 151.44 85.42 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.607 0.718 . . . . 0.0 111.112 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 167.56 24.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.26 . . . . 0.0 112.362 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.491 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.1 tp -125.88 139.72 53.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.961 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 85' ' ' VAL . 1.9 mp0 -117.01 146.69 42.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.623 HG12 HG11 ' A' ' 59' ' ' VAL . 58.4 t -139.51 134.22 39.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.137 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -140.79 141.12 34.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.859 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.667 ' C ' HD22 ' A' ' 50' ' ' LEU . 98.9 t -123.32 127.49 74.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.056 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.667 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -125.11 124.57 42.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.77 167.87 47.49 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -47.78 0.86 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -71.44 -38.63 71.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.931 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.28 34.93 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.501 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.446 HD21 ' OE2' ' A' ' 57' ' ' GLU . 8.4 tp -94.44 149.21 21.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.87 0.367 . . . . 0.0 110.903 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.7 t -115.64 116.25 51.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.146 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.446 ' OE2' HD21 ' A' ' 55' ' ' LEU . 30.2 mm-40 -115.63 139.32 24.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.719 0.771 . . . . 0.0 110.851 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 174.74 9.03 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.771 2.314 . . . . 0.0 112.381 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.623 HG11 HG12 ' A' ' 47' ' ' VAL . 13.7 m -140.34 162.13 24.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.079 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' O ' HG13 ' A' ' 71' ' ' VAL . 23.7 t-20 -117.59 138.54 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.5 p -131.68 119.93 43.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.072 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 92.2 t -138.81 126.32 26.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -79.09 133.29 36.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.813 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -75.29 -46.51 33.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.884 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.15 -23.81 9.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.444 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.4 -44.15 10.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.891 0.376 . . . . 0.0 110.873 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.6 33.94 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.417 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.2 p -150.93 177.59 9.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.329 . . . . 0.0 111.144 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.6 m80 -145.99 126.62 14.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 35.0 m -86.04 142.49 28.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.111 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.404 HG13 ' O ' ' A' ' 60' ' ' ASN . 95.4 t -132.48 108.47 13.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.092 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.473 HG22 ' HB2' ' A' ' 32' ' ' SER . 27.8 p -97.6 142.31 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.089 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 8.7 p90 -161.49 175.75 11.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.946 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -150.42 114.27 3.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.639 0.733 . . . . 0.0 111.137 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 89.09 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.697 2.265 . . . . 0.0 112.329 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 75' ' ' PRO . 44.4 t -35.67 -53.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -122.44 166.64 14.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.953 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -89.69 166.48 13.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.84 179.59 16.12 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.71 86.45 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.691 2.261 . . . . 0.0 112.345 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -76.93 171.66 14.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.1 ttp -143.8 113.25 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 49' ' ' VAL . 85.1 t -109.06 96.11 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.084 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 2.0 m -81.46 145.52 30.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.491 ' CG1' HD11 ' A' ' 45' ' ' LEU . 88.7 t -139.29 138.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.094 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -125.92 170.19 11.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.923 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.845 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.2 t80 -155.24 110.69 3.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.962 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.687 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 61.63 39.77 14.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.115 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 65.52 35.52 7.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.828 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -145.49 105.02 3.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -53.44 118.01 3.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.684 HD11 ' HE1' ' A' ' 97' ' ' PHE . 47.0 pt -57.18 153.43 25.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.567 0.698 . . . . 0.0 111.163 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 5.15 1.82 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.665 2.244 . . . . 0.0 112.354 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 75.8 mtt85 -118.49 6.32 11.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.54 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -119.8 154.07 54.93 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.612 0.72 . . . . 0.0 110.835 -179.803 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.76 178.86 24.0 Favored 'Cis proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.717 -1.784 . . . . 0.0 112.318 0.016 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.885 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.7 m-85 -115.5 126.56 54.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.4 ptmt -90.94 107.42 19.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.9 t -117.67 107.82 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.13 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -84.62 97.64 9.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.8 t -69.19 147.39 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.134 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 61.6 mt -112.24 155.51 43.45 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.641 0.734 . . . . 0.0 110.949 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.68 123.93 10.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.723 2.282 . . . . 0.0 112.31 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 103' ' ' PRO . 59.6 m -34.61 -32.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.192 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.488 ' N ' ' O ' ' A' ' 103' ' ' PRO . 15.6 m-85 -100.22 136.06 40.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.21 7.33 16.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.916 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . 41.73 41.44 1.77 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.4 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.799 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.7 m -119.34 176.38 5.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.928 0.394 . . . . 0.0 110.848 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.1 m -151.97 161.82 42.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.853 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 157.64 -148.13 17.19 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.477 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.5 m -66.17 107.07 1.82 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.904 0.383 . . . . 0.0 110.803 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.4 p -94.77 148.31 22.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.839 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.22 -74.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.516 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.9 p -38.1 152.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.836 0.35 . . . . 0.0 111.167 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.1 t -95.71 131.21 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.407 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.1 m-20 -130.29 96.21 25.4 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.63 0.729 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.9 Cg_endo -69.74 3.11 2.95 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 50.3 m -102.77 -0.29 31.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.0 mmpt? -103.94 -8.82 19.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -85.79 128.18 39.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 15' ' ' LYS . 1.2 mppt? -126.83 171.15 11.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.873 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 35' ' ' VAL . 18.2 pt -144.08 135.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.99 126.58 17.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.3 171.38 38.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -32.58 18.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.637 2.225 . . . . 0.0 112.365 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.9 -36.05 65.41 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.618 HD13 HG13 ' A' ' 16' ' ' ILE . 4.7 mt -87.04 -15.5 38.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.851 0.358 . . . . 0.0 110.901 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.67 178.65 3.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.513 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 90.0 p -92.48 -11.77 33.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.96 46.03 3.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.455 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 97.8 t -95.69 142.21 14.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 111.092 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -118.55 153.65 33.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.845 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.51 145.36 47.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.072 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.6 mtt180 59.59 42.23 17.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.95 148.35 30.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.126 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -70.5 112.31 6.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.513 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.1 mm-40 -117.43 128.95 55.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.4 t -148.41 161.16 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.494 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -151.85 -176.08 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.8 m -117.86 128.79 55.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.167 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 16' ' ' ILE . 86.2 t -109.34 107.98 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.152 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -88.79 103.93 16.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.943 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.2 p -122.61 27.24 7.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 28.1 t -68.82 -37.32 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.872 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -81.07 -19.87 42.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.436 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.71 -37.5 76.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 131.58 -143.12 14.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.449 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.551 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -113.69 19.0 17.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.827 0.346 . . . . 0.0 110.875 -179.906 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.721 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.15 151.37 81.42 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.562 0.696 . . . . 0.0 111.153 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.452 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.6 Cg_endo -69.72 167.1 25.37 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.501 HD22 HG11 ' A' ' 35' ' ' VAL . 11.0 tp -127.29 130.97 50.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.901 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -118.57 143.91 46.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.826 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 85' ' ' VAL . 81.8 t -137.44 124.56 29.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.152 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -115.07 149.04 38.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.503 HG23 ' CG2' ' A' ' 59' ' ' VAL . 48.6 t -123.7 120.59 60.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.211 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 50' ' ' LEU . 2.5 mm? -96.68 175.21 6.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.34 159.73 24.17 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.478 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -41.75 4.06 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.689 2.26 . . . . 0.0 112.397 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.22 -14.9 34.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 114.58 36.58 1.28 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.439 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.563 HD23 ' OE2' ' A' ' 57' ' ' GLU . 11.4 tp -100.27 146.55 26.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 0.0 110.939 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 37.8 t -116.21 123.76 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.204 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.563 ' OE2' HD23 ' A' ' 55' ' ' LEU . 27.1 mp0 -117.07 140.62 27.29 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.637 0.732 . . . . 0.0 110.853 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 176.96 6.11 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.659 2.239 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.539 HG12 ' N ' ' A' ' 60' ' ' ASN . 61.8 t -144.29 160.16 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.152 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.539 ' N ' HG12 ' A' ' 59' ' ' VAL . 20.5 t30 -106.79 138.3 43.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 95.9 t -132.77 113.31 20.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 67.1 t -141.15 125.37 17.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -75.15 142.83 43.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -80.24 -43.2 21.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.5 -20.91 13.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.454 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -92.99 -39.44 11.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.887 0.375 . . . . 0.0 110.842 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.43 34.48 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.503 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 67.9 p -151.74 176.82 11.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.819 0.342 . . . . 0.0 111.146 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.6 m80 -142.96 129.7 20.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.3 m -86.76 137.71 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.494 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 33.1 t -130.11 101.51 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 64.3 p -95.31 144.32 25.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.166 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.491 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 3.9 p90 -163.88 168.32 19.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -146.09 115.99 4.74 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.607 0.718 . . . . 0.0 111.161 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.491 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.0 Cg_endo -69.76 93.42 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.658 2.239 . . . . 0.0 112.357 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 t -34.77 -58.85 0.5 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -120.87 168.76 11.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -86.53 170.24 12.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.47 178.16 15.22 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 93.71 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.705 2.27 . . . . 0.0 112.352 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -94.91 171.55 8.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 ttp -147.72 120.26 8.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.21 96.49 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.8 t -78.58 150.46 32.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 47' ' ' VAL . 86.2 t -140.86 133.77 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.077 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 39.7 tttt -125.02 170.0 11.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.5 t80 -157.41 112.81 2.8 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.721 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.49 35.57 22.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.141 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 71.4 30.73 2.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -139.16 105.82 5.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.926 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -56.69 112.24 1.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.621 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.5 pt -50.46 152.73 3.04 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.641 0.734 . . . . 0.0 111.141 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 4.27 2.33 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.55 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.9 mmm180 -114.85 -1.26 13.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.805 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -113.51 154.27 45.56 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.607 0.717 . . . . 0.0 110.863 -179.745 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.1 Cg_endo -69.84 179.67 21.81 Favored 'Cis proline' 0 C--O 1.232 0.191 0 C-N-CA 122.646 -1.814 . . . . 0.0 112.299 0.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.621 ' HE2' HD11 ' A' ' 92' ' ' ILE . 85.9 m-85 -120.87 119.54 32.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.63 116.23 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.51 102.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -85.18 102.31 13.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.39 147.21 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.174 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.2 mt -117.54 154.81 50.76 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.604 0.716 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 123.81 10.46 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.716 2.277 . . . . 0.0 112.338 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.3 m -39.6 -30.33 0.07 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.139 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -108.23 139.72 42.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -108.98 81.6 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -73.46 87.01 1.56 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.855 -179.78 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.444 -0.263 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.3 p -157.79 109.85 2.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.84 0.352 . . . . 0.0 110.838 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 93.2 p -76.65 141.09 41.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -94.72 -67.67 1.02 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.449 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -133.22 92.9 3.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.853 0.359 . . . . 0.0 110.855 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -88.7 42.15 1.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.869 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 53.9 60.36 8.5 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.506 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.4 p -119.0 147.4 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.863 0.363 . . . . 0.0 111.099 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.3 t -102.86 136.3 36.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.083 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.03 97.08 18.87 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.905 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 -2.05 9.54 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.719 2.279 . . . . 0.0 112.295 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 44.5 p -101.71 17.68 22.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.894 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 mmpt? -121.05 -7.37 9.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.881 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -84.66 128.49 38.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.16 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.6 mtpt -124.28 168.08 13.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.936 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.743 HG22 HG13 ' A' ' 35' ' ' VAL . 13.1 pt -144.83 134.79 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.173 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.07 130.58 22.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.041 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.64 168.82 35.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -32.09 19.18 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.298 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.4 -43.78 84.99 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.528 HD13 HG13 ' A' ' 16' ' ' ILE . 4.4 mt -78.33 -26.23 46.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 110.922 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -49.48 172.68 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.487 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.5 m -86.35 -18.62 31.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.822 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -82.83 45.46 3.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.519 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 ' CD ' ' A' ' 31' ' ' GLN . 43.9 t -94.95 142.5 13.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.871 0.367 . . . . 0.0 111.102 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.835 ' HB2' HG21 ' A' ' 29' ' ' VAL . 49.7 mtm180 -117.79 160.01 22.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.576 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -78.2 149.58 33.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.091 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 51.6 mtm-85 55.63 32.04 18.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.85 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.835 HG21 ' HB2' ' A' ' 26' ' ' ARG . 61.4 t -121.48 140.02 46.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.11 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.7 tp -65.8 110.84 2.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 54.7 mm-40 -113.12 133.12 55.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 22.1 t -146.37 154.35 41.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.544 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.1 p90 -148.13 -178.49 6.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.878 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.5 m -122.22 132.02 54.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.174 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.743 HG13 HG22 ' A' ' 16' ' ' ILE . 45.3 t -112.07 105.12 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -86.07 98.22 10.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.474 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 95.6 p -113.03 25.33 11.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.8 t -72.57 -37.49 68.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -74.39 -20.78 59.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.99 -38.67 64.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.063 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.58 -136.49 8.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.573 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.53 20.0 13.12 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.759 0.314 . . . . 0.0 110.839 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.747 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.99 151.67 82.02 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.556 0.693 . . . . 0.0 111.091 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 166.73 26.6 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.381 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -124.72 135.13 52.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -116.9 145.86 43.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.941 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 59' ' ' VAL . 60.2 t -134.18 147.68 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.125 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -152.07 133.29 14.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.687 HG23 ' CG2' ' A' ' 59' ' ' VAL . 87.6 t -116.92 124.98 73.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.623 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.2 mm? -123.65 121.67 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.946 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.21 172.83 8.81 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.487 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.71 -48.44 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.707 2.271 . . . . 0.0 112.373 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -71.83 -39.2 69.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.84 32.79 0.12 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.506 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.457 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 9.1 tp -91.3 153.32 20.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.807 0.336 . . . . 0.0 110.92 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.457 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.8 t -115.37 130.08 70.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.068 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -133.12 140.85 38.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.699 0.761 . . . . 0.0 110.869 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 170.68 15.95 Favored 'Trans proline' 0 C--N 1.343 0.247 0 C-N-CA 122.617 2.211 . . . . 0.0 112.419 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 47' ' ' VAL . 67.2 t -141.52 154.66 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.721 ' O ' HG13 ' A' ' 71' ' ' VAL . 9.4 t-20 -100.35 137.69 38.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.599 ' O ' HG13 ' A' ' 61' ' ' VAL . 10.6 p -133.54 116.55 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 82.3 t -138.31 130.29 38.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.134 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -82.3 140.48 33.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -79.95 -45.33 18.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.09 -25.22 8.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -88.11 -41.63 12.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.877 0.37 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.96 34.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 62.3 p -149.35 177.5 9.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.139 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.6 m-70 -145.92 123.73 11.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 65.7 m -85.23 136.47 33.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.166 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.721 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.6 t -129.09 112.71 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.4 p -103.93 146.72 28.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.9 p90 -165.79 177.44 7.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.986 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.1 m -154.31 113.74 2.47 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.551 0.691 . . . . 0.0 111.109 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.2 Cg_endo -69.82 93.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.642 2.228 . . . . 0.0 112.333 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 75' ' ' PRO . 31.2 t -34.14 -59.78 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -116.35 167.81 10.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.937 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -83.76 166.26 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.836 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.78 169.31 12.32 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.98 91.24 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.605 2.203 . . . . 0.0 112.276 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.415 ' CD1' ' HD3' ' A' ' 52' ' ' PRO . 4.3 m-85 -82.97 172.06 13.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 17.6 ttp -140.74 118.72 11.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.846 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 49' ' ' VAL . 71.8 t -110.26 96.88 5.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.178 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.3 m -81.6 145.08 30.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.924 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 98.0 t -138.75 137.29 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.108 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 43.1 tttt -123.22 169.1 11.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.899 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.747 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.6 t80 -155.59 111.46 3.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.666 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.56 37.9 12.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.036 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.418 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 5.6 m-20 66.4 35.34 5.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.817 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -145.78 104.99 3.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -52.26 113.0 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.622 HD11 ' CE2' ' A' ' 97' ' ' PHE . 45.6 pt -51.37 153.14 3.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.604 0.716 . . . . 0.0 111.179 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 4.89 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.696 2.264 . . . . 0.0 112.326 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.508 ' HB2' HD12 ' A' ' 92' ' ' ILE . 20.1 mmt180 -116.98 1.54 12.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.841 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.538 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.09 154.34 48.51 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.661 0.743 . . . . 0.0 110.883 -179.798 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.2 Cg_endo -69.78 177.47 28.8 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.654 -1.811 . . . . 0.0 112.353 -0.022 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.622 ' CE2' HD11 ' A' ' 92' ' ' ILE . 86.9 m-85 -116.84 146.29 42.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.839 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.03 131.49 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.914 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 69.5 t -134.98 101.62 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.113 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -82.78 94.0 7.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.918 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -71.07 145.22 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.073 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 57.3 mt -118.77 155.82 52.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.634 0.731 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.2 Cg_endo -69.67 116.25 4.46 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.672 2.248 . . . . 0.0 112.408 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 52.1 m -34.01 -33.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.498 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.5 m-85 -81.82 48.09 1.17 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.955 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -90.19 35.93 0.87 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.914 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.23 41.63 0.61 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.105 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.7 m . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.874 -179.787 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 t 65.11 42.93 3.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.867 0.365 . . . . 0.0 110.896 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.6 t -109.71 147.1 33.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.859 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 138.8 178.71 16.57 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.466 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 90.6 p -102.21 115.46 30.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.353 . . . . 0.0 110.824 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.1 m -93.26 43.15 1.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.897 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 56.98 49.94 67.75 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.53 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -130.12 143.94 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.866 0.365 . . . . 0.0 111.094 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.8 t -108.08 135.21 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.194 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -133.79 96.86 16.02 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.652 0.739 . . . . 0.0 110.801 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -1.5 8.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.642 2.228 . . . . 0.0 112.364 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 48.0 m -100.97 12.56 37.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.819 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.1 mmpt? -117.47 -9.16 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.413 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -82.38 135.84 24.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.8 mtpm? -132.64 168.0 19.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.819 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.815 HD11 ' CE2' ' A' ' 97' ' ' PHE . 36.8 pt -144.33 135.37 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.98 133.14 26.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.056 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.01 175.36 40.13 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.445 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 -35.35 12.72 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.667 2.245 . . . . 0.0 112.362 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.36 -42.56 83.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.534 HD13 HG13 ' A' ' 16' ' ' ILE . 11.8 mt -77.45 -28.33 52.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.943 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.85 176.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 t -92.01 -18.03 24.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.906 0.384 . . . . 0.0 110.839 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.26 48.76 4.09 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.11 140.56 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.336 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 52.4 mtt180 -118.46 148.63 42.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.51 42.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 44.7 mtp180 54.73 39.19 31.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.6 t -134.79 143.15 38.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.154 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 22.5 tp -66.24 114.43 5.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.973 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.511 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 42.3 mm-40 -117.73 128.3 54.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.2 t -139.86 164.82 28.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.822 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.564 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -157.86 167.89 28.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -107.3 131.19 54.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.603 HG13 HG22 ' A' ' 16' ' ' ILE . 58.1 t -111.41 105.27 18.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.083 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -88.5 103.17 15.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.9 p -117.96 26.12 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.817 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.1 t -71.67 -39.05 70.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.861 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -72.99 -22.09 60.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.26 -41.58 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.084 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 139.23 -136.67 8.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.596 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.22 18.24 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.839 0.352 . . . . 0.0 110.983 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.683 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.37 152.0 83.51 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.568 0.699 . . . . 0.0 111.102 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.81 166.79 26.46 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 0.0 112.272 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.5 tp -125.48 139.57 53.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.483 ' O ' HG13 ' A' ' 85' ' ' VAL . 12.4 tt0 -125.27 148.03 48.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 85' ' ' VAL . 40.2 t -140.82 152.12 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.111 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 49.4 mtm-85 -153.16 138.53 17.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 83' ' ' VAL . 93.4 t -118.31 124.09 72.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.1 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.51 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.2 mm? -113.32 152.34 30.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.927 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.67 168.48 22.7 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.472 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.85 -44.74 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.675 2.25 . . . . 0.0 112.299 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -78.14 -29.67 48.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.37 28.38 0.48 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.476 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.4 tp -88.85 144.37 26.26 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -115.93 117.1 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.108 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -112.94 141.98 26.47 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.7 0.762 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 175.85 7.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG13 ' A' ' 71' ' ' VAL . 23.4 t -144.35 153.63 15.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.092 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 27.3 t-20 -99.63 139.16 35.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.832 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.1 t -133.26 108.38 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 86.4 t -131.51 129.67 62.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.1 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -84.13 133.65 34.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -74.42 -44.24 52.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.49 -25.2 9.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.3 m-20 -88.42 -44.38 10.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.908 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.33 33.49 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.513 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 73.3 p -147.64 177.13 9.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 41.3 m80 -145.4 131.56 19.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.3 m -92.81 134.94 34.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.57 HG13 ' O ' ' A' ' 60' ' ' ASN . 39.3 t -129.7 106.36 13.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.145 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.7 p -103.67 140.82 37.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.195 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.557 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 15.7 p90 -156.78 -176.02 5.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -156.53 112.2 2.03 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 121.569 0.699 . . . . 0.0 111.081 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.557 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.81 90.22 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.695 2.263 . . . . 0.0 112.359 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 75' ' ' PRO . 27.8 m -33.85 -57.61 0.45 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.934 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -118.73 166.36 12.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -85.34 172.28 11.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.908 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.07 174.15 13.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.472 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.73 89.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.628 2.219 . . . . 0.0 112.386 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -86.25 164.35 17.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 39.7 ttp -137.32 119.02 15.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 49' ' ' VAL . 92.8 t -105.07 95.91 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.133 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 41.3 t -80.51 143.26 33.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 46' ' ' GLU . 87.0 t -139.25 142.98 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.45 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 14.5 tttp -129.62 168.37 16.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.616 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.9 t80 -154.03 114.68 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.683 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.7 36.06 22.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.127 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.45 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 0.8 OUTLIER 68.57 35.3 3.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.861 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.409 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 28.6 mt-10 -147.59 105.17 3.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -50.39 120.13 4.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.681 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.7 pt -58.62 153.93 37.94 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.634 0.73 . . . . 0.0 111.105 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 5.72 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.66 2.24 . . . . 0.0 112.39 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -119.81 8.17 11.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.84 153.71 60.42 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.5 Cg_endo -69.72 177.93 27.06 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.399 -0.05 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.815 ' CE2' HD11 ' A' ' 16' ' ' ILE . 52.2 m-85 -115.2 127.96 55.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.929 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.2 ptpt -87.72 110.07 20.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.99 101.64 9.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -83.11 103.64 12.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.5 t -70.22 143.72 14.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -112.26 155.91 42.86 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.584 0.707 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.494 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.77 121.29 7.98 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.688 2.258 . . . . 0.0 112.307 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 33.3 m -35.24 -31.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.188 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.6 m-85 -110.09 161.27 15.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -96.19 109.76 22.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -84.81 41.26 0.85 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.032 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.843 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.382 0 N-CA-C 112.538 -0.225 . . . . 0.0 112.538 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.9 t 53.65 42.25 31.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.892 0.377 . . . . 0.0 110.903 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.5 t -45.42 163.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.44 113.19 0.51 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.525 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 61.8 m -91.47 138.9 31.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.866 0.365 . . . . 0.0 110.842 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 83.5 p -144.84 158.35 43.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.876 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.7 65.83 0.48 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.513 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.486 HG22 ' N ' ' A' ' 9' ' ' VAL . 11.5 p -106.79 159.51 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.911 0.386 . . . . 0.0 111.094 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.486 ' N ' HG22 ' A' ' 8' ' ' VAL . 53.5 t -97.78 134.4 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.091 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -128.46 95.33 33.22 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.627 0.727 . . . . 0.0 110.859 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.87 9.2 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.645 2.23 . . . . 0.0 112.37 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.4 p -99.71 9.06 43.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.811 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.9 mmpt? -113.06 -6.64 13.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.889 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -86.5 127.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.4 mtmm -124.44 168.16 13.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.738 HD11 ' CE2' ' A' ' 97' ' ' PHE . 25.9 pt -144.07 136.34 22.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.165 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.54 144.96 33.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.094 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.34 177.06 30.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -39.67 6.21 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.689 2.259 . . . . 0.0 112.34 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.61 -30.26 13.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.45 HD13 HG13 ' A' ' 16' ' ' ILE . 15.1 mt -95.6 -22.52 17.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.862 0.363 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.47 164.67 5.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p -83.95 14.56 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.924 0.393 . . . . 0.0 110.898 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.9 44.25 1.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.457 HG13 ' NE2' ' A' ' 31' ' ' GLN . 76.3 t -95.65 149.12 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.849 0.357 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 93.0 mtt-85 -124.31 153.63 41.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.4 151.94 40.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 54.47 39.29 30.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.3 t -134.13 144.62 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.3 tp -66.85 113.9 5.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.918 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 48.2 mm-40 -117.43 130.03 56.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 25.0 t -143.74 163.32 33.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.835 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.522 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -154.88 -177.8 6.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.4 m -119.06 131.03 55.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.629 HG13 HG22 ' A' ' 16' ' ' ILE . 59.1 t -111.7 105.07 18.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.11 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -86.5 102.54 14.19 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.456 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.7 p -119.31 29.01 7.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.3 t -76.29 -34.53 59.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.3 mttp -80.17 -16.09 55.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -79.05 -38.25 36.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.128 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -141.4 12.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.559 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -114.98 19.02 16.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.763 0.316 . . . . 0.0 110.854 -179.908 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.8 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.24 151.47 83.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.606 0.717 . . . . 0.0 111.154 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 166.76 26.42 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.262 . . . . 0.0 112.376 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -126.18 136.54 52.97 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -121.9 146.38 47.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.778 ' CG1' HG11 ' A' ' 59' ' ' VAL . 84.9 t -138.77 129.11 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.198 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.3 ttm-85 -125.05 140.26 53.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.464 HG23 HG22 ' A' ' 59' ' ' VAL . 92.1 t -119.82 116.97 52.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.463 HD11 HG22 ' A' ' 56' ' ' VAL . 2.0 mm? -115.37 125.69 53.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.28 175.23 15.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.0 Cg_endo -69.73 -43.27 2.79 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.31 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.421 ' HB2' ' NH1' ' A' ' 53' ' ' ARG . 0.0 OUTLIER -75.3 -38.08 60.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.865 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.67 33.24 0.14 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.481 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.459 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 6.4 tp -90.33 155.84 18.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 110.937 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 HD11 ' A' ' 50' ' ' LEU . 91.9 t -117.94 118.65 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -117.38 143.37 31.91 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.679 0.752 . . . . 0.0 110.886 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 168.18 22.32 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.688 2.259 . . . . 0.0 112.359 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.778 HG11 ' CG1' ' A' ' 47' ' ' VAL . 3.5 t -140.59 144.49 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.125 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.681 ' O ' HG13 ' A' ' 71' ' ' VAL . 26.2 t-20 -93.12 138.41 31.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.504 ' O ' HG13 ' A' ' 61' ' ' VAL . 9.5 p -133.23 117.97 30.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 80.4 t -135.55 138.44 48.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -89.63 138.54 31.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.865 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.45 -46.38 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.58 -25.08 9.3 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.531 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -87.94 -43.63 11.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.821 0.343 . . . . 0.0 110.785 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.56 33.85 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.431 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 70.8 p -150.43 177.66 9.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.822 0.344 . . . . 0.0 111.114 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -145.7 127.36 15.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 54.6 m -86.38 132.5 33.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.145 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.1 t -125.58 111.01 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.081 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 61.9 p -102.38 147.02 27.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.108 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 6.6 p90 -165.36 173.47 11.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.6 m -149.49 113.87 3.51 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.577 0.703 . . . . 0.0 111.125 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.79 93.3 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.702 2.268 . . . . 0.0 112.292 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 3.7 m -34.26 -45.52 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.882 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -135.29 170.76 15.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.412 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.1 pp20? -86.2 177.63 7.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.33 173.98 14.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 83.45 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.684 2.256 . . . . 0.0 112.343 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.8 m-85 -78.43 172.53 13.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.947 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.6 ttp -143.68 115.61 8.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.827 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.1 t -104.36 95.4 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.129 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 33.8 t -77.32 147.26 36.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.4 t -139.93 137.44 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.079 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.427 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 17.3 tttp -128.65 169.36 14.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.8 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.2 t80 -155.0 110.76 3.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.741 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.71 39.79 17.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.044 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.427 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 39.3 m-20 67.15 32.66 6.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.968 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -142.55 105.22 4.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -53.79 116.89 2.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.663 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.5 pt -56.13 153.12 19.45 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.593 0.711 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 4.69 2.05 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.653 2.235 . . . . 0.0 112.421 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.463 ' HB2' HD12 ' A' ' 92' ' ' ILE . 39.3 mmt180 -117.19 4.53 12.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.909 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -117.96 153.98 51.24 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.672 0.749 . . . . 0.0 110.873 -179.85 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.8 -178.83 17.64 Favored 'Cis proline' 0 C--N 1.341 0.15 0 C-N-CA 122.756 -1.768 . . . . 0.0 112.303 0.089 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.738 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.4 m-85 -118.48 125.38 49.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 29.8 pttt -83.52 109.87 17.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 94.7 t -123.36 101.86 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.099 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 12.5 tttp -84.19 94.08 8.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.992 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.412 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 63.4 t -63.39 145.94 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 65.9 mt -111.23 155.95 41.86 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.554 0.692 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.72 122.4 9.09 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.7 2.266 . . . . 0.0 112.33 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -34.12 -35.21 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.461 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 -79.07 142.06 36.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.841 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -124.35 151.05 44.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.895 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -90.76 36.31 0.9 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 98.0 p . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.819 -179.752 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.9 m -117.88 166.83 12.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.902 0.382 . . . . 0.0 110.837 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.2 m -129.39 151.44 50.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.854 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.36 138.83 5.84 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.502 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.5 t 40.88 42.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.824 0.345 . . . . 0.0 110.844 -179.729 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.8 t -140.37 113.98 8.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.52 63.55 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.548 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 9' ' ' VAL . 13.5 p -71.36 156.61 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 111.076 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.465 ' N ' HG22 ' A' ' 8' ' ' VAL . 54.8 t -97.42 124.7 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 m-20 -121.15 98.22 47.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.623 0.725 . . . . 0.0 110.862 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.74 2.4 3.55 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.684 2.256 . . . . 0.0 112.389 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 51.0 m -97.43 -6.74 33.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 39' ' ' LYS . 8.0 mmmm -96.48 -7.09 35.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.917 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -89.37 124.12 41.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -127.27 169.15 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.536 HG13 HD13 ' A' ' 21' ' ' LEU . 29.9 pt -141.66 133.31 27.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.101 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.79 129.09 22.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 175.51 42.08 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.86 -34.33 14.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.704 2.27 . . . . 0.0 112.28 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.19 -32.5 67.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.469 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.536 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -91.64 -14.54 29.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.65 -175.12 4.31 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.495 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.8 t -95.61 -15.59 22.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.906 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.03 47.15 3.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.478 HG13 ' NE2' ' A' ' 31' ' ' GLN . 55.4 t -97.0 142.39 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 111.197 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 66.9 mtt180 -119.4 150.8 39.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.42 152.57 42.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.079 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.4 mtp180 52.81 41.66 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.932 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.9 t -135.14 149.23 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.0 tp -69.41 113.11 6.42 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.48 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 28.9 mm-40 -118.9 126.75 52.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.887 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 35.1 t -142.17 161.87 36.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.878 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.55 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.4 p90 -151.65 -176.16 5.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.918 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 90.1 m -118.27 134.73 54.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.517 HG11 ' CD2' ' A' ' 45' ' ' LEU . 40.4 t -113.85 105.91 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.11 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -90.62 109.85 21.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -126.45 27.76 6.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.8 m -70.13 -36.39 74.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.468 ' CB ' ' HB3' ' A' ' 13' ' ' LYS . 39.4 mtmt -84.44 -7.7 59.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.912 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.402 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -81.88 -34.72 29.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.07 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.26 -139.56 11.14 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.478 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.809 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.75 19.83 14.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.813 0.34 . . . . 0.0 110.864 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.908 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.74 150.21 78.53 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.625 0.726 . . . . 0.0 111.042 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.461 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 54.4 Cg_endo -69.75 168.55 21.2 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.68 2.254 . . . . 0.0 112.386 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.517 ' CD2' HG11 ' A' ' 35' ' ' VAL . 7.4 tp -127.52 128.73 46.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -108.75 155.06 21.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.953 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.671 HG12 HG11 ' A' ' 59' ' ' VAL . 65.5 t -141.58 135.97 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 -142.37 142.06 32.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.966 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -124.37 131.24 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.158 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -102.5 179.24 4.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -128.05 153.6 19.48 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.49 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -26.02 27.78 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.695 2.263 . . . . 0.0 112.293 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.36 12.58 10.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.95 27.92 8.05 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 15.0 tp -94.35 145.34 24.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.399 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -115.5 140.71 35.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.158 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -131.29 145.63 58.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.597 0.713 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 172.64 12.3 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.294 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.671 HG11 HG12 ' A' ' 47' ' ' VAL . 3.7 m -144.21 159.66 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.142 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 11.5 t-20 -123.04 140.97 52.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.8 p -133.39 117.03 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.142 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.7 t -139.47 132.04 36.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.093 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -80.2 136.21 36.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -75.04 -42.32 57.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.95 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.82 -23.04 15.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -90.44 -43.28 10.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 33.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.509 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 70.9 p -151.71 177.75 10.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.3 m80 -141.73 127.05 18.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.939 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.0 m -86.79 139.88 30.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.164 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.585 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.7 t -131.45 107.69 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -95.43 141.46 28.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.537 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.9 p90 -159.44 167.46 28.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.6 m -145.28 113.67 4.82 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.58 0.705 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.537 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.9 Cg_endo -69.69 94.62 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.684 2.256 . . . . 0.0 112.392 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' PRO . 5.7 m -34.16 -55.4 0.5 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -130.33 158.96 38.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.911 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -72.37 172.95 9.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.925 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.82 176.2 14.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 84.06 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.723 2.282 . . . . 0.0 112.312 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -82.68 173.85 11.53 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 ttp -150.77 129.81 12.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.911 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -115.88 97.99 6.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -80.72 132.71 35.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.774 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 99.0 t -128.25 134.55 64.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.145 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -124.11 167.25 14.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.908 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.9 t80 -153.96 105.61 2.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.826 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.49 42.65 2.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.13 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.0 33.52 14.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -143.19 105.72 4.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -55.06 112.59 1.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.65 HD11 ' CE2' ' A' ' 97' ' ' PHE . 44.8 pt -50.42 152.99 2.83 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.6 0.714 . . . . 0.0 111.152 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.441 ' HG2' ' NH1' ' A' ' 94' ' ' ARG . 54.5 Cg_endo -69.73 8.3 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.716 2.277 . . . . 0.0 112.368 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.501 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 0.6 OUTLIER -120.7 -2.47 9.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.526 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.3 t -111.56 152.55 44.09 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.675 0.75 . . . . 0.0 110.844 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.526 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.77 175.17 37.64 Favored 'Cis proline' 0 C--O 1.231 0.153 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.317 0.017 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.65 ' CE2' HD11 ' A' ' 92' ' ' ILE . 82.4 m-85 -115.45 117.7 31.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -77.97 115.56 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.871 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.5 t -128.01 103.91 11.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 24.3 ttpt -83.32 99.27 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.929 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.3 t -68.51 145.67 13.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.118 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.3 mt -112.08 155.32 43.59 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.631 0.729 . . . . 0.0 110.875 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' TYR . 52.9 Cg_endo -69.83 121.7 8.37 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.246 . . . . 0.0 112.319 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.1 m -33.87 -36.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.173 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.446 ' N ' ' O ' ' A' ' 103' ' ' PRO . 31.3 m-85 -86.91 107.94 18.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.986 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -115.35 87.59 2.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.926 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -88.18 41.61 1.01 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.083 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 75.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.843 -179.814 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.6 t . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.826 0.346 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -118.23 94.96 47.82 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.569 0.699 . . . . 0.0 110.883 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -0.11 6.45 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.77 2.313 . . . . 0.0 112.312 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.7 m -99.12 1.87 45.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.852 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -104.65 -6.76 20.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -90.12 129.31 41.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.115 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.27 176.19 8.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.833 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.627 HD11 ' CE1' ' A' ' 97' ' ' PHE . 13.2 pt -145.61 134.59 17.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.158 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.98 120.74 13.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.087 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.52 168.76 40.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -26.48 27.54 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.723 2.282 . . . . 0.0 112.292 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.76 -25.58 70.57 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.484 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.614 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -98.73 -9.98 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.883 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.08 -178.48 14.6 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.528 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.8 m -91.58 -6.93 51.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.905 0.383 . . . . 0.0 110.863 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.4 47.24 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.491 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.661 HG13 ' NE2' ' A' ' 31' ' ' GLN . 88.1 t -98.01 139.85 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 111.105 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.822 ' HB2' HG21 ' A' ' 29' ' ' VAL . 80.8 mtt-85 -121.97 146.23 47.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.826 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.654 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.28 151.82 39.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.085 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.2 mtt180 53.83 37.0 25.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.904 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.822 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.2 t -127.47 148.82 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.169 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.4 tp -71.56 111.38 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.661 ' NE2' HG13 ' A' ' 25' ' ' VAL . 36.5 mm-40 -114.92 127.48 55.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.8 t -144.44 155.86 43.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.532 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.2 p90 -148.02 -178.21 6.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.866 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -121.17 129.88 53.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.505 HG11 ' CD2' ' A' ' 45' ' ' LEU . 47.6 t -108.26 106.37 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -88.98 111.82 22.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.9 p -128.11 24.41 5.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 t -68.36 -34.71 76.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.25 -8.24 57.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.42 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -83.0 -35.33 25.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.12 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.29 -144.07 15.36 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.415 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.744 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -110.43 17.71 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.796 0.332 . . . . 0.0 110.917 -179.906 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.838 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.01 148.65 81.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.579 0.704 . . . . 0.0 111.095 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 167.67 23.77 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.68 2.253 . . . . 0.0 112.317 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.505 ' CD2' HG11 ' A' ' 35' ' ' VAL . 6.9 tp -125.43 127.32 46.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -110.95 148.42 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.92 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 48' ' ' ARG . 35.7 t -139.45 153.9 24.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.411 ' N ' HG12 ' A' ' 47' ' ' VAL . 18.5 mtp85 -157.36 138.04 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.88 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 83' ' ' VAL . 77.2 t -117.98 116.65 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.095 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.98 123.28 49.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.95 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.22 178.56 1.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.499 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.581 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.5 Cg_endo -69.77 -39.2 6.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.628 2.219 . . . . 0.0 112.365 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.425 ' CZ ' HE22 ' A' ' 77' ' ' GLN . 0.0 OUTLIER -87.21 -28.77 22.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.843 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.9 34.37 0.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.53 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.607 HD21 ' OE2' ' A' ' 57' ' ' GLU . 18.1 tp -83.16 156.45 23.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.898 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 56' ' ' VAL . 12.7 p -119.46 111.72 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.15 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.607 ' OE2' HD21 ' A' ' 55' ' ' LEU . 8.0 mm-40 -112.8 143.5 29.18 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 110.875 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 169.41 19.04 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.676 2.251 . . . . 0.0 112.336 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.5 m -142.65 157.07 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.658 ' O ' HG13 ' A' ' 71' ' ' VAL . 36.6 t30 -109.63 143.51 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.13 120.82 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 97.8 t -136.08 132.12 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.134 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -87.04 128.75 35.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.911 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -71.37 -42.1 68.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.868 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.14 -20.95 25.44 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.83 -42.74 9.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.47 36.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.496 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 64.7 p -153.11 176.38 11.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.14 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -143.92 133.99 24.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.2 m -96.35 132.9 41.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.134 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.2 t -126.37 108.16 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.135 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 51.8 p -98.28 142.26 30.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.106 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.493 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 7.2 p90 -159.73 169.28 24.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -145.04 113.77 4.91 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.64 0.733 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.493 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.73 97.12 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.374 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 75' ' ' PRO . 57.8 p -35.35 -47.98 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . 0.425 HE22 ' CZ ' ' A' ' 53' ' ' ARG . 7.0 pt20 -132.08 -175.54 3.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.5 pp20? -101.47 170.27 8.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.5 176.81 14.57 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.533 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 88.07 0.55 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.581 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.4 m-85 -85.21 173.67 10.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.942 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 23.6 ttp -146.62 117.49 7.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.919 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 49' ' ' VAL . 63.0 t -107.56 100.26 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.0 t -84.46 148.48 26.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.8 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.3 t -142.57 138.85 28.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.079 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -126.52 169.27 13.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.829 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.8 t80 -156.45 105.0 2.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.838 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.81 42.04 2.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.058 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 64.0 32.93 12.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.899 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -143.11 105.01 4.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.953 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -54.54 109.5 0.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.584 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.5 pt -47.52 152.95 1.09 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.648 0.737 . . . . 0.0 111.122 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 3.93 2.48 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.629 2.219 . . . . 0.0 112.374 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 39.1 mmt-85 -113.31 -4.15 13.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -111.84 154.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.685 0.755 . . . . 0.0 110.838 -179.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.7 -179.97 20.55 Favored 'Cis proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 -1.797 . . . . 0.0 112.353 -0.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.627 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.5 m-85 -120.62 118.86 31.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -82.06 105.16 12.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.7 t -116.38 105.21 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 43.8 tttm -82.49 102.55 11.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 38.9 t -70.21 150.73 9.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.113 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.53 153.84 52.16 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.598 0.713 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.87 122.65 9.3 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.681 2.254 . . . . 0.0 112.305 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 53.5 m -34.7 -34.51 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.173 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.458 ' N ' ' O ' ' A' ' 103' ' ' PRO . 64.9 m-85 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.887 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.5 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.76 0.314 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -128.89 95.73 31.08 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -2.73 10.65 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.752 2.301 . . . . 0.0 112.316 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.7 p -98.99 9.31 43.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.796 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -113.79 -7.65 13.23 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.5 p -83.85 125.1 40.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.109 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -120.9 173.66 7.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.593 HG22 HG13 ' A' ' 35' ' ' VAL . 38.1 pt -147.02 137.6 17.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.72 138.22 32.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.084 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.3 168.84 27.0 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -30.97 21.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.668 2.245 . . . . 0.0 112.354 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -52.55 -46.65 58.55 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.483 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.585 HD11 HD12 ' A' ' 16' ' ' ILE . 6.0 mt -76.64 -28.63 56.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.875 0.369 . . . . 0.0 110.982 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -47.62 169.83 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.479 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 69.7 m -87.06 -7.92 57.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -93.7 49.21 2.3 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 20' ' ' GLY . 70.1 t -101.05 142.31 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.772 0.32 . . . . 0.0 111.15 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.493 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.0 mtt180 -118.33 147.89 43.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -67.71 149.61 49.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 56.18 40.73 30.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.493 HG21 ' HB2' ' A' ' 26' ' ' ARG . 53.6 t -133.62 148.11 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.099 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 18.6 tp -68.18 114.52 6.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.423 ' NE2' HG13 ' A' ' 25' ' ' VAL . 44.4 mm-40 -120.64 128.36 52.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.927 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.3 t -144.9 150.69 37.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.548 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 1.4 p90 -139.58 -178.29 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -121.0 133.78 55.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.12 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.593 HG13 HG22 ' A' ' 16' ' ' ILE . 44.6 t -115.34 107.57 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -91.33 106.86 18.81 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.46 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.1 p -117.01 20.4 13.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 50.6 p -63.05 -42.52 99.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? -77.03 -15.06 59.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.498 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -78.6 -32.38 47.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.062 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.01 -140.11 11.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.504 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.68 22.69 12.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.858 0.361 . . . . 0.0 110.949 -179.933 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.763 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.27 151.64 75.48 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.708 . . . . 0.0 111.074 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 167.05 25.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.659 2.239 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.7 tp -125.78 139.06 53.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.981 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -121.24 145.26 48.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.9 t -134.22 141.18 44.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -146.64 130.99 17.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 83' ' ' VAL . 82.0 t -116.21 125.15 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -115.07 144.2 44.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.72 169.7 43.1 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.552 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -31.74 19.91 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.624 2.216 . . . . 0.0 112.369 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -95.36 -27.37 15.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.881 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 133.28 27.46 0.56 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.8 tp -86.79 148.66 25.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.895 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.3 t -110.96 121.54 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.123 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.569 ' OE1' HG12 ' A' ' 49' ' ' VAL . 4.5 mp0 -112.62 142.92 27.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.641 0.734 . . . . 0.0 110.906 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.18 22.24 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.337 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.74 157.55 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.443 HD21 HG23 ' A' ' 62' ' ' VAL . 40.8 t30 -115.32 140.92 48.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.861 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 84.5 t -132.22 107.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.12 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.443 HG23 HD21 ' A' ' 60' ' ' ASN . 91.4 t -131.64 119.13 41.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.136 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t0 -76.07 133.47 40.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.859 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -72.37 -43.33 64.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.71 -24.7 10.09 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.437 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -86.99 -39.1 15.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.78 34.21 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.552 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.479 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 72.6 p -150.16 176.74 10.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.837 0.351 . . . . 0.0 111.144 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.479 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.4 m-70 -145.78 131.18 18.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.859 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 21.9 m -91.61 139.58 30.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.548 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 99.3 t -129.59 102.32 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.111 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 46.7 p -92.51 138.81 31.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.173 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -164.01 160.78 22.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 29' ' ' VAL . 84.9 m -137.98 117.27 9.88 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.607 0.718 . . . . 0.0 111.152 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' SER . 53.8 Cg_endo -69.74 90.45 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.689 2.259 . . . . 0.0 112.305 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' PRO . 64.6 p -34.97 -53.6 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.881 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -122.22 158.39 29.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pp20? -79.7 174.95 11.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.948 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.35 177.16 14.89 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.516 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 86.59 0.59 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.623 2.216 . . . . 0.0 112.32 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -79.07 169.75 17.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -145.16 119.08 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.892 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 49' ' ' VAL . 90.1 t -110.89 97.12 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.141 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.4 m -81.4 142.56 32.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 87.2 t -135.61 145.14 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.404 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 23.7 tttt -132.35 168.66 17.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.733 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.1 t80 -154.39 105.74 2.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.969 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.763 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.49 44.39 5.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.186 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.404 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.1 m-20 63.2 33.3 14.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -142.49 105.06 4.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -56.21 111.62 1.01 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.636 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.7 pt -49.24 153.2 1.78 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.59 0.709 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 4.41 2.16 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.664 2.243 . . . . 0.0 112.377 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.419 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 9.4 mtm-85 -116.18 0.09 12.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.544 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -115.21 153.32 47.36 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.644 0.735 . . . . 0.0 110.803 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.544 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.5 Cg_endo -69.76 171.26 54.53 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.35 -0.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.636 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.1 m-85 -109.78 140.8 43.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.3 ptmm? -100.75 110.32 22.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 98.9 t -119.44 101.95 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.1 tttm -81.0 101.6 9.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.9 t -73.22 147.66 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.128 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.8 mt -114.96 154.79 47.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 0.0 110.86 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.0 Cg_endo -69.74 124.16 10.82 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.671 2.247 . . . . 0.0 112.346 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.407 ' C ' ' O ' ' A' ' 103' ' ' PRO . 51.5 m -36.34 -30.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.185 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.479 ' N ' ' O ' ' A' ' 103' ' ' PRO . 70.1 m-85 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.882 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 59.3 t . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.117 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -132.7 95.94 19.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.6 0.714 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 -0.81 7.36 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.705 2.27 . . . . 0.0 112.412 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 55.8 p -99.92 7.62 44.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.932 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.3 mmpt? -112.16 -9.62 13.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.419 ' H ' HG12 ' A' ' 14' ' ' VAL . 1.2 p -84.32 121.77 37.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -118.12 173.68 6.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.718 HG22 HG13 ' A' ' 35' ' ' VAL . 23.1 pt -146.86 135.93 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.185 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.59 156.57 45.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.059 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 143.07 177.02 17.67 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.86 -33.76 15.56 Favored 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.662 2.241 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -53.57 -23.5 20.66 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.538 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.498 HD13 HG13 ' A' ' 16' ' ' ILE . 7.7 mt -109.67 -19.95 13.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.88 0.372 . . . . 0.0 110.925 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -59.83 166.81 9.48 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.6 m -82.6 11.22 6.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.881 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.83 43.4 1.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.409 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.434 HG13 ' CD ' ' A' ' 31' ' ' GLN . 59.7 t -101.97 143.85 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.908 0.385 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -124.68 155.48 39.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.866 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.7 150.32 43.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.7 mtm-85 57.26 37.78 28.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.12 147.76 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.085 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.9 tp -69.0 113.14 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.519 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 51.0 mm-40 -117.76 130.9 56.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.429 ' HB2' HG22 ' A' ' 72' ' ' THR . 36.0 t -144.83 150.89 37.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.875 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.557 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 8.7 p90 -141.52 176.88 8.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 60.5 m -119.43 135.88 54.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.175 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.718 HG13 HG22 ' A' ' 16' ' ' ILE . 46.4 t -113.22 105.97 19.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.056 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -84.93 103.32 13.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.86 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 81.2 p -116.88 25.68 10.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 p -73.68 -29.76 62.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.854 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 30.5 mmtm -90.37 -5.47 56.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.919 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -89.46 -34.68 16.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.65 -140.18 11.6 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.396 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.34 20.98 12.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.798 0.332 . . . . 0.0 110.895 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.758 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.34 151.37 75.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.598 0.713 . . . . 0.0 111.049 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.9 20.14 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.745 2.296 . . . . 0.0 112.373 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.651 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.7 tp -132.0 135.4 46.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.918 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -112.19 152.97 27.75 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 HG11 ' A' ' 59' ' ' VAL . 21.5 t -138.72 132.91 41.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.156 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 48.8 mtm180 -139.11 132.75 30.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' VAL . 81.6 t -117.18 121.28 67.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 10.8 mt -116.94 129.29 55.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.27 175.03 40.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.534 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.442 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.79 -32.62 18.08 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.712 2.275 . . . . 0.0 112.308 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.29 -25.87 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.887 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 130.84 22.86 1.0 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.499 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 16.7 tp -74.08 149.04 41.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 0.0 110.838 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.3 t -113.7 112.93 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -113.15 141.63 26.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.611 0.719 . . . . 0.0 110.893 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 174.88 8.86 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.623 2.215 . . . . 0.0 112.362 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 HG12 ' A' ' 47' ' ' VAL . 8.9 m -144.32 162.83 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.714 ' O ' HG13 ' A' ' 71' ' ' VAL . 19.0 t30 -119.49 145.02 46.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.896 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.457 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.3 p -132.46 120.48 42.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.141 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.536 HG23 ' ND2' ' A' ' 60' ' ' ASN . 57.6 t -133.59 122.58 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -82.17 127.23 32.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.926 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -71.76 -47.71 51.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.52 -16.17 24.25 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -95.14 -38.22 10.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.963 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.69 33.97 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.457 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.6 p -152.76 176.15 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 111.175 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.457 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.2 m-70 -145.85 130.7 18.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.968 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.7 m -92.89 139.78 30.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.157 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.714 HG13 ' O ' ' A' ' 60' ' ' ASN . 36.9 t -131.22 108.94 15.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.171 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.429 HG22 ' HB2' ' A' ' 32' ' ' SER . 38.3 p -93.34 146.42 23.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.103 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 9.3 p90 -163.26 166.87 22.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.5 m -144.22 110.64 5.05 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 121.612 0.72 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.73 91.9 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.724 2.283 . . . . 0.0 112.315 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 22.8 t -34.21 -50.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.801 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -129.62 173.61 10.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.888 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.92 170.21 10.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.861 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.73 172.59 13.18 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.461 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 90.85 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.704 2.27 . . . . 0.0 112.367 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.442 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.0 m-85 -85.07 161.65 19.61 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -131.42 112.8 13.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.842 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 49' ' ' VAL . 96.3 t -103.51 95.98 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.8 t -79.34 145.7 33.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.651 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.1 t -143.54 130.13 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.137 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.3 tttt -118.13 169.81 9.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.758 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.3 t80 -156.89 106.12 2.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.707 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.3 40.79 3.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.13 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.99 34.57 11.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.856 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -145.7 105.03 3.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -54.17 114.53 1.65 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.863 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.677 HD11 ' HE1' ' A' ' 97' ' ' PHE . 48.2 pt -52.12 152.81 5.36 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.574 0.702 . . . . 0.0 111.178 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 4.29 2.27 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.701 2.267 . . . . 0.0 112.296 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -116.13 1.33 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.848 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.543 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -115.23 153.83 47.38 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.683 0.754 . . . . 0.0 110.825 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.69 -179.41 18.97 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.392 -0.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.709 ' CE2' HD11 ' A' ' 16' ' ' ILE . 85.2 m-85 -119.45 123.38 43.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.912 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 8.5 pttp -83.89 96.77 8.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 86.9 t -102.28 103.99 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.103 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 23.9 ttpt -85.0 102.53 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.87 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.4 t -75.38 143.43 13.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.134 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 33.8 mt -107.79 154.51 40.92 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.52 0.676 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.7 Cg_endo -69.7 122.51 9.2 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.3 m -33.97 -36.21 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.44 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.8 m-85 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.865 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.838 0.352 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.41 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 3.7 t0 -131.85 96.86 19.6 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.799 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 -0.43 6.89 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.676 2.251 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -99.38 6.95 45.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -112.99 -7.2 13.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -86.33 126.93 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -125.57 170.37 11.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.648 HD11 ' CE2' ' A' ' 97' ' ' PHE . 41.1 pt -145.25 137.01 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.173 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.21 143.26 34.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.076 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.0 169.97 24.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.72 -29.71 23.63 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.703 2.268 . . . . 0.0 112.343 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.59 -45.93 94.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.501 HD13 HG13 ' A' ' 16' ' ' ILE . 12.5 mt -73.91 -26.9 60.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.876 0.369 . . . . 0.0 110.933 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -51.16 169.35 0.36 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.501 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.5 p -85.26 -7.78 58.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.914 0.388 . . . . 0.0 110.841 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.67 44.7 2.73 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.508 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.478 HG13 ' NE2' ' A' ' 31' ' ' GLN . 97.7 t -92.15 143.0 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.831 0.348 . . . . 0.0 111.181 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.722 ' HB2' HG21 ' A' ' 29' ' ' VAL . 46.5 mtm180 -118.33 156.17 29.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.52 147.08 44.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 82.5 mtm-85 54.94 35.79 25.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' A' ' 26' ' ' ARG . 23.3 t -121.71 151.84 25.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.126 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.402 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 7.9 tp -75.62 109.33 9.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.478 ' NE2' HG13 ' A' ' 25' ' ' VAL . 40.7 mm-40 -112.72 127.64 56.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 23.1 t -143.85 149.51 37.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.451 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 9.8 p90 -145.85 171.25 15.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -110.68 130.61 55.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.506 HG22 HG22 ' A' ' 16' ' ' ILE . 100.0 t -108.55 107.05 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.126 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -90.56 106.73 18.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 86.8 p -121.87 25.95 8.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.915 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 78.1 p -71.25 -35.85 71.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.861 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -80.02 -14.91 58.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.918 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.29 -38.2 43.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.13 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -138.19 9.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.609 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.19 17.73 13.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.885 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.75 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.92 151.52 84.29 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.525 0.679 . . . . 0.0 111.119 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 166.87 26.0 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.703 2.269 . . . . 0.0 112.362 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -122.92 136.33 54.82 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -119.21 139.47 51.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.885 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 59' ' ' VAL . 48.8 t -130.73 144.44 37.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.079 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 20.1 ttm180 -148.11 141.8 25.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -122.78 122.04 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.138 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -108.13 151.34 26.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.44 167.35 32.5 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.471 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -29.84 23.47 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' NH1' HD13 ' A' ' 55' ' ' LEU . 0.0 OUTLIER -118.18 3.62 12.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.55 62.98 0.5 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.542 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.45 HD13 ' NH1' ' A' ' 53' ' ' ARG . 10.1 tp -120.48 134.75 55.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.872 0.368 . . . . 0.0 110.911 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.1 t -102.78 129.78 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.157 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -134.46 141.43 38.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.655 0.741 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 168.47 21.41 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.689 2.259 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 47' ' ' VAL . 39.7 t -142.64 151.61 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.484 HD21 HG23 ' A' ' 62' ' ' VAL . 8.6 t30 -100.82 138.52 37.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.85 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.488 ' O ' HG13 ' A' ' 61' ' ' VAL . 6.2 p -133.43 112.47 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.181 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.484 HG23 HD21 ' A' ' 60' ' ' ASN . 66.1 t -133.4 127.61 54.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -84.08 130.87 34.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -72.21 -46.14 57.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.24 -22.21 11.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -88.6 -40.59 13.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.814 0.34 . . . . 0.0 110.852 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.28 33.99 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.509 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.575 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.7 p -150.2 175.39 11.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.876 0.369 . . . . 0.0 111.107 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.575 ' CD2' ' C ' ' A' ' 68' ' ' THR . 6.2 m-70 -147.0 125.21 12.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 38.8 m -85.7 141.28 29.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.451 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.0 t -131.13 104.56 9.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.9 p -96.89 135.13 39.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.132 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.503 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.6 p90 -155.4 175.05 14.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.913 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 29' ' ' VAL . 89.7 m -151.71 117.18 3.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.526 0.679 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.503 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.3 Cg_endo -69.77 98.12 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.723 2.282 . . . . 0.0 112.357 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' PRO . 1.5 t -34.32 -60.3 0.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.883 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -127.36 164.19 22.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -72.73 167.36 20.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 132.46 171.08 12.68 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.443 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 92.76 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.678 2.252 . . . . 0.0 112.363 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -87.94 173.99 8.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 18.3 ttp -148.5 117.17 6.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.79 96.64 4.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.101 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -79.0 144.71 34.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.872 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 55.7 t -139.58 135.91 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -126.47 169.62 12.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.9 t80 -155.71 117.9 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.75 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 57.04 31.58 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.126 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.0 t70 74.22 31.74 1.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -141.79 106.69 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -53.73 114.89 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.678 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.4 pt -53.49 152.79 8.37 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.667 0.746 . . . . 0.0 111.136 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 4.47 2.19 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.535 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.7 mmt180 -115.64 0.76 13.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.881 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.527 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -114.72 153.36 46.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.622 0.725 . . . . 0.0 110.855 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.85 178.63 25.01 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.285 0.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.678 ' HE1' HD11 ' A' ' 92' ' ' ILE . 81.8 m-85 -117.2 117.73 30.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.897 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -78.49 113.33 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.836 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -128.99 101.95 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.119 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.5 tttm -83.95 102.51 12.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.9 t -67.15 145.67 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.177 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.7 mt -114.03 156.17 44.39 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.8 121.28 7.96 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.687 2.258 . . . . 0.0 112.351 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.429 ' C ' ' O ' ' A' ' 103' ' ' PRO . 54.0 m -35.21 -31.75 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.075 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.496 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.941 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.6 t . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.827 0.346 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.414 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.0 t0 -134.14 96.21 16.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.635 0.731 . . . . 0.0 110.897 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 1.49 4.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.747 2.298 . . . . 0.0 112.305 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 63.7 m -99.2 -5.23 30.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.5 mmpt? -97.9 -7.66 29.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.9 p -86.43 131.17 35.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.193 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mppt? -128.44 172.61 10.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.864 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.614 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 24.2 pt -143.3 134.96 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.122 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.93 128.17 20.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.79 163.59 28.21 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -24.88 29.44 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.664 2.243 . . . . 0.0 112.365 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.77 95.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.614 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.1 mt -84.13 -17.19 40.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.973 0.416 . . . . 0.0 110.968 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.31 176.71 1.31 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.509 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -91.26 -13.29 33.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.986 0.422 . . . . 0.0 110.87 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.47 49.86 3.49 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.521 HG13 ' NE2' ' A' ' 31' ' ' GLN . 74.6 t -99.34 147.15 7.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.798 0.332 . . . . 0.0 111.103 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.508 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.26 144.84 48.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.418 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.76 150.45 44.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 45.7 mtm180 54.65 43.05 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.508 HG21 ' HB2' ' A' ' 26' ' ' ARG . 75.8 t -135.06 147.65 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -69.96 113.93 7.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.945 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.521 ' NE2' HG13 ' A' ' 25' ' ' VAL . 42.4 mm-40 -120.51 129.02 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.8 t -144.75 157.72 44.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.614 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.3 p90 -147.21 179.95 7.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.931 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 58.2 m -120.08 130.82 54.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.142 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 16' ' ' ILE . 61.2 t -110.72 109.07 27.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -89.83 110.39 21.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 25.6 p -125.75 24.73 7.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.757 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 89.0 p -69.64 -33.76 73.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.7 mmmt -86.31 -12.66 48.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.58 -35.3 46.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.133 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.82 -138.86 10.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.566 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.583 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -121.14 19.37 11.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.745 0.307 . . . . 0.0 110.852 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.857 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.86 151.78 79.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.604 0.716 . . . . 0.0 111.103 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 167.16 25.27 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.486 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.4 tp -125.32 136.0 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.911 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -120.94 149.38 42.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.91 150.15 20.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.196 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -148.58 136.16 20.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 83' ' ' VAL . 93.5 t -116.4 124.8 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -123.89 133.73 53.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.53 -179.86 49.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.491 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -45.17 1.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.674 2.25 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.488 ' NE ' HE22 ' A' ' 77' ' ' GLN . 0.1 OUTLIER -76.2 -35.24 59.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.889 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.9 31.59 0.26 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.401 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 11.2 tp -85.31 152.04 23.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.917 0.389 . . . . 0.0 110.886 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.401 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 92.4 t -119.25 122.59 69.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -120.25 142.64 34.08 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.56 0.695 . . . . 0.0 110.97 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 169.01 19.94 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.632 2.221 . . . . 0.0 112.33 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.7 m -138.29 167.7 21.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.2 t30 -114.34 140.67 48.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 93.1 t -133.32 114.9 21.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.166 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.403 HG23 HD21 ' A' ' 60' ' ' ASN . 96.0 t -140.47 117.55 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -73.63 139.45 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.933 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -78.42 -45.56 21.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.61 -20.7 11.95 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.447 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.95 -39.03 13.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.807 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.59 34.96 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.487 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.8 p -153.27 177.39 10.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 111.072 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.1 m-70 -144.8 130.59 19.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.87 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 81.8 m -88.54 140.98 28.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.47 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.0 t -133.04 102.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.146 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 45.2 p -95.09 143.84 26.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.494 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 5.2 p90 -163.35 175.46 10.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.971 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -151.91 116.95 3.07 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.651 0.738 . . . . 0.0 111.121 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.494 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.76 92.92 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.664 2.243 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 75' ' ' PRO . 40.2 t -34.44 -54.7 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.854 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . 0.488 HE22 ' NE ' ' A' ' 53' ' ' ARG . 7.3 pt20 -125.83 171.71 10.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.969 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -84.82 172.81 11.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.52 170.04 12.99 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.5 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.13 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.726 2.284 . . . . 0.0 112.319 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -83.11 168.59 16.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.978 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.5 ttp -139.54 117.95 12.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 49' ' ' VAL . 90.9 t -107.21 97.59 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.128 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 m -81.53 147.44 29.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.832 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.486 ' CG1' HD11 ' A' ' 45' ' ' LEU . 64.5 t -140.94 138.11 34.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.6 tttt -125.27 173.91 8.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.567 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.7 t80 -160.44 110.54 1.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.974 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.857 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.68 38.31 18.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.154 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 68.02 34.02 4.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -144.23 105.02 4.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.875 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -54.39 108.38 0.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.486 HD12 ' HB2' ' A' ' 94' ' ' ARG . 45.8 pt -46.9 153.02 0.87 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.583 0.706 . . . . 0.0 111.144 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.68 2.04 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.668 2.245 . . . . 0.0 112.347 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.486 ' HB2' HD12 ' A' ' 92' ' ' ILE . 84.2 mmt-85 -114.48 -3.73 12.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 0.9 OUTLIER -112.28 154.45 44.43 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.631 0.729 . . . . 0.0 110.848 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.0 Cg_endo -69.72 -178.53 16.86 Favored 'Cis proline' 0 C--N 1.342 0.206 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.38 -0.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.614 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 81.2 m-85 -121.25 132.78 55.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 ptmt -93.16 108.31 19.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.7 t -118.59 103.68 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.104 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 106.85 13.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.908 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 41.5 t -76.81 138.08 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.155 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.6 mt -108.64 155.24 40.91 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 121.675 0.75 . . . . 0.0 110.941 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.6 Cg_endo -69.73 122.46 9.14 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.782 2.321 . . . . 0.0 112.296 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 103' ' ' PRO . 91.9 m -34.83 -35.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.084 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.442 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.4 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.0 t . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.853 0.359 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.1 t0 -133.23 96.18 17.66 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.598 0.713 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.7 Cg_endo -69.72 -1.63 8.78 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.682 2.255 . . . . 0.0 112.359 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.5 p -98.11 5.93 48.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.808 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -110.53 -7.74 14.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -86.29 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.106 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.9 mttt -127.21 173.72 9.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.931 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.792 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.4 pt -147.35 135.79 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.4 153.19 46.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.142 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.52 174.6 20.35 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -36.04 11.46 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.671 2.247 . . . . 0.0 112.315 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.28 -32.68 29.87 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.561 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.434 HD13 HG13 ' A' ' 16' ' ' ILE . 13.0 mt -94.4 -21.38 18.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.912 0.387 . . . . 0.0 110.95 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.43 167.96 2.67 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -87.49 13.75 9.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.893 0.378 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.02 44.9 1.37 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.518 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.452 HG13 ' NE2' ' A' ' 31' ' ' GLN . 60.0 t -97.14 145.96 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 111.095 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.464 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.1 mtt85 -120.89 151.65 39.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.887 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -69.56 150.73 46.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.068 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.9 mtp180 55.09 41.55 31.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.464 HG21 ' HB2' ' A' ' 26' ' ' ARG . 59.3 t -133.88 144.33 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.2 tp -68.43 112.99 5.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.452 ' NE2' HG13 ' A' ' 25' ' ' VAL . 54.5 mm-40 -117.47 130.66 56.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.2 t -144.89 149.1 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.54 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.4 p90 -140.08 179.77 6.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.946 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 89.3 m -117.8 131.55 56.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.606 HG11 HD22 ' A' ' 45' ' ' LEU . 92.8 t -110.38 105.47 18.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.096 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' HG22 ' A' ' 68' ' ' THR . 18.9 t70 -89.67 101.76 14.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.858 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 82.6 p -117.33 27.94 8.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.1 t -70.04 -38.13 75.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 37.7 mttp -76.06 -14.88 60.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -81.2 -38.59 26.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.09 -137.44 9.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.532 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.597 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.86 19.91 12.32 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.793 0.33 . . . . 0.0 110.912 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.711 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.18 151.62 81.47 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.585 0.707 . . . . 0.0 111.084 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 166.86 26.18 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.685 2.256 . . . . 0.0 112.322 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.606 HD22 HG11 ' A' ' 35' ' ' VAL . 5.0 tp -129.61 129.37 44.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -108.73 151.71 25.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.9 t -139.53 144.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.084 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -149.64 135.06 18.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.832 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 83' ' ' VAL . 61.5 t -116.73 128.36 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.1 mt -125.12 121.15 33.41 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.949 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.29 174.44 7.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.534 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -43.62 2.52 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.625 2.216 . . . . 0.0 112.381 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.6 -32.2 47.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.1 32.64 0.3 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.46 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.452 HD21 ' OE2' ' A' ' 57' ' ' GLU . 9.4 tp -85.85 149.69 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 0.0 110.874 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -114.38 115.23 48.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.452 ' OE2' HD21 ' A' ' 55' ' ' LEU . 65.3 mm-40 -113.79 142.84 28.42 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 169.58 18.59 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.237 . . . . 0.0 112.299 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.23 167.94 19.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.139 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 t30 -123.21 140.6 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 85.5 t -133.21 113.84 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 85.5 t -138.32 119.85 17.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.093 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -75.12 136.58 41.1 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.765 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -75.69 -43.44 47.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.88 -24.9 9.84 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.506 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -86.05 -44.21 12.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.837 0.351 . . . . 0.0 110.898 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.34 33.57 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.493 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.433 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 64.0 p -149.92 177.78 9.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.86 0.362 . . . . 0.0 111.078 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.433 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.3 m-70 -144.99 133.56 22.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 52.4 m -93.02 141.49 28.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.148 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.54 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 66.4 t -131.36 103.28 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.172 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.6 p -95.19 136.86 35.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.131 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.468 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 8.0 p90 -157.41 176.12 13.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.7 m -150.78 115.35 3.24 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.586 0.708 . . . . 0.0 111.122 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.468 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.8 95.04 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.345 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 13.4 t -38.91 -54.79 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.772 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -121.98 169.94 10.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.497 ' C ' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -86.97 173.75 9.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.86 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.11 176.23 15.05 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.488 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 89.15 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.699 2.266 . . . . 0.0 112.279 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.62 163.54 25.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.938 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 16.3 ttp -135.17 113.09 11.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.856 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 49' ' ' VAL . 69.3 t -105.48 97.78 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.116 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.5 t -82.98 144.29 30.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.899 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.573 ' CG1' HD11 ' A' ' 45' ' ' LEU . 55.7 t -139.83 142.37 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.433 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 39.9 tttt -128.29 170.56 12.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.711 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.5 t80 -156.42 109.42 2.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.674 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.27 40.82 11.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.433 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 4.9 m-20 64.31 35.99 9.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.887 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -147.05 105.04 3.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -52.48 117.01 2.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.652 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.5 pt -55.61 153.16 16.06 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.58 0.705 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 4.74 2.01 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 2.251 . . . . 0.0 112.412 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.42 ' HB2' HD12 ' A' ' 92' ' ' ILE . 29.7 mmt85 -117.04 2.96 12.74 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.64 153.98 49.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.637 0.732 . . . . 0.0 110.861 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.69 -179.92 20.38 Favored 'Cis proline' 0 C--O 1.231 0.135 0 C-N-CA 122.663 -1.807 . . . . 0.0 112.37 -0.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 16' ' ' ILE . 80.1 m-85 -117.45 128.98 55.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.878 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -93.64 107.34 19.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.9 t -119.43 107.04 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 19.8 ttpt -81.96 105.5 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.885 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.8 152.49 6.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.18 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 68.4 mt -117.55 154.83 50.79 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.575 0.702 . . . . 0.0 110.93 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.7 122.21 8.91 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.692 2.261 . . . . 0.0 112.377 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m -34.83 -32.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.152 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.6 m-85 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.1 t . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.75 0.31 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.443 ' CG ' ' HG2' ' A' ' 13' ' ' LYS . 8.8 t0 -123.95 95.1 44.71 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.614 0.721 . . . . 0.0 110.897 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 0.78 5.12 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.71 2.273 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 m -100.7 3.67 42.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.443 ' HG2' ' CG ' ' A' ' 10' ' ' ASP . 14.4 mmmt -104.74 -12.12 16.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 36' ' ' ASP . 6.4 p -84.37 133.67 28.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.0 mtmt -135.69 169.94 16.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.616 HG13 HD13 ' A' ' 21' ' ' LEU . 26.3 pt -142.67 137.25 27.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 143.79 33.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.077 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 155.83 178.57 30.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.87 -38.81 7.06 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.656 2.237 . . . . 0.0 112.315 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.27 -24.99 11.0 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.498 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.616 HD13 HG13 ' A' ' 16' ' ' ILE . 3.3 mt -104.41 -22.16 13.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.864 0.364 . . . . 0.0 110.896 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -58.19 176.82 1.84 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.469 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -91.17 11.78 22.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.884 0.374 . . . . 0.0 110.853 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.84 47.03 1.09 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.505 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.5 HG13 ' CD ' ' A' ' 31' ' ' GLN . 72.4 t -98.54 138.29 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.805 0.336 . . . . 0.0 111.11 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.579 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.4 mtt85 -118.76 146.33 44.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.425 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -66.69 151.51 47.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.034 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 56.18 35.6 25.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.579 HG21 ' HB2' ' A' ' 26' ' ' ARG . 76.2 t -128.91 154.4 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.434 ' N ' HG12 ' A' ' 29' ' ' VAL . 12.1 tp -76.19 112.24 12.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.5 ' CD ' HG13 ' A' ' 25' ' ' VAL . 61.8 mm-40 -113.83 127.54 56.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 13.6 t -142.19 154.1 44.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.872 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.569 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.0 p90 -149.54 176.2 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.948 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 96.1 m -114.64 138.01 51.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.146 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 16' ' ' ILE . 52.3 t -117.48 106.97 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.7 t70 -85.78 110.65 19.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.6 p -125.34 25.77 7.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.8 t -75.67 -35.82 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.876 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? -81.6 -18.52 44.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -75.29 -39.98 59.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.139 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.8 -140.66 11.42 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.826 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -116.35 16.97 15.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.785 0.326 . . . . 0.0 110.907 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.757 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.63 151.3 84.85 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.61 0.719 . . . . 0.0 111.063 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.436 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.7 Cg_endo -69.77 167.37 24.65 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.652 2.234 . . . . 0.0 112.297 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.593 HD11 ' CG1' ' A' ' 85' ' ' VAL . 10.8 tp -128.19 131.11 48.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.897 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -111.86 151.53 29.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.82 149.81 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.46 ' HG2' HD23 ' A' ' 50' ' ' LEU . 2.5 ttp-105 -152.61 143.12 22.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 58.3 t -118.69 122.06 68.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.46 HD23 ' HG2' ' A' ' 48' ' ' ARG . 4.0 mm? -110.48 128.92 55.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.59 165.03 52.6 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.502 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.528 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.75 -26.29 27.76 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.743 2.295 . . . . 0.0 112.365 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.09 3.35 9.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.08 65.16 0.52 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.48 148.0 44.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.59 118.64 57.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -120.65 141.69 32.78 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.639 0.733 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 169.21 19.39 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.663 2.242 . . . . 0.0 112.378 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.8 m -144.31 162.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 29.9 t30 -125.2 141.15 52.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 61' ' ' VAL . 3.6 p -133.52 110.94 15.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 74.7 t -139.79 116.04 9.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -67.45 138.8 56.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.3 m-80 -73.18 -41.98 63.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.89 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.21 -22.05 12.59 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.485 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -91.58 -43.05 9.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.357 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.77 34.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.413 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 57.3 p -152.23 177.87 10.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.413 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.1 m-70 -143.76 125.12 14.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.864 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 31.3 m -84.03 139.02 32.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.569 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 73.3 t -131.3 106.71 12.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.5 p -97.07 147.4 24.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.1 p90 -166.02 164.37 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 92.0 m -140.85 112.38 6.88 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.623 0.725 . . . . 0.0 111.129 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.69 100.59 0.82 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.367 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 75' ' ' PRO . 33.3 t -34.86 -57.85 0.53 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -129.86 166.5 19.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.419 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 5.7 pm0 -76.25 172.11 13.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.887 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.92 173.83 13.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.457 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 93.93 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.528 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 6.3 m-85 -90.11 173.91 7.92 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 27.7 ttp -147.61 117.74 7.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.841 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 93.2 t -106.29 100.22 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 12.4 t -84.37 143.49 29.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.81 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 45' ' ' LEU . 84.4 t -141.21 135.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -122.28 171.69 8.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.738 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 12.9 t80 -157.56 112.81 2.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.929 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.757 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.45 32.51 20.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.083 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 73.47 31.4 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.808 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -141.99 105.05 4.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -53.36 107.9 0.28 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.513 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.9 pt -45.93 153.0 0.69 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.609 0.719 . . . . 0.0 111.104 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 4.31 2.26 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.361 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 14.2 mmm180 -113.46 -4.65 13.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.836 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.546 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -112.21 153.98 44.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.659 0.742 . . . . 0.0 110.845 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.546 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.4 Cg_endo -69.65 179.15 22.84 Favored 'Cis proline' 0 C--N 1.341 0.168 0 C-N-CA 122.8 -1.75 . . . . 0.0 112.347 -0.116 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.513 ' HE2' HD11 ' A' ' 92' ' ' ILE . 89.5 m-85 -120.21 114.8 22.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 106.08 9.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.901 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 79.7 t -117.51 106.71 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.078 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -85.91 96.88 9.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.889 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.419 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 47.7 t -63.61 147.28 12.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.065 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.5 mt -113.02 154.05 45.12 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.59 0.709 . . . . 0.0 110.958 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.5 Cg_endo -69.71 124.06 10.73 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.741 2.294 . . . . 0.0 112.345 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.415 ' C ' ' O ' ' A' ' 103' ' ' PRO . 88.6 m -35.58 -32.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.473 ' N ' ' O ' ' A' ' 103' ' ' PRO . 23.0 m-85 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.9 t . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.875 0.369 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.2 t0 -128.08 96.92 30.39 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.58 0.705 . . . . 0.0 110.832 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.5 Cg_endo -69.71 -0.43 6.86 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.687 2.258 . . . . 0.0 112.369 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.2 p -99.67 10.39 41.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.863 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 mmpt? -114.82 -8.78 12.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.898 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.1 p -83.87 123.11 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.166 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -116.69 173.33 6.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.6 HG22 HG13 ' A' ' 35' ' ' VAL . 33.0 pt -147.13 138.82 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.89 138.1 31.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.95 167.59 22.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.541 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.75 -24.93 29.17 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.85 -28.09 65.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.472 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.546 HD11 HD12 ' A' ' 16' ' ' ILE . 6.7 mt -98.13 -19.78 17.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.41 166.37 5.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.7 t -83.29 8.59 13.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.972 0.415 . . . . 0.0 110.922 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.14 51.0 0.73 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.416 HG13 ' NE2' ' A' ' 31' ' ' GLN . 68.7 t -102.08 141.78 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.845 0.355 . . . . 0.0 111.102 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.643 ' HB2' HG21 ' A' ' 29' ' ' VAL . 75.3 mtt85 -118.97 150.75 39.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.74 150.16 48.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.442 ' HB3' ' NH1' ' A' ' 28' ' ' ARG . 12.2 mtp-105 54.91 40.32 31.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.643 HG21 ' HB2' ' A' ' 26' ' ' ARG . 66.4 t -129.9 150.74 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.7 tp -73.94 110.36 8.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.951 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.416 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.3 mm-40 -115.3 127.68 55.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.3 t -143.44 149.48 37.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 1.0 OUTLIER -141.33 -178.38 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 88.4 m -123.21 137.67 54.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.6 HG13 HG22 ' A' ' 16' ' ' ILE . 46.7 t -117.65 107.18 21.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.48 94.74 9.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.875 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.489 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 59.9 p -103.64 20.02 18.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.9 t -68.41 -34.94 76.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.814 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -82.75 -12.24 57.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -83.35 -39.66 20.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.047 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.654 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 135.66 -146.97 18.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.5 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.781 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.07 14.99 24.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.928 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.58 151.32 84.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.619 0.723 . . . . 0.0 111.046 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 169.36 19.1 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.64 2.227 . . . . 0.0 112.377 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.8 tp -124.82 139.47 53.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -112.96 143.4 44.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.548 HG12 HG11 ' A' ' 59' ' ' VAL . 88.9 t -135.72 131.1 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -141.12 143.0 34.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.23 132.38 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.5 mp -120.57 148.46 43.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.09 172.69 36.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.427 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.4 Cg_endo -69.82 -30.75 21.49 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.657 2.238 . . . . 0.0 112.325 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.86 4.78 17.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 105.45 66.5 0.67 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.54 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 26.9 tp -118.36 138.59 52.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.911 0.386 . . . . 0.0 110.91 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.1 t -109.02 108.98 26.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -110.93 143.13 27.66 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.618 0.723 . . . . 0.0 110.875 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 168.02 22.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.655 2.237 . . . . 0.0 112.363 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.548 HG11 HG12 ' A' ' 47' ' ' VAL . 30.0 m -141.83 163.15 19.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.063 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -115.47 141.31 48.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.866 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 86.9 t -132.86 116.31 26.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 76.6 t -138.25 124.74 26.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -80.45 132.75 35.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 -72.84 -40.74 65.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 114.42 -27.37 8.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -83.27 -47.27 11.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.846 0.355 . . . . 0.0 110.931 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.28 30.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.529 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.498 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.4 p -144.76 177.78 8.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.498 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.5 m-70 -146.66 132.16 18.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 23.2 m -93.16 141.86 27.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.144 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.484 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 57.8 t -132.85 104.78 7.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.17 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -94.74 139.97 30.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.495 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -159.36 171.54 19.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.863 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 29' ' ' VAL . 29.2 m -147.07 114.97 4.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.567 0.699 . . . . 0.0 111.149 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.495 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.6 Cg_endo -69.73 91.39 0.51 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.346 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.5 t -34.08 -59.64 0.42 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -121.56 158.34 28.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.886 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -77.19 173.67 11.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.07 176.9 14.64 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 86.19 0.58 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.678 2.252 . . . . 0.0 112.387 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.427 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.1 m-85 -83.0 173.59 11.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.5 ttp -149.16 120.83 8.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.0 t -109.43 100.17 10.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.9 t -82.99 145.4 29.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.848 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.3 t -140.52 138.42 36.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.103 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -126.79 172.99 9.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.667 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.5 t80 -160.18 109.47 1.76 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.731 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.0 37.84 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.047 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 67.94 34.18 4.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -144.35 105.07 4.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.59 111.68 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.601 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.0 pt -49.41 153.03 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.683 0.754 . . . . 0.0 111.1 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 3.85 2.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.71 2.273 . . . . 0.0 112.327 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.438 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 19.6 mmm180 -114.08 -2.03 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.862 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.548 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -113.61 153.27 45.86 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.681 0.753 . . . . 0.0 110.849 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.548 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.78 175.83 35.07 Favored 'Cis proline' 0 C--N 1.341 0.151 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.318 0.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.601 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.8 m-85 -116.15 118.07 31.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -78.7 107.24 11.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.903 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 96.1 t -119.26 102.92 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.101 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -83.58 100.42 10.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.8 145.09 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.173 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.6 mt -111.69 154.67 43.88 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.589 0.709 . . . . 0.0 110.958 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.9 Cg_endo -69.66 123.33 10.03 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.67 2.246 . . . . 0.0 112.334 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 103' ' ' PRO . 49.7 m -36.11 -30.82 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.171 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.485 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.8 m-85 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.2 t . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.822 0.344 . . . . 0.0 111.124 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.2 t0 -125.88 99.45 32.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.564 0.697 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.6 Cg_endo -69.81 0.37 5.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.66 2.24 . . . . 0.0 112.386 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.7 p -98.7 9.09 44.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.999 0.428 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -114.18 -8.02 12.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.8 p -84.54 123.5 39.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.215 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.4 mtpp -119.66 167.74 11.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.746 HG22 HG13 ' A' ' 35' ' ' VAL . 37.6 pt -144.09 140.06 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.8 165.92 26.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 133.82 176.11 14.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.41 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.65 -41.44 4.42 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.715 2.277 . . . . 0.0 112.321 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -44.77 -35.44 4.32 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.494 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.439 HD11 HD12 ' A' ' 16' ' ' ILE . 8.2 mt -94.43 -26.6 16.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.897 0.379 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -50.86 163.81 0.92 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.479 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.4 m -86.24 22.91 1.67 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.959 0.409 . . . . 0.0 110.904 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.69 38.05 2.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.582 HG13 ' CD ' ' A' ' 31' ' ' GLN . 78.9 t -89.41 144.3 9.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.558 ' HB2' HG21 ' A' ' 29' ' ' VAL . 65.6 mtt180 -121.63 149.8 42.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.486 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.04 150.16 48.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.6 mtt85 55.35 34.83 23.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.876 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 74' ' ' THR . 73.2 t -127.46 146.98 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.7 tp -68.25 111.6 4.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.582 ' CD ' HG13 ' A' ' 25' ' ' VAL . 58.0 mm-40 -116.66 126.62 53.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.592 ' HB2' HG22 ' A' ' 72' ' ' THR . 14.3 t -144.45 148.43 34.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.481 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -140.86 177.61 7.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.791 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 82.6 m -118.36 141.17 48.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.215 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.746 HG13 HG22 ' A' ' 16' ' ' ILE . 38.2 t -118.09 109.47 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -92.32 98.23 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.1 p -111.71 21.38 16.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.5 p -67.01 -35.4 79.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.839 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -79.16 -15.89 57.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.61 -38.68 47.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.092 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.49 -138.45 9.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.444 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.84 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.8 16.35 16.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.88 0.371 . . . . 0.0 110.956 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.764 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.78 151.64 84.64 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.581 0.705 . . . . 0.0 111.105 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.487 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.1 Cg_endo -69.77 169.27 19.31 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.622 2.215 . . . . 0.0 112.327 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -127.32 135.4 50.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.961 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -120.42 145.42 47.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 49.7 t -137.49 145.93 28.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.108 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -146.38 138.16 24.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.69 ' O ' HD22 ' A' ' 50' ' ' LEU . 84.8 t -115.41 129.15 72.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.035 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.69 HD22 ' O ' ' A' ' 49' ' ' VAL . 3.3 mm? -126.2 119.52 27.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.85 177.77 3.76 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.531 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.435 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 53.7 Cg_endo -69.7 -41.39 4.39 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.649 2.232 . . . . 0.0 112.4 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.435 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -84.05 -33.66 24.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.976 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.31 33.21 0.15 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.739 HD21 ' OE2' ' A' ' 57' ' ' GLU . 11.1 tp -85.52 155.67 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.887 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.469 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 94.3 t -119.33 111.1 31.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.739 ' OE2' HD21 ' A' ' 55' ' ' LEU . 18.3 mm-40 -106.13 143.15 26.35 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.651 0.738 . . . . 0.0 110.876 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.691 2.261 . . . . 0.0 112.34 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 m -139.98 162.83 24.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 47.1 t30 -118.88 143.6 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.936 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 74.0 t -129.51 116.31 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.518 HG23 ' HB ' ' A' ' 70' ' ' THR . 0.1 OUTLIER -134.98 110.77 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.203 179.87 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -72.15 129.05 37.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -72.73 -44.74 61.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.856 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.11 -24.31 10.09 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -85.87 -46.49 10.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.841 0.353 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.7 30.54 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.537 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.527 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.3 p -145.89 177.63 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 111.098 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.527 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.5 m-70 -147.82 131.41 16.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . 0.518 ' HB ' HG23 ' A' ' 62' ' ' VAL . 3.4 m -94.78 137.51 33.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.515 HG13 ' O ' ' A' ' 60' ' ' ASN . 35.6 t -127.04 107.35 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.592 HG22 ' HB2' ' A' ' 32' ' ' SER . 35.1 p -92.68 141.06 28.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.193 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -163.94 161.59 22.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.973 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 29' ' ' VAL . 17.3 m -137.38 117.19 10.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.603 0.716 . . . . 0.0 111.117 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.75 94.59 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.349 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 75' ' ' PRO . 43.0 t -35.88 -54.88 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -125.12 168.94 12.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -85.35 173.68 10.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.33 175.42 14.22 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.465 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 90.13 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.702 2.268 . . . . 0.0 112.364 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -81.06 169.75 17.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.947 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 11.2 ttp -145.31 115.73 7.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.5 t -107.58 97.14 5.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -79.83 142.88 34.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 89.5 t -138.05 142.0 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.084 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.437 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 15.5 tttp -130.49 168.05 17.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.941 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.764 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.7 t80 -154.61 115.99 4.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.944 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.644 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.41 33.27 22.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.115 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.437 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 11.6 m-20 71.04 33.5 2.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -144.4 105.34 4.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.891 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -49.99 114.14 1.02 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.84 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.552 HD11 ' HE2' ' A' ' 97' ' ' PHE . 42.1 pt -54.56 153.52 10.35 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.661 0.743 . . . . 0.0 111.113 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.68 4.33 2.22 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.424 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 53.1 mtp85 -114.5 0.29 13.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.908 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.523 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -115.71 153.37 47.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.684 0.754 . . . . 0.0 110.866 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.73 178.01 26.82 Favored 'Cis proline' 0 C--O 1.232 0.18 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.396 -0.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.642 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.3 m-85 -117.84 116.47 27.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.0 pttm -81.65 108.8 15.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.02 104.14 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -81.35 103.01 10.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.2 t -71.25 144.61 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 77.2 mt -111.88 154.5 44.09 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.583 0.706 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.495 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.4 Cg_endo -69.69 123.84 10.52 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.724 2.283 . . . . 0.0 112.324 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.9 m -34.12 -33.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.193 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.495 ' N ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m-85 . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.775 0.321 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -130.53 96.64 23.44 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.4 Cg_endo -69.76 0.3 5.85 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.663 2.242 . . . . 0.0 112.347 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 30.8 m -98.46 -7.12 29.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -94.23 -5.15 47.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -90.42 135.73 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.152 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 22.8 mtmt -133.42 168.9 17.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 97' ' ' PHE . 42.2 pt -142.9 139.42 27.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.066 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.72 153.67 43.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.32 171.68 17.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -29.14 24.27 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 0.0 112.372 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.79 -29.43 67.37 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.411 HD13 HG13 ' A' ' 16' ' ' ILE . 5.2 mt -97.04 -26.43 15.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.894 0.378 . . . . 0.0 110.965 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.92 168.33 2.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.564 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.8 p -83.86 18.49 1.99 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.21 40.83 2.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.459 HG13 ' CD ' ' A' ' 31' ' ' GLN . 58.3 t -92.96 147.46 5.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.572 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.0 mtm180 -123.03 157.26 33.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.835 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -75.35 149.48 38.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 42.5 mtt180 54.09 30.27 11.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.572 HG21 ' HB2' ' A' ' 26' ' ' ARG . 19.1 t -119.99 144.48 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.178 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.5 tp -67.81 110.12 3.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.584 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 59.6 mm-40 -113.29 126.95 55.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.923 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -143.2 152.53 41.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.5 p90 -146.39 -176.48 5.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 48.0 m -122.23 135.5 54.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.09 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.664 HG13 HG22 ' A' ' 16' ' ' ILE . 40.1 t -113.15 108.75 26.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -91.47 104.04 16.59 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.913 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.0 p -121.4 30.19 6.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.9 t -73.04 -36.61 66.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.853 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 6.4 mmpt? -79.95 -16.95 54.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.859 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.05 -38.64 63.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.042 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.7 -137.25 9.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.577 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.31 18.91 12.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.868 0.366 . . . . 0.0 110.973 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.733 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.35 151.89 83.5 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.71 . . . . 0.0 111.076 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 166.64 26.92 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.673 2.249 . . . . 0.0 112.338 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.466 ' CD2' HG11 ' A' ' 35' ' ' VAL . 15.4 tp -126.08 134.49 51.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -119.4 147.52 44.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 59' ' ' VAL . 65.6 t -137.3 149.77 25.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -152.26 136.85 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.837 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 83' ' ' VAL . 71.9 t -119.43 126.18 75.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.169 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.7 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.6 mm? -123.58 122.9 39.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.6 -179.36 1.66 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.472 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.74 -47.93 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.14 -37.25 61.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.919 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.24 33.38 0.13 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.464 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.3 tp -85.37 147.96 26.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.915 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.4 t -107.87 126.0 64.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.106 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -127.92 140.35 37.93 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.603 0.716 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 168.65 20.95 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.702 2.268 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 47' ' ' VAL . 44.5 t -139.91 149.33 22.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.191 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.639 ' O ' HG13 ' A' ' 71' ' ' VAL . 10.3 t30 -98.67 139.18 34.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.82 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 p -131.94 123.48 51.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.196 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.502 HG23 HD21 ' A' ' 60' ' ' ASN . 59.5 t -141.28 129.43 22.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.174 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.22 132.06 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.84 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -73.23 -48.04 38.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.83 -21.04 10.59 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -90.43 -43.97 9.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.8 32.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.572 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 63.2 p -151.02 177.73 9.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 111.152 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.572 ' CD2' ' C ' ' A' ' 68' ' ' THR . 5.3 m-70 -146.61 131.07 17.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.846 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 26.2 m -90.21 138.41 31.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.196 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 60' ' ' ASN . 47.4 t -130.37 110.37 18.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.171 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 55.7 p -101.04 145.33 28.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.188 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.584 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.0 p90 -164.91 169.06 16.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -146.29 112.6 4.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.586 0.708 . . . . 0.0 111.089 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.466 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.81 94.39 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.665 2.243 . . . . 0.0 112.383 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.7 t -34.23 -59.43 0.44 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -116.3 168.75 9.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 pm0 -89.21 169.37 11.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.86 177.71 15.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 93.9 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.661 2.241 . . . . 0.0 112.393 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 3.3 m-85 -88.28 172.98 9.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 7.5 ttp -144.43 117.13 8.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 49' ' ' VAL . 81.2 t -108.57 95.69 4.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.134 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.7 t -79.72 147.2 32.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.411 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.8 t -142.54 134.27 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.149 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -121.44 168.64 11.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.989 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.688 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.0 t80 -154.9 106.86 2.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.733 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 65.4 42.22 3.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.072 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 62.96 34.83 13.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -146.32 105.05 3.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -51.2 114.93 1.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.822 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.712 HD11 ' HE1' ' A' ' 97' ' ' PHE . 38.1 pt -53.79 153.26 8.58 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.542 0.687 . . . . 0.0 111.198 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.66 5.83 1.51 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.267 . . . . 0.0 112.361 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.552 ' HB2' HD12 ' A' ' 92' ' ' ILE . 12.1 mmm180 -118.49 3.61 11.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.804 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.522 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -118.48 153.26 51.88 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.724 0.773 . . . . 0.0 110.838 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.81 176.68 31.76 Favored 'Cis proline' 0 C--N 1.343 0.243 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.41 -0.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 16' ' ' ILE . 72.8 m-85 -114.86 121.68 43.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.882 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 pttp -80.94 107.71 13.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 57.8 t -119.2 106.43 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.164 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -89.12 99.1 12.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.9 t -65.75 150.69 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 78.1 mt -118.94 154.69 53.19 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.618 0.723 . . . . 0.0 110.932 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.447 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.76 119.08 6.08 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.718 2.279 . . . . 0.0 112.299 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.6 m -39.38 -27.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.447 ' N ' ' O ' ' A' ' 103' ' ' PRO . 4.7 m-85 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.949 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 72.9 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.947 0.403 . . . . 0.0 111.087 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -133.21 98.18 15.76 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.549 0.69 . . . . 0.0 110.863 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.73 -2.02 9.44 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.751 2.301 . . . . 0.0 112.344 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.2 m -100.07 13.87 32.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.827 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -9.03 10.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.79 134.34 27.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.187 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -129.44 174.29 9.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.969 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.822 HD11 ' CE2' ' A' ' 97' ' ' PHE . 27.4 pt -150.01 135.97 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.127 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.3 154.74 44.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.129 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 146.15 178.54 21.67 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.48 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -39.55 6.5 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.711 2.274 . . . . 0.0 112.407 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -47.8 -35.61 12.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.549 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.472 HD13 HG13 ' A' ' 16' ' ' ILE . 9.4 mt -93.48 -27.49 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.88 167.95 1.0 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.1 m -85.57 16.86 3.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.961 0.41 . . . . 0.0 110.91 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.35 40.17 2.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.676 HG13 ' CD ' ' A' ' 31' ' ' GLN . 64.9 t -93.02 139.6 17.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 111.153 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.551 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.74 148.15 45.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.869 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -65.36 154.86 37.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 23.1 mtm180 50.65 41.72 26.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.894 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 27' ' ' ALA . 70.0 t -134.23 151.32 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.2 tp -73.97 111.21 8.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.987 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.676 ' CD ' HG13 ' A' ' 25' ' ' VAL . 65.2 mm-40 -112.01 127.33 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.0 t -141.03 149.98 42.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.559 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.4 p90 -144.62 168.77 19.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.825 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 92.7 m -110.18 130.09 55.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.177 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.584 HG13 HG22 ' A' ' 16' ' ' ILE . 65.2 t -111.41 105.61 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.117 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -87.01 104.72 16.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.775 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 75.7 p -118.72 27.2 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.909 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.9 p -74.22 -37.41 63.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.821 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -73.93 -23.32 59.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.62 -41.28 72.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.092 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.48 -135.19 7.44 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.45 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.548 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.98 19.55 13.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.764 0.316 . . . . 0.0 110.901 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.842 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.65 152.01 80.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.671 0.748 . . . . 0.0 111.047 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 165.94 29.33 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.691 2.26 . . . . 0.0 112.328 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 tp -125.36 136.68 53.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.937 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -121.13 143.4 49.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.33 144.98 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.449 ' HG2' ' CD1' ' A' ' 50' ' ' LEU . 12.7 ttm180 -148.24 144.6 27.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.481 HG12 ' OE1' ' A' ' 57' ' ' GLU . 67.3 t -120.89 130.37 74.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.454 HD13 ' CE ' ' A' ' 82' ' ' MET . 3.8 mp -125.11 134.78 52.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.46 173.88 54.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.444 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.4 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 54.6 Cg_endo -69.72 -44.36 2.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.427 ' CD ' HE22 ' A' ' 77' ' ' GLN . 0.2 OUTLIER -79.21 -35.52 41.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.943 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 138.77 31.32 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.436 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.534 HD23 ' OE2' ' A' ' 57' ' ' GLU . 10.7 tp -91.63 150.11 21.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.1 t -110.62 132.12 59.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.098 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.534 ' OE2' HD23 ' A' ' 55' ' ' LEU . 48.0 mp0 -120.02 142.74 33.95 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.631 0.729 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 167.93 23.1 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.346 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.8 m -144.31 164.79 13.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.155 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.552 ' O ' HG13 ' A' ' 71' ' ' VAL . 58.6 t30 -122.85 142.69 50.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 89.8 t -133.5 103.06 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.2 t -127.96 115.25 38.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.159 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -71.12 135.0 47.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -75.64 -43.09 49.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.22 -26.0 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.487 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -85.66 -40.09 16.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.863 0.363 . . . . 0.0 110.872 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.82 34.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.478 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.2 p -151.47 177.65 10.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.168 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -145.77 131.38 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.842 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 51.9 m -90.84 137.74 32.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.132 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.559 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 40.3 t -133.19 105.72 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.061 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 71.1 p -98.32 142.15 30.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.223 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.564 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 10.0 p90 -156.53 169.89 23.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.964 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.3 m -145.74 110.67 4.48 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.552 0.691 . . . . 0.0 111.233 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.546 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.75 94.52 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.661 2.241 . . . . 0.0 112.372 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 60.6 p -39.38 -27.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . 0.462 ' N ' ' O ' ' A' ' 75' ' ' PRO . 10.4 pt20 -147.74 175.49 10.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.98 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.93 173.28 7.67 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.72 174.76 13.86 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.547 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.71 81.66 0.79 Allowed 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.697 2.265 . . . . 0.0 112.382 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -80.52 147.33 30.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.908 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . 0.454 ' CE ' HD13 ' A' ' 50' ' ' LEU . 3.1 tmm? -117.61 127.09 53.62 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.03 95.3 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 t -76.1 139.92 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.825 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 64.9 t -138.86 129.8 34.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.158 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.426 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 40.4 tttt -121.6 170.52 9.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.842 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.0 t80 -157.09 107.82 2.31 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.69 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.16 41.82 5.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.113 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.426 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 44.0 m-20 63.22 36.07 12.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -146.15 104.97 3.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -53.75 117.34 3.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.87 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.788 HD11 ' HE1' ' A' ' 97' ' ' PHE . 40.3 pt -55.75 153.57 15.8 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.657 0.741 . . . . 0.0 111.113 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.401 ' HD2' ' HB ' ' A' ' 92' ' ' ILE . 53.8 Cg_endo -69.74 6.2 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.727 2.285 . . . . 0.0 112.377 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.503 ' HB2' HD12 ' A' ' 92' ' ' ILE . 15.0 mmm180 -120.59 5.55 10.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.973 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -119.93 153.37 54.96 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.688 0.756 . . . . 0.0 110.781 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.71 172.95 46.4 Favored 'Cis proline' 0 C--N 1.342 0.21 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.3 -0.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.822 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.1 m-85 -110.43 139.82 45.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.824 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 34.0 mttm -100.29 107.3 19.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.1 t -117.06 101.54 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.087 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 39.9 tttp -81.0 97.78 7.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 49.4 t -69.61 144.14 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 42.1 mt -109.56 155.17 41.78 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.573 0.701 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.3 Cg_endo -69.82 123.22 9.86 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.737 2.291 . . . . 0.0 112.368 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.434 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -33.87 -35.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.182 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 103' ' ' PRO . 20.0 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 76.8 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.827 0.346 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 13.7 m-20 -129.43 96.72 26.88 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.648 0.737 . . . . 0.0 110.803 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.76 -1.5 8.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.318 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.8 m -100.39 12.29 37.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.5 mmpt? -116.54 -7.41 11.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -85.85 127.07 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.214 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -121.68 173.28 7.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.913 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.851 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.8 pt -148.47 134.38 11.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.07 152.17 45.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.124 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 149.08 176.58 22.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.495 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -38.65 7.55 Favored 'Trans proline' 0 N--CA 1.466 -0.118 0 C-N-CA 122.709 2.273 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.92 -24.39 13.8 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.554 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.445 HD13 HG13 ' A' ' 16' ' ' ILE . 6.5 mt -105.77 -18.23 14.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.949 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.62 177.85 3.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 97.9 p -92.31 15.0 14.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.36 . . . . 0.0 110.854 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.03 42.88 1.78 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.481 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.495 HG13 ' NE2' ' A' ' 31' ' ' GLN . 75.9 t -96.46 141.13 15.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.884 0.373 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.509 ' HB2' HG21 ' A' ' 29' ' ' VAL . 88.7 mtt180 -121.11 148.84 43.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.45 150.18 48.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 58.7 mtt-85 53.98 41.09 32.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.878 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.6 t -132.85 143.59 39.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.078 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.1 tp -66.82 114.03 5.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.495 ' NE2' HG13 ' A' ' 25' ' ' VAL . 53.7 mm-40 -116.49 134.7 54.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.858 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 28.9 t -146.94 148.98 32.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.492 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 2.5 p90 -142.73 173.14 11.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 73.8 m -112.79 133.32 54.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.192 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.682 HG13 HG22 ' A' ' 16' ' ' ILE . 41.0 t -112.95 106.75 21.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.141 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -88.5 99.41 12.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.502 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.5 p -112.99 26.08 10.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.848 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.4 p -72.62 -38.14 67.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.834 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -76.43 -17.11 59.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.952 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.39 -38.36 41.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.42 -138.79 9.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.574 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.4 20.68 12.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.798 0.332 . . . . 0.0 110.913 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.784 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.05 151.54 76.02 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.567 0.698 . . . . 0.0 111.085 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 166.56 27.19 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.292 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.473 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.4 tp -125.72 135.86 52.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.892 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -116.05 142.33 46.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.844 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.575 HG12 HG11 ' A' ' 59' ' ' VAL . 60.9 t -130.0 142.3 44.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.433 ' HG2' ' CD2' ' A' ' 50' ' ' LEU . 20.2 ttm180 -148.16 142.46 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.474 ' C ' HD22 ' A' ' 50' ' ' LEU . 49.0 t -121.2 133.51 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.162 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.474 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.5 mm? -124.78 133.19 53.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.928 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.13 170.26 53.56 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.504 179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -42.26 3.54 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -82.51 -34.85 27.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.13 31.65 0.19 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.428 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.9 tp -91.7 146.01 24.12 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.97 125.88 67.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.154 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -118.86 141.81 30.76 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.621 0.724 . . . . 0.0 110.932 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 171.5 14.44 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.662 2.241 . . . . 0.0 112.336 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.575 HG11 HG12 ' A' ' 47' ' ' VAL . 21.0 m -142.29 165.77 16.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.502 ' O ' HG13 ' A' ' 71' ' ' VAL . 34.6 t30 -124.24 143.3 50.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.872 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.472 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.4 p -133.47 118.52 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.116 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.44 HG23 ' ND2' ' A' ' 60' ' ' ASN . 60.1 t -134.91 121.62 34.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.203 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -75.04 137.2 41.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.794 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -80.64 -40.97 24.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.1 -29.73 7.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -82.79 -47.12 12.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.786 0.327 . . . . 0.0 110.87 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.38 30.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.513 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.4 p -144.14 177.34 8.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.826 0.346 . . . . 0.0 111.044 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.513 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.0 m-70 -146.07 127.63 15.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 97.2 m -88.38 138.94 30.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.179 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 60' ' ' ASN . 64.4 t -129.75 109.81 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.146 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -97.68 140.2 32.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.136 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.459 ' CE2' ' HB2' ' A' ' 31' ' ' GLN . 5.9 p90 -159.72 170.69 20.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.93 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 m -146.02 116.15 4.79 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 111.147 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.419 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.2 Cg_endo -69.74 92.97 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.683 2.256 . . . . 0.0 112.36 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 m -35.92 -51.59 0.71 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.848 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -131.78 163.17 28.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.6 170.35 16.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.81 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.77 172.66 13.28 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 84.2 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.37 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -76.54 173.57 11.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.1 ttp -144.95 114.37 7.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.803 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -103.51 96.91 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.125 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.1 t -80.3 139.91 36.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.934 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.473 ' CG1' HD11 ' A' ' 45' ' ' LEU . 51.5 t -136.11 140.59 43.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.453 ' HE3' ' N ' ' A' ' 90' ' ' GLU . 18.2 tttp -128.61 169.22 14.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.919 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.739 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.0 t80 -153.86 107.7 3.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.959 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.784 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.65 43.02 5.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.092 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.445 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 32.8 m-20 62.65 36.95 13.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.453 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 14.9 mt-10 -147.58 105.05 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -52.58 118.32 3.53 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.726 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.2 pt -57.75 153.07 33.29 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.646 0.736 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 4.34 2.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.711 2.274 . . . . 0.0 112.362 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HB2' HD12 ' A' ' 92' ' ' ILE . 73.9 mtp85 -116.94 4.93 12.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -117.8 153.72 50.91 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.722 0.772 . . . . 0.0 110.827 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.71 178.36 25.6 Favored 'Cis proline' 0 C--N 1.342 0.211 0 C-N-CA 122.743 -1.774 . . . . 0.0 112.383 -0.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.851 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.0 m-85 -115.56 119.92 37.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 ptpt -79.7 100.0 7.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 90.9 t -108.35 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.0 ttpm? -83.2 98.61 9.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.934 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.35 145.34 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.121 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 82.0 mt -110.35 154.3 43.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.614 0.721 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.71 124.22 10.89 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.707 2.271 . . . . 0.0 112.289 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.423 ' C ' ' O ' ' A' ' 103' ' ' PRO . 77.9 m -34.73 -32.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 67.1 m-85 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.9 t . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.883 0.373 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 15.5 m-20 -125.76 98.11 34.68 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.546 0.689 . . . . 0.0 110.851 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.7 Cg_endo -69.77 -1.87 9.22 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.689 2.26 . . . . 0.0 112.321 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.4 ' HA ' ' CD ' ' A' ' 93' ' ' PRO . 53.3 p -101.66 14.48 31.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.893 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.432 ' NZ ' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -117.59 -9.62 10.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.883 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.79 134.66 27.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HD3' ' CZ ' ' A' ' 94' ' ' ARG . 14.0 mmmt -127.67 173.27 10.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.519 HG22 HG13 ' A' ' 35' ' ' VAL . 26.5 pt -148.55 134.82 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.166 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.63 130.13 22.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.181 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.84 170.04 34.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -35.9 11.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.66 2.24 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.35 -42.77 50.72 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.446 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.469 HD11 ' CD2' ' A' ' 33' ' ' PHE . 5.1 mt -80.78 -20.03 43.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.906 0.384 . . . . 0.0 110.929 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.81 174.21 0.48 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 91.2 p -89.47 -13.89 36.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.932 0.396 . . . . 0.0 110.833 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -90.43 52.14 3.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.469 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 79.4 t -99.94 143.61 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.852 0.358 . . . . 0.0 111.09 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.689 ' HB2' HG21 ' A' ' 29' ' ' VAL . 48.6 mtt85 -118.43 148.59 42.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.928 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.563 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.22 152.56 45.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.159 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 54.45 35.15 22.54 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.689 HG21 ' HB2' ' A' ' 26' ' ' ARG . 98.5 t -127.1 149.47 32.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.068 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -71.87 112.01 7.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.942 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.536 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 40.5 mm-40 -116.28 126.79 54.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.8 t -143.46 163.0 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.553 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 2.0 p90 -155.07 -176.96 6.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.1 m -120.87 129.79 53.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.106 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.519 HG13 HG22 ' A' ' 16' ' ' ILE . 55.5 t -108.68 105.74 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.069 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -86.54 98.91 11.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.842 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 87' ' ' TYR . 97.5 p -113.18 31.19 6.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.1 t -73.48 -40.99 63.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -73.87 -24.79 59.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.933 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.727 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.1 -32.86 72.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.103 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.573 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 126.26 -147.47 16.75 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.475 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.845 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -106.64 18.41 21.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.803 0.335 . . . . 0.0 110.92 -179.914 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.746 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.21 151.61 85.86 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.583 0.706 . . . . 0.0 111.078 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 167.49 24.28 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.681 2.254 . . . . 0.0 112.297 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 tp -122.96 144.49 49.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -130.25 143.79 50.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.901 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.513 ' CG1' HG11 ' A' ' 59' ' ' VAL . 46.1 t -136.71 153.74 30.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.416 ' N ' HG12 ' A' ' 47' ' ' VAL . 39.2 mtt180 -155.71 145.19 21.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.4 t -125.72 125.96 69.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.156 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.39 126.54 49.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.65 176.98 23.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.471 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -49.24 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.641 2.227 . . . . 0.0 112.372 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -72.56 -37.24 68.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.98 37.37 0.11 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.444 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.41 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 8.7 tp -91.32 150.65 21.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.877 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.41 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.5 t -114.95 126.72 72.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -127.16 141.63 41.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.653 0.74 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.84 168.03 22.84 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.704 2.27 . . . . 0.0 112.327 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' CG1' ' A' ' 47' ' ' VAL . 44.0 t -138.41 149.8 24.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.5 t30 -96.37 137.87 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.565 ' O ' HG13 ' A' ' 61' ' ' VAL . 13.3 p -133.51 114.36 20.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 84.9 t -135.56 123.56 37.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -77.01 134.63 38.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -76.88 -42.06 41.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.57 9.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.548 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.408 ' CG ' ' N ' ' A' ' 67' ' ' GLY . 0.6 OUTLIER -83.75 -46.96 11.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 0.0 110.891 -179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.408 ' N ' ' CG ' ' A' ' 66' ' ' ASP . . . 164.03 30.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.444 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.5 p -144.54 177.77 8.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.767 0.318 . . . . 0.0 111.155 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.6 m-70 -147.19 124.92 11.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.1 m -83.24 139.7 32.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.159 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.553 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 60.5 t -131.45 106.27 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.4 p -100.18 145.49 27.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -165.45 174.32 10.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.2 m -152.05 114.11 2.92 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 121.53 0.681 . . . . 0.0 111.123 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 94.38 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 0.0 112.357 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.7 m -38.04 -49.64 1.3 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -127.13 158.26 37.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -78.54 170.52 16.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.52 175.09 13.88 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.465 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 83.24 0.7 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.646 2.231 . . . . 0.0 112.315 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -77.99 171.84 14.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 19.2 ttp -143.74 119.03 10.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 91.6 t -104.21 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.0 t -84.22 138.14 33.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 91.1 t -133.86 141.42 44.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.14 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.412 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 28.3 tttt -130.51 168.42 17.08 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.746 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.6 t80 -153.54 108.7 3.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.711 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.88 42.58 7.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.412 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.2 m-20 63.18 35.31 12.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -145.63 104.99 3.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -51.75 121.79 7.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.728 HD11 ' CE2' ' A' ' 97' ' ' PHE . 33.5 pt -59.74 153.25 53.71 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.673 0.749 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.4 ' CD ' ' HA ' ' A' ' 12' ' ' SER . 54.1 Cg_endo -69.8 6.02 1.49 Allowed 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.565 2.176 . . . . 0.0 112.419 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.541 ' HB2' HD12 ' A' ' 92' ' ' ILE . 11.9 mtt85 -121.55 9.57 10.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.41 153.54 58.89 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.747 0.784 . . . . 0.0 110.832 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.8 Cg_endo -69.88 176.78 31.57 Favored 'Cis proline' 0 C--N 1.343 0.253 0 C-N-CA 122.6 -1.834 . . . . 0.0 112.325 0.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 92' ' ' ILE . 84.8 m-85 -113.99 132.02 56.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.4 ptmm? -87.28 111.65 21.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.2 t -123.49 101.66 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -84.99 100.05 11.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 81.5 t -71.23 148.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.132 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 60.4 mt -113.86 155.5 45.12 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 0.0 110.908 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.6 Cg_endo -69.71 121.63 8.32 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.69 2.26 . . . . 0.0 112.378 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 103' ' ' PRO . 99.5 m -33.96 -34.94 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.139 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.468 ' N ' ' O ' ' A' ' 103' ' ' PRO . 26.7 m-85 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.5 t . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.828 0.347 . . . . 0.0 111.124 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -129.88 95.42 28.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 0.0 110.878 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 -0.79 7.47 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.668 2.245 . . . . 0.0 112.385 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.8 m -98.7 2.1 46.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.819 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -108.48 -7.16 15.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.416 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -88.86 123.93 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.157 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -123.21 174.46 7.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.757 HG22 HG13 ' A' ' 35' ' ' VAL . 20.5 pt -145.59 133.45 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.09 135.69 29.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.99 170.46 35.2 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.444 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -31.64 20.27 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.349 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.89 -42.6 98.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.661 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.8 mt -77.39 -23.72 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.82 173.85 0.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.445 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.5 m -87.16 -11.84 48.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.96 0.409 . . . . 0.0 110.859 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.28 45.33 3.26 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.432 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -93.19 146.49 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 0.0 111.138 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.781 ' HB2' HG21 ' A' ' 29' ' ' VAL . 28.7 mtm-85 -121.27 151.32 40.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.839 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.479 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -70.72 147.07 49.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.063 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.0 mtm-85 56.32 33.68 22.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.781 HG21 ' HB2' ' A' ' 26' ' ' ARG . 85.8 t -123.74 143.8 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.2 tp -68.0 111.05 4.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.968 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.435 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 52.3 mm-40 -114.13 130.45 56.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 38.6 t -145.48 148.76 33.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.867 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.661 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.9 p90 -140.66 -178.22 5.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 98.8 m -119.92 129.13 54.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.757 HG13 HG22 ' A' ' 16' ' ' ILE . 55.4 t -108.94 106.11 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.144 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -87.57 107.19 18.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 84.5 p -123.12 22.09 9.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.877 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.3 t -66.78 -35.96 81.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.886 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.4 mmtm -83.1 -8.64 59.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -82.91 -34.32 26.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.149 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.15 -135.48 8.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.514 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.51 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -122.77 22.1 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.857 0.361 . . . . 0.0 110.945 -179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.819 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.25 151.71 75.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.579 0.704 . . . . 0.0 111.071 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.441 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.3 Cg_endo -69.77 166.52 27.31 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.39 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.4 tp -124.26 134.88 53.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -119.41 147.06 44.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.3 t -136.97 150.38 26.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.149 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 18.6 mtt-85 -154.23 133.37 12.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.619 ' C ' HD22 ' A' ' 50' ' ' LEU . 62.0 t -112.91 128.61 69.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.141 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.619 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -124.44 127.45 47.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.971 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.72 179.71 37.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.479 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.517 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.84 -37.95 8.28 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.669 2.246 . . . . 0.0 112.316 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.62 -31.27 21.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.913 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.06 30.19 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.8 tp -81.75 147.51 29.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.936 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.3 t -110.41 105.63 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.128 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -96.46 144.91 28.66 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.671 0.748 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 168.12 22.52 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.717 2.278 . . . . 0.0 112.317 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.5 m -142.75 167.45 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.426 ' ND2' ' C ' ' A' ' 60' ' ' ASN . 0.4 OUTLIER -125.05 141.74 51.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.5 t -132.84 111.03 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.169 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 90.3 t -138.93 115.42 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.146 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.523 ' OD2' ' CE1' ' A' ' 69' ' ' HIS . 10.2 t70 -72.51 139.9 47.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.884 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -77.68 -43.25 31.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.46 ' N ' ' OD1' ' A' ' 63' ' ' ASP . . . 115.38 -20.07 14.19 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.473 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -91.61 -41.73 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.876 0.37 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.13 33.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.433 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.508 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 71.0 p -149.34 177.33 9.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.796 0.331 . . . . 0.0 111.158 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.523 ' CE1' ' OD2' ' A' ' 63' ' ' ASP . 12.5 m-70 -146.94 125.06 12.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 34.5 m -84.53 140.4 31.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.083 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.539 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 67.3 t -131.03 103.78 8.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.139 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.0 p -93.44 139.29 30.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.2 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.498 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.1 p90 -159.9 169.15 24.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.927 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -147.14 115.66 4.32 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.631 0.729 . . . . 0.0 111.104 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.498 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.74 99.01 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.255 . . . . 0.0 112.331 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 75' ' ' PRO . 32.5 t -35.6 -54.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.859 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -128.77 177.55 6.98 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.18 166.35 14.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.99 173.14 13.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.555 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 92.49 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.366 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.517 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.3 m-85 -92.0 151.97 20.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . 0.455 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.7 tmm? -119.91 129.19 54.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.873 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.45 95.84 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.159 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -79.24 139.06 38.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 61.5 t -136.92 134.22 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.425 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 42.7 tttt -123.25 167.18 14.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.819 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 10.9 t80 -154.5 105.55 2.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.808 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.8 42.96 4.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.09 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.425 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 13.2 m-20 63.35 32.94 14.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -142.69 105.11 4.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -56.98 111.79 1.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.718 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.3 pt -49.5 152.86 2.12 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 111.097 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 4.11 2.41 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.651 2.234 . . . . 0.0 112.365 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 49.7 mtt85 -115.04 -1.28 13.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -113.37 153.83 45.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.672 0.748 . . . . 0.0 110.863 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.3 Cg_endo -69.74 177.96 27.02 Favored 'Cis proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.351 -0.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.724 ' CE2' HD11 ' A' ' 16' ' ' ILE . 79.9 m-85 -116.93 140.83 49.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -100.2 111.46 23.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -121.52 103.45 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.078 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.3 tttp -81.91 103.25 11.44 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.61 143.14 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.07 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 74.7 mt -111.83 155.76 42.69 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.557 0.694 . . . . 0.0 110.964 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.493 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.85 123.54 10.18 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.656 2.237 . . . . 0.0 112.334 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 54.4 m -39.02 -25.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.493 ' N ' ' O ' ' A' ' 103' ' ' PRO . 10.3 m-85 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.863 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.5 t . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.843 0.354 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 17.9 m-20 -131.73 97.62 18.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.611 0.72 . . . . 0.0 110.819 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.2 Cg_endo -69.76 -1.75 9.0 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.645 2.23 . . . . 0.0 112.365 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -101.12 14.04 33.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.8 mmpt? -117.83 -8.38 10.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -84.31 132.4 31.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.119 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.2 mtmt -126.49 169.48 12.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.885 HD11 ' CE2' ' A' ' 97' ' ' PHE . 37.3 pt -145.74 133.81 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.144 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.65 146.18 35.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 160.13 172.15 26.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -33.41 16.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.674 2.249 . . . . 0.0 112.366 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.431 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -57.45 -42.05 93.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.474 HD11 ' CD2' ' A' ' 33' ' ' PHE . 8.6 mt -80.43 -25.87 38.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.17 176.63 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.479 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.7 t -89.46 -16.58 30.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.976 0.417 . . . . 0.0 110.917 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.82 47.79 3.86 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.431 HG21 ' O ' ' A' ' 20' ' ' GLY . 66.1 t -99.81 141.5 16.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.784 0.326 . . . . 0.0 111.156 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -117.64 151.54 37.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.67 152.41 42.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 55.32 40.2 31.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.27 144.37 34.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 14.7 tp -66.4 115.17 6.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 47.6 mm-40 -120.32 127.06 52.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.867 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . 0.473 ' HB2' HG22 ' A' ' 72' ' ' THR . 32.5 t -141.45 149.63 41.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.839 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.474 ' CD2' HD11 ' A' ' 21' ' ' LEU . 3.5 p90 -142.18 176.55 8.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 83.9 m -114.21 136.96 52.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.725 HG13 HG22 ' A' ' 16' ' ' ILE . 41.5 t -115.16 105.33 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.158 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -87.74 98.47 11.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.903 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 95.5 p -114.4 30.36 7.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.928 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 87.9 p -76.68 -34.68 58.21 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -76.6 -22.01 54.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.56 -41.34 60.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.075 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.593 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 138.34 -147.04 18.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.482 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.838 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -107.18 17.01 23.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.845 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.39 151.44 85.42 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.607 0.718 . . . . 0.0 111.112 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 167.56 24.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.26 . . . . 0.0 112.362 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.491 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.1 tp -125.88 139.72 53.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.961 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 85' ' ' VAL . 1.9 mp0 -117.01 146.69 42.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.623 HG12 HG11 ' A' ' 59' ' ' VAL . 58.4 t -139.51 134.22 39.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.137 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -140.79 141.12 34.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.859 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.667 ' C ' HD22 ' A' ' 50' ' ' LEU . 98.9 t -123.32 127.49 74.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.056 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.667 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -125.11 124.57 42.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.77 167.87 47.49 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -47.78 0.86 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -71.44 -38.63 71.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.931 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.28 34.93 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.501 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.446 HD21 ' OE2' ' A' ' 57' ' ' GLU . 8.4 tp -94.44 149.21 21.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.87 0.367 . . . . 0.0 110.903 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.7 t -115.64 116.25 51.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.146 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.446 ' OE2' HD21 ' A' ' 55' ' ' LEU . 30.2 mm-40 -115.63 139.32 24.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.719 0.771 . . . . 0.0 110.851 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 174.74 9.03 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.771 2.314 . . . . 0.0 112.381 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.623 HG11 HG12 ' A' ' 47' ' ' VAL . 13.7 m -140.34 162.13 24.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.079 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' O ' HG13 ' A' ' 71' ' ' VAL . 33.9 t30 -117.59 138.54 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.5 p -131.68 119.93 43.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.072 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 92.2 t -138.81 126.32 26.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -79.09 133.29 36.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.813 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -75.29 -46.51 33.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.884 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.15 -23.81 9.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.444 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.4 -44.15 10.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.891 0.376 . . . . 0.0 110.873 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.6 33.94 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.417 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.2 p -150.93 177.59 9.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.329 . . . . 0.0 111.144 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.4 m-70 -145.99 126.62 14.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 35.0 m -86.04 142.49 28.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.111 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.404 HG13 ' O ' ' A' ' 60' ' ' ASN . 95.4 t -132.48 108.47 13.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.092 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.473 HG22 ' HB2' ' A' ' 32' ' ' SER . 27.8 p -97.6 142.31 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.089 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 8.7 p90 -161.49 175.75 11.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.946 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -150.42 114.27 3.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.639 0.733 . . . . 0.0 111.137 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 89.09 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.697 2.265 . . . . 0.0 112.329 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 75' ' ' PRO . 44.4 t -35.67 -53.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -122.44 166.64 14.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.953 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -89.69 166.48 13.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.84 179.59 16.12 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.71 86.45 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.691 2.261 . . . . 0.0 112.345 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -76.93 171.66 14.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.1 ttp -143.8 113.25 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 49' ' ' VAL . 85.1 t -109.06 96.11 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.084 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 2.0 m -81.46 145.52 30.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.491 ' CG1' HD11 ' A' ' 45' ' ' LEU . 88.7 t -139.29 138.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.094 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -125.92 170.19 11.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.923 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.845 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.2 t80 -155.24 110.69 3.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.962 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.687 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 61.63 39.77 14.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.115 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 65.52 35.52 7.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.828 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -145.49 105.02 3.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -53.44 118.01 3.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.684 HD11 ' HE1' ' A' ' 97' ' ' PHE . 47.0 pt -57.18 153.43 25.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.567 0.698 . . . . 0.0 111.163 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 5.15 1.82 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.665 2.244 . . . . 0.0 112.354 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 75.8 mtt85 -118.49 6.32 11.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.54 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -119.8 154.07 54.93 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.612 0.72 . . . . 0.0 110.835 -179.803 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.76 178.86 24.0 Favored 'Cis proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.717 -1.784 . . . . 0.0 112.318 0.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.885 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.7 m-85 -115.5 126.56 54.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.4 ptmt -90.94 107.42 19.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.9 t -117.67 107.82 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.13 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -84.62 97.64 9.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.8 t -69.19 147.39 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.134 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 61.6 mt -112.24 155.51 43.45 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.641 0.734 . . . . 0.0 110.949 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.68 123.93 10.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.723 2.282 . . . . 0.0 112.31 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 103' ' ' PRO . 59.6 m -34.61 -32.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.192 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.488 ' N ' ' O ' ' A' ' 103' ' ' PRO . 15.6 m-85 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.964 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.885 0.374 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.407 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.1 m-20 -130.29 96.21 25.4 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.63 0.729 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.9 Cg_endo -69.74 3.11 2.95 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 50.3 m -102.77 -0.29 31.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.0 mmpt? -103.94 -8.82 19.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -85.79 128.18 39.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 15' ' ' LYS . 1.2 mppt? -126.83 171.15 11.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.873 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 35' ' ' VAL . 18.2 pt -144.08 135.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.99 126.58 17.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.3 171.38 38.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -32.58 18.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.637 2.225 . . . . 0.0 112.365 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.9 -36.05 65.41 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.618 HD13 HG13 ' A' ' 16' ' ' ILE . 4.7 mt -87.04 -15.5 38.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.851 0.358 . . . . 0.0 110.901 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.67 178.65 3.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.513 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 90.0 p -92.48 -11.77 33.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.96 46.03 3.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.455 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 97.8 t -95.69 142.21 14.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 111.092 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -118.55 153.65 33.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.845 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.51 145.36 47.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.072 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.6 mtt180 59.59 42.23 17.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.95 148.35 30.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.126 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -70.5 112.31 6.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.513 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.1 mm-40 -117.43 128.95 55.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.4 t -148.41 161.16 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.494 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -151.85 -176.08 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.8 m -117.86 128.79 55.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.167 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 16' ' ' ILE . 86.2 t -109.34 107.98 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.152 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -88.79 103.93 16.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.943 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.2 p -122.61 27.24 7.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 28.1 t -68.82 -37.32 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.872 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -81.07 -19.87 42.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.436 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.71 -37.5 76.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 131.58 -143.12 14.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.449 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.551 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -113.69 19.0 17.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.827 0.346 . . . . 0.0 110.875 -179.906 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.721 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.15 151.37 81.42 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.562 0.696 . . . . 0.0 111.153 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.452 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.6 Cg_endo -69.72 167.1 25.37 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.501 HD22 HG11 ' A' ' 35' ' ' VAL . 11.0 tp -127.29 130.97 50.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.901 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -118.57 143.91 46.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.826 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 85' ' ' VAL . 81.8 t -137.44 124.56 29.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.152 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -115.07 149.04 38.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.503 HG23 ' CG2' ' A' ' 59' ' ' VAL . 48.6 t -123.7 120.59 60.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.211 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 50' ' ' LEU . 2.5 mm? -96.68 175.21 6.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.34 159.73 24.17 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.478 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -41.75 4.06 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.689 2.26 . . . . 0.0 112.397 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.22 -14.9 34.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 114.58 36.58 1.28 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.439 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.563 HD23 ' OE2' ' A' ' 57' ' ' GLU . 11.4 tp -100.27 146.55 26.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 0.0 110.939 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 37.8 t -116.21 123.76 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.204 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.563 ' OE2' HD23 ' A' ' 55' ' ' LEU . 27.1 mp0 -117.07 140.62 27.29 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.637 0.732 . . . . 0.0 110.853 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 176.96 6.11 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.659 2.239 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.539 HG12 ' N ' ' A' ' 60' ' ' ASN . 61.8 t -144.29 160.16 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.152 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.539 ' N ' HG12 ' A' ' 59' ' ' VAL . 20.5 t30 -106.79 138.3 43.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 95.9 t -132.77 113.31 20.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 67.1 t -141.15 125.37 17.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -75.15 142.83 43.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -80.24 -43.2 21.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.5 -20.91 13.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.454 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -92.99 -39.44 11.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.887 0.375 . . . . 0.0 110.842 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.43 34.48 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.503 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.4 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 67.9 p -151.74 176.82 11.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.819 0.342 . . . . 0.0 111.146 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.4 ' CD2' ' C ' ' A' ' 68' ' ' THR . 18.4 m-70 -142.96 129.7 20.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.3 m -86.76 137.71 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.494 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 33.1 t -130.11 101.51 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 64.3 p -95.31 144.32 25.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.166 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.491 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 3.9 p90 -163.88 168.32 19.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -146.09 115.99 4.74 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.607 0.718 . . . . 0.0 111.161 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.491 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.0 Cg_endo -69.76 93.42 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.658 2.239 . . . . 0.0 112.357 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 t -34.77 -58.85 0.5 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -120.87 168.76 11.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -86.53 170.24 12.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.47 178.16 15.22 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 93.71 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.705 2.27 . . . . 0.0 112.352 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -94.91 171.55 8.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 ttp -147.72 120.26 8.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.21 96.49 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.8 t -78.58 150.46 32.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 47' ' ' VAL . 86.2 t -140.86 133.77 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.077 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 39.7 tttt -125.02 170.0 11.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.5 t80 -157.41 112.81 2.8 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.721 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.49 35.57 22.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.141 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 71.4 30.73 2.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -139.16 105.82 5.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.926 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -56.69 112.24 1.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.621 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.5 pt -50.46 152.73 3.04 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.641 0.734 . . . . 0.0 111.141 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 4.27 2.33 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.55 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.9 mmm180 -114.85 -1.26 13.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.805 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -113.51 154.27 45.56 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.607 0.717 . . . . 0.0 110.863 -179.745 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.1 Cg_endo -69.84 179.67 21.81 Favored 'Cis proline' 0 C--O 1.232 0.191 0 C-N-CA 122.646 -1.814 . . . . 0.0 112.299 0.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.621 ' HE2' HD11 ' A' ' 92' ' ' ILE . 85.9 m-85 -120.87 119.54 32.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.63 116.23 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.51 102.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -85.18 102.31 13.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.39 147.21 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.174 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.2 mt -117.54 154.81 50.76 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.604 0.716 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 123.81 10.46 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.716 2.277 . . . . 0.0 112.338 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.3 m -39.6 -30.33 0.07 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.139 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 -179.885 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.3 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.843 0.354 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.03 97.08 18.87 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.905 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 -2.05 9.54 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.719 2.279 . . . . 0.0 112.295 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 44.5 p -101.71 17.68 22.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.894 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 mmpt? -121.05 -7.37 9.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.881 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -84.66 128.49 38.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.16 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.6 mtpt -124.28 168.08 13.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.936 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.743 HG22 HG13 ' A' ' 35' ' ' VAL . 13.1 pt -144.83 134.79 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.173 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.07 130.58 22.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.041 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.64 168.82 35.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -32.09 19.18 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.298 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.4 -43.78 84.99 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.528 HD13 HG13 ' A' ' 16' ' ' ILE . 4.4 mt -78.33 -26.23 46.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 110.922 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -49.48 172.68 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.487 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.5 m -86.35 -18.62 31.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.822 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -82.83 45.46 3.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.519 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 ' CD ' ' A' ' 31' ' ' GLN . 43.9 t -94.95 142.5 13.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.871 0.367 . . . . 0.0 111.102 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.835 ' HB2' HG21 ' A' ' 29' ' ' VAL . 49.7 mtm180 -117.79 160.01 22.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.576 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -78.2 149.58 33.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.091 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 51.6 mtm-85 55.63 32.04 18.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.85 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.835 HG21 ' HB2' ' A' ' 26' ' ' ARG . 61.4 t -121.48 140.02 46.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.11 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.7 tp -65.8 110.84 2.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 54.7 mm-40 -113.12 133.12 55.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 22.1 t -146.37 154.35 41.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.544 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.1 p90 -148.13 -178.49 6.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.878 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.5 m -122.22 132.02 54.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.174 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.743 HG13 HG22 ' A' ' 16' ' ' ILE . 45.3 t -112.07 105.12 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -86.07 98.22 10.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.474 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 95.6 p -113.03 25.33 11.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.8 t -72.57 -37.49 68.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -74.39 -20.78 59.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.99 -38.67 64.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.063 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.58 -136.49 8.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.573 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.53 20.0 13.12 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.759 0.314 . . . . 0.0 110.839 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.747 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.99 151.67 82.02 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.556 0.693 . . . . 0.0 111.091 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 166.73 26.6 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.381 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -124.72 135.13 52.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -116.9 145.86 43.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.941 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 59' ' ' VAL . 60.2 t -134.18 147.68 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.125 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -152.07 133.29 14.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.687 HG23 ' CG2' ' A' ' 59' ' ' VAL . 87.6 t -116.92 124.98 73.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.623 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.2 mm? -123.65 121.67 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.946 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.21 172.83 8.81 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.487 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.71 -48.44 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.707 2.271 . . . . 0.0 112.373 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -71.83 -39.2 69.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.84 32.79 0.12 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.506 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.457 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 9.1 tp -91.3 153.32 20.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.807 0.336 . . . . 0.0 110.92 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.457 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.8 t -115.37 130.08 70.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.068 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -133.12 140.85 38.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.699 0.761 . . . . 0.0 110.869 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 170.68 15.95 Favored 'Trans proline' 0 C--N 1.343 0.247 0 C-N-CA 122.617 2.211 . . . . 0.0 112.419 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 47' ' ' VAL . 67.2 t -141.52 154.66 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.721 ' O ' HG13 ' A' ' 71' ' ' VAL . 1.2 t30 -100.35 137.69 38.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.599 ' O ' HG13 ' A' ' 61' ' ' VAL . 10.6 p -133.54 116.55 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 82.3 t -138.31 130.29 38.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.134 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -82.3 140.48 33.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -79.95 -45.33 18.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.09 -25.22 8.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -88.11 -41.63 12.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.877 0.37 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.96 34.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 62.3 p -149.35 177.5 9.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.139 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.6 m-70 -145.92 123.73 11.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 65.7 m -85.23 136.47 33.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.166 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.721 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.6 t -129.09 112.71 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.4 p -103.93 146.72 28.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.9 p90 -165.79 177.44 7.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.986 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.1 m -154.31 113.74 2.47 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.551 0.691 . . . . 0.0 111.109 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.2 Cg_endo -69.82 93.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.642 2.228 . . . . 0.0 112.333 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 75' ' ' PRO . 31.2 t -34.14 -59.78 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -116.35 167.81 10.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.937 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -83.76 166.26 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.836 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.78 169.31 12.32 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.98 91.24 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.605 2.203 . . . . 0.0 112.276 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.415 ' CD1' ' HD3' ' A' ' 52' ' ' PRO . 4.3 m-85 -82.97 172.06 13.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 17.6 ttp -140.74 118.72 11.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.846 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 49' ' ' VAL . 71.8 t -110.26 96.88 5.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.178 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.3 m -81.6 145.08 30.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.924 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 98.0 t -138.75 137.29 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.108 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 43.1 tttt -123.22 169.1 11.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.899 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.747 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.6 t80 -155.59 111.46 3.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.666 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.56 37.9 12.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.036 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.418 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 5.6 m-20 66.4 35.34 5.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.817 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -145.78 104.99 3.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -52.26 113.0 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.622 HD11 ' CE2' ' A' ' 97' ' ' PHE . 45.6 pt -51.37 153.14 3.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.604 0.716 . . . . 0.0 111.179 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 4.89 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.696 2.264 . . . . 0.0 112.326 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.508 ' HB2' HD12 ' A' ' 92' ' ' ILE . 20.1 mmt180 -116.98 1.54 12.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.841 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.538 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.09 154.34 48.51 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.661 0.743 . . . . 0.0 110.883 -179.798 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.2 Cg_endo -69.78 177.47 28.8 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.654 -1.811 . . . . 0.0 112.353 -0.022 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.622 ' CE2' HD11 ' A' ' 92' ' ' ILE . 86.9 m-85 -116.84 146.29 42.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.839 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.03 131.49 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.914 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 69.5 t -134.98 101.62 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.113 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -82.78 94.0 7.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.918 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -71.07 145.22 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.073 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 57.3 mt -118.77 155.82 52.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.634 0.731 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.2 Cg_endo -69.67 116.25 4.46 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.672 2.248 . . . . 0.0 112.408 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 52.1 m -34.01 -33.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.498 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.5 m-85 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.955 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.798 0.332 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -133.79 96.86 16.02 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.652 0.739 . . . . 0.0 110.801 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -1.5 8.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.642 2.228 . . . . 0.0 112.364 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 48.0 m -100.97 12.56 37.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.819 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.1 mmpt? -117.47 -9.16 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.413 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -82.38 135.84 24.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.8 mtpm? -132.64 168.0 19.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.819 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.815 HD11 ' CE2' ' A' ' 97' ' ' PHE . 36.8 pt -144.33 135.37 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.98 133.14 26.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.056 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.01 175.36 40.13 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.445 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 -35.35 12.72 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.667 2.245 . . . . 0.0 112.362 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.36 -42.56 83.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.534 HD13 HG13 ' A' ' 16' ' ' ILE . 11.8 mt -77.45 -28.33 52.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.943 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.85 176.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 t -92.01 -18.03 24.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.906 0.384 . . . . 0.0 110.839 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.26 48.76 4.09 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.11 140.56 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.336 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 52.4 mtt180 -118.46 148.63 42.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.51 42.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 44.7 mtp180 54.73 39.19 31.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.6 t -134.79 143.15 38.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.154 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 22.5 tp -66.24 114.43 5.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.973 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.511 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 42.3 mm-40 -117.73 128.3 54.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.2 t -139.86 164.82 28.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.822 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.564 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -157.86 167.89 28.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -107.3 131.19 54.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.603 HG13 HG22 ' A' ' 16' ' ' ILE . 58.1 t -111.41 105.27 18.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.083 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -88.5 103.17 15.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.9 p -117.96 26.12 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.817 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.1 t -71.67 -39.05 70.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.861 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -72.99 -22.09 60.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.26 -41.58 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.084 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 139.23 -136.67 8.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.596 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.22 18.24 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.839 0.352 . . . . 0.0 110.983 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.683 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.37 152.0 83.51 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.568 0.699 . . . . 0.0 111.102 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.81 166.79 26.46 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 0.0 112.272 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.5 tp -125.48 139.57 53.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.483 ' O ' HG13 ' A' ' 85' ' ' VAL . 12.4 tt0 -125.27 148.03 48.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 85' ' ' VAL . 40.2 t -140.82 152.12 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.111 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 49.4 mtm-85 -153.16 138.53 17.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 83' ' ' VAL . 93.4 t -118.31 124.09 72.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.1 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.51 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.2 mm? -113.32 152.34 30.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.927 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.67 168.48 22.7 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.472 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.85 -44.74 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.675 2.25 . . . . 0.0 112.299 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -78.14 -29.67 48.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.37 28.38 0.48 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.476 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.4 tp -88.85 144.37 26.26 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -115.93 117.1 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.108 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -112.94 141.98 26.47 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.7 0.762 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 175.85 7.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG13 ' A' ' 71' ' ' VAL . 23.4 t -144.35 153.63 15.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.092 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 13.2 t30 -99.63 139.16 35.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.832 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.1 t -133.26 108.38 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.402 HG23 HD21 ' A' ' 60' ' ' ASN . 86.4 t -131.51 129.67 62.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.1 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -84.13 133.65 34.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -74.42 -44.24 52.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.49 -25.2 9.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.3 m-20 -88.42 -44.38 10.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.908 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.33 33.49 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.513 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 73.3 p -147.64 177.13 9.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -145.4 131.56 19.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.3 m -92.81 134.94 34.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.57 HG13 ' O ' ' A' ' 60' ' ' ASN . 39.3 t -129.7 106.36 13.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.145 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.7 p -103.67 140.82 37.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.195 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.557 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 15.7 p90 -156.78 -176.02 5.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -156.53 112.2 2.03 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 121.569 0.699 . . . . 0.0 111.081 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.557 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.81 90.22 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.695 2.263 . . . . 0.0 112.359 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 75' ' ' PRO . 27.8 m -33.85 -57.61 0.45 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.934 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -118.73 166.36 12.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -85.34 172.28 11.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.908 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.07 174.15 13.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.472 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.73 89.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.628 2.219 . . . . 0.0 112.386 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -86.25 164.35 17.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 39.7 ttp -137.32 119.02 15.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 49' ' ' VAL . 92.8 t -105.07 95.91 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.133 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 41.3 t -80.51 143.26 33.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 46' ' ' GLU . 87.0 t -139.25 142.98 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.45 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 14.5 tttp -129.62 168.37 16.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.616 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.9 t80 -154.03 114.68 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.683 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.7 36.06 22.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.127 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.45 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 0.8 OUTLIER 68.57 35.3 3.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.861 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.409 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 28.6 mt-10 -147.59 105.17 3.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -50.39 120.13 4.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.681 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.7 pt -58.62 153.93 37.94 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.634 0.73 . . . . 0.0 111.105 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 5.72 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.66 2.24 . . . . 0.0 112.39 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -119.81 8.17 11.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.84 153.71 60.42 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.5 Cg_endo -69.72 177.93 27.06 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.399 -0.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.815 ' CE2' HD11 ' A' ' 16' ' ' ILE . 52.2 m-85 -115.2 127.96 55.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.929 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.2 ptpt -87.72 110.07 20.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.99 101.64 9.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -83.11 103.64 12.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.5 t -70.22 143.72 14.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -112.26 155.91 42.86 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.584 0.707 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.494 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.77 121.29 7.98 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.688 2.258 . . . . 0.0 112.307 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 33.3 m -35.24 -31.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.188 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.6 m-85 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -128.46 95.33 33.22 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.627 0.727 . . . . 0.0 110.859 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.87 9.2 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.645 2.23 . . . . 0.0 112.37 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.4 p -99.71 9.06 43.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.811 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.9 mmpt? -113.06 -6.64 13.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.889 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -86.5 127.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.4 mtmm -124.44 168.16 13.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.738 HD11 ' CE2' ' A' ' 97' ' ' PHE . 25.9 pt -144.07 136.34 22.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.165 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.54 144.96 33.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.094 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.34 177.06 30.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -39.67 6.21 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.689 2.259 . . . . 0.0 112.34 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.61 -30.26 13.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.45 HD13 HG13 ' A' ' 16' ' ' ILE . 15.1 mt -95.6 -22.52 17.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.862 0.363 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.47 164.67 5.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p -83.95 14.56 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.924 0.393 . . . . 0.0 110.898 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.9 44.25 1.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.457 HG13 ' NE2' ' A' ' 31' ' ' GLN . 76.3 t -95.65 149.12 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.849 0.357 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 93.0 mtt-85 -124.31 153.63 41.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.4 151.94 40.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 54.47 39.29 30.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.3 t -134.13 144.62 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.3 tp -66.85 113.9 5.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.918 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 48.2 mm-40 -117.43 130.03 56.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 25.0 t -143.74 163.32 33.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.835 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.522 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -154.88 -177.8 6.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.4 m -119.06 131.03 55.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.629 HG13 HG22 ' A' ' 16' ' ' ILE . 59.1 t -111.7 105.07 18.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.11 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -86.5 102.54 14.19 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.456 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.7 p -119.31 29.01 7.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.3 t -76.29 -34.53 59.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.3 mttp -80.17 -16.09 55.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -79.05 -38.25 36.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.128 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -141.4 12.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.559 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -114.98 19.02 16.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.763 0.316 . . . . 0.0 110.854 -179.908 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.8 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.24 151.47 83.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.606 0.717 . . . . 0.0 111.154 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 166.76 26.42 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.262 . . . . 0.0 112.376 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -126.18 136.54 52.97 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -121.9 146.38 47.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.778 ' CG1' HG11 ' A' ' 59' ' ' VAL . 84.9 t -138.77 129.11 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.198 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.3 ttm-85 -125.05 140.26 53.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.464 HG23 HG22 ' A' ' 59' ' ' VAL . 92.1 t -119.82 116.97 52.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.463 HD11 HG22 ' A' ' 56' ' ' VAL . 2.0 mm? -115.37 125.69 53.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.28 175.23 15.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.0 Cg_endo -69.73 -43.27 2.79 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.31 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.429 ' CZ ' HE22 ' A' ' 77' ' ' GLN . 0.0 OUTLIER -75.3 -38.08 60.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.865 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.67 33.24 0.14 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.481 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.459 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 6.4 tp -90.33 155.84 18.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 110.937 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 HD11 ' A' ' 50' ' ' LEU . 91.9 t -117.94 118.65 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -117.38 143.37 31.91 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.679 0.752 . . . . 0.0 110.886 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 168.18 22.32 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.688 2.259 . . . . 0.0 112.359 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.778 HG11 ' CG1' ' A' ' 47' ' ' VAL . 3.5 t -140.59 144.49 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.125 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.681 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.1 t30 -93.12 138.41 31.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.504 ' O ' HG13 ' A' ' 61' ' ' VAL . 9.5 p -133.23 117.97 30.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.509 HG23 HD21 ' A' ' 60' ' ' ASN . 80.4 t -135.55 138.44 48.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.149 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -89.63 138.54 31.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.865 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -81.45 -46.38 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.58 -25.08 9.3 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.531 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -87.94 -43.63 11.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.821 0.343 . . . . 0.0 110.785 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.56 33.85 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.431 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.547 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.8 p -150.43 177.66 9.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.822 0.344 . . . . 0.0 111.114 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.547 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.9 m-70 -145.7 127.36 15.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 54.6 m -86.38 132.5 33.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.145 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.1 t -125.58 111.01 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.081 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 61.9 p -102.38 147.02 27.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.108 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 6.6 p90 -165.36 173.47 11.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.6 m -149.49 113.87 3.51 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.577 0.703 . . . . 0.0 111.125 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.79 93.3 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.702 2.268 . . . . 0.0 112.292 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 3.7 m -34.26 -45.52 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.882 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . 0.429 HE22 ' CZ ' ' A' ' 53' ' ' ARG . 6.6 pt20 -135.29 170.76 15.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.891 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.412 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.1 pp20? -86.2 177.63 7.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.33 173.98 14.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 83.45 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.684 2.256 . . . . 0.0 112.343 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.8 m-85 -78.43 172.53 13.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.947 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.6 ttp -143.68 115.61 8.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.827 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.1 t -104.36 95.4 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.129 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 33.8 t -77.32 147.26 36.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.4 t -139.93 137.44 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.079 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.427 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 17.3 tttp -128.65 169.36 14.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.8 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.2 t80 -155.0 110.76 3.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.741 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.71 39.79 17.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.044 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.427 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 39.3 m-20 67.15 32.66 6.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.968 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -142.55 105.22 4.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -53.79 116.89 2.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.663 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.5 pt -56.13 153.12 19.45 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.593 0.711 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 4.69 2.05 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.653 2.235 . . . . 0.0 112.421 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.463 ' HB2' HD12 ' A' ' 92' ' ' ILE . 39.3 mmt180 -117.19 4.53 12.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.909 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -117.96 153.98 51.24 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.672 0.749 . . . . 0.0 110.873 -179.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.8 -178.83 17.64 Favored 'Cis proline' 0 C--N 1.341 0.15 0 C-N-CA 122.756 -1.768 . . . . 0.0 112.303 0.089 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.738 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.4 m-85 -118.48 125.38 49.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 29.8 pttt -83.52 109.87 17.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 94.7 t -123.36 101.86 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.099 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 12.5 tttp -84.19 94.08 8.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.992 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.412 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 63.4 t -63.39 145.94 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 65.9 mt -111.23 155.95 41.86 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.554 0.692 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.72 122.4 9.09 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.7 2.266 . . . . 0.0 112.33 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -34.12 -35.21 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.461 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.841 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.8 t . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.794 0.33 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 m-20 -121.15 98.22 47.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.623 0.725 . . . . 0.0 110.862 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.74 2.4 3.55 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.684 2.256 . . . . 0.0 112.389 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 51.0 m -97.43 -6.74 33.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 39' ' ' LYS . 8.0 mmmm -96.48 -7.09 35.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.917 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -89.37 124.12 41.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -127.27 169.15 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.536 HG13 HD13 ' A' ' 21' ' ' LEU . 29.9 pt -141.66 133.31 27.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.101 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.79 129.09 22.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 175.51 42.08 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.86 -34.33 14.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.704 2.27 . . . . 0.0 112.28 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.19 -32.5 67.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.469 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.536 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -91.64 -14.54 29.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.65 -175.12 4.31 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.495 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.8 t -95.61 -15.59 22.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.906 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.03 47.15 3.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.478 HG13 ' NE2' ' A' ' 31' ' ' GLN . 55.4 t -97.0 142.39 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 111.197 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 66.9 mtt180 -119.4 150.8 39.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.42 152.57 42.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.079 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.4 mtp180 52.81 41.66 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.932 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.9 t -135.14 149.23 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.0 tp -69.41 113.11 6.42 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.48 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 28.9 mm-40 -118.9 126.75 52.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.887 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 35.1 t -142.17 161.87 36.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.878 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.55 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.4 p90 -151.65 -176.16 5.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.918 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 90.1 m -118.27 134.73 54.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.517 HG11 ' CD2' ' A' ' 45' ' ' LEU . 40.4 t -113.85 105.91 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.11 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -90.62 109.85 21.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -126.45 27.76 6.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.8 m -70.13 -36.39 74.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.468 ' CB ' ' HB3' ' A' ' 13' ' ' LYS . 39.4 mtmt -84.44 -7.7 59.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.912 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.402 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -81.88 -34.72 29.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.07 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.26 -139.56 11.14 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.478 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.809 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.75 19.83 14.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.813 0.34 . . . . 0.0 110.864 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.908 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.74 150.21 78.53 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.625 0.726 . . . . 0.0 111.042 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.461 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 54.4 Cg_endo -69.75 168.55 21.2 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.68 2.254 . . . . 0.0 112.386 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.517 ' CD2' HG11 ' A' ' 35' ' ' VAL . 7.4 tp -127.52 128.73 46.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -108.75 155.06 21.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.953 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.671 HG12 HG11 ' A' ' 59' ' ' VAL . 65.5 t -141.58 135.97 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 -142.37 142.06 32.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.966 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -124.37 131.24 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.158 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -102.5 179.24 4.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -128.05 153.6 19.48 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.49 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -26.02 27.78 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.695 2.263 . . . . 0.0 112.293 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.36 12.58 10.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.95 27.92 8.05 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 15.0 tp -94.35 145.34 24.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.399 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -115.5 140.71 35.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.158 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -131.29 145.63 58.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.597 0.713 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 172.64 12.3 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.294 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.671 HG11 HG12 ' A' ' 47' ' ' VAL . 3.7 m -144.21 159.66 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.142 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 48.1 t30 -123.04 140.97 52.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.8 p -133.39 117.03 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.142 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.7 t -139.47 132.04 36.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.093 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -80.2 136.21 36.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -75.04 -42.32 57.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.95 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.82 -23.04 15.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -90.44 -43.28 10.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 33.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.509 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.9 p -151.71 177.75 10.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.8 m-70 -141.73 127.05 18.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.939 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.0 m -86.79 139.88 30.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.164 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.585 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.7 t -131.45 107.69 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -95.43 141.46 28.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.537 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.9 p90 -159.44 167.46 28.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.6 m -145.28 113.67 4.82 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.58 0.705 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.537 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.9 Cg_endo -69.69 94.62 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.684 2.256 . . . . 0.0 112.392 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' PRO . 5.7 m -34.16 -55.4 0.5 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -130.33 158.96 38.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.911 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -72.37 172.95 9.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.925 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.82 176.2 14.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 84.06 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.723 2.282 . . . . 0.0 112.312 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -82.68 173.85 11.53 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 ttp -150.77 129.81 12.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.911 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -115.88 97.99 6.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -80.72 132.71 35.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.774 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 99.0 t -128.25 134.55 64.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.145 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -124.11 167.25 14.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.908 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.9 t80 -153.96 105.61 2.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.826 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.49 42.65 2.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.13 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.0 33.52 14.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -143.19 105.72 4.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -55.06 112.59 1.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.65 HD11 ' CE2' ' A' ' 97' ' ' PHE . 44.8 pt -50.42 152.99 2.83 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.6 0.714 . . . . 0.0 111.152 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.441 ' HG2' ' NH1' ' A' ' 94' ' ' ARG . 54.5 Cg_endo -69.73 8.3 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.716 2.277 . . . . 0.0 112.368 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.501 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 0.6 OUTLIER -120.7 -2.47 9.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.526 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.3 t -111.56 152.55 44.09 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.675 0.75 . . . . 0.0 110.844 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.526 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.77 175.17 37.64 Favored 'Cis proline' 0 C--O 1.231 0.153 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.317 0.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.65 ' CE2' HD11 ' A' ' 92' ' ' ILE . 82.4 m-85 -115.45 117.7 31.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -77.97 115.56 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.871 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.5 t -128.01 103.91 11.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 24.3 ttpt -83.32 99.27 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.929 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.3 t -68.51 145.67 13.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.118 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.3 mt -112.08 155.32 43.59 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.631 0.729 . . . . 0.0 110.875 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' TYR . 52.9 Cg_endo -69.83 121.7 8.37 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.246 . . . . 0.0 112.319 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.1 m -33.87 -36.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.173 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.446 ' N ' ' O ' ' A' ' 103' ' ' PRO . 31.3 m-85 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.986 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 112.494 -0.243 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.8 t -90.03 114.92 26.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.959 0.409 . . . . 0.0 110.818 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 84.2 p -145.55 135.8 23.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.874 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 118.62 148.82 8.53 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.495 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.1 t -125.1 96.89 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.888 0.375 . . . . 0.0 110.891 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.9 t -148.47 145.95 28.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.827 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.33 50.32 0.89 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.423 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.433 HG22 ' N ' ' A' ' 9' ' ' VAL . 13.4 p -93.08 155.04 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.933 0.397 . . . . 0.0 111.12 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.433 ' N ' HG22 ' A' ' 8' ' ' VAL . 52.6 t -98.25 125.66 51.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.211 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -118.23 94.96 47.82 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.569 0.699 . . . . 0.0 110.883 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -0.11 6.45 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.77 2.313 . . . . 0.0 112.312 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.7 m -99.12 1.87 45.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.852 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -104.65 -6.76 20.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -90.12 129.31 41.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.115 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.27 176.19 8.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.833 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.627 HD11 ' CE1' ' A' ' 97' ' ' PHE . 13.2 pt -145.61 134.59 17.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.158 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.98 120.74 13.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.087 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.52 168.76 40.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.475 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -26.48 27.54 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.723 2.282 . . . . 0.0 112.292 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.76 -25.58 70.57 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.484 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.614 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -98.73 -9.98 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.883 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.08 -178.48 14.6 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.528 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.8 m -91.58 -6.93 51.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.905 0.383 . . . . 0.0 110.863 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.4 47.24 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.491 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.661 HG13 ' NE2' ' A' ' 31' ' ' GLN . 88.1 t -98.01 139.85 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 111.105 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.822 ' HB2' HG21 ' A' ' 29' ' ' VAL . 80.8 mtt-85 -121.97 146.23 47.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.826 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.654 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.28 151.82 39.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.085 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.2 mtt180 53.83 37.0 25.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.904 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.822 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.2 t -127.47 148.82 32.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.169 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 10.4 tp -71.56 111.38 6.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.661 ' NE2' HG13 ' A' ' 25' ' ' VAL . 36.5 mm-40 -114.92 127.48 55.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.8 t -144.44 155.86 43.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.841 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.532 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.2 p90 -148.02 -178.21 6.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.866 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -121.17 129.88 53.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.505 HG11 ' CD2' ' A' ' 45' ' ' LEU . 47.6 t -108.26 106.37 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -88.98 111.82 22.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.9 p -128.11 24.41 5.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 t -68.36 -34.71 76.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.848 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.25 -8.24 57.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.42 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -83.0 -35.33 25.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.12 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.29 -144.07 15.36 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.415 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.744 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -110.43 17.71 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.796 0.332 . . . . 0.0 110.917 -179.906 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.838 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.01 148.65 81.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.579 0.704 . . . . 0.0 111.095 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 167.67 23.77 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.68 2.253 . . . . 0.0 112.317 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.505 ' CD2' HG11 ' A' ' 35' ' ' VAL . 6.9 tp -125.43 127.32 46.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.913 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -110.95 148.42 32.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.92 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 48' ' ' ARG . 35.7 t -139.45 153.9 24.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.411 ' N ' HG12 ' A' ' 47' ' ' VAL . 18.5 mtp85 -157.36 138.04 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.88 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 83' ' ' VAL . 77.2 t -117.98 116.65 52.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.095 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.98 123.28 49.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.95 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.22 178.56 1.98 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.499 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.581 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.5 Cg_endo -69.77 -39.2 6.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.628 2.219 . . . . 0.0 112.365 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.425 ' CZ ' HE22 ' A' ' 77' ' ' GLN . 0.0 OUTLIER -87.21 -28.77 22.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.843 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.9 34.37 0.24 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.53 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.607 HD21 ' OE2' ' A' ' 57' ' ' GLU . 18.1 tp -83.16 156.45 23.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.88 0.372 . . . . 0.0 110.898 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 56' ' ' VAL . 12.7 p -119.46 111.72 34.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.15 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.607 ' OE2' HD21 ' A' ' 55' ' ' LEU . 8.0 mm-40 -112.8 143.5 29.18 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 110.875 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 169.41 19.04 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.676 2.251 . . . . 0.0 112.336 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.5 m -142.65 157.07 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.658 ' O ' HG13 ' A' ' 71' ' ' VAL . 36.6 t30 -109.63 143.51 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.13 120.82 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 97.8 t -136.08 132.12 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.134 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -87.04 128.75 35.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.911 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -71.37 -42.1 68.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.868 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.14 -20.95 25.44 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.83 -42.74 9.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.47 36.06 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.496 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 64.7 p -153.11 176.38 11.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.14 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -143.92 133.99 24.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.2 m -96.35 132.9 41.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.134 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.2 t -126.37 108.16 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.135 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 51.8 p -98.28 142.26 30.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.106 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.493 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 7.2 p90 -159.73 169.28 24.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -145.04 113.77 4.91 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.64 0.733 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.493 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.2 Cg_endo -69.73 97.12 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.374 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 75' ' ' PRO . 57.8 p -35.35 -47.98 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.843 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . 0.425 HE22 ' CZ ' ' A' ' 53' ' ' ARG . 7.0 pt20 -132.08 -175.54 3.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.5 pp20? -101.47 170.27 8.32 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.5 176.81 14.57 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.533 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 88.07 0.55 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.581 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.4 m-85 -85.21 173.67 10.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.942 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 23.6 ttp -146.62 117.49 7.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.919 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.816 HG22 HG22 ' A' ' 49' ' ' VAL . 63.0 t -107.56 100.26 10.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.096 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.0 t -84.46 148.48 26.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.8 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.3 t -142.57 138.85 28.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.079 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -126.52 169.27 13.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.829 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.8 t80 -156.45 105.0 2.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.838 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.81 42.04 2.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.058 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 64.0 32.93 12.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.899 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -143.11 105.01 4.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.953 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -54.54 109.5 0.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.584 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.5 pt -47.52 152.95 1.09 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.648 0.737 . . . . 0.0 111.122 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 3.93 2.48 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.629 2.219 . . . . 0.0 112.374 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 39.1 mmt-85 -113.31 -4.15 13.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.883 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -111.84 154.08 44.21 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.685 0.755 . . . . 0.0 110.838 -179.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.7 -179.97 20.55 Favored 'Cis proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 -1.797 . . . . 0.0 112.353 -0.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.627 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.5 m-85 -120.62 118.86 31.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -82.06 105.16 12.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.7 t -116.38 105.21 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.099 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 43.8 tttm -82.49 102.55 11.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 38.9 t -70.21 150.73 9.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.113 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -118.53 153.84 52.16 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.598 0.713 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.458 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.87 122.65 9.3 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.681 2.254 . . . . 0.0 112.305 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 53.5 m -34.7 -34.51 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.173 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.458 ' N ' ' O ' ' A' ' 103' ' ' PRO . 64.9 m-85 -97.86 120.0 37.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -85.96 120.43 27.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.7 78.85 8.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 31.3 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.846 -179.787 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 3' ' ' SER . 82.1 p -130.17 167.05 19.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.855 0.359 . . . . 0.0 110.884 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 2' ' ' SER . 78.7 p 36.77 42.26 0.21 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.871 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -77.74 -98.09 0.2 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.1 t -82.33 109.89 17.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.902 0.382 . . . . 0.0 110.845 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 87.7 p -163.6 155.1 16.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.46 83.41 0.16 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.428 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.89 148.71 27.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.889 0.376 . . . . 0.0 111.16 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 37.5 t -92.61 130.28 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.152 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -128.89 95.73 31.08 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -2.73 10.65 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.752 2.301 . . . . 0.0 112.316 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.7 p -98.99 9.31 43.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.796 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -113.79 -7.65 13.23 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.5 p -83.85 125.1 40.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.109 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -120.9 173.66 7.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.593 HG22 HG13 ' A' ' 35' ' ' VAL . 38.1 pt -147.02 137.6 17.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.72 138.22 32.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.084 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.3 168.84 27.0 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -30.97 21.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.668 2.245 . . . . 0.0 112.354 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -52.55 -46.65 58.55 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.483 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.585 HD11 HD12 ' A' ' 16' ' ' ILE . 6.0 mt -76.64 -28.63 56.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.875 0.369 . . . . 0.0 110.982 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -47.62 169.83 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.479 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 69.7 m -87.06 -7.92 57.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.873 0.368 . . . . 0.0 110.867 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -93.7 49.21 2.3 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 20' ' ' GLY . 70.1 t -101.05 142.31 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.772 0.32 . . . . 0.0 111.15 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.493 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.0 mtt180 -118.33 147.89 43.04 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -67.71 149.61 49.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 56.18 40.73 30.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.493 HG21 ' HB2' ' A' ' 26' ' ' ARG . 53.6 t -133.62 148.11 30.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.099 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 18.6 tp -68.18 114.52 6.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.423 ' NE2' HG13 ' A' ' 25' ' ' VAL . 44.4 mm-40 -120.64 128.36 52.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.927 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.3 t -144.9 150.69 37.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.548 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 1.4 p90 -139.58 -178.29 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.873 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -121.0 133.78 55.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.12 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.593 HG13 HG22 ' A' ' 16' ' ' ILE . 44.6 t -115.34 107.57 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -91.33 106.86 18.81 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.46 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.1 p -117.01 20.4 13.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 50.6 p -63.05 -42.52 99.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.7 mtmp? -77.03 -15.06 59.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.907 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.498 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -78.6 -32.38 47.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.062 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.01 -140.11 11.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.504 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.68 22.69 12.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.858 0.361 . . . . 0.0 110.949 -179.933 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.763 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.27 151.64 75.48 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.708 . . . . 0.0 111.074 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 167.05 25.58 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.659 2.239 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.7 tp -125.78 139.06 53.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.981 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -121.24 145.26 48.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.9 t -134.22 141.18 44.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 58.1 mtm180 -146.64 130.99 17.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.863 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 83' ' ' VAL . 82.0 t -116.21 125.15 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.09 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -115.07 144.2 44.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.72 169.7 43.1 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.552 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -31.74 19.91 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.624 2.216 . . . . 0.0 112.369 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -95.36 -27.37 15.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.881 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 133.28 27.46 0.56 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.8 tp -86.79 148.66 25.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.867 0.365 . . . . 0.0 110.895 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 92.3 t -110.96 121.54 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.123 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.569 ' OE1' HG12 ' A' ' 49' ' ' VAL . 4.5 mp0 -112.62 142.92 27.98 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.641 0.734 . . . . 0.0 110.906 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.18 22.24 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.337 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.74 157.55 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.119 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.443 HD21 HG23 ' A' ' 62' ' ' VAL . 40.8 t30 -115.32 140.92 48.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.861 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 84.5 t -132.22 107.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.12 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.443 HG23 HD21 ' A' ' 60' ' ' ASN . 91.4 t -131.64 119.13 41.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.136 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 23.4 t0 -76.07 133.47 40.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.859 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -72.37 -43.33 64.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.71 -24.7 10.09 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.437 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -86.99 -39.1 15.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.78 34.21 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.552 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.479 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 72.6 p -150.16 176.74 10.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.837 0.351 . . . . 0.0 111.144 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.479 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.4 m-70 -145.78 131.18 18.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.859 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 21.9 m -91.61 139.58 30.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.156 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.548 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 99.3 t -129.59 102.32 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.111 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 46.7 p -92.51 138.81 31.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.173 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -164.01 160.78 22.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.952 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 29' ' ' VAL . 84.9 m -137.98 117.27 9.88 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.607 0.718 . . . . 0.0 111.152 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' SER . 53.8 Cg_endo -69.74 90.45 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.689 2.259 . . . . 0.0 112.305 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' PRO . 64.6 p -34.97 -53.6 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.881 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -122.22 158.39 29.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.896 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.3 pp20? -79.7 174.95 11.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.948 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.35 177.16 14.89 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.516 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 86.59 0.59 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.623 2.216 . . . . 0.0 112.32 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -79.07 169.75 17.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -145.16 119.08 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.892 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.655 HG22 HG22 ' A' ' 49' ' ' VAL . 90.1 t -110.89 97.12 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.141 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 3.4 m -81.4 142.56 32.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.865 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 87.2 t -135.61 145.14 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.404 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 23.7 tttt -132.35 168.66 17.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.733 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.1 t80 -154.39 105.74 2.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.969 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.763 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.49 44.39 5.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.186 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.404 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.1 m-20 63.2 33.3 14.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.891 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -142.49 105.06 4.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -56.21 111.62 1.01 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.636 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.7 pt -49.24 153.2 1.78 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.59 0.709 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 4.41 2.16 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.664 2.243 . . . . 0.0 112.377 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.419 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 9.4 mtm-85 -116.18 0.09 12.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.544 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -115.21 153.32 47.36 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.644 0.735 . . . . 0.0 110.803 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.544 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.5 Cg_endo -69.76 171.26 54.53 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.35 -0.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.636 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.1 m-85 -109.78 140.8 43.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.3 ptmm? -100.75 110.32 22.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 98.9 t -119.44 101.95 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.1 tttm -81.0 101.6 9.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.864 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.9 t -73.22 147.66 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.128 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.8 mt -114.96 154.79 47.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.609 0.719 . . . . 0.0 110.86 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.0 Cg_endo -69.74 124.16 10.82 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.671 2.247 . . . . 0.0 112.346 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.407 ' C ' ' O ' ' A' ' 103' ' ' PRO . 51.5 m -36.34 -30.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.185 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.479 ' N ' ' O ' ' A' ' 103' ' ' PRO . 70.1 m-85 -102.17 143.56 31.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.882 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.9 p-10 -109.06 121.79 45.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.916 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.419 ' O ' ' C ' ' A' ' 108' ' ' SER . . . -111.66 78.73 1.14 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 107' ' ' ALA . 1.5 t . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.78 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 96.0 p -159.99 125.94 4.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.855 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 m -61.21 148.54 40.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.845 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.4 -129.37 2.59 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.557 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.6 t -94.64 138.55 32.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.948 0.404 . . . . 0.0 110.781 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -69.48 90.54 0.54 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.08 69.4 0.27 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.486 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.6 p -132.84 143.63 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.897 0.38 . . . . 0.0 111.1 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.33 133.88 51.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.117 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -132.7 95.94 19.16 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.6 0.714 . . . . 0.0 110.859 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 -0.81 7.36 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.705 2.27 . . . . 0.0 112.412 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 55.8 p -99.92 7.62 44.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.932 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.3 mmpt? -112.16 -9.62 13.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.419 ' H ' HG12 ' A' ' 14' ' ' VAL . 1.2 p -84.32 121.77 37.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.6 mtpm? -118.12 173.68 6.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.718 HG22 HG13 ' A' ' 35' ' ' VAL . 23.1 pt -146.86 135.93 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.185 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.59 156.57 45.68 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.059 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 143.07 177.02 17.67 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.86 -33.76 15.56 Favored 'Trans proline' 0 C--O 1.23 0.117 0 C-N-CA 122.662 2.241 . . . . 0.0 112.305 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -53.57 -23.5 20.66 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.538 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.498 HD13 HG13 ' A' ' 16' ' ' ILE . 7.7 mt -109.67 -19.95 13.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.88 0.372 . . . . 0.0 110.925 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -59.83 166.81 9.48 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.6 m -82.6 11.22 6.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.881 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.83 43.4 1.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.409 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.434 HG13 ' CD ' ' A' ' 31' ' ' GLN . 59.7 t -101.97 143.85 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.908 0.385 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -124.68 155.48 39.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.866 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.7 150.32 43.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.035 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.7 mtm-85 57.26 37.78 28.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.883 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.12 147.76 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.085 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.9 tp -69.0 113.14 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.519 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 51.0 mm-40 -117.76 130.9 56.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.967 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.429 ' HB2' HG22 ' A' ' 72' ' ' THR . 36.0 t -144.83 150.89 37.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.875 -179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.557 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 8.7 p90 -141.52 176.88 8.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 60.5 m -119.43 135.88 54.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.175 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.718 HG13 HG22 ' A' ' 16' ' ' ILE . 46.4 t -113.22 105.97 19.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.056 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.9 t0 -84.93 103.32 13.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.86 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 81.2 p -116.88 25.68 10.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.909 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 p -73.68 -29.76 62.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.854 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 30.5 mmtm -90.37 -5.47 56.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.919 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -89.46 -34.68 16.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.117 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.65 -140.18 11.6 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.396 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.34 20.98 12.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.798 0.332 . . . . 0.0 110.895 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.758 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.34 151.37 75.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.598 0.713 . . . . 0.0 111.049 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.9 20.14 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.745 2.296 . . . . 0.0 112.373 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.651 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.7 tp -132.0 135.4 46.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.918 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -112.19 152.97 27.75 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.411 HG12 HG11 ' A' ' 59' ' ' VAL . 21.5 t -138.72 132.91 41.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.156 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 48.8 mtm180 -139.11 132.75 30.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.848 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' VAL . 81.6 t -117.18 121.28 67.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 10.8 mt -116.94 129.29 55.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.27 175.03 40.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.534 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.442 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.79 -32.62 18.08 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.712 2.275 . . . . 0.0 112.308 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.29 -25.87 17.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.887 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 130.84 22.86 1.0 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.499 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 16.7 tp -74.08 149.04 41.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.886 0.374 . . . . 0.0 110.838 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.3 t -113.7 112.93 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.161 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -113.15 141.63 26.0 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.611 0.719 . . . . 0.0 110.893 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 174.88 8.86 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.623 2.215 . . . . 0.0 112.362 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 HG12 ' A' ' 47' ' ' VAL . 8.9 m -144.32 162.83 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.714 ' O ' HG13 ' A' ' 71' ' ' VAL . 19.0 t30 -119.49 145.02 46.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.896 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.457 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.3 p -132.46 120.48 42.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.141 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.536 HG23 ' ND2' ' A' ' 60' ' ' ASN . 57.6 t -133.59 122.58 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -82.17 127.23 32.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.926 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.7 m-80 -71.76 -47.71 51.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.52 -16.17 24.25 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -95.14 -38.22 10.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.963 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.69 33.97 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.457 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.6 p -152.76 176.15 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 111.175 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.457 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.2 m-70 -145.85 130.7 18.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.968 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.7 m -92.89 139.78 30.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.157 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.714 HG13 ' O ' ' A' ' 60' ' ' ASN . 36.9 t -131.22 108.94 15.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.171 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.429 HG22 ' HB2' ' A' ' 32' ' ' SER . 38.3 p -93.34 146.42 23.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.103 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 9.3 p90 -163.26 166.87 22.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.5 m -144.22 110.64 5.05 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 121.612 0.72 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.73 91.9 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.724 2.283 . . . . 0.0 112.315 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 22.8 t -34.21 -50.25 0.4 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.801 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -129.62 173.61 10.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.888 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.92 170.21 10.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.861 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.73 172.59 13.18 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.461 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 90.85 0.51 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.704 2.27 . . . . 0.0 112.367 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.442 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.0 m-85 -85.07 161.65 19.61 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.4 ttp -131.42 112.8 13.02 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.842 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 49' ' ' VAL . 96.3 t -103.51 95.98 4.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.8 t -79.34 145.7 33.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.651 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.1 t -143.54 130.13 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.137 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.3 tttt -118.13 169.81 9.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.758 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.3 t80 -156.89 106.12 2.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.707 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.3 40.79 3.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.13 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.99 34.57 11.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.856 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -145.7 105.03 3.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -54.17 114.53 1.65 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.863 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.677 HD11 ' HE1' ' A' ' 97' ' ' PHE . 48.2 pt -52.12 152.81 5.36 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.574 0.702 . . . . 0.0 111.178 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 4.29 2.27 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.701 2.267 . . . . 0.0 112.296 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -116.13 1.33 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.848 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.543 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -115.23 153.83 47.38 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.683 0.754 . . . . 0.0 110.825 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.543 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.69 -179.41 18.97 Favored 'Cis proline' 0 C--N 1.341 0.175 0 C-N-CA 122.68 -1.8 . . . . 0.0 112.392 -0.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.709 ' CE2' HD11 ' A' ' 16' ' ' ILE . 85.2 m-85 -119.45 123.38 43.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.912 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 8.5 pttp -83.89 96.77 8.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 86.9 t -102.28 103.99 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.103 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 23.9 ttpt -85.0 102.53 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.87 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.4 t -75.38 143.43 13.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.134 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 33.8 mt -107.79 154.51 40.92 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.52 0.676 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.7 Cg_endo -69.7 122.51 9.2 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.386 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.3 m -33.97 -36.21 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.16 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.44 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.8 m-85 -76.21 139.1 41.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.865 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -155.7 116.94 3.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -101.73 80.51 2.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.139 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.802 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 87.8 p 41.72 41.89 1.92 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.874 0.369 . . . . 0.0 110.906 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.6 m -79.2 92.18 5.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.864 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -46.6 139.62 7.21 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.465 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 95.2 p -165.41 135.02 3.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.788 0.328 . . . . 0.0 110.851 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 97.8 p -124.81 148.77 47.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 67.97 90.07 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.497 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -137.19 139.62 43.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.368 . . . . 0.0 111.131 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.3 t -120.9 134.46 64.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.156 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.41 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 3.7 t0 -131.85 96.86 19.6 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 0.0 110.799 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 -0.43 6.89 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.676 2.251 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -99.38 6.95 45.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -112.99 -7.2 13.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.93 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -86.33 126.93 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.7 mtmm -125.57 170.37 11.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.926 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.648 HD11 ' CE2' ' A' ' 97' ' ' PHE . 41.1 pt -145.25 137.01 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.173 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.21 143.26 34.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.076 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.0 169.97 24.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.72 -29.71 23.63 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.703 2.268 . . . . 0.0 112.343 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.59 -45.93 94.82 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.501 HD13 HG13 ' A' ' 16' ' ' ILE . 12.5 mt -73.91 -26.9 60.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.876 0.369 . . . . 0.0 110.933 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -51.16 169.35 0.36 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.501 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.5 p -85.26 -7.78 58.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.914 0.388 . . . . 0.0 110.841 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -91.67 44.7 2.73 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.508 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.478 HG13 ' NE2' ' A' ' 31' ' ' GLN . 97.7 t -92.15 143.0 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.831 0.348 . . . . 0.0 111.181 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.722 ' HB2' HG21 ' A' ' 29' ' ' VAL . 46.5 mtm180 -118.33 156.17 29.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.52 147.08 44.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 82.5 mtm-85 54.94 35.79 25.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.912 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' A' ' 26' ' ' ARG . 23.3 t -121.71 151.84 25.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.126 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.402 ' N ' ' CG1' ' A' ' 29' ' ' VAL . 7.9 tp -75.62 109.33 9.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.478 ' NE2' HG13 ' A' ' 25' ' ' VAL . 40.7 mm-40 -112.72 127.64 56.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 23.1 t -143.85 149.51 37.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.451 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 9.8 p90 -145.85 171.25 15.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.891 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.2 m -110.68 130.61 55.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.506 HG22 HG22 ' A' ' 16' ' ' ILE . 100.0 t -108.55 107.05 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.126 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -90.56 106.73 18.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 86.8 p -121.87 25.95 8.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.915 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 78.1 p -71.25 -35.85 71.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.861 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -80.02 -14.91 58.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.918 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.29 -38.2 43.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.13 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -138.19 9.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.609 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.19 17.73 13.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.885 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.75 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.92 151.52 84.29 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.525 0.679 . . . . 0.0 111.119 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.65 166.87 26.0 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.703 2.269 . . . . 0.0 112.362 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -122.92 136.33 54.82 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -119.21 139.47 51.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.885 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 59' ' ' VAL . 48.8 t -130.73 144.44 37.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.079 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 20.1 ttm180 -148.11 141.8 25.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 92.6 t -122.78 122.04 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.138 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -108.13 151.34 26.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.95 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.44 167.35 32.5 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.471 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -29.84 23.47 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.683 2.255 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' NH1' HD13 ' A' ' 55' ' ' LEU . 0.0 OUTLIER -118.18 3.62 12.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.86 -179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.55 62.98 0.5 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.542 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.45 HD13 ' NH1' ' A' ' 53' ' ' ARG . 10.1 tp -120.48 134.75 55.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.872 0.368 . . . . 0.0 110.911 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.1 t -102.78 129.78 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.157 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -134.46 141.43 38.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.655 0.741 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 168.47 21.41 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.689 2.259 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.439 HG11 HG11 ' A' ' 47' ' ' VAL . 39.7 t -142.64 151.61 17.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.132 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.484 HD21 HG23 ' A' ' 62' ' ' VAL . 8.6 t30 -100.82 138.52 37.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.85 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.488 ' O ' HG13 ' A' ' 61' ' ' VAL . 6.2 p -133.43 112.47 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.181 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.484 HG23 HD21 ' A' ' 60' ' ' ASN . 66.1 t -133.4 127.61 54.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -84.08 130.87 34.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.848 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -72.21 -46.14 57.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.24 -22.21 11.4 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -88.6 -40.59 13.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.814 0.34 . . . . 0.0 110.852 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.28 33.99 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.509 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.575 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.7 p -150.2 175.39 11.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.876 0.369 . . . . 0.0 111.107 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.575 ' CD2' ' C ' ' A' ' 68' ' ' THR . 6.2 m-70 -147.0 125.21 12.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 38.8 m -85.7 141.28 29.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.451 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 61.0 t -131.13 104.56 9.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.074 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 38.9 p -96.89 135.13 39.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.132 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.503 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.6 p90 -155.4 175.05 14.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.913 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 29' ' ' VAL . 89.7 m -151.71 117.18 3.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.526 0.679 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.503 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.3 Cg_endo -69.77 98.12 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.723 2.282 . . . . 0.0 112.357 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' PRO . 1.5 t -34.32 -60.3 0.42 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.883 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -127.36 164.19 22.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -72.73 167.36 20.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 132.46 171.08 12.68 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.443 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 92.76 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.678 2.252 . . . . 0.0 112.363 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -87.94 173.99 8.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 18.3 ttp -148.5 117.17 6.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.869 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.79 96.64 4.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.101 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -79.0 144.71 34.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.872 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 55.7 t -139.58 135.91 39.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.184 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -126.47 169.62 12.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.9 t80 -155.71 117.9 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.75 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 57.04 31.58 20.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.126 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.0 t70 74.22 31.74 1.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 12.8 mt-10 -141.79 106.69 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -53.73 114.89 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.678 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.4 pt -53.49 152.79 8.37 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.667 0.746 . . . . 0.0 111.136 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 4.47 2.19 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.535 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.7 mmt180 -115.64 0.76 13.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.881 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.527 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -114.72 153.36 46.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.622 0.725 . . . . 0.0 110.855 -179.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.85 178.63 25.01 Favored 'Cis proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 -1.793 . . . . 0.0 112.285 0.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.678 ' HE1' HD11 ' A' ' 92' ' ' ILE . 81.8 m-85 -117.2 117.73 30.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.897 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 42.5 mttp -78.49 113.33 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.836 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -128.99 101.95 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.119 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 33.5 tttm -83.95 102.51 12.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.9 t -67.15 145.67 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.177 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.7 mt -114.03 156.17 44.39 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.592 0.71 . . . . 0.0 110.894 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.1 Cg_endo -69.8 121.28 7.96 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.687 2.258 . . . . 0.0 112.351 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.429 ' C ' ' O ' ' A' ' 103' ' ' PRO . 54.0 m -35.21 -31.75 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.075 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.496 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 -112.34 167.64 10.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.941 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -124.59 172.72 9.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.903 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -117.33 41.67 2.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.085 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 58.3 m . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.772 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.7 p -117.28 166.59 12.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.844 0.354 . . . . 0.0 110.89 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.4 m -70.11 108.91 4.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.902 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.7 -174.84 4.21 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.504 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.7 t 41.49 41.76 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.877 0.37 . . . . 0.0 110.883 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.5 m -104.35 120.05 40.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.846 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.97 95.34 0.69 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.533 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.459 HG22 ' N ' ' A' ' 9' ' ' VAL . 11.7 p -123.43 158.41 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.869 0.366 . . . . 0.0 111.077 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.459 ' N ' HG22 ' A' ' 8' ' ' VAL . 53.6 t -97.54 132.84 41.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.414 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.0 t0 -134.14 96.21 16.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.635 0.731 . . . . 0.0 110.897 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.76 1.49 4.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.747 2.298 . . . . 0.0 112.305 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 63.7 m -99.2 -5.23 30.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.5 mmpt? -97.9 -7.66 29.79 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.9 p -86.43 131.17 35.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.193 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mppt? -128.44 172.61 10.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.864 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.614 HD11 ' CZ ' ' A' ' 97' ' ' PHE . 24.2 pt -143.3 134.96 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.122 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.93 128.17 20.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.79 163.59 28.21 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 -24.88 29.44 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.664 2.243 . . . . 0.0 112.365 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.77 95.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.614 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.1 mt -84.13 -17.19 40.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.973 0.416 . . . . 0.0 110.968 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.31 176.71 1.31 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.509 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.5 t -91.26 -13.29 33.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.986 0.422 . . . . 0.0 110.87 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.47 49.86 3.49 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.521 HG13 ' NE2' ' A' ' 31' ' ' GLN . 74.6 t -99.34 147.15 7.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.798 0.332 . . . . 0.0 111.103 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.508 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.26 144.84 48.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.418 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -63.76 150.45 44.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 45.7 mtm180 54.65 43.05 30.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.508 HG21 ' HB2' ' A' ' 26' ' ' ARG . 75.8 t -135.06 147.65 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.094 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -69.96 113.93 7.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.945 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.521 ' NE2' HG13 ' A' ' 25' ' ' VAL . 42.4 mm-40 -120.51 129.02 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.922 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.8 t -144.75 157.72 44.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.614 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.3 p90 -147.21 179.95 7.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.931 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 58.2 m -120.08 130.82 54.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.142 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 16' ' ' ILE . 61.2 t -110.72 109.07 27.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.188 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -89.83 110.39 21.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 25.6 p -125.75 24.73 7.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.757 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 89.0 p -69.64 -33.76 73.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.7 mmmt -86.31 -12.66 48.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.884 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.58 -35.3 46.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.133 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.82 -138.86 10.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.566 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.583 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -121.14 19.37 11.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.745 0.307 . . . . 0.0 110.852 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.857 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.86 151.78 79.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.604 0.716 . . . . 0.0 111.103 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 167.16 25.27 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.486 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.4 tp -125.32 136.0 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.911 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -120.94 149.38 42.72 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.91 150.15 20.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.196 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.8 mmm180 -148.58 136.16 20.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 83' ' ' VAL . 93.5 t -116.4 124.8 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.4 mp -123.89 133.73 53.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.53 -179.86 49.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.491 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -45.17 1.68 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.674 2.25 . . . . 0.0 112.34 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.488 ' NE ' HE22 ' A' ' 77' ' ' GLN . 0.1 OUTLIER -76.2 -35.24 59.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.889 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.9 31.59 0.26 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.401 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 11.2 tp -85.31 152.04 23.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.917 0.389 . . . . 0.0 110.886 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.401 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 92.4 t -119.25 122.59 69.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -120.25 142.64 34.08 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.56 0.695 . . . . 0.0 110.97 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 169.01 19.94 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.632 2.221 . . . . 0.0 112.33 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.7 m -138.29 167.7 21.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.406 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.2 t30 -114.34 140.67 48.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 93.1 t -133.32 114.9 21.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.166 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.403 HG23 HD21 ' A' ' 60' ' ' ASN . 96.0 t -140.47 117.55 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -73.63 139.45 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.933 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 -78.42 -45.56 21.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.61 -20.7 11.95 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.447 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.95 -39.03 13.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.807 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.59 34.96 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.487 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.8 p -153.27 177.39 10.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 111.072 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.1 m-70 -144.8 130.59 19.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.87 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 81.8 m -88.54 140.98 28.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.47 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 48.0 t -133.04 102.54 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.146 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 45.2 p -95.09 143.84 26.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.494 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 5.2 p90 -163.35 175.46 10.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.971 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -151.91 116.95 3.07 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.651 0.738 . . . . 0.0 111.121 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.494 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.76 92.92 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.664 2.243 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.451 ' C ' ' O ' ' A' ' 75' ' ' PRO . 40.2 t -34.44 -54.7 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.854 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . 0.488 HE22 ' NE ' ' A' ' 53' ' ' ARG . 7.3 pt20 -125.83 171.71 10.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.969 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -84.82 172.81 11.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.52 170.04 12.99 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.5 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.13 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.726 2.284 . . . . 0.0 112.319 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -83.11 168.59 16.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.978 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.5 ttp -139.54 117.95 12.1 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 49' ' ' VAL . 90.9 t -107.21 97.59 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.128 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 1.8 m -81.53 147.44 29.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.832 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.486 ' CG1' HD11 ' A' ' 45' ' ' LEU . 64.5 t -140.94 138.11 34.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 34.6 tttt -125.27 173.91 8.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.567 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.7 t80 -160.44 110.54 1.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.974 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.857 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.68 38.31 18.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.154 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 68.02 34.02 4.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -144.23 105.02 4.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.875 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -54.39 108.38 0.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.888 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.486 HD12 ' HB2' ' A' ' 94' ' ' ARG . 45.8 pt -46.9 153.02 0.87 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.583 0.706 . . . . 0.0 111.144 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 4.68 2.04 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.668 2.245 . . . . 0.0 112.347 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.486 ' HB2' HD12 ' A' ' 92' ' ' ILE . 84.2 mmt-85 -114.48 -3.73 12.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 0.9 OUTLIER -112.28 154.45 44.43 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.631 0.729 . . . . 0.0 110.848 -179.785 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.0 Cg_endo -69.72 -178.53 16.86 Favored 'Cis proline' 0 C--N 1.342 0.206 0 C-N-CA 122.629 -1.821 . . . . 0.0 112.38 -0.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.614 ' CZ ' HD11 ' A' ' 16' ' ' ILE . 81.2 m-85 -121.25 132.78 55.01 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.6 ptmt -93.16 108.31 19.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 97.7 t -118.59 103.68 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.104 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 106.85 13.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.908 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 41.5 t -76.81 138.08 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.155 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.6 mt -108.64 155.24 40.91 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 121.675 0.75 . . . . 0.0 110.941 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.6 Cg_endo -69.73 122.46 9.14 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.782 2.321 . . . . 0.0 112.296 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 103' ' ' PRO . 91.9 m -34.83 -35.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.084 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.442 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.4 m-85 -93.84 147.34 23.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.53 38.21 2.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.862 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.98 93.26 1.35 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.014 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 23.6 t . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.894 -179.88 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.8 m -81.98 164.43 21.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.835 0.35 . . . . 0.0 110.859 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.9 p -75.22 -52.95 9.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.852 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 144.67 -137.04 6.98 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.54 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m -118.19 168.89 10.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 110.851 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.7 t -122.93 171.71 9.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.35 -65.93 0.36 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.503 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -62.93 163.07 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.866 0.365 . . . . 0.0 111.106 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.0 t -120.62 135.65 60.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.119 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.1 t0 -133.23 96.18 17.66 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.598 0.713 . . . . 0.0 110.927 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.7 Cg_endo -69.72 -1.63 8.78 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.682 2.255 . . . . 0.0 112.359 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.5 p -98.11 5.93 48.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.808 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.5 mmpt? -110.53 -7.74 14.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -86.29 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.106 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.9 mttt -127.21 173.72 9.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.931 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.792 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.4 pt -147.35 135.79 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.4 153.19 46.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.142 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.52 174.6 20.35 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.477 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -36.04 11.46 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.671 2.247 . . . . 0.0 112.315 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.28 -32.68 29.87 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.561 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.434 HD13 HG13 ' A' ' 16' ' ' ILE . 13.0 mt -94.4 -21.38 18.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.912 0.387 . . . . 0.0 110.95 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.43 167.96 2.67 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -87.49 13.75 9.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.893 0.378 . . . . 0.0 110.875 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.02 44.9 1.37 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.518 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.452 HG13 ' NE2' ' A' ' 31' ' ' GLN . 60.0 t -97.14 145.96 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.794 0.33 . . . . 0.0 111.095 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.464 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.1 mtt85 -120.89 151.65 39.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.887 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -69.56 150.73 46.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.068 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.9 mtp180 55.09 41.55 31.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.464 HG21 ' HB2' ' A' ' 26' ' ' ARG . 59.3 t -133.88 144.33 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.2 tp -68.43 112.99 5.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.452 ' NE2' HG13 ' A' ' 25' ' ' VAL . 54.5 mm-40 -117.47 130.66 56.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.2 t -144.89 149.1 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.54 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.4 p90 -140.08 179.77 6.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.946 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 89.3 m -117.8 131.55 56.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.606 HG11 HD22 ' A' ' 45' ' ' LEU . 92.8 t -110.38 105.47 18.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.096 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' HG22 ' A' ' 68' ' ' THR . 18.9 t70 -89.67 101.76 14.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.858 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 82.6 p -117.33 27.94 8.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.1 t -70.04 -38.13 75.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 37.7 mttp -76.06 -14.88 60.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -81.2 -38.59 26.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.101 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.09 -137.44 9.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.532 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.597 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.86 19.91 12.32 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.793 0.33 . . . . 0.0 110.912 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.711 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.18 151.62 81.47 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.585 0.707 . . . . 0.0 111.084 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 166.86 26.18 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.685 2.256 . . . . 0.0 112.322 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.606 HD22 HG11 ' A' ' 35' ' ' VAL . 5.0 tp -129.61 129.37 44.28 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -108.73 151.71 25.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.9 t -139.53 144.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.084 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.9 mmt180 -149.64 135.06 18.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.832 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 83' ' ' VAL . 61.5 t -116.73 128.36 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.1 mt -125.12 121.15 33.41 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.949 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.29 174.44 7.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.534 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -43.62 2.52 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.625 2.216 . . . . 0.0 112.381 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.6 -32.2 47.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.1 32.64 0.3 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.46 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.452 HD21 ' OE2' ' A' ' 57' ' ' GLU . 9.4 tp -85.85 149.69 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 0.0 110.874 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -114.38 115.23 48.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.452 ' OE2' HD21 ' A' ' 55' ' ' LEU . 65.3 mm-40 -113.79 142.84 28.42 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 0.0 110.892 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 169.58 18.59 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.237 . . . . 0.0 112.299 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.23 167.94 19.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.139 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.8 t30 -123.21 140.6 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 85.5 t -133.21 113.84 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 85.5 t -138.32 119.85 17.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.093 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -75.12 136.58 41.1 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.765 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -75.69 -43.44 47.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.88 -24.9 9.84 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.506 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -86.05 -44.21 12.48 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.837 0.351 . . . . 0.0 110.898 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.34 33.57 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.493 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.433 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 64.0 p -149.92 177.78 9.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.86 0.362 . . . . 0.0 111.078 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.433 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.3 m-70 -144.99 133.56 22.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 52.4 m -93.02 141.49 28.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.148 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.54 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 66.4 t -131.36 103.28 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.172 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.6 p -95.19 136.86 35.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.131 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.468 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 8.0 p90 -157.41 176.12 13.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.7 m -150.78 115.35 3.24 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.586 0.708 . . . . 0.0 111.122 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.468 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.6 Cg_endo -69.8 95.04 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.345 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 13.4 t -38.91 -54.79 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.772 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -121.98 169.94 10.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.497 ' C ' ' CD ' ' A' ' 78' ' ' GLU . 0.0 OUTLIER -86.97 173.75 9.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.86 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.11 176.23 15.05 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.488 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 89.15 0.53 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.699 2.266 . . . . 0.0 112.279 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.62 163.54 25.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.938 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 16.3 ttp -135.17 113.09 11.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.856 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 49' ' ' VAL . 69.3 t -105.48 97.78 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.116 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.5 t -82.98 144.29 30.08 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.899 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.573 ' CG1' HD11 ' A' ' 45' ' ' LEU . 55.7 t -139.83 142.37 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.433 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 39.9 tttt -128.29 170.56 12.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.711 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.5 t80 -156.42 109.42 2.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.674 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.27 40.82 11.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.102 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.433 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 4.9 m-20 64.31 35.99 9.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.887 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -147.05 105.04 3.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -52.48 117.01 2.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.652 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.5 pt -55.61 153.16 16.06 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.58 0.705 . . . . 0.0 111.245 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 4.74 2.01 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.676 2.251 . . . . 0.0 112.412 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.42 ' HB2' HD12 ' A' ' 92' ' ' ILE . 29.7 mmt85 -117.04 2.96 12.74 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.88 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.64 153.98 49.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.637 0.732 . . . . 0.0 110.861 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.69 -179.92 20.38 Favored 'Cis proline' 0 C--O 1.231 0.135 0 C-N-CA 122.663 -1.807 . . . . 0.0 112.37 -0.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.792 ' CE2' HD11 ' A' ' 16' ' ' ILE . 80.1 m-85 -117.45 128.98 55.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.878 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -93.64 107.34 19.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 92.9 t -119.43 107.04 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 19.8 ttpt -81.96 105.5 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.885 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.8 152.49 6.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.18 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 68.4 mt -117.55 154.83 50.79 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.575 0.702 . . . . 0.0 110.93 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.7 122.21 8.91 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.692 2.261 . . . . 0.0 112.377 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m -34.83 -32.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.152 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 5.6 m-85 -90.05 38.71 0.93 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 7.5 t70 -81.82 123.62 28.96 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.894 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -108.41 78.53 1.17 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.082 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.4 t . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.84 -179.794 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 m -67.61 -56.87 7.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.818 0.342 . . . . 0.0 110.78 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 44.5 m -74.78 86.36 2.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.859 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -128.03 -123.24 2.58 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.527 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -94.96 164.58 12.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 110.888 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.1 t -46.02 -60.54 2.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.65 66.98 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.509 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 30.7 m -69.18 165.35 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 111.024 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.1 t -99.18 134.04 39.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.211 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.443 ' CG ' ' HG2' ' A' ' 13' ' ' LYS . 8.8 t0 -123.95 95.1 44.71 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.614 0.721 . . . . 0.0 110.897 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 0.78 5.12 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.71 2.273 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 m -100.7 3.67 42.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.443 ' HG2' ' CG ' ' A' ' 10' ' ' ASP . 14.4 mmmt -104.74 -12.12 16.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 36' ' ' ASP . 6.4 p -84.37 133.67 28.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.0 mtmt -135.69 169.94 16.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.616 HG13 HD13 ' A' ' 21' ' ' LEU . 26.3 pt -142.67 137.25 27.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 143.79 33.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.077 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 155.83 178.57 30.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.87 -38.81 7.06 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.656 2.237 . . . . 0.0 112.315 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.27 -24.99 11.0 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.498 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.616 HD13 HG13 ' A' ' 16' ' ' ILE . 3.3 mt -104.41 -22.16 13.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.864 0.364 . . . . 0.0 110.896 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -58.19 176.82 1.84 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.469 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -91.17 11.78 22.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.884 0.374 . . . . 0.0 110.853 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.84 47.03 1.09 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.505 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.5 HG13 ' CD ' ' A' ' 31' ' ' GLN . 72.4 t -98.54 138.29 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.805 0.336 . . . . 0.0 111.11 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.579 ' HB2' HG21 ' A' ' 29' ' ' VAL . 57.4 mtt85 -118.76 146.33 44.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.425 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -66.69 151.51 47.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.034 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 56.18 35.6 25.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.579 HG21 ' HB2' ' A' ' 26' ' ' ARG . 76.2 t -128.91 154.4 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.125 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.434 ' N ' HG12 ' A' ' 29' ' ' VAL . 12.1 tp -76.19 112.24 12.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.5 ' CD ' HG13 ' A' ' 25' ' ' VAL . 61.8 mm-40 -113.83 127.54 56.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 13.6 t -142.19 154.1 44.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.872 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.569 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.0 p90 -149.54 176.2 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.948 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 96.1 m -114.64 138.01 51.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.146 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 16' ' ' ILE . 52.3 t -117.48 106.97 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.7 t70 -85.78 110.65 19.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.6 p -125.34 25.77 7.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.8 t -75.67 -35.82 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.876 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 3.6 mmpt? -81.6 -18.52 44.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -75.29 -39.98 59.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.139 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.8 -140.66 11.42 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.487 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.826 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -116.35 16.97 15.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.785 0.326 . . . . 0.0 110.907 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.757 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.63 151.3 84.85 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.61 0.719 . . . . 0.0 111.063 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.436 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.7 Cg_endo -69.77 167.37 24.65 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.652 2.234 . . . . 0.0 112.297 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.593 HD11 ' CG1' ' A' ' 85' ' ' VAL . 10.8 tp -128.19 131.11 48.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.897 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -111.86 151.53 29.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 54.9 t -140.82 149.81 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.46 ' HG2' HD23 ' A' ' 50' ' ' LEU . 2.5 ttp-105 -152.61 143.12 22.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 58.3 t -118.69 122.06 68.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.46 HD23 ' HG2' ' A' ' 48' ' ' ARG . 4.0 mm? -110.48 128.92 55.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.59 165.03 52.6 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.502 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.528 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.75 -26.29 27.76 Favored 'Trans proline' 0 N--CA 1.465 -0.157 0 C-N-CA 122.743 2.295 . . . . 0.0 112.365 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.09 3.35 9.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.08 65.16 0.52 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.491 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.48 148.0 44.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.866 0.365 . . . . 0.0 110.896 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.59 118.64 57.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -120.65 141.69 32.78 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.639 0.733 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 169.21 19.39 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.663 2.242 . . . . 0.0 112.378 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.8 m -144.31 162.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 29.9 t30 -125.2 141.15 52.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 61' ' ' VAL . 3.6 p -133.52 110.94 15.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 74.7 t -139.79 116.04 9.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -67.45 138.8 56.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.3 m-80 -73.18 -41.98 63.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.89 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.21 -22.05 12.59 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.485 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -91.58 -43.05 9.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.357 . . . . 0.0 110.871 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.77 34.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.413 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 57.3 p -152.23 177.87 10.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.848 0.356 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.413 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.1 m-70 -143.76 125.12 14.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.864 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 31.3 m -84.03 139.02 32.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.123 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.569 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 73.3 t -131.3 106.71 12.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.5 p -97.07 147.4 24.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.471 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.1 p90 -166.02 164.37 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 92.0 m -140.85 112.38 6.88 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.623 0.725 . . . . 0.0 111.129 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.69 100.59 0.82 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.367 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 75' ' ' PRO . 33.3 t -34.86 -57.85 0.53 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -129.86 166.5 19.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.419 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 5.7 pm0 -76.25 172.11 13.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.887 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.92 173.83 13.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.457 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 93.93 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.528 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 6.3 m-85 -90.11 173.91 7.92 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.884 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 27.7 ttp -147.61 117.74 7.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.841 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 93.2 t -106.29 100.22 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 12.4 t -84.37 143.49 29.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.81 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.593 ' CG1' HD11 ' A' ' 45' ' ' LEU . 84.4 t -141.21 135.04 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.123 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -122.28 171.69 8.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.951 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.738 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 12.9 t80 -157.56 112.81 2.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.929 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.757 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.45 32.51 20.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.083 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 73.47 31.4 1.34 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.808 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -141.99 105.05 4.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -53.36 107.9 0.28 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.513 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.9 pt -45.93 153.0 0.69 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.609 0.719 . . . . 0.0 111.104 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 4.31 2.26 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.361 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 14.2 mmm180 -113.46 -4.65 13.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.836 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.546 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -112.21 153.98 44.52 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.659 0.742 . . . . 0.0 110.845 -179.82 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.546 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.4 Cg_endo -69.65 179.15 22.84 Favored 'Cis proline' 0 C--N 1.341 0.168 0 C-N-CA 122.8 -1.75 . . . . 0.0 112.347 -0.116 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.513 ' HE2' HD11 ' A' ' 92' ' ' ILE . 89.5 m-85 -120.21 114.8 22.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 106.08 9.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.901 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 79.7 t -117.51 106.71 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.078 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 35.3 tttt -85.91 96.88 9.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.889 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.419 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 47.7 t -63.61 147.28 12.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.065 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 46.5 mt -113.02 154.05 45.12 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.59 0.709 . . . . 0.0 110.958 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.5 Cg_endo -69.71 124.06 10.73 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.741 2.294 . . . . 0.0 112.345 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.415 ' C ' ' O ' ' A' ' 103' ' ' PRO . 88.6 m -35.58 -32.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.473 ' N ' ' O ' ' A' ' 103' ' ' PRO . 23.0 m-85 -101.28 154.81 18.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -125.05 36.42 4.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.796 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -79.87 43.45 0.59 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.828 -179.725 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.0 p -141.14 170.91 14.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.888 0.375 . . . . 0.0 110.849 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 66.4 m -99.47 145.0 27.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.839 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.47 162.21 47.35 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.6 m -96.49 147.69 23.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.7 t -123.9 113.54 18.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.809 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 159.22 -42.06 0.48 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.457 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 3.8 p -85.45 138.26 19.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 111.15 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.9 t -103.77 130.47 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.422 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 10.2 t0 -128.08 96.92 30.39 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.58 0.705 . . . . 0.0 110.832 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.5 Cg_endo -69.71 -0.43 6.86 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.687 2.258 . . . . 0.0 112.369 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.2 p -99.67 10.39 41.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.863 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 mmpt? -114.82 -8.78 12.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.898 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.1 p -83.87 123.11 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.166 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -116.69 173.33 6.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.6 HG22 HG13 ' A' ' 35' ' ' VAL . 33.0 pt -147.13 138.82 18.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.139 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.89 138.1 31.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.076 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 161.95 167.59 22.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.541 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.75 -24.93 29.17 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.85 -28.09 65.35 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.472 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.546 HD11 HD12 ' A' ' 16' ' ' ILE . 6.7 mt -98.13 -19.78 17.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -57.41 166.37 5.58 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.7 t -83.29 8.59 13.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.972 0.415 . . . . 0.0 110.922 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -111.14 51.0 0.73 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.416 HG13 ' NE2' ' A' ' 31' ' ' GLN . 68.7 t -102.08 141.78 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.845 0.355 . . . . 0.0 111.102 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.643 ' HB2' HG21 ' A' ' 29' ' ' VAL . 75.3 mtt85 -118.97 150.75 39.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.74 150.16 48.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.442 ' HB3' ' NH1' ' A' ' 28' ' ' ARG . 12.2 mtp-105 54.91 40.32 31.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.857 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.643 HG21 ' HB2' ' A' ' 26' ' ' ARG . 66.4 t -129.9 150.74 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.149 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 12.7 tp -73.94 110.36 8.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.951 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.416 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.3 mm-40 -115.3 127.68 55.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.3 t -143.44 149.48 37.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CD1' ' N ' ' A' ' 33' ' ' PHE . 1.0 OUTLIER -141.33 -178.38 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 88.4 m -123.21 137.67 54.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.6 HG13 HG22 ' A' ' 16' ' ' ILE . 46.7 t -117.65 107.18 21.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -87.48 94.74 9.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.875 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.489 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 59.9 p -103.64 20.02 18.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.833 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.9 t -68.41 -34.94 76.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.814 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 27.6 mmtp -82.75 -12.24 57.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -83.35 -39.66 20.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.047 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.654 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 135.66 -146.97 18.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.5 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.781 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.07 14.99 24.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.797 0.332 . . . . 0.0 110.928 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.731 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -75.58 151.32 84.96 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.619 0.723 . . . . 0.0 111.046 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 169.36 19.1 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.64 2.227 . . . . 0.0 112.377 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.8 tp -124.82 139.47 53.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -112.96 143.4 44.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.548 HG12 HG11 ' A' ' 59' ' ' VAL . 88.9 t -135.72 131.1 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -141.12 143.0 34.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.23 132.38 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.5 mp -120.57 148.46 43.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.09 172.69 36.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.427 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.4 Cg_endo -69.82 -30.75 21.49 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.657 2.238 . . . . 0.0 112.325 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.86 4.78 17.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.822 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 105.45 66.5 0.67 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.54 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 26.9 tp -118.36 138.59 52.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.911 0.386 . . . . 0.0 110.91 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.1 t -109.02 108.98 26.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -110.93 143.13 27.66 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.618 0.723 . . . . 0.0 110.875 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 168.02 22.81 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.655 2.237 . . . . 0.0 112.363 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.548 HG11 HG12 ' A' ' 47' ' ' VAL . 30.0 m -141.83 163.15 19.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.063 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -115.47 141.31 48.23 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.866 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 86.9 t -132.86 116.31 26.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.081 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 76.6 t -138.25 124.74 26.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -80.45 132.75 35.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.809 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 -72.84 -40.74 65.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 114.42 -27.37 8.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.487 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -83.27 -47.27 11.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.846 0.355 . . . . 0.0 110.931 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.28 30.36 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.529 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.498 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.4 p -144.76 177.78 8.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.498 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.5 m-70 -146.66 132.16 18.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 23.2 m -93.16 141.86 27.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.144 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.484 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 57.8 t -132.85 104.78 7.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.17 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 34.9 p -94.74 139.97 30.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.495 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -159.36 171.54 19.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.863 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 29' ' ' VAL . 29.2 m -147.07 114.97 4.27 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.567 0.699 . . . . 0.0 111.149 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.495 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.6 Cg_endo -69.73 91.39 0.51 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.346 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.5 t -34.08 -59.64 0.42 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -121.56 158.34 28.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.886 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -77.19 173.67 11.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.07 176.9 14.64 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 86.19 0.58 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.678 2.252 . . . . 0.0 112.387 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.427 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.1 m-85 -83.0 173.59 11.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 24.5 ttp -149.16 120.83 8.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.835 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.0 t -109.43 100.17 10.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.119 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.9 t -82.99 145.4 29.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.848 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.3 t -140.52 138.42 36.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.103 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -126.79 172.99 9.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.667 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.5 t80 -160.18 109.47 1.76 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.731 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.0 37.84 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.047 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 67.94 34.18 4.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -144.35 105.07 4.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.59 111.68 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.601 HD11 ' HE2' ' A' ' 97' ' ' PHE . 47.0 pt -49.41 153.03 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.683 0.754 . . . . 0.0 111.1 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 3.85 2.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.71 2.273 . . . . 0.0 112.327 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.438 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 19.6 mmm180 -114.08 -2.03 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.862 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.548 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -113.61 153.27 45.86 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.681 0.753 . . . . 0.0 110.849 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.548 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.78 175.83 35.07 Favored 'Cis proline' 0 C--N 1.341 0.151 0 C-N-CA 122.692 -1.795 . . . . 0.0 112.318 0.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.601 ' HE2' HD11 ' A' ' 92' ' ' ILE . 87.8 m-85 -116.15 118.07 31.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 44.5 mttm -78.7 107.24 11.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.903 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 96.1 t -119.26 102.92 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.101 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -83.58 100.42 10.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.8 145.09 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.173 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.6 mt -111.69 154.67 43.88 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.589 0.709 . . . . 0.0 110.958 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.9 Cg_endo -69.66 123.33 10.03 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.67 2.246 . . . . 0.0 112.334 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 103' ' ' PRO . 49.7 m -36.11 -30.82 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.171 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.485 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.8 m-85 -83.18 140.07 32.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.68 96.26 9.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.838 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.91 44.03 0.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 61.0 p . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.903 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.248 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 t -157.89 161.48 38.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.931 0.396 . . . . 0.0 110.862 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -53.58 113.06 1.04 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.876 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -39.2 113.16 0.28 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.471 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 95.7 p -106.06 119.16 38.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.877 0.37 . . . . 0.0 110.807 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.5 t -118.69 107.37 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.898 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.442 ' O ' ' C ' ' A' ' 8' ' ' VAL . . . -150.71 -68.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.503 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' A' ' 7' ' ' GLY . 28.3 t -33.97 135.73 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.855 0.36 . . . . 0.0 111.129 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.2 t -82.15 125.46 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 8.2 t0 -125.88 99.45 32.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.564 0.697 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.6 Cg_endo -69.81 0.37 5.78 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.66 2.24 . . . . 0.0 112.386 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.7 p -98.7 9.09 44.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.999 0.428 . . . . 0.0 110.86 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -114.18 -8.02 12.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.8 p -84.54 123.5 39.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.215 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.4 mtpp -119.66 167.74 11.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.746 HG22 HG13 ' A' ' 35' ' ' VAL . 37.6 pt -144.09 140.06 24.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.8 165.92 26.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.075 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 133.82 176.11 14.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.41 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.65 -41.44 4.42 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.715 2.277 . . . . 0.0 112.321 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -44.77 -35.44 4.32 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.494 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.439 HD11 HD12 ' A' ' 16' ' ' ILE . 8.2 mt -94.43 -26.6 16.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.897 0.379 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -50.86 163.81 0.92 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.479 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.4 m -86.24 22.91 1.67 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.959 0.409 . . . . 0.0 110.904 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.69 38.05 2.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.503 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.582 HG13 ' CD ' ' A' ' 31' ' ' GLN . 78.9 t -89.41 144.3 9.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.558 ' HB2' HG21 ' A' ' 29' ' ' VAL . 65.6 mtt180 -121.63 149.8 42.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.865 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.486 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.04 150.16 48.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.135 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.6 mtt85 55.35 34.83 23.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.876 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 74' ' ' THR . 73.2 t -127.46 146.98 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.7 tp -68.25 111.6 4.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.582 ' CD ' HG13 ' A' ' 25' ' ' VAL . 58.0 mm-40 -116.66 126.62 53.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.592 ' HB2' HG22 ' A' ' 72' ' ' THR . 14.3 t -144.45 148.43 34.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.84 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.481 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -140.86 177.61 7.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.791 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 82.6 m -118.36 141.17 48.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.215 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.746 HG13 HG22 ' A' ' 16' ' ' ILE . 38.2 t -118.09 109.47 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -92.32 98.23 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.1 p -111.71 21.38 16.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.886 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.5 p -67.01 -35.4 79.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.839 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -79.16 -15.89 57.43 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.61 -38.68 47.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.092 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.49 -138.45 9.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.444 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.84 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.8 16.35 16.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.88 0.371 . . . . 0.0 110.956 -179.892 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.764 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.78 151.64 84.64 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.581 0.705 . . . . 0.0 111.105 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.487 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.1 Cg_endo -69.77 169.27 19.31 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.622 2.215 . . . . 0.0 112.327 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.7 tp -127.32 135.4 50.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.961 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -120.42 145.42 47.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.927 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 49.7 t -137.49 145.93 28.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.108 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -146.38 138.16 24.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.69 ' O ' HD22 ' A' ' 50' ' ' LEU . 84.8 t -115.41 129.15 72.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.035 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.69 HD22 ' O ' ' A' ' 49' ' ' VAL . 3.3 mm? -126.2 119.52 27.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.85 177.77 3.76 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.531 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.435 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 53.7 Cg_endo -69.7 -41.39 4.39 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.649 2.232 . . . . 0.0 112.4 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.435 ' CD ' ' HG2' ' A' ' 52' ' ' PRO . 0.2 OUTLIER -84.05 -33.66 24.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.976 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.31 33.21 0.15 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.739 HD21 ' OE2' ' A' ' 57' ' ' GLU . 11.1 tp -85.52 155.67 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.887 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.469 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 94.3 t -119.33 111.1 31.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.739 ' OE2' HD21 ' A' ' 55' ' ' LEU . 18.3 mm-40 -106.13 143.15 26.35 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.651 0.738 . . . . 0.0 110.876 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.691 2.261 . . . . 0.0 112.34 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 m -139.98 162.83 24.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 47.1 t30 -118.88 143.6 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.936 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 74.0 t -129.51 116.31 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.518 HG23 ' HB ' ' A' ' 70' ' ' THR . 0.1 OUTLIER -134.98 110.77 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.203 179.87 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -72.15 129.05 37.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.85 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -72.73 -44.74 61.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.856 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.11 -24.31 10.09 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.469 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -85.87 -46.49 10.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.841 0.353 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.7 30.54 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.537 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.527 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 60.3 p -145.89 177.63 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 111.098 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.527 ' CD2' ' C ' ' A' ' 68' ' ' THR . 12.5 m-70 -147.82 131.41 16.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . 0.518 ' HB ' HG23 ' A' ' 62' ' ' VAL . 3.4 m -94.78 137.51 33.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.159 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.515 HG13 ' O ' ' A' ' 60' ' ' ASN . 35.6 t -127.04 107.35 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.592 HG22 ' HB2' ' A' ' 32' ' ' SER . 35.1 p -92.68 141.06 28.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.193 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 3.1 p90 -163.94 161.59 22.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.973 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 29' ' ' VAL . 17.3 m -137.38 117.19 10.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.603 0.716 . . . . 0.0 111.117 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.1 Cg_endo -69.75 94.59 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.349 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 75' ' ' PRO . 43.0 t -35.88 -54.88 0.75 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -125.12 168.94 12.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -85.35 173.68 10.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.33 175.42 14.22 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.465 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 90.13 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.702 2.268 . . . . 0.0 112.364 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -81.06 169.75 17.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.947 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 11.2 ttp -145.31 115.73 7.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.5 t -107.58 97.14 5.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.1 t -79.83 142.88 34.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.855 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 89.5 t -138.05 142.0 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.084 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.437 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 15.5 tttp -130.49 168.05 17.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.941 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.764 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.7 t80 -154.61 115.99 4.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.944 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.644 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.41 33.27 22.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.115 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.437 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 11.6 m-20 71.04 33.5 2.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.921 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -144.4 105.34 4.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.891 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -49.99 114.14 1.02 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.84 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.552 HD11 ' HE2' ' A' ' 97' ' ' PHE . 42.1 pt -54.56 153.52 10.35 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.661 0.743 . . . . 0.0 111.113 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.68 4.33 2.22 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.68 2.254 . . . . 0.0 112.34 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.424 ' HB3' ' CZ ' ' A' ' 97' ' ' PHE . 53.1 mtp85 -114.5 0.29 13.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.908 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.523 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -115.71 153.37 47.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.684 0.754 . . . . 0.0 110.866 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.6 Cg_endo -69.73 178.01 26.82 Favored 'Cis proline' 0 C--O 1.232 0.18 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.396 -0.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.642 ' CE1' HD11 ' A' ' 16' ' ' ILE . 86.3 m-85 -117.84 116.47 27.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.0 pttm -81.65 108.8 15.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.02 104.14 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.119 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -81.35 103.01 10.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.871 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.2 t -71.25 144.61 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 77.2 mt -111.88 154.5 44.09 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.583 0.706 . . . . 0.0 110.919 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.495 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.4 Cg_endo -69.69 123.84 10.52 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.724 2.283 . . . . 0.0 112.324 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.9 m -34.12 -33.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.193 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.495 ' N ' ' O ' ' A' ' 103' ' ' PRO . 57.6 m-85 -95.09 126.65 40.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -92.05 121.5 33.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.934 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -68.02 81.87 0.21 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.101 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 46.5 m . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.459 -0.256 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.6 m -151.87 164.34 37.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.36 . . . . 0.0 110.9 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 t -97.1 123.5 40.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.905 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.45 155.63 7.31 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.2 t -95.43 135.88 36.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.919 0.39 . . . . 0.0 110.873 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.2 p -94.62 162.97 13.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.818 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -150.6 74.0 0.27 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.53 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.35 141.42 44.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.943 0.401 . . . . 0.0 111.086 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -107.52 133.73 51.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -130.53 96.64 23.44 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.607 0.718 . . . . 0.0 110.883 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.4 Cg_endo -69.76 0.3 5.85 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.663 2.242 . . . . 0.0 112.347 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 30.8 m -98.46 -7.12 29.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -94.23 -5.15 47.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -90.42 135.73 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.152 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 22.8 mtmt -133.42 168.9 17.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 97' ' ' PHE . 42.2 pt -142.9 139.42 27.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.066 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.72 153.67 43.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 148.32 171.68 17.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -29.14 24.27 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 0.0 112.372 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.79 -29.43 67.37 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.411 HD13 HG13 ' A' ' 16' ' ' ILE . 5.2 mt -97.04 -26.43 15.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.894 0.378 . . . . 0.0 110.965 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -55.92 168.33 2.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.564 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.8 p -83.86 18.49 1.99 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.926 0.393 . . . . 0.0 110.866 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.21 40.83 2.19 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.459 HG13 ' CD ' ' A' ' 31' ' ' GLN . 58.3 t -92.96 147.46 5.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.572 ' HB2' HG21 ' A' ' 29' ' ' VAL . 50.0 mtm180 -123.03 157.26 33.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.835 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -75.35 149.48 38.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.027 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 42.5 mtt180 54.09 30.27 11.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.572 HG21 ' HB2' ' A' ' 26' ' ' ARG . 19.1 t -119.99 144.48 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.178 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.5 tp -67.81 110.12 3.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.584 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 59.6 mm-40 -113.29 126.95 55.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.923 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 32.5 t -143.2 152.53 41.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.51 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.5 p90 -146.39 -176.48 5.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 48.0 m -122.23 135.5 54.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.09 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.664 HG13 HG22 ' A' ' 16' ' ' ILE . 40.1 t -113.15 108.75 26.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -91.47 104.04 16.59 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.913 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.0 p -121.4 30.19 6.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.9 t -73.04 -36.61 66.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.853 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 6.4 mmpt? -79.95 -16.95 54.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.859 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.05 -38.64 63.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.042 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 134.7 -137.25 9.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.577 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -119.31 18.91 12.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.868 0.366 . . . . 0.0 110.973 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.733 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.35 151.89 83.5 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.71 . . . . 0.0 111.076 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 166.64 26.92 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.673 2.249 . . . . 0.0 112.338 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.466 ' CD2' HG11 ' A' ' 35' ' ' VAL . 15.4 tp -126.08 134.49 51.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -119.4 147.52 44.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.929 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 59' ' ' VAL . 65.6 t -137.3 149.77 25.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -152.26 136.85 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.837 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 83' ' ' VAL . 71.9 t -119.43 126.18 75.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.169 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.7 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.6 mm? -123.58 122.9 39.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -59.6 -179.36 1.66 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.472 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.6 Cg_endo -69.74 -47.93 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.684 2.256 . . . . 0.0 112.358 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.14 -37.25 61.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.919 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.24 33.38 0.13 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.464 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 10.3 tp -85.37 147.96 26.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.915 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.4 t -107.87 126.0 64.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.106 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -127.92 140.35 37.93 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.603 0.716 . . . . 0.0 110.915 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 168.65 20.95 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.702 2.268 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.612 HG11 HG11 ' A' ' 47' ' ' VAL . 44.5 t -139.91 149.33 22.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.191 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.639 ' O ' HG13 ' A' ' 71' ' ' VAL . 10.3 t30 -98.67 139.18 34.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.82 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 p -131.94 123.48 51.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.196 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.502 HG23 HD21 ' A' ' 60' ' ' ASN . 59.5 t -141.28 129.43 22.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.174 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.22 132.06 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.84 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -73.23 -48.04 38.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.83 -21.04 10.59 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -90.43 -43.97 9.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.914 0.388 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.8 32.69 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.572 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 63.2 p -151.02 177.73 9.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.843 0.354 . . . . 0.0 111.152 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.572 ' CD2' ' C ' ' A' ' 68' ' ' THR . 5.3 m-70 -146.61 131.07 17.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.846 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 26.2 m -90.21 138.41 31.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.196 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 60' ' ' ASN . 47.4 t -130.37 110.37 18.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.171 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 55.7 p -101.04 145.33 28.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.188 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.584 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 7.0 p90 -164.91 169.06 16.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -146.29 112.6 4.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.586 0.708 . . . . 0.0 111.089 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.466 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.81 94.39 0.53 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.665 2.243 . . . . 0.0 112.383 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 75' ' ' PRO . 8.7 t -34.23 -59.43 0.44 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -116.3 168.75 9.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.5 pm0 -89.21 169.37 11.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.86 177.71 15.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 93.9 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.661 2.241 . . . . 0.0 112.393 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 3.3 m-85 -88.28 172.98 9.04 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 7.5 ttp -144.43 117.13 8.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 49' ' ' VAL . 81.2 t -108.57 95.69 4.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.134 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.7 t -79.72 147.2 32.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.411 ' CG1' HD11 ' A' ' 45' ' ' LEU . 85.8 t -142.54 134.27 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.149 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -121.44 168.64 11.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.989 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.688 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.0 t80 -154.9 106.86 2.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.733 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 65.4 42.22 3.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.072 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 62.96 34.83 13.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -146.32 105.05 3.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -51.2 114.93 1.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.822 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.712 HD11 ' HE1' ' A' ' 97' ' ' PHE . 38.1 pt -53.79 153.26 8.58 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.542 0.687 . . . . 0.0 111.198 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.66 5.83 1.51 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.267 . . . . 0.0 112.361 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.552 ' HB2' HD12 ' A' ' 92' ' ' ILE . 12.1 mmm180 -118.49 3.61 11.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.804 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.522 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -118.48 153.26 51.88 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.724 0.773 . . . . 0.0 110.838 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.81 176.68 31.76 Favored 'Cis proline' 0 C--N 1.343 0.243 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.41 -0.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 16' ' ' ILE . 72.8 m-85 -114.86 121.68 43.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.882 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 pttp -80.94 107.71 13.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 57.8 t -119.2 106.43 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.164 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 7.8 ttpm? -89.12 99.1 12.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.9 t -65.75 150.69 10.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 78.1 mt -118.94 154.69 53.19 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.618 0.723 . . . . 0.0 110.932 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.562 ' CG ' ' HB2' ' A' ' 107' ' ' ALA . 53.1 Cg_endo -69.76 119.08 6.08 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.718 2.279 . . . . 0.0 112.299 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.6 m -39.38 -27.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.183 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.51 ' O ' ' N ' ' A' ' 107' ' ' ALA . 4.7 m-85 -82.25 38.54 0.55 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.949 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 105' ' ' TYR . 0.9 OUTLIER 36.44 29.37 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.813 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.562 ' HB2' ' CG ' ' A' ' 103' ' ' PRO . . . 44.81 49.33 8.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 37.3 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.77 -179.705 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.5 m 54.65 44.94 27.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.864 0.364 . . . . 0.0 110.886 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.3 p -144.02 140.56 29.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.858 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.49 144.46 7.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.498 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -69.11 169.45 11.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.876 0.37 . . . . 0.0 110.857 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.0 m -123.39 116.56 23.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.902 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.61 89.56 1.07 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.485 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.3 m -115.54 153.59 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.356 . . . . 0.0 111.128 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 72.9 t -101.22 131.3 49.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 0.9 OUTLIER -133.21 98.18 15.76 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.549 0.69 . . . . 0.0 110.863 179.928 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.8 Cg_endo -69.73 -2.02 9.44 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.751 2.301 . . . . 0.0 112.344 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.2 m -100.07 13.87 32.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.827 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -9.03 10.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.79 134.34 27.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.187 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -129.44 174.29 9.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.969 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.822 HD11 ' CE2' ' A' ' 97' ' ' PHE . 27.4 pt -150.01 135.97 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.127 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.3 154.74 44.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.129 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 146.15 178.54 21.67 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.48 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 -39.55 6.5 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.711 2.274 . . . . 0.0 112.407 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -47.8 -35.61 12.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.549 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.472 HD13 HG13 ' A' ' 16' ' ' ILE . 9.4 mt -93.48 -27.49 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.88 167.95 1.0 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.453 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 34.1 m -85.57 16.86 3.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.961 0.41 . . . . 0.0 110.91 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.35 40.17 2.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.676 HG13 ' CD ' ' A' ' 31' ' ' GLN . 64.9 t -93.02 139.6 17.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 111.153 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.551 ' HB2' HG21 ' A' ' 29' ' ' VAL . 89.2 mtt180 -121.74 148.15 45.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.869 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -65.36 154.86 37.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 23.1 mtm180 50.65 41.72 26.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.894 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 27' ' ' ALA . 70.0 t -134.23 151.32 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.2 tp -73.97 111.21 8.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.987 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.676 ' CD ' HG13 ' A' ' 25' ' ' VAL . 65.2 mm-40 -112.01 127.33 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.0 t -141.03 149.98 42.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.559 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 11.4 p90 -144.62 168.77 19.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.825 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 92.7 m -110.18 130.09 55.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.177 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.584 HG13 HG22 ' A' ' 16' ' ' ILE . 65.2 t -111.41 105.61 19.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.117 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -87.01 104.72 16.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.775 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 75.7 p -118.72 27.2 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.909 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.9 p -74.22 -37.41 63.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.821 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 21.9 mttp -73.93 -23.32 59.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.62 -41.28 72.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.092 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.48 -135.19 7.44 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.45 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.548 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -117.98 19.55 13.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.764 0.316 . . . . 0.0 110.901 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.842 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.65 152.01 80.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.671 0.748 . . . . 0.0 111.047 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 165.94 29.33 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.691 2.26 . . . . 0.0 112.328 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.5 tp -125.36 136.68 53.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.937 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -121.13 143.4 49.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.33 144.98 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.449 ' HG2' ' CD1' ' A' ' 50' ' ' LEU . 12.7 ttm180 -148.24 144.6 27.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.481 HG12 ' OE1' ' A' ' 57' ' ' GLU . 67.3 t -120.89 130.37 74.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.454 HD13 ' CE ' ' A' ' 82' ' ' MET . 3.8 mp -125.11 134.78 52.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.46 173.88 54.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.444 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.4 ' HG2' ' CD ' ' A' ' 53' ' ' ARG . 54.6 Cg_endo -69.72 -44.36 2.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.427 ' CD ' HE22 ' A' ' 77' ' ' GLN . 0.2 OUTLIER -79.21 -35.52 41.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.943 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 138.77 31.32 0.21 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.436 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.534 HD23 ' OE2' ' A' ' 57' ' ' GLU . 10.7 tp -91.63 150.11 21.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.1 t -110.62 132.12 59.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.098 179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.534 ' OE2' HD23 ' A' ' 55' ' ' LEU . 48.0 mp0 -120.02 142.74 33.95 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.631 0.729 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 167.93 23.1 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.625 2.216 . . . . 0.0 112.346 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.8 m -144.31 164.79 13.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.155 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.552 ' O ' HG13 ' A' ' 71' ' ' VAL . 58.6 t30 -122.85 142.69 50.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 89.8 t -133.5 103.06 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.2 t -127.96 115.25 38.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.159 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -71.12 135.0 47.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.85 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -75.64 -43.09 49.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.22 -26.0 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.487 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -85.66 -40.09 16.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.863 0.363 . . . . 0.0 110.872 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.82 34.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.478 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.2 p -151.47 177.65 10.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.745 0.307 . . . . 0.0 111.168 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -145.77 131.38 18.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.842 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 51.9 m -90.84 137.74 32.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.132 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.559 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 40.3 t -133.19 105.72 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.061 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 71.1 p -98.32 142.15 30.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.223 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.564 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 10.0 p90 -156.53 169.89 23.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.964 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.3 m -145.74 110.67 4.48 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.552 0.691 . . . . 0.0 111.233 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.546 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.75 94.52 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.661 2.241 . . . . 0.0 112.372 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 60.6 p -39.38 -27.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . 0.462 ' N ' ' O ' ' A' ' 75' ' ' PRO . 10.4 pt20 -147.74 175.49 10.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.98 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.93 173.28 7.67 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.72 174.76 13.86 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.547 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.71 81.66 0.79 Allowed 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.697 2.265 . . . . 0.0 112.382 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -80.52 147.33 30.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.908 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . 0.454 ' CE ' HD13 ' A' ' 50' ' ' LEU . 3.1 tmm? -117.61 127.09 53.62 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.03 95.3 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 t -76.1 139.92 41.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.825 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 64.9 t -138.86 129.8 34.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.158 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.426 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 40.4 tttt -121.6 170.52 9.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.85 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.842 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.0 t80 -157.09 107.82 2.31 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.69 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.16 41.82 5.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.113 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.426 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 44.0 m-20 63.22 36.07 12.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -146.15 104.97 3.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -53.75 117.34 3.08 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.87 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.788 HD11 ' HE1' ' A' ' 97' ' ' PHE . 40.3 pt -55.75 153.57 15.8 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.657 0.741 . . . . 0.0 111.113 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.401 ' HD2' ' HB ' ' A' ' 92' ' ' ILE . 53.8 Cg_endo -69.74 6.2 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.727 2.285 . . . . 0.0 112.377 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.503 ' HB2' HD12 ' A' ' 92' ' ' ILE . 15.0 mmm180 -120.59 5.55 10.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.973 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.2 t -119.93 153.37 54.96 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.688 0.756 . . . . 0.0 110.781 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.6 Cg_endo -69.71 172.95 46.4 Favored 'Cis proline' 0 C--N 1.342 0.21 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.3 -0.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.822 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.1 m-85 -110.43 139.82 45.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.824 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 34.0 mttm -100.29 107.3 19.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 93.1 t -117.06 101.54 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.087 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 39.9 tttp -81.0 97.78 7.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 49.4 t -69.61 144.14 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.142 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 42.1 mt -109.56 155.17 41.78 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.573 0.701 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.3 Cg_endo -69.82 123.22 9.86 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.737 2.291 . . . . 0.0 112.368 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.434 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -33.87 -35.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.182 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 103' ' ' PRO . 20.0 m-85 -105.45 159.45 15.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -118.96 96.38 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.867 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -124.55 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.122 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 12.7 t . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.875 -179.77 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.439 -0.265 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.4 t -161.15 134.54 6.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.967 0.413 . . . . 0.0 110.752 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.7 m -151.24 142.51 23.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.895 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.49 -160.64 25.52 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.439 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.9 t -135.2 155.77 50.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.852 0.358 . . . . 0.0 110.849 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 95.1 p -83.0 40.0 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.49 -63.41 2.36 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.434 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.423 HG22 ' N ' ' A' ' 9' ' ' VAL . 11.8 p -42.99 155.74 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.789 0.328 . . . . 0.0 111.152 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.423 ' N ' HG22 ' A' ' 8' ' ' VAL . 76.8 t -95.68 132.16 40.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.403 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 13.7 m-20 -129.43 96.72 26.88 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.648 0.737 . . . . 0.0 110.803 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.76 -1.5 8.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.318 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.8 m -100.39 12.29 37.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.5 mmpt? -116.54 -7.41 11.63 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -85.85 127.07 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.214 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mttt -121.68 173.28 7.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.913 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.851 HD11 ' CE2' ' A' ' 97' ' ' PHE . 31.8 pt -148.47 134.38 11.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.135 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.07 152.17 45.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.124 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 149.08 176.58 22.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.495 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -38.65 7.55 Favored 'Trans proline' 0 N--CA 1.466 -0.118 0 C-N-CA 122.709 2.273 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.92 -24.39 13.8 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.554 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.445 HD13 HG13 ' A' ' 16' ' ' ILE . 6.5 mt -105.77 -18.23 14.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.861 0.362 . . . . 0.0 110.949 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.62 177.85 3.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.485 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 97.9 p -92.31 15.0 14.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.855 0.36 . . . . 0.0 110.854 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -116.03 42.88 1.78 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.481 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.495 HG13 ' NE2' ' A' ' 31' ' ' GLN . 75.9 t -96.46 141.13 15.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.884 0.373 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.509 ' HB2' HG21 ' A' ' 29' ' ' VAL . 88.7 mtt180 -121.11 148.84 43.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.45 150.18 48.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 58.7 mtt-85 53.98 41.09 32.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.878 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 26' ' ' ARG . 46.6 t -132.85 143.59 39.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.078 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.1 tp -66.82 114.03 5.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.931 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.495 ' NE2' HG13 ' A' ' 25' ' ' VAL . 53.7 mm-40 -116.49 134.7 54.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.858 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 28.9 t -146.94 148.98 32.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.492 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 2.5 p90 -142.73 173.14 11.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 73.8 m -112.79 133.32 54.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.192 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.682 HG13 HG22 ' A' ' 16' ' ' ILE . 41.0 t -112.95 106.75 21.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.141 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -88.5 99.41 12.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.502 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.5 p -112.99 26.08 10.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.848 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 91.4 p -72.62 -38.14 67.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.834 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -76.43 -17.11 59.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.952 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -78.39 -38.36 41.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.42 -138.79 9.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.574 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.4 20.68 12.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.798 0.332 . . . . 0.0 110.913 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.784 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -79.05 151.54 76.02 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.567 0.698 . . . . 0.0 111.085 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 166.56 27.19 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.673 2.249 . . . . 0.0 112.292 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.473 HD11 ' CG1' ' A' ' 85' ' ' VAL . 5.4 tp -125.72 135.86 52.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.892 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -116.05 142.33 46.95 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.844 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.575 HG12 HG11 ' A' ' 59' ' ' VAL . 60.9 t -130.0 142.3 44.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.433 ' HG2' ' CD2' ' A' ' 50' ' ' LEU . 20.2 ttm180 -148.16 142.46 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.474 ' C ' HD22 ' A' ' 50' ' ' LEU . 49.0 t -121.2 133.51 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.162 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.474 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.5 mm? -124.78 133.19 53.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.928 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.13 170.26 53.56 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.504 179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -42.26 3.54 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -82.51 -34.85 27.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.13 31.65 0.19 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.428 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 8.9 tp -91.7 146.01 24.12 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.797 0.332 . . . . 0.0 110.946 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.97 125.88 67.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.154 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -118.86 141.81 30.76 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.621 0.724 . . . . 0.0 110.932 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 171.5 14.44 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.662 2.241 . . . . 0.0 112.336 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.575 HG11 HG12 ' A' ' 47' ' ' VAL . 21.0 m -142.29 165.77 16.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.121 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.502 ' O ' HG13 ' A' ' 71' ' ' VAL . 34.6 t30 -124.24 143.3 50.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.872 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.472 ' O ' HG13 ' A' ' 61' ' ' VAL . 7.4 p -133.47 118.52 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.116 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.44 HG23 ' ND2' ' A' ' 60' ' ' ASN . 60.1 t -134.91 121.62 34.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.203 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -75.04 137.2 41.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.794 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -80.64 -40.97 24.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.91 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.1 -29.73 7.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -82.79 -47.12 12.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.786 0.327 . . . . 0.0 110.87 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.38 30.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.471 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.513 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.4 p -144.14 177.34 8.66 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.826 0.346 . . . . 0.0 111.044 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.513 ' CD2' ' C ' ' A' ' 68' ' ' THR . 10.0 m-70 -146.07 127.63 15.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 97.2 m -88.38 138.94 30.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.179 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 60' ' ' ASN . 64.4 t -129.75 109.81 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.146 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -97.68 140.2 32.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.136 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.459 ' CE2' ' HB2' ' A' ' 31' ' ' GLN . 5.9 p90 -159.72 170.69 20.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.93 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 m -146.02 116.15 4.79 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.62 0.724 . . . . 0.0 111.147 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.419 ' O ' ' C ' ' A' ' 76' ' ' SER . 54.2 Cg_endo -69.74 92.97 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.683 2.256 . . . . 0.0 112.36 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 m -35.92 -51.59 0.71 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.848 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -131.78 163.17 28.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -77.6 170.35 16.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.81 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.77 172.66 13.28 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.68 84.2 0.65 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.37 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -76.54 173.57 11.39 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 13.1 ttp -144.95 114.37 7.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.803 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -103.51 96.91 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.125 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.1 t -80.3 139.91 36.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.934 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.473 ' CG1' HD11 ' A' ' 45' ' ' LEU . 51.5 t -136.11 140.59 43.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.453 ' HE3' ' N ' ' A' ' 90' ' ' GLU . 18.2 tttp -128.61 169.22 14.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.919 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.739 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 6.0 t80 -153.86 107.7 3.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.959 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.784 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 63.65 43.02 5.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.092 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.445 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 32.8 m-20 62.65 36.95 13.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.453 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 14.9 mt-10 -147.58 105.05 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -52.58 118.32 3.53 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.906 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.726 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.2 pt -57.75 153.07 33.29 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.646 0.736 . . . . 0.0 111.155 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 4.34 2.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.711 2.274 . . . . 0.0 112.362 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HB2' HD12 ' A' ' 92' ' ' ILE . 73.9 mtp85 -116.94 4.93 12.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.534 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -117.8 153.72 50.91 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.722 0.772 . . . . 0.0 110.827 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.1 Cg_endo -69.71 178.36 25.6 Favored 'Cis proline' 0 C--N 1.342 0.211 0 C-N-CA 122.743 -1.774 . . . . 0.0 112.383 -0.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.851 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.0 m-85 -115.56 119.92 37.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 ptpt -79.7 100.0 7.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 90.9 t -108.35 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.138 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.0 ttpm? -83.2 98.61 9.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.934 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.35 145.34 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.121 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 82.0 mt -110.35 154.3 43.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.614 0.721 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.71 124.22 10.89 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.707 2.271 . . . . 0.0 112.289 179.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.423 ' C ' ' O ' ' A' ' 103' ' ' PRO . 77.9 m -34.73 -32.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.116 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.49 ' N ' ' O ' ' A' ' 103' ' ' PRO . 67.1 m-85 -109.09 168.26 9.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.892 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -120.47 151.68 39.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.835 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.25 79.43 7.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.08 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 32.6 p . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.821 -179.785 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 t -81.15 100.5 9.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.861 0.362 . . . . 0.0 110.891 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.4 m -92.43 92.66 8.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.853 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.2 141.64 6.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.1 t -64.47 105.95 1.04 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.889 0.376 . . . . 0.0 110.85 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 75.0 m -110.09 150.81 28.04 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.903 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.41 52.0 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.455 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.0 p -104.31 145.83 12.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.104 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.9 t -106.98 125.31 63.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.181 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 15.5 m-20 -125.76 98.11 34.68 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.546 0.689 . . . . 0.0 110.851 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.7 Cg_endo -69.77 -1.87 9.22 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.689 2.26 . . . . 0.0 112.321 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.4 ' HA ' ' CD ' ' A' ' 93' ' ' PRO . 53.3 p -101.66 14.48 31.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.893 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.432 ' NZ ' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -117.59 -9.62 10.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.883 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.79 134.66 27.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.093 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HD3' ' CZ ' ' A' ' 94' ' ' ARG . 14.0 mmmt -127.67 173.27 10.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.519 HG22 HG13 ' A' ' 35' ' ' VAL . 26.5 pt -148.55 134.82 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.166 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.63 130.13 22.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.181 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.84 170.04 34.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -35.9 11.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.66 2.24 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -51.35 -42.77 50.72 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.446 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.469 HD11 ' CD2' ' A' ' 33' ' ' PHE . 5.1 mt -80.78 -20.03 43.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.906 0.384 . . . . 0.0 110.929 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -53.81 174.21 0.48 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.451 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 91.2 p -89.47 -13.89 36.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.932 0.396 . . . . 0.0 110.833 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -90.43 52.14 3.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.469 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 79.4 t -99.94 143.61 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.852 0.358 . . . . 0.0 111.09 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.689 ' HB2' HG21 ' A' ' 29' ' ' VAL . 48.6 mtt85 -118.43 148.59 42.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.928 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.563 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -68.22 152.56 45.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.159 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 54.45 35.15 22.54 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.689 HG21 ' HB2' ' A' ' 26' ' ' ARG . 98.5 t -127.1 149.47 32.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.068 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.0 tp -71.87 112.01 7.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.942 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.536 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 40.5 mm-40 -116.28 126.79 54.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.8 t -143.46 163.0 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.553 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 2.0 p90 -155.07 -176.96 6.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 87.1 m -120.87 129.79 53.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.106 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.519 HG13 HG22 ' A' ' 16' ' ' ILE . 55.5 t -108.68 105.74 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.069 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -86.54 98.91 11.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.842 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 87' ' ' TYR . 97.5 p -113.18 31.19 6.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.1 t -73.48 -40.99 63.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -73.87 -24.79 59.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.933 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.727 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.1 -32.86 72.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.103 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.573 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 126.26 -147.47 16.75 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.475 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.845 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -106.64 18.41 21.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.803 0.335 . . . . 0.0 110.92 -179.914 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.746 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.21 151.61 85.86 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.583 0.706 . . . . 0.0 111.078 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 167.49 24.28 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.681 2.254 . . . . 0.0 112.297 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.1 tp -122.96 144.49 49.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -130.25 143.79 50.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.901 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.513 ' CG1' HG11 ' A' ' 59' ' ' VAL . 46.1 t -136.71 153.74 30.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.129 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.416 ' N ' HG12 ' A' ' 47' ' ' VAL . 39.2 mtt180 -155.71 145.19 21.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.4 t -125.72 125.96 69.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.156 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.39 126.54 49.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.65 176.98 23.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.471 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -49.24 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.641 2.227 . . . . 0.0 112.372 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -72.56 -37.24 68.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 139.98 37.37 0.11 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.444 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.41 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 8.7 tp -91.32 150.65 21.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.877 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.41 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.5 t -114.95 126.72 72.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -127.16 141.63 41.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.653 0.74 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.84 168.03 22.84 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.704 2.27 . . . . 0.0 112.327 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' CG1' ' A' ' 47' ' ' VAL . 44.0 t -138.41 149.8 24.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.5 t30 -96.37 137.87 34.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.565 ' O ' HG13 ' A' ' 61' ' ' VAL . 13.3 p -133.51 114.36 20.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 84.9 t -135.56 123.56 37.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.094 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -77.01 134.63 38.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -76.88 -42.06 41.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.57 9.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.548 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.408 ' CG ' ' N ' ' A' ' 67' ' ' GLY . 0.6 OUTLIER -83.75 -46.96 11.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 0.0 110.891 -179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.408 ' N ' ' CG ' ' A' ' 66' ' ' ASP . . . 164.03 30.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.444 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 66.5 p -144.54 177.77 8.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.767 0.318 . . . . 0.0 111.155 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.6 m-70 -147.19 124.92 11.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 89.1 m -83.24 139.7 32.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.159 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.553 ' HB ' ' CE1' ' A' ' 33' ' ' PHE . 60.5 t -131.45 106.27 11.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 37.4 p -100.18 145.49 27.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 6.8 p90 -165.45 174.32 10.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.925 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.2 m -152.05 114.11 2.92 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 121.53 0.681 . . . . 0.0 111.123 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 94.38 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 0.0 112.357 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.7 m -38.04 -49.64 1.3 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -127.13 158.26 37.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.1 pm0 -78.54 170.52 16.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.52 175.09 13.88 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.465 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 83.24 0.7 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.646 2.231 . . . . 0.0 112.315 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -77.99 171.84 14.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 19.2 ttp -143.74 119.03 10.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 91.6 t -104.21 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.153 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 30.0 t -84.22 138.14 33.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.851 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 91.1 t -133.86 141.42 44.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.14 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.412 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 28.3 tttt -130.51 168.42 17.08 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.746 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 9.6 t80 -153.54 108.7 3.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.949 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.711 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.88 42.58 7.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.412 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 1.2 m-20 63.18 35.31 12.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -145.63 104.99 3.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -51.75 121.79 7.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.728 HD11 ' CE2' ' A' ' 97' ' ' PHE . 33.5 pt -59.74 153.25 53.71 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.673 0.749 . . . . 0.0 111.144 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.4 ' CD ' ' HA ' ' A' ' 12' ' ' SER . 54.1 Cg_endo -69.8 6.02 1.49 Allowed 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.565 2.176 . . . . 0.0 112.419 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.541 ' HB2' HD12 ' A' ' 92' ' ' ILE . 11.9 mtt85 -121.55 9.57 10.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.41 153.54 58.89 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.747 0.784 . . . . 0.0 110.832 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.8 Cg_endo -69.88 176.78 31.57 Favored 'Cis proline' 0 C--N 1.343 0.253 0 C-N-CA 122.6 -1.834 . . . . 0.0 112.325 0.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 92' ' ' ILE . 84.8 m-85 -113.99 132.02 56.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.854 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.4 ptmm? -87.28 111.65 21.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.2 t -123.49 101.66 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 34.9 ttpt -84.99 100.05 11.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 81.5 t -71.23 148.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.132 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 60.4 mt -113.86 155.5 45.12 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 0.0 110.908 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.6 Cg_endo -69.71 121.63 8.32 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.69 2.26 . . . . 0.0 112.378 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 103' ' ' PRO . 99.5 m -33.96 -34.94 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.139 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.468 ' N ' ' O ' ' A' ' 103' ' ' PRO . 26.7 m-85 -106.61 156.39 18.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.95 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -113.94 96.88 6.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -68.06 82.92 0.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 60.2 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 -179.8 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.431 -0.268 . . . . 0.0 112.431 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 m -68.94 122.98 19.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.871 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 4' ' ' GLY . 15.1 t -109.23 163.29 13.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.838 -179.784 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 3' ' ' SER . . . -35.82 131.83 0.75 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.445 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.443 ' O ' ' C ' ' A' ' 6' ' ' SER . 16.5 m -103.65 108.31 19.54 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.91 0.386 . . . . 0.0 110.903 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.443 ' C ' ' O ' ' A' ' 5' ' ' SER . 2.7 m 34.65 42.14 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.841 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 83.39 108.38 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.469 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.2 m -74.59 152.42 6.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.145 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.5 t -107.93 136.76 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.124 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -129.88 95.42 28.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 0.0 110.878 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.81 -0.79 7.47 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.668 2.245 . . . . 0.0 112.385 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.8 m -98.7 2.1 46.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.819 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -108.48 -7.16 15.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.416 HG12 ' H ' ' A' ' 14' ' ' VAL . 1.7 p -88.86 123.93 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.157 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -123.21 174.46 7.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.757 HG22 HG13 ' A' ' 35' ' ' VAL . 20.5 pt -145.59 133.45 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.09 135.69 29.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.99 170.46 35.2 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.444 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -31.64 20.27 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.349 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -59.89 -42.6 98.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.661 HD11 ' CD2' ' A' ' 33' ' ' PHE . 7.8 mt -77.39 -23.72 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -52.82 173.85 0.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.445 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.5 m -87.16 -11.84 48.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.96 0.409 . . . . 0.0 110.859 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.28 45.33 3.26 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.432 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -93.19 146.49 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 0.0 111.138 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.781 ' HB2' HG21 ' A' ' 29' ' ' VAL . 28.7 mtm-85 -121.27 151.32 40.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.839 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.479 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -70.72 147.07 49.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.063 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 67.0 mtm-85 56.32 33.68 22.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.823 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.781 HG21 ' HB2' ' A' ' 26' ' ' ARG . 85.8 t -123.74 143.8 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.2 tp -68.0 111.05 4.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.968 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.435 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 52.3 mm-40 -114.13 130.45 56.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 38.6 t -145.48 148.76 33.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.867 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.661 ' CD2' HD11 ' A' ' 21' ' ' LEU . 1.9 p90 -140.66 -178.22 5.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.879 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 98.8 m -119.92 129.13 54.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.108 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.757 HG13 HG22 ' A' ' 16' ' ' ILE . 55.4 t -108.94 106.11 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.144 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -87.57 107.19 18.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 84.5 p -123.12 22.09 9.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.877 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.3 t -66.78 -35.96 81.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.886 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.4 mmtm -83.1 -8.64 59.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -82.91 -34.32 26.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.149 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 132.15 -135.48 8.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.514 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.51 ' N ' HD13 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -122.77 22.1 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.857 0.361 . . . . 0.0 110.945 -179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.819 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -79.25 151.71 75.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.579 0.704 . . . . 0.0 111.071 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.441 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.3 Cg_endo -69.77 166.52 27.31 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.39 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.4 tp -124.26 134.88 53.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -119.41 147.06 44.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.876 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.3 t -136.97 150.38 26.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.149 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 18.6 mtt-85 -154.23 133.37 12.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.619 ' C ' HD22 ' A' ' 50' ' ' LEU . 62.0 t -112.91 128.61 69.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.141 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.619 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -124.44 127.45 47.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.971 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.72 179.71 37.17 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.479 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.517 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.84 -37.95 8.28 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.669 2.246 . . . . 0.0 112.316 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.62 -31.27 21.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.913 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 135.06 30.19 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.8 tp -81.75 147.51 29.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.36 . . . . 0.0 110.936 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.3 t -110.41 105.63 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.128 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -96.46 144.91 28.66 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.671 0.748 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 168.12 22.52 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.717 2.278 . . . . 0.0 112.317 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.5 m -142.75 167.45 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.426 ' ND2' ' C ' ' A' ' 60' ' ' ASN . 0.4 OUTLIER -125.05 141.74 51.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.5 t -132.84 111.03 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.169 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 90.3 t -138.93 115.42 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.146 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.523 ' OD2' ' CE1' ' A' ' 69' ' ' HIS . 10.2 t70 -72.51 139.9 47.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.884 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -77.68 -43.25 31.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.938 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.46 ' N ' ' OD1' ' A' ' 63' ' ' ASP . . . 115.38 -20.07 14.19 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.473 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -91.61 -41.73 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.876 0.37 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.13 33.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.433 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.508 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 71.0 p -149.34 177.33 9.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.796 0.331 . . . . 0.0 111.158 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.523 ' CE1' ' OD2' ' A' ' 63' ' ' ASP . 12.5 m-70 -146.94 125.06 12.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 34.5 m -84.53 140.4 31.47 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.083 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.539 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 67.3 t -131.03 103.78 8.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.139 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 41.0 p -93.44 139.29 30.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.2 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.498 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.1 p90 -159.9 169.15 24.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.927 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.0 m -147.14 115.66 4.32 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.631 0.729 . . . . 0.0 111.104 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.498 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 53.8 Cg_endo -69.74 99.01 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.255 . . . . 0.0 112.331 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 75' ' ' PRO . 32.5 t -35.6 -54.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.859 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -128.77 177.55 6.98 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.18 166.35 14.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.99 173.14 13.31 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.555 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 92.49 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.366 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.517 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 5.3 m-85 -92.0 151.97 20.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.909 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . 0.455 ' C ' ' SD ' ' A' ' 82' ' ' MET . 3.7 tmm? -119.91 129.19 54.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.873 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.45 95.84 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.159 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -79.24 139.06 38.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 61.5 t -136.92 134.22 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.425 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 42.7 tttt -123.25 167.18 14.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.819 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 10.9 t80 -154.5 105.55 2.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.808 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 64.8 42.96 4.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.09 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.425 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 13.2 m-20 63.35 32.94 14.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -142.69 105.11 4.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -56.98 111.79 1.14 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.718 HD11 ' HE1' ' A' ' 97' ' ' PHE . 46.3 pt -49.5 152.86 2.12 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 111.097 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 4.11 2.41 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.651 2.234 . . . . 0.0 112.365 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.49 ' HB2' HD12 ' A' ' 92' ' ' ILE . 49.7 mtt85 -115.04 -1.28 13.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.542 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -113.37 153.83 45.52 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.672 0.748 . . . . 0.0 110.863 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.542 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.3 Cg_endo -69.74 177.96 27.02 Favored 'Cis proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 -1.801 . . . . 0.0 112.351 -0.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.724 ' CE2' HD11 ' A' ' 16' ' ' ILE . 79.9 m-85 -116.93 140.83 49.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 43.1 mttm -100.2 111.46 23.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 89.6 t -121.52 103.45 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.078 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.3 tttp -81.91 103.25 11.44 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.932 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.61 143.14 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.07 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 74.7 mt -111.83 155.76 42.69 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.557 0.694 . . . . 0.0 110.964 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.493 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.85 123.54 10.18 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.656 2.237 . . . . 0.0 112.334 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 54.4 m -39.02 -25.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.493 ' N ' ' O ' ' A' ' 103' ' ' PRO . 10.3 m-85 -98.46 143.78 28.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.863 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -164.53 113.27 1.12 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.896 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -104.68 43.68 1.08 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.113 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.7 p . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.857 -179.801 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.4 m -60.54 151.78 27.73 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.962 0.411 . . . . 0.0 110.788 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 90.7 p -104.27 42.59 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.881 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.04 122.65 5.09 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.49 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 31.3 m -136.18 173.09 12.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.836 0.35 . . . . 0.0 110.868 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.8 t -123.41 129.09 50.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.892 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.39 61.75 1.3 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.438 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.0 p -127.16 143.43 40.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.739 0.304 . . . . 0.0 111.158 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 73.5 t -117.39 131.23 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.144 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.402 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 17.9 m-20 -131.73 97.62 18.79 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.611 0.72 . . . . 0.0 110.819 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.2 Cg_endo -69.76 -1.75 9.0 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.645 2.23 . . . . 0.0 112.365 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 m -101.12 14.04 33.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.8 mmpt? -117.83 -8.38 10.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -84.31 132.4 31.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.119 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 29.2 mtmt -126.49 169.48 12.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.885 HD11 ' CE2' ' A' ' 97' ' ' PHE . 37.3 pt -145.74 133.81 16.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.144 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.65 146.18 35.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.075 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 160.13 172.15 26.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -33.41 16.58 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.674 2.249 . . . . 0.0 112.366 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.431 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -57.45 -42.05 93.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.497 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.474 HD11 ' CD2' ' A' ' 33' ' ' PHE . 8.6 mt -80.43 -25.87 38.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -51.17 176.63 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.479 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.7 t -89.46 -16.58 30.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.976 0.417 . . . . 0.0 110.917 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.82 47.79 3.86 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.431 HG21 ' O ' ' A' ' 20' ' ' GLY . 66.1 t -99.81 141.5 16.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.784 0.326 . . . . 0.0 111.156 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -117.64 151.54 37.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.67 152.41 42.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 33.0 mtt180 55.32 40.2 31.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.884 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -135.27 144.37 34.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 14.7 tp -66.4 115.17 6.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.892 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 47.6 mm-40 -120.32 127.06 52.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.867 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . 0.473 ' HB2' HG22 ' A' ' 72' ' ' THR . 32.5 t -141.45 149.63 41.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.839 -179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.474 ' CD2' HD11 ' A' ' 21' ' ' LEU . 3.5 p90 -142.18 176.55 8.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 83.9 m -114.21 136.96 52.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.725 HG13 HG22 ' A' ' 16' ' ' ILE . 41.5 t -115.16 105.33 18.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.158 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -87.74 98.47 11.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.903 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 95.5 p -114.4 30.36 7.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.928 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 87.9 p -76.68 -34.68 58.21 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -76.6 -22.01 54.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.915 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.56 -41.34 60.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.075 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.593 ' C ' HD13 ' A' ' 42' ' ' LEU . . . 138.34 -147.04 18.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.482 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.838 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -107.18 17.01 23.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.855 0.359 . . . . 0.0 110.939 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.845 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -75.39 151.44 85.42 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.607 0.718 . . . . 0.0 111.112 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 167.56 24.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.689 2.26 . . . . 0.0 112.362 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.491 HD11 ' CG1' ' A' ' 85' ' ' VAL . 6.1 tp -125.88 139.72 53.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.961 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 85' ' ' VAL . 1.9 mp0 -117.01 146.69 42.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.623 HG12 HG11 ' A' ' 59' ' ' VAL . 58.4 t -139.51 134.22 39.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.137 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -140.79 141.12 34.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.859 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.667 ' C ' HD22 ' A' ' 50' ' ' LEU . 98.9 t -123.32 127.49 74.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.056 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.667 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.0 mm? -125.11 124.57 42.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.77 167.87 47.49 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -47.78 0.86 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.664 2.243 . . . . 0.0 112.352 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -71.44 -38.63 71.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.931 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.28 34.93 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.501 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.446 HD21 ' OE2' ' A' ' 57' ' ' GLU . 8.4 tp -94.44 149.21 21.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.87 0.367 . . . . 0.0 110.903 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.7 t -115.64 116.25 51.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.146 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.446 ' OE2' HD21 ' A' ' 55' ' ' LEU . 30.2 mm-40 -115.63 139.32 24.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.719 0.771 . . . . 0.0 110.851 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 174.74 9.03 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.771 2.314 . . . . 0.0 112.381 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.623 HG11 HG12 ' A' ' 47' ' ' VAL . 13.7 m -140.34 162.13 24.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.079 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' O ' HG13 ' A' ' 71' ' ' VAL . 33.9 t30 -117.59 138.54 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.5 p -131.68 119.93 43.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.072 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 92.2 t -138.81 126.32 26.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -79.09 133.29 36.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.813 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -75.29 -46.51 33.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.884 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.15 -23.81 9.66 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.444 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -88.4 -44.15 10.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.891 0.376 . . . . 0.0 110.873 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.6 33.94 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.417 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 68.2 p -150.93 177.59 9.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.329 . . . . 0.0 111.144 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 13.4 m-70 -145.99 126.62 14.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.869 179.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 35.0 m -86.04 142.49 28.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.111 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.404 HG13 ' O ' ' A' ' 60' ' ' ASN . 95.4 t -132.48 108.47 13.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.092 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.473 HG22 ' HB2' ' A' ' 32' ' ' SER . 27.8 p -97.6 142.31 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.089 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.531 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 8.7 p90 -161.49 175.75 11.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.946 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -150.42 114.27 3.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.639 0.733 . . . . 0.0 111.137 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.475 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.73 89.09 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.697 2.265 . . . . 0.0 112.329 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 75' ' ' PRO . 44.4 t -35.67 -53.34 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.885 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -122.44 166.64 14.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.953 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -89.69 166.48 13.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.84 179.59 16.12 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.71 86.45 0.57 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.691 2.261 . . . . 0.0 112.345 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -76.93 171.66 14.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 6.1 ttp -143.8 113.25 6.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 49' ' ' VAL . 85.1 t -109.06 96.11 4.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.084 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 2.0 m -81.46 145.52 30.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.491 ' CG1' HD11 ' A' ' 45' ' ' LEU . 88.7 t -139.29 138.49 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.094 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 33.3 tttt -125.92 170.19 11.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.923 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.845 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 8.2 t80 -155.24 110.69 3.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.962 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.687 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 61.63 39.77 14.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.115 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 65.52 35.52 7.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.828 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 29.0 mt-10 -145.49 105.02 3.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -53.44 118.01 3.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.684 HD11 ' HE1' ' A' ' 97' ' ' PHE . 47.0 pt -57.18 153.43 25.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.567 0.698 . . . . 0.0 111.163 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 5.15 1.82 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.665 2.244 . . . . 0.0 112.354 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 75.8 mtt85 -118.49 6.32 11.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.54 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -119.8 154.07 54.93 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.612 0.72 . . . . 0.0 110.835 -179.803 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.54 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.76 178.86 24.0 Favored 'Cis proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.717 -1.784 . . . . 0.0 112.318 0.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.885 ' CE2' HD11 ' A' ' 16' ' ' ILE . 68.7 m-85 -115.5 126.56 54.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.87 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.4 ptmt -90.94 107.42 19.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 62.9 t -117.67 107.82 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.13 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -84.62 97.64 9.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.8 t -69.19 147.39 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.134 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 61.6 mt -112.24 155.51 43.45 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.641 0.734 . . . . 0.0 110.949 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.68 123.93 10.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.723 2.282 . . . . 0.0 112.31 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 103' ' ' PRO . 59.6 m -34.61 -32.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.192 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.488 ' N ' ' O ' ' A' ' 103' ' ' PRO . 15.6 m-85 -100.22 136.06 40.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.21 7.33 16.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.916 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . 41.73 41.44 1.77 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.103 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 29.4 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 -179.799 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.7 m -119.34 176.38 5.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.928 0.394 . . . . 0.0 110.848 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.1 m -151.97 161.82 42.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.853 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 157.64 -148.13 17.19 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.477 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.5 m -66.17 107.07 1.82 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.904 0.383 . . . . 0.0 110.803 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.4 p -94.77 148.31 22.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.839 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.22 -74.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.516 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.9 p -38.1 152.34 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.836 0.35 . . . . 0.0 111.167 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.1 t -95.71 131.21 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.099 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.407 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.1 m-20 -130.29 96.21 25.4 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.63 0.729 . . . . 0.0 110.84 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 54.9 Cg_endo -69.74 3.11 2.95 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.706 2.271 . . . . 0.0 112.382 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 50.3 m -102.77 -0.29 31.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.884 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.0 mmpt? -103.94 -8.82 19.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 p -85.79 128.18 39.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.151 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.412 ' N ' ' HD3' ' A' ' 15' ' ' LYS . 1.2 mppt? -126.83 171.15 11.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.873 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 35' ' ' VAL . 18.2 pt -144.08 135.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.99 126.58 17.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.3 171.38 38.54 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.477 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 -32.58 18.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.637 2.225 . . . . 0.0 112.365 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.9 -36.05 65.41 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.506 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.618 HD13 HG13 ' A' ' 16' ' ' ILE . 4.7 mt -87.04 -15.5 38.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.851 0.358 . . . . 0.0 110.901 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.67 178.65 3.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.513 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 90.0 p -92.48 -11.77 33.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.96 46.03 3.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.455 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.513 HG13 ' NE2' ' A' ' 31' ' ' GLN . 97.8 t -95.69 142.21 14.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 111.092 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 95.1 mtt180 -118.55 153.65 33.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.845 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -72.51 145.36 47.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.072 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.6 mtt180 59.59 42.23 17.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -133.95 148.35 30.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.126 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.8 tp -70.5 112.31 6.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.513 ' NE2' HG13 ' A' ' 25' ' ' VAL . 47.1 mm-40 -117.43 128.95 55.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 20.4 t -148.41 161.16 42.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.837 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.494 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -151.85 -176.08 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.8 m -117.86 128.79 55.18 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.167 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 16' ' ' ILE . 86.2 t -109.34 107.98 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.152 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -88.79 103.93 16.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.943 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 17.2 p -122.61 27.24 7.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 28.1 t -68.82 -37.32 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.872 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -81.07 -19.87 42.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.436 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -69.71 -37.5 76.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.111 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 131.58 -143.12 14.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.449 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.551 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -113.69 19.0 17.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.827 0.346 . . . . 0.0 110.875 -179.906 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.721 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -77.15 151.37 81.42 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.562 0.696 . . . . 0.0 111.153 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.452 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 53.6 Cg_endo -69.72 167.1 25.37 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.501 HD22 HG11 ' A' ' 35' ' ' VAL . 11.0 tp -127.29 130.97 50.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.901 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -118.57 143.91 46.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.826 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 85' ' ' VAL . 81.8 t -137.44 124.56 29.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.152 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -115.07 149.04 38.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.503 HG23 ' CG2' ' A' ' 59' ' ' VAL . 48.6 t -123.7 120.59 60.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.211 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 50' ' ' LEU . 2.5 mm? -96.68 175.21 6.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.34 159.73 24.17 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.478 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 -41.75 4.06 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.689 2.26 . . . . 0.0 112.397 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.22 -14.9 34.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 114.58 36.58 1.28 Allowed Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.439 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.563 HD23 ' OE2' ' A' ' 57' ' ' GLU . 11.4 tp -100.27 146.55 26.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 0.0 110.939 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 37.8 t -116.21 123.76 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.204 179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.563 ' OE2' HD23 ' A' ' 55' ' ' LEU . 27.1 mp0 -117.07 140.62 27.29 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.637 0.732 . . . . 0.0 110.853 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 176.96 6.11 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.659 2.239 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.539 HG12 ' N ' ' A' ' 60' ' ' ASN . 61.8 t -144.29 160.16 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.152 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.539 ' N ' HG12 ' A' ' 59' ' ' VAL . 20.5 t30 -106.79 138.3 43.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 95.9 t -132.77 113.31 20.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 67.1 t -141.15 125.37 17.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.133 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -75.15 142.83 43.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -80.24 -43.2 21.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 115.5 -20.91 13.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.454 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -92.99 -39.44 11.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.887 0.375 . . . . 0.0 110.842 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.43 34.48 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.503 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.4 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 67.9 p -151.74 176.82 11.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.819 0.342 . . . . 0.0 111.146 -179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.4 ' CD2' ' C ' ' A' ' 68' ' ' THR . 18.4 m-70 -142.96 129.7 20.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.3 m -86.76 137.71 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.137 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.494 ' HB ' ' CZ ' ' A' ' 33' ' ' PHE . 33.1 t -130.11 101.51 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.089 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 64.3 p -95.31 144.32 25.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.166 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.491 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 3.9 p90 -163.88 168.32 19.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -146.09 115.99 4.74 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.607 0.718 . . . . 0.0 111.161 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.491 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.0 Cg_endo -69.76 93.42 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.658 2.239 . . . . 0.0 112.357 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 75' ' ' PRO . 23.2 t -34.77 -58.85 0.5 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -120.87 168.76 11.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -86.53 170.24 12.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.851 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.47 178.16 15.22 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.475 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 93.71 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.705 2.27 . . . . 0.0 112.352 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -94.91 171.55 8.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 9.5 ttp -147.72 120.26 8.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 90.3 t -105.21 96.49 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.8 t -78.58 150.46 32.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.649 HG22 HG22 ' A' ' 47' ' ' VAL . 86.2 t -140.86 133.77 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.077 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 39.7 tttt -125.02 170.0 11.58 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.699 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 7.5 t80 -157.41 112.81 2.8 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.721 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.49 35.57 22.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.141 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 71.4 30.73 2.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -139.16 105.82 5.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.926 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -56.69 112.24 1.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.621 HD11 ' HE2' ' A' ' 97' ' ' PHE . 44.5 pt -50.46 152.73 3.04 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.641 0.734 . . . . 0.0 111.141 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 4.27 2.33 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.55 ' HB2' HD12 ' A' ' 92' ' ' ILE . 22.9 mmm180 -114.85 -1.26 13.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.805 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -113.51 154.27 45.56 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.607 0.717 . . . . 0.0 110.863 -179.745 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.1 Cg_endo -69.84 179.67 21.81 Favored 'Cis proline' 0 C--O 1.232 0.191 0 C-N-CA 122.646 -1.814 . . . . 0.0 112.299 0.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.621 ' HE2' HD11 ' A' ' 92' ' ' ILE . 85.9 m-85 -120.87 119.54 32.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.895 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.63 116.23 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 87.5 t -129.51 102.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -85.18 102.31 13.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.39 147.21 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.174 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 66.2 mt -117.54 154.81 50.76 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.604 0.716 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 123.81 10.46 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.716 2.277 . . . . 0.0 112.338 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.3 m -39.6 -30.33 0.07 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.139 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -108.23 139.72 42.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -108.98 81.6 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -73.46 87.01 1.56 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.855 -179.78 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.444 -0.263 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.3 p -157.79 109.85 2.34 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.84 0.352 . . . . 0.0 110.838 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 93.2 p -76.65 141.09 41.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -94.72 -67.67 1.02 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.449 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -133.22 92.9 3.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.853 0.359 . . . . 0.0 110.855 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -88.7 42.15 1.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.869 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 53.9 60.36 8.5 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.506 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.4 p -119.0 147.4 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.863 0.363 . . . . 0.0 111.099 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 69.3 t -102.86 136.3 36.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.083 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.03 97.08 18.87 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.905 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 -2.05 9.54 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.719 2.279 . . . . 0.0 112.295 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 44.5 p -101.71 17.68 22.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.894 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 mmpt? -121.05 -7.37 9.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.881 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.414 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -84.66 128.49 38.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.16 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.6 mtpt -124.28 168.08 13.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.936 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.743 HG22 HG13 ' A' ' 35' ' ' VAL . 13.1 pt -144.83 134.79 19.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.173 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.07 130.58 22.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.041 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.64 168.82 35.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.457 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -32.09 19.18 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.732 2.288 . . . . 0.0 112.298 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.4 -43.78 84.99 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.528 HD13 HG13 ' A' ' 16' ' ' ILE . 4.4 mt -78.33 -26.23 46.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 110.922 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 25' ' ' VAL . . . -49.48 172.68 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.487 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.5 m -86.35 -18.62 31.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.822 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -82.83 45.46 3.42 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.519 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 ' CD ' ' A' ' 31' ' ' GLN . 43.9 t -94.95 142.5 13.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.871 0.367 . . . . 0.0 111.102 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.835 ' HB2' HG21 ' A' ' 29' ' ' VAL . 49.7 mtm180 -117.79 160.01 22.09 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.576 ' O ' HG23 ' A' ' 29' ' ' VAL . . . -78.2 149.58 33.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.091 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 51.6 mtm-85 55.63 32.04 18.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.85 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.835 HG21 ' HB2' ' A' ' 26' ' ' ARG . 61.4 t -121.48 140.02 46.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.11 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 8.7 tp -65.8 110.84 2.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.924 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 54.7 mm-40 -113.12 133.12 55.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 22.1 t -146.37 154.35 41.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.544 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 3.1 p90 -148.13 -178.49 6.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.878 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.5 m -122.22 132.02 54.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.174 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.743 HG13 HG22 ' A' ' 16' ' ' ILE . 45.3 t -112.07 105.12 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -86.07 98.22 10.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.911 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.474 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 95.6 p -113.03 25.33 11.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.8 t -72.57 -37.49 68.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -74.39 -20.78 59.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.99 -38.67 64.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.063 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 136.58 -136.49 8.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.511 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.573 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.53 20.0 13.12 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.759 0.314 . . . . 0.0 110.839 -179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.747 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.99 151.67 82.02 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.556 0.693 . . . . 0.0 111.091 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 166.73 26.6 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.381 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -124.72 135.13 52.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 18.6 tt0 -116.9 145.86 43.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.941 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 59' ' ' VAL . 60.2 t -134.18 147.68 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.125 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -152.07 133.29 14.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.687 HG23 ' CG2' ' A' ' 59' ' ' VAL . 87.6 t -116.92 124.98 73.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.623 HD22 ' C ' ' A' ' 49' ' ' VAL . 4.2 mm? -123.65 121.67 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.946 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.21 172.83 8.81 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.487 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 81' ' ' TYR . 53.7 Cg_endo -69.71 -48.44 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.707 2.271 . . . . 0.0 112.373 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -71.83 -39.2 69.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 141.84 32.79 0.12 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.506 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.457 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 9.1 tp -91.3 153.32 20.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.807 0.336 . . . . 0.0 110.92 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.457 ' N ' ' HG ' ' A' ' 55' ' ' LEU . 87.8 t -115.37 130.08 70.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.068 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -133.12 140.85 38.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.699 0.761 . . . . 0.0 110.869 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 170.68 15.95 Favored 'Trans proline' 0 C--N 1.343 0.247 0 C-N-CA 122.617 2.211 . . . . 0.0 112.419 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.826 HG11 HG11 ' A' ' 47' ' ' VAL . 67.2 t -141.52 154.66 20.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.721 ' O ' HG13 ' A' ' 71' ' ' VAL . 1.2 t30 -100.35 137.69 38.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.599 ' O ' HG13 ' A' ' 61' ' ' VAL . 10.6 p -133.54 116.55 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 82.3 t -138.31 130.29 38.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.134 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -82.3 140.48 33.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.0 m-80 -79.95 -45.33 18.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.09 -25.22 8.92 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -88.11 -41.63 12.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.877 0.37 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.96 34.28 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.475 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 62.3 p -149.35 177.5 9.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.829 0.347 . . . . 0.0 111.139 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 68' ' ' THR . 7.6 m-70 -145.92 123.73 11.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.918 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 65.7 m -85.23 136.47 33.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.166 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.721 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.6 t -129.09 112.71 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 59.4 p -103.93 146.72 28.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.561 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 7.9 p90 -165.79 177.44 7.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.986 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.1 m -154.31 113.74 2.47 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.551 0.691 . . . . 0.0 111.109 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.561 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.2 Cg_endo -69.82 93.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.642 2.228 . . . . 0.0 112.333 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 75' ' ' PRO . 31.2 t -34.14 -59.78 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -116.35 167.81 10.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.937 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -83.76 166.26 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.836 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.78 169.31 12.32 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.494 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.98 91.24 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.605 2.203 . . . . 0.0 112.276 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.415 ' CD1' ' HD3' ' A' ' 52' ' ' PRO . 4.3 m-85 -82.97 172.06 13.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 17.6 ttp -140.74 118.72 11.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.846 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 49' ' ' VAL . 71.8 t -110.26 96.88 5.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.178 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 4.3 m -81.6 145.08 30.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.924 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 98.0 t -138.75 137.29 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.108 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HE2' ' C ' ' A' ' 89' ' ' ASP . 43.1 tttt -123.22 169.1 11.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.899 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.747 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.6 t80 -155.59 111.46 3.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.666 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 62.56 37.9 12.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.036 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.418 ' C ' ' HE2' ' A' ' 86' ' ' LYS . 5.6 m-20 66.4 35.34 5.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.817 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -145.78 104.99 3.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.882 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -52.26 113.0 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.622 HD11 ' CE2' ' A' ' 97' ' ' PHE . 45.6 pt -51.37 153.14 3.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.604 0.716 . . . . 0.0 111.179 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 4.89 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.696 2.264 . . . . 0.0 112.326 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.508 ' HB2' HD12 ' A' ' 92' ' ' ILE . 20.1 mmt180 -116.98 1.54 12.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.841 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.538 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -116.09 154.34 48.51 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.661 0.743 . . . . 0.0 110.883 -179.798 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.538 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.2 Cg_endo -69.78 177.47 28.8 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.654 -1.811 . . . . 0.0 112.353 -0.022 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.622 ' CE2' HD11 ' A' ' 92' ' ' ILE . 86.9 m-85 -116.84 146.29 42.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.839 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.03 131.49 46.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.914 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 69.5 t -134.98 101.62 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.113 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -82.78 94.0 7.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.918 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -71.07 145.22 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.073 179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 57.3 mt -118.77 155.82 52.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.634 0.731 . . . . 0.0 110.91 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 105' ' ' TYR . 54.2 Cg_endo -69.67 116.25 4.46 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.672 2.248 . . . . 0.0 112.408 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.44 ' C ' ' O ' ' A' ' 103' ' ' PRO . 52.1 m -34.01 -33.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.498 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.5 m-85 -81.82 48.09 1.17 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.955 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -90.19 35.93 0.87 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.914 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -81.23 41.63 0.61 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.105 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 3.7 m . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.874 -179.787 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 t 65.11 42.93 3.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.867 0.365 . . . . 0.0 110.896 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.6 t -109.71 147.1 33.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.859 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 138.8 178.71 16.57 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.466 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 90.6 p -102.21 115.46 30.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.353 . . . . 0.0 110.824 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.1 m -93.26 43.15 1.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.897 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 56.98 49.94 67.75 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.53 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -130.12 143.94 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.866 0.365 . . . . 0.0 111.094 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 77.8 t -108.08 135.21 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.194 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -133.79 96.86 16.02 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.652 0.739 . . . . 0.0 110.801 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -1.5 8.58 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.642 2.228 . . . . 0.0 112.364 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 48.0 m -100.97 12.56 37.46 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.819 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.1 mmpt? -117.47 -9.16 10.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.874 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.413 HG12 ' H ' ' A' ' 14' ' ' VAL . 2.1 p -82.38 135.84 24.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.8 mtpm? -132.64 168.0 19.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.819 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.815 HD11 ' CE2' ' A' ' 97' ' ' PHE . 36.8 pt -144.33 135.37 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.98 133.14 26.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.056 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.01 175.36 40.13 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.445 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 -35.35 12.72 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.667 2.245 . . . . 0.0 112.362 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.36 -42.56 83.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.534 HD13 HG13 ' A' ' 16' ' ' ILE . 11.8 mt -77.45 -28.33 52.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.943 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -48.85 176.12 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.454 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 t -92.01 -18.03 24.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.906 0.384 . . . . 0.0 110.839 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -85.26 48.76 4.09 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.11 140.56 16.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.336 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 52.4 mtt180 -118.46 148.63 42.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.51 42.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.114 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 44.7 mtp180 54.73 39.19 31.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.6 t -134.79 143.15 38.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.154 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 22.5 tp -66.24 114.43 5.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.973 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.511 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 42.3 mm-40 -117.73 128.3 54.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.896 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 8.2 t -139.86 164.82 28.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.822 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.564 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.2 p90 -157.86 167.89 28.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 85.5 m -107.3 131.19 54.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.603 HG13 HG22 ' A' ' 16' ' ' ILE . 58.1 t -111.41 105.27 18.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.083 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -88.5 103.17 15.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.852 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 87.9 p -117.96 26.12 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.817 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.1 t -71.67 -39.05 70.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.861 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -72.99 -22.09 60.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.26 -41.58 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.084 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 139.23 -136.67 8.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.596 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -118.22 18.24 13.8 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.839 0.352 . . . . 0.0 110.983 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.683 ' HB1' ' HB2' ' A' ' 88' ' ' ALA . . . -76.37 152.0 83.51 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.568 0.699 . . . . 0.0 111.102 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.81 166.79 26.46 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 0.0 112.272 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.5 tp -125.48 139.57 53.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.891 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.483 ' O ' HG13 ' A' ' 85' ' ' VAL . 12.4 tt0 -125.27 148.03 48.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 85' ' ' VAL . 40.2 t -140.82 152.12 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.111 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 49.4 mtm-85 -153.16 138.53 17.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 83' ' ' VAL . 93.4 t -118.31 124.09 72.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.1 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.51 HD22 ' C ' ' A' ' 49' ' ' VAL . 3.2 mm? -113.32 152.34 30.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.927 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -98.67 168.48 22.7 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.472 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.85 -44.74 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.675 2.25 . . . . 0.0 112.299 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -78.14 -29.67 48.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.897 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.37 28.38 0.48 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.476 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 14.4 tp -88.85 144.37 26.26 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.864 0.364 . . . . 0.0 110.887 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -115.93 117.1 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.108 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -112.94 141.98 26.47 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.7 0.762 . . . . 0.0 110.85 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 175.85 7.59 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG13 ' A' ' 71' ' ' VAL . 23.4 t -144.35 153.63 15.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.092 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 13.2 t30 -99.63 139.16 35.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.832 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 88.1 t -133.26 108.38 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.402 HG23 HD21 ' A' ' 60' ' ' ASN . 86.4 t -131.51 129.67 62.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.1 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -84.13 133.65 34.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -74.42 -44.24 52.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.49 -25.2 9.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 44.3 m-20 -88.42 -44.38 10.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.908 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.33 33.49 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.513 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 73.3 p -147.64 177.13 9.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -145.4 131.56 19.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 28.3 m -92.81 134.94 34.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.57 HG13 ' O ' ' A' ' 60' ' ' ASN . 39.3 t -129.7 106.36 13.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.145 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.7 p -103.67 140.82 37.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.195 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.557 ' CE2' ' HD3' ' A' ' 75' ' ' PRO . 15.7 p90 -156.78 -176.02 5.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -156.53 112.2 2.03 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 121.569 0.699 . . . . 0.0 111.081 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.557 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.9 Cg_endo -69.81 90.22 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.695 2.263 . . . . 0.0 112.359 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 75' ' ' PRO . 27.8 m -33.85 -57.61 0.45 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.934 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -118.73 166.36 12.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -85.34 172.28 11.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.908 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.07 174.15 13.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.472 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.73 89.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.628 2.219 . . . . 0.0 112.386 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -86.25 164.35 17.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 39.7 ttp -137.32 119.02 15.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.574 HG22 HG22 ' A' ' 49' ' ' VAL . 92.8 t -105.07 95.91 4.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.133 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 41.3 t -80.51 143.26 33.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 46' ' ' GLU . 87.0 t -139.25 142.98 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.45 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 14.5 tttp -129.62 168.37 16.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.616 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 4.9 t80 -154.03 114.68 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.683 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 59.7 36.06 22.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.127 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.45 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 0.8 OUTLIER 68.57 35.3 3.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.861 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.409 ' N ' ' HE3' ' A' ' 86' ' ' LYS . 28.6 mt-10 -147.59 105.17 3.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -50.39 120.13 4.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.681 HD11 ' HE1' ' A' ' 97' ' ' PHE . 43.7 pt -58.62 153.93 37.94 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.634 0.73 . . . . 0.0 111.105 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 5.72 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.66 2.24 . . . . 0.0 112.39 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -119.81 8.17 11.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.865 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.541 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.1 t -121.84 153.71 60.42 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.541 ' C ' ' HA ' ' A' ' 95' ' ' SER . 54.5 Cg_endo -69.72 177.93 27.06 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.689 -1.796 . . . . 0.0 112.399 -0.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.815 ' CE2' HD11 ' A' ' 16' ' ' ILE . 52.2 m-85 -115.2 127.96 55.86 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.929 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.2 ptpt -87.72 110.07 20.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.857 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.99 101.64 9.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -83.11 103.64 12.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 65.5 t -70.22 143.72 14.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 49.1 mt -112.26 155.91 42.86 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.584 0.707 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.494 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.8 Cg_endo -69.77 121.29 7.98 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.688 2.258 . . . . 0.0 112.307 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' PRO . 33.3 m -35.24 -31.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.188 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.494 ' N ' ' O ' ' A' ' 103' ' ' PRO . 8.6 m-85 -110.09 161.27 15.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -96.19 109.76 22.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -84.81 41.26 0.85 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.032 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.843 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.382 0 N-CA-C 112.538 -0.225 . . . . 0.0 112.538 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.9 t 53.65 42.25 31.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.892 0.377 . . . . 0.0 110.903 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.5 t -45.42 163.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.903 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.44 113.19 0.51 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.525 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 61.8 m -91.47 138.9 31.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.866 0.365 . . . . 0.0 110.842 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 83.5 p -144.84 158.35 43.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.858 -179.876 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.7 65.83 0.48 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.513 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.486 HG22 ' N ' ' A' ' 9' ' ' VAL . 11.5 p -106.79 159.51 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.911 0.386 . . . . 0.0 111.094 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.486 ' N ' HG22 ' A' ' 8' ' ' VAL . 53.5 t -97.78 134.4 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.091 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -128.46 95.33 33.22 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.627 0.727 . . . . 0.0 110.859 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.87 9.2 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.645 2.23 . . . . 0.0 112.37 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.4 p -99.71 9.06 43.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.811 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.9 mmpt? -113.06 -6.64 13.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.889 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -86.5 127.93 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.4 mtmm -124.44 168.16 13.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.738 HD11 ' CE2' ' A' ' 97' ' ' PHE . 25.9 pt -144.07 136.34 22.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.165 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.54 144.96 33.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.094 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.34 177.06 30.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -39.67 6.21 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.689 2.259 . . . . 0.0 112.34 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.61 -30.26 13.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.45 HD13 HG13 ' A' ' 16' ' ' ILE . 15.1 mt -95.6 -22.52 17.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.862 0.363 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.47 164.67 5.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 88.7 p -83.95 14.56 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.924 0.393 . . . . 0.0 110.898 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -115.9 44.25 1.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.523 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.457 HG13 ' NE2' ' A' ' 31' ' ' GLN . 76.3 t -95.65 149.12 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.849 0.357 . . . . 0.0 111.106 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 93.0 mtt-85 -124.31 153.63 41.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -73.4 151.94 40.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 54.47 39.29 30.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.3 t -134.13 144.62 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.133 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 15.3 tp -66.85 113.9 5.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.918 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.554 ' HB2' ' CE1' ' A' ' 73' ' ' TYR . 48.2 mm-40 -117.43 130.03 56.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.94 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 25.0 t -143.74 163.32 33.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.835 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.522 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 1.8 p90 -154.88 -177.8 6.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.9 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 91.4 m -119.06 131.03 55.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.629 HG13 HG22 ' A' ' 16' ' ' ILE . 59.1 t -111.7 105.07 18.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.11 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -86.5 102.54 14.19 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.456 ' HB2' ' CZ ' ' A' ' 87' ' ' TYR . 88.7 p -119.31 29.01 7.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.3 t -76.29 -34.53 59.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.857 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 38.3 mttp -80.17 -16.09 55.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -79.05 -38.25 36.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.128 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 137.41 -141.4 12.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.559 ' C ' ' CD2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -114.98 19.02 16.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.763 0.316 . . . . 0.0 110.854 -179.908 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.8 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -76.24 151.47 83.57 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.606 0.717 . . . . 0.0 111.154 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.69 166.76 26.42 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.262 . . . . 0.0 112.376 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.3 tp -126.18 136.54 52.97 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.941 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -121.9 146.38 47.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.778 ' CG1' HG11 ' A' ' 59' ' ' VAL . 84.9 t -138.77 129.11 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.198 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.3 ttm-85 -125.05 140.26 53.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.464 HG23 HG22 ' A' ' 59' ' ' VAL . 92.1 t -119.82 116.97 52.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.463 HD11 HG22 ' A' ' 56' ' ' VAL . 2.0 mm? -115.37 125.69 53.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -65.28 175.23 15.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.481 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.489 ' HD3' ' CE1' ' A' ' 81' ' ' TYR . 54.0 Cg_endo -69.73 -43.27 2.79 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.31 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.429 ' CZ ' HE22 ' A' ' 77' ' ' GLN . 0.0 OUTLIER -75.3 -38.08 60.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.865 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 140.67 33.24 0.14 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.481 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.459 ' HG ' ' N ' ' A' ' 56' ' ' VAL . 6.4 tp -90.33 155.84 18.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 110.937 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 HD11 ' A' ' 50' ' ' LEU . 91.9 t -117.94 118.65 58.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -117.38 143.37 31.91 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.679 0.752 . . . . 0.0 110.886 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 168.18 22.32 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.688 2.259 . . . . 0.0 112.359 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.778 HG11 ' CG1' ' A' ' 47' ' ' VAL . 3.5 t -140.59 144.49 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.125 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.681 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.1 t30 -93.12 138.41 31.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.504 ' O ' HG13 ' A' ' 61' ' ' VAL . 9.5 p -133.23 117.97 30.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.509 HG23 HD21 ' A' ' 60' ' ' ASN . 80.4 t -135.55 138.44 48.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.149 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -89.63 138.54 31.38 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.865 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -81.45 -46.38 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 116.58 -25.08 9.3 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.531 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -87.94 -43.63 11.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.821 0.343 . . . . 0.0 110.785 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.56 33.85 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.431 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.547 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.8 p -150.43 177.66 9.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.822 0.344 . . . . 0.0 111.114 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.547 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.9 m-70 -145.7 127.36 15.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 54.6 m -86.38 132.5 33.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.145 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 60' ' ' ASN . 61.1 t -125.58 111.01 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.081 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 61.9 p -102.38 147.02 27.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.108 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.554 ' CE1' ' HB2' ' A' ' 31' ' ' GLN . 6.6 p90 -165.36 173.47 11.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.6 m -149.49 113.87 3.51 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.577 0.703 . . . . 0.0 111.125 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.531 ' HD3' ' CE2' ' A' ' 73' ' ' TYR . 53.3 Cg_endo -69.79 93.3 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.702 2.268 . . . . 0.0 112.292 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 75' ' ' PRO . 3.7 m -34.26 -45.52 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.882 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . 0.429 HE22 ' CZ ' ' A' ' 53' ' ' ARG . 6.6 pt20 -135.29 170.76 15.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.891 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.412 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . 1.1 pp20? -86.2 177.63 7.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.33 173.98 14.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 83.45 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.684 2.256 . . . . 0.0 112.343 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.489 ' CE1' ' HD3' ' A' ' 52' ' ' PRO . 4.8 m-85 -78.43 172.53 13.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.947 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.6 ttp -143.68 115.61 8.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.827 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 96.1 t -104.36 95.4 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.129 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 33.8 t -77.32 147.26 36.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.938 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.4 t -139.93 137.44 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.079 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.427 ' HE3' ' C ' ' A' ' 89' ' ' ASP . 17.3 tttp -128.65 169.36 14.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.8 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 5.2 t80 -155.0 110.76 3.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.907 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.741 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 60.71 39.79 17.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.044 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.427 ' C ' ' HE3' ' A' ' 86' ' ' LYS . 39.3 m-20 67.15 32.66 6.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.968 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -142.55 105.22 4.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -53.79 116.89 2.76 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.663 HD11 ' HE1' ' A' ' 97' ' ' PHE . 45.5 pt -56.13 153.12 19.45 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.593 0.711 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.77 4.69 2.05 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.653 2.235 . . . . 0.0 112.421 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.463 ' HB2' HD12 ' A' ' 92' ' ' ILE . 39.3 mmt180 -117.19 4.53 12.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.909 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.532 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.0 OUTLIER -117.96 153.98 51.24 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.672 0.749 . . . . 0.0 110.873 -179.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.3 Cg_endo -69.8 -178.83 17.64 Favored 'Cis proline' 0 C--N 1.341 0.15 0 C-N-CA 122.756 -1.768 . . . . 0.0 112.303 0.089 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.738 ' CE2' HD11 ' A' ' 16' ' ' ILE . 77.4 m-85 -118.48 125.38 49.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 29.8 pttt -83.52 109.87 17.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 94.7 t -123.36 101.86 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.099 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 12.5 tttp -84.19 94.08 8.31 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.992 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.412 ' CG1' ' HA ' ' A' ' 78' ' ' GLU . 63.4 t -63.39 145.94 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 65.9 mt -111.23 155.95 41.86 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.554 0.692 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' TYR . 53.5 Cg_endo -69.72 122.4 9.09 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.7 2.266 . . . . 0.0 112.33 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 97.8 m -34.12 -35.21 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.461 ' N ' ' O ' ' A' ' 103' ' ' PRO . 6.2 m-85 -79.07 142.06 36.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.841 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -124.35 151.05 44.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.895 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -90.76 36.31 0.9 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 98.0 p . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.819 -179.752 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.9 m -117.88 166.83 12.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.902 0.382 . . . . 0.0 110.837 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.2 m -129.39 151.44 50.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.854 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.36 138.83 5.84 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.502 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.5 t 40.88 42.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.824 0.345 . . . . 0.0 110.844 -179.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.8 t -140.37 113.98 8.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.52 63.55 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.548 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 9' ' ' VAL . 13.5 p -71.36 156.61 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 111.076 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.465 ' N ' HG22 ' A' ' 8' ' ' VAL . 54.8 t -97.42 124.7 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.427 ' HA ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 m-20 -121.15 98.22 47.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.623 0.725 . . . . 0.0 110.862 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 10' ' ' ASP . 53.9 Cg_endo -69.74 2.4 3.55 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.684 2.256 . . . . 0.0 112.389 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 51.0 m -97.43 -6.74 33.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 39' ' ' LYS . 8.0 mmmm -96.48 -7.09 35.67 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.917 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -89.37 124.12 41.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -127.27 169.15 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.88 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.536 HG13 HD13 ' A' ' 21' ' ' LEU . 29.9 pt -141.66 133.31 27.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.101 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.79 129.09 22.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.096 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 175.51 42.08 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.86 -34.33 14.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.704 2.27 . . . . 0.0 112.28 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.19 -32.5 67.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.469 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.536 HD13 HG13 ' A' ' 16' ' ' ILE . 4.8 mt -91.64 -14.54 29.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.65 -175.12 4.31 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.495 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.8 t -95.61 -15.59 22.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.906 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.03 47.15 3.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.478 HG13 ' NE2' ' A' ' 31' ' ' GLN . 55.4 t -97.0 142.39 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 111.197 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 66.9 mtt180 -119.4 150.8 39.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -71.42 152.57 42.99 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.079 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 30.4 mtp180 52.81 41.66 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.932 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.9 t -135.14 149.23 28.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.0 tp -69.41 113.11 6.42 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.48 ' HB2' ' CE2' ' A' ' 73' ' ' TYR . 28.9 mm-40 -118.9 126.75 52.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.887 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 35.1 t -142.17 161.87 36.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.878 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.55 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 5.4 p90 -151.65 -176.16 5.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.918 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 90.1 m -118.27 134.73 54.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.517 HG11 ' CD2' ' A' ' 45' ' ' LEU . 40.4 t -113.85 105.91 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.11 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -90.62 109.85 21.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 90.8 p -126.45 27.76 6.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.8 m -70.13 -36.39 74.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.468 ' CB ' ' HB3' ' A' ' 13' ' ' LYS . 39.4 mtmt -84.44 -7.7 59.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.912 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.402 ' HB1' ' CE2' ' A' ' 87' ' ' TYR . . . -81.88 -34.72 29.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.07 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 128.26 -139.56 11.14 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.478 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.809 HD22 ' H ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -115.75 19.83 14.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.813 0.34 . . . . 0.0 110.864 -179.86 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.908 ' HB3' ' CE2' ' A' ' 87' ' ' TYR . . . -77.74 150.21 78.53 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.625 0.726 . . . . 0.0 111.042 179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.461 ' O ' ' CD1' ' A' ' 87' ' ' TYR . 54.4 Cg_endo -69.75 168.55 21.2 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.68 2.254 . . . . 0.0 112.386 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.517 ' CD2' HG11 ' A' ' 35' ' ' VAL . 7.4 tp -127.52 128.73 46.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -108.75 155.06 21.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.953 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.671 HG12 HG11 ' A' ' 59' ' ' VAL . 65.5 t -141.58 135.97 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 -142.37 142.06 32.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.966 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 60.9 t -124.37 131.24 73.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.158 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -102.5 179.24 4.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.911 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -128.05 153.6 19.48 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.49 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -26.02 27.78 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.695 2.263 . . . . 0.0 112.293 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.36 12.58 10.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.95 27.92 8.05 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 15.0 tp -94.35 145.34 24.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.399 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -115.5 140.71 35.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.158 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -131.29 145.63 58.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.597 0.713 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 172.64 12.3 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.714 2.276 . . . . 0.0 112.294 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.671 HG11 HG12 ' A' ' 47' ' ' VAL . 3.7 m -144.21 159.66 15.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.142 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 48.1 t30 -123.04 140.97 52.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.8 p -133.39 117.03 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.142 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.7 t -139.47 132.04 36.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.093 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -80.2 136.21 36.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -75.04 -42.32 57.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.95 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 112.82 -23.04 15.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -90.44 -43.28 10.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.843 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 33.77 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.509 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.446 ' C ' ' CD2' ' A' ' 69' ' ' HIS . 70.9 p -151.71 177.75 10.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.816 0.341 . . . . 0.0 111.111 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' CD2' ' C ' ' A' ' 68' ' ' THR . 8.8 m-70 -141.73 127.05 18.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.939 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 55.0 m -86.79 139.88 30.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.164 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.585 HG13 ' O ' ' A' ' 60' ' ' ASN . 48.7 t -131.45 107.69 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 50.7 p -95.43 141.46 28.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.537 ' CE1' ' HD3' ' A' ' 75' ' ' PRO . 4.9 p90 -159.44 167.46 28.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.6 m -145.28 113.67 4.82 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.58 0.705 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.537 ' HD3' ' CE1' ' A' ' 73' ' ' TYR . 54.9 Cg_endo -69.69 94.62 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.684 2.256 . . . . 0.0 112.392 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' PRO . 5.7 m -34.16 -55.4 0.5 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.865 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -130.33 158.96 38.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.911 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -72.37 172.95 9.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.925 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.82 176.2 14.37 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.528 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 84.06 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.723 2.282 . . . . 0.0 112.312 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -82.68 173.85 11.53 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' MET . . . . . . . . . . . . . 5.4 ttp -150.77 129.81 12.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.911 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 87.1 t -115.88 97.99 6.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 29.8 t -80.72 132.71 35.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.774 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 99.0 t -128.25 134.55 64.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.145 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -124.11 167.25 14.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.908 ' CE2' ' HB3' ' A' ' 43' ' ' ALA . 11.9 t80 -153.96 105.61 2.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.826 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . . . 66.49 42.65 2.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.13 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.0 33.52 14.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -143.19 105.72 4.46 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -55.06 112.59 1.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.65 HD11 ' CE2' ' A' ' 97' ' ' PHE . 44.8 pt -50.42 152.99 2.83 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.6 0.714 . . . . 0.0 111.152 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.441 ' HG2' ' NH1' ' A' ' 94' ' ' ARG . 54.5 Cg_endo -69.73 8.3 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.716 2.277 . . . . 0.0 112.368 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.501 ' HB3' ' CE1' ' A' ' 97' ' ' PHE . 0.6 OUTLIER -120.7 -2.47 9.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.844 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.526 ' HA ' ' C ' ' A' ' 96' ' ' PRO . 1.3 t -111.56 152.55 44.09 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.675 0.75 . . . . 0.0 110.844 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.526 ' C ' ' HA ' ' A' ' 95' ' ' SER . 53.7 Cg_endo -69.77 175.17 37.64 Favored 'Cis proline' 0 C--O 1.231 0.153 0 C-N-CA 122.666 -1.806 . . . . 0.0 112.317 0.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.65 ' CE2' HD11 ' A' ' 92' ' ' ILE . 82.4 m-85 -115.45 117.7 31.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -77.97 115.56 17.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.871 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 99.5 t -128.01 103.91 11.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 24.3 ttpt -83.32 99.27 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.929 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.3 t -68.51 145.67 13.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.118 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 59.3 mt -112.08 155.32 43.59 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.631 0.729 . . . . 0.0 110.875 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' TYR . 52.9 Cg_endo -69.83 121.7 8.37 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.246 . . . . 0.0 112.319 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.443 ' C ' ' O ' ' A' ' 103' ' ' PRO . 95.1 m -33.87 -36.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.173 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.446 ' N ' ' O ' ' A' ' 103' ' ' PRO . 31.3 m-85 -86.91 107.94 18.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.986 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -115.35 87.59 2.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.926 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -88.18 41.61 1.01 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.083 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 75.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.843 -179.814 . . . . . . . . 0 0 . 1 stop_ save_